{"meta":{"query_hash":"108a9af0a2b0","filters":{"venue":"Clinical Therapeutics"},"cohort_total":337,"direct_labels_cover":3,"predictions_cover":337,"exported":337,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/108a9af0a2b0","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Therapeutics"},"results":[{"id":"W1757837840","doi":"10.1016/j.clinthera.2015.09.008","title":"Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Bayer (Canada); McGill University Health Centre; Regina Qu'Appelle Health Region; McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Daiichi Sankyo Europe; Bayer Canada; Health Canada; Daiichi-Sankyo; Centro para el Desarrollo Tecnológico Industrial","keywords":"Medicine; Apixaban; Rivaroxaban; Medical prescription; Dabigatran; Warfarin; Vitamin K antagonist; Specialty; Reimbursement; Emergency medicine; Family medicine; Internal medicine; Atrial fibrillation; Pharmacology; Health care","score_opus":0.42848721035720433,"score_gpt":0.46562411824112226,"score_spread":0.037136907883917936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1757837840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98972267,0.00044122228,0.000051005332,0.005434762,0.00074511464,0.00017585844,0.0000022371719,0.000023129078,0.0034040115],"genre_scores_gemma":[0.99573714,0.00013710854,0.00036952784,0.0018851771,0.0003103778,5.952186e-7,0.000015784617,0.000013825815,0.0015304665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858534,0.0001276112,0.0006139142,0.00019070598,0.0002460668,0.0002363586],"domain_scores_gemma":[0.9993313,0.00020355986,0.00007807718,0.00021891244,0.00003571522,0.00013241611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074994005,0.00010461816,0.00044237403,0.0001341975,0.000010876733,0.000009931686,0.00008219882,0.00008503867,0.00007250296],"category_scores_gemma":[0.0001284755,0.00008708622,0.00007691079,0.000286276,0.00003470234,0.000046501187,0.000042242318,0.00021002631,0.00001900112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014571712,0.000018625562,0.94839525,0.0000039085658,0.00003263632,0.000040511328,0.00004144987,0.000077100274,0.000005157173,0.00006281422,0.002323646,0.048853174],"study_design_scores_gemma":[0.0033083807,0.000098513265,0.935557,0.00002775992,0.000047722766,0.0000017164945,0.00013205911,0.0053864955,0.000011910973,0.00013928639,0.05518308,0.000106098116],"about_ca_topic_score_codex":0.082137756,"about_ca_topic_score_gemma":0.39222154,"teacher_disagreement_score":0.31008378,"about_ca_system_score_codex":0.0001683867,"about_ca_system_score_gemma":0.00035957794,"threshold_uncertainty_score":0.92397434},"labels":[],"label_agreement":null},{"id":"W1834728951","doi":"10.1016/j.clinthera.2015.05.496","title":"Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Medicine; Liraglutide; Glycemic; Sitagliptin; Exenatide; Type 2 diabetes; Type 2 Diabetes Mellitus; Hypoglycemia; Glycated hemoglobin; Diabetes mellitus; Intensive care medicine; Internal medicine; Insulin; Endocrinology","score_opus":0.17725695700058516,"score_gpt":0.40807014869875863,"score_spread":0.23081319169817346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834728951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712384,0.00095784105,0.000022275348,0.0005365396,0.00015366188,0.00081538555,0.00000451086,0.0000070167157,0.0003789094],"genre_scores_gemma":[0.9977046,0.00012979894,0.0014086692,0.00052298134,0.000032768156,0.000029093579,0.000009544615,0.000014576301,0.00014795487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890846,0.00008325775,0.00041289447,0.00015573142,0.00023348365,0.0002061449],"domain_scores_gemma":[0.9987301,0.000599739,0.00012241375,0.00030349338,0.00013798982,0.00010626957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005212437,0.00011218852,0.0004101658,0.000033492255,0.00001467984,0.0000037969487,0.00008442395,0.000026528323,0.0000101085],"category_scores_gemma":[0.00014995754,0.00006387516,0.00004793268,0.00022696998,0.000040500163,0.000015179923,0.00003653166,0.00006579527,0.0000023968728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030466513,0.0003199542,0.90080833,0.00002650368,0.00038164688,0.0000026953476,0.0004599597,0.0015347194,0.000121739715,0.000016886217,0.000049710183,0.09597321],"study_design_scores_gemma":[0.014174241,0.02056643,0.87120235,0.00046669794,0.0015643121,9.588438e-7,0.0025454117,0.06168917,0.007114389,0.000106528154,0.020205138,0.00036438304],"about_ca_topic_score_codex":0.04896872,"about_ca_topic_score_gemma":0.21609654,"teacher_disagreement_score":0.16712782,"about_ca_system_score_codex":0.00029913065,"about_ca_system_score_gemma":0.00071803294,"threshold_uncertainty_score":0.95736426},"labels":[],"label_agreement":null},{"id":"W1852447234","doi":"10.1016/j.clinthera.2015.09.005","title":"Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Pfizer","keywords":"Medicine; Edoxaban; Apixaban; Atrial fibrillation; Stroke (engine); Internal medicine; Cardiology; Dabigatran; Rivaroxaban; Warfarin","score_opus":0.45136527407979105,"score_gpt":0.5043384124887784,"score_spread":0.052973138408987375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1852447234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698255,0.00023496686,0.025798626,0.00031218602,0.0004770983,0.0030189608,0.000011354937,0.000039003833,0.0002823129],"genre_scores_gemma":[0.9954567,0.000052178755,0.003132752,0.000042262083,0.0009049612,0.0000047317853,0.00009553431,0.000021883518,0.00028898063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984708,0.00028116553,0.00063271023,0.00021448788,0.00025024495,0.0001505989],"domain_scores_gemma":[0.9982061,0.0010216951,0.00024673538,0.00021911999,0.00022156954,0.000084805586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017947301,0.00012282426,0.00055906794,0.000093064096,0.000020915122,0.000011019903,0.00005711,0.00013040335,0.0000065897157],"category_scores_gemma":[0.00024604055,0.0000970182,0.00031268012,0.00018423641,0.00008323949,0.00007790885,0.000022110724,0.00009728557,0.0000035130743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0125408685,0.000034326986,0.9623342,0.00012406203,0.00034464823,0.000001228309,0.00007608079,0.0026111708,0.000158796,0.0006006503,0.000015500545,0.021158462],"study_design_scores_gemma":[0.050207276,0.0054216436,0.87331223,0.00039777404,0.0011463767,0.0000034082566,0.000317951,0.024583193,0.0009774454,0.0023595532,0.040930633,0.00034253686],"about_ca_topic_score_codex":0.000004986824,"about_ca_topic_score_gemma":0.000008718066,"teacher_disagreement_score":0.089021996,"about_ca_system_score_codex":0.000058567766,"about_ca_system_score_gemma":0.00012987581,"threshold_uncertainty_score":0.39562875},"labels":[],"label_agreement":null},{"id":"W1860761366","doi":"10.1016/j.clinthera.2015.08.016","title":"Adherence to Guidelines and the Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions Criteria for Colchicine Dosing for Gout Treatment in Beneficiaries of the Nova Scotia Seniors’ Pharmacare Program","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Capital District Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Colchicine; Gout; Dosing; Medical prescription; Population; Retrospective cohort study; Internal medicine; Logistic regression; Pharmacology; Environmental health","score_opus":0.32673742593127697,"score_gpt":0.4798560805670381,"score_spread":0.15311865463576113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1860761366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739797,0.0013387784,0.011449843,0.006105382,0.0005508277,0.0063987337,0.00011964923,0.000030682448,0.000026388094],"genre_scores_gemma":[0.9283852,0.000084004416,0.0697028,0.001160835,0.00027616607,0.00019403899,0.00001662377,0.000034841934,0.00014547905],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978515,0.00017152472,0.0011336386,0.00031882225,0.00025545675,0.0002690574],"domain_scores_gemma":[0.9977232,0.00066066696,0.0003312853,0.00044381694,0.00074579864,0.000095223164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014462844,0.00021700442,0.0006875614,0.000055251126,0.00007853514,0.00003137796,0.00021106072,0.00015343828,0.0000053590584],"category_scores_gemma":[0.0010824697,0.00011832159,0.00027078186,0.00024857293,0.00036368665,0.00005445205,0.0001026919,0.00017763316,3.6588213e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024596184,0.003935924,0.21450768,0.00093267945,0.0028739553,0.000005459153,0.02480895,0.0008984937,0.02140264,0.0011482692,0.001394045,0.70349574],"study_design_scores_gemma":[0.24625735,0.04114564,0.20778817,0.007427368,0.023889484,0.00019267997,0.0375865,0.3130066,0.038832836,0.0037291937,0.07766544,0.002478711],"about_ca_topic_score_codex":0.00021490014,"about_ca_topic_score_gemma":0.00014643028,"teacher_disagreement_score":0.701017,"about_ca_system_score_codex":0.000041656538,"about_ca_system_score_gemma":0.0002623387,"threshold_uncertainty_score":0.48250145},"labels":[],"label_agreement":null},{"id":"W1964964540","doi":"10.1016/s0149-2918(03)80302-8","title":"The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults","year":2003,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"","keywords":"Medicine; Budesonide; Asthma; Intensive care medicine; Dosing; Disease; Disease management; Indirect costs; Intervention (counseling); Corticosteroid; Pediatrics; Physical therapy; Internal medicine; Psychiatry","score_opus":0.0739177559814197,"score_gpt":0.42922756041279553,"score_spread":0.35530980443137583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964964540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16435833,0.83422065,0.0000016545013,0.000022925737,0.00002628265,0.0012364367,0.000024947885,0.0000035867474,0.00010519328],"genre_scores_gemma":[0.03184132,0.967751,0.000032258205,0.00024632207,0.00003774574,0.000029787492,0.0000048957454,0.00003155646,0.000025115223],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997449,0.0006710929,0.0012057599,0.0002688713,0.000198853,0.00020644313],"domain_scores_gemma":[0.9981913,0.00075400906,0.000468936,0.00049103535,0.000032020816,0.00006268773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001025032,0.00028112496,0.0012521554,0.00007645232,0.000030939576,0.000015999982,0.000203594,0.00022298313,0.000008778177],"category_scores_gemma":[0.000028617484,0.00012024654,0.00039544352,0.00023062377,0.0005468895,0.000016029728,0.00005542451,0.00041734206,9.864533e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016701047,0.0003885727,0.052628133,0.0012165499,0.00068700773,0.000013407092,0.00012612913,1.6002707e-7,1.0185259e-7,0.000047752343,0.0000049142604,0.94472027],"study_design_scores_gemma":[0.0051635015,0.0022639884,0.68137467,0.017423289,0.0015699058,0.00016319293,0.0005912029,0.000014497381,3.7320734e-7,0.00015435118,0.29090884,0.00037218156],"about_ca_topic_score_codex":0.00001237792,"about_ca_topic_score_gemma":0.000007847711,"teacher_disagreement_score":0.9443481,"about_ca_system_score_codex":0.000022232942,"about_ca_system_score_gemma":0.00010468012,"threshold_uncertainty_score":0.49035117},"labels":[],"label_agreement":null},{"id":"W1973228727","doi":"10.1016/j.clinthera.2012.01.023","title":"The Influence of Sparse Data Sampling on Population Pharmacokinetics: A Post Hoc Analysis of a Pharmacokinetic Study of Morphine in Healthy Volunteers","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Statistical Methods and Bayesian Inference","field":"Mathematics","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital; University of Manitoba","funders":"","keywords":"Medicine; Population; Pharmacokinetics; NONMEM; Sampling (signal processing); Post-hoc analysis; Statistics; Internal medicine; Mathematics; Computer science","score_opus":0.3908157888608869,"score_gpt":0.552516115098791,"score_spread":0.16170032623790404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973228727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849681,0.0001963458,0.013928762,0.000103417144,0.0001466092,0.0004907929,0.00014052073,0.000014187657,0.000011248752],"genre_scores_gemma":[0.96243554,0.00039748175,0.036875255,0.00019448585,0.00005148467,0.000007653151,0.000013576389,0.000023123921,0.00000137219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622416,0.0008098617,0.0019556193,0.000278814,0.00044184242,0.00028972622],"domain_scores_gemma":[0.9875669,0.010307244,0.0008062503,0.0009856119,0.00023609189,0.00009789756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036071634,0.00017568366,0.00083410554,0.00019668859,0.000035608966,0.0000081690605,0.00063730916,0.00008589896,0.000020591438],"category_scores_gemma":[0.0022051702,0.00012311593,0.00011954597,0.00095272064,0.00021481594,0.00007439818,0.00017228014,0.00034141226,6.606948e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050308937,0.010589343,0.78079957,0.0003152478,0.0031136745,0.0000021539788,0.002331797,0.0027658404,0.001759468,0.017478582,0.0000167888,0.17579661],"study_design_scores_gemma":[0.002522626,0.0026765538,0.92996144,0.000115769675,0.0032284956,5.560881e-7,0.00056396873,0.05024168,0.00007695755,0.010309646,0.00008352078,0.00021876939],"about_ca_topic_score_codex":0.00015311345,"about_ca_topic_score_gemma":0.00008099217,"teacher_disagreement_score":0.17557785,"about_ca_system_score_codex":0.000021835824,"about_ca_system_score_gemma":0.000034893375,"threshold_uncertainty_score":0.5020522},"labels":[],"label_agreement":null},{"id":"W1973246342","doi":"10.1016/j.clinthera.2007.12.020","title":"Efficacy of oral nicorandil in patients with end-stage renal disease: A retrospective chart review after coronary angioplasty in japanese patients receiving hemodialysis","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Conventional PCI; Nicorandil; Hemodialysis; Angina; Percutaneous coronary intervention; End stage renal disease; Internal medicine; Canadian Cardiovascular Society; Angioplasty; Coronary artery disease; Retrospective cohort study; Cardiology; Myocardial infarction","score_opus":0.02225726843849323,"score_gpt":0.32659062749628703,"score_spread":0.3043333590577938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973246342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672616,0.0018141303,0.0000067851365,0.000111124406,0.0001572753,0.0009655516,0.000029517609,0.000017582015,0.00017188356],"genre_scores_gemma":[0.9965347,0.0020845945,0.0001347165,0.0008812259,0.00006731281,0.000015455385,0.00013900358,0.000034140765,0.00010883049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974018,0.00017312072,0.0010683145,0.0004504673,0.00056599587,0.00034034075],"domain_scores_gemma":[0.9984864,0.00036084524,0.0002729118,0.00048086542,0.00018584967,0.00021312079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011543897,0.00023524997,0.0009593546,0.00012935323,0.000022882898,0.0000049728533,0.00009017316,0.00018112343,0.00009830355],"category_scores_gemma":[0.00032389106,0.00016707658,0.00036933442,0.0005589514,0.00020152831,0.00006787595,0.00007289698,0.0004959928,0.000005985161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011408949,0.0022409982,0.967354,0.00016794451,0.00011893586,0.00005144677,0.0002123145,0.0000011895082,0.000028735889,6.4301616e-7,0.000019841575,0.018395],"study_design_scores_gemma":[0.01118372,0.00079772825,0.98448217,0.0023290126,0.0003698265,8.080877e-7,0.000019591445,0.0000146245475,0.000051716394,0.0000023993996,0.00055902574,0.00018935473],"about_ca_topic_score_codex":0.00001106369,"about_ca_topic_score_gemma":0.000027192833,"teacher_disagreement_score":0.018205645,"about_ca_system_score_codex":0.00015939148,"about_ca_system_score_gemma":0.0000971173,"threshold_uncertainty_score":0.6813185},"labels":[],"label_agreement":null},{"id":"W1973950693","doi":"10.1016/s0149-2918(01)80065-5","title":"Consensus statement on the modern therapy of paget's disease of bone from a western osteoporosis alliance symposium","year":2001,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Bone health and treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; University of British Columbia","funders":"","keywords":"Medicine; Osteoporosis; Guideline; Calcitonin; Bisphosphonate; Etidronic acid; Dosing; Internal medicine; Bone disease; Intensive care medicine; Pathology","score_opus":0.3307660876622017,"score_gpt":0.4804914865254082,"score_spread":0.14972539886320646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973950693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006408507,0.98734474,0.000011614623,0.0024452582,0.0003468357,0.002562462,0.0007013484,0.000029753895,0.00014945518],"genre_scores_gemma":[0.0024750347,0.9932508,0.00015288671,0.0028311356,0.00013976534,0.00012698806,0.00020789503,0.0000942803,0.00072125177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951321,0.000695159,0.0026798092,0.0005678843,0.000547993,0.00037708998],"domain_scores_gemma":[0.9934439,0.0029434077,0.0016378862,0.0014284678,0.00016505632,0.0003812632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069336424,0.00052721857,0.0029914635,0.000048962618,0.00005343968,0.000010526983,0.00024022209,0.0003898292,0.00006563866],"category_scores_gemma":[0.00007304464,0.00029110085,0.0011173262,0.00019947208,0.00040337135,0.000012157636,0.000053280204,0.00065295555,0.000038412247],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014644657,0.002964454,0.0044332375,0.0027921917,0.0022217836,0.00008894226,0.00010744519,9.4783235e-7,0.000001231872,0.000020619385,0.00019832756,0.9857063],"study_design_scores_gemma":[0.003718948,0.001909011,0.0013622284,0.013256061,0.003482073,0.0000056723825,0.000015584626,0.000046037687,0.0000060304324,0.000546637,0.97535795,0.0002937743],"about_ca_topic_score_codex":0.000056646586,"about_ca_topic_score_gemma":0.000009117574,"teacher_disagreement_score":0.9854126,"about_ca_system_score_codex":0.00008627396,"about_ca_system_score_gemma":0.0007964813,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W1974743586","doi":"10.1016/j.clinthera.2012.01.006","title":"Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; University of British Columbia; Michael Smith Health Research BC","keywords":"Medicine; Discontinuation; Glatiramer acetate; Proportional hazards model; Persistence (discontinuity); Internal medicine; Population; Retrospective cohort study; Hazard ratio; Multivariate analysis; Pediatrics; Disease; Confidence interval","score_opus":0.3217392063662144,"score_gpt":0.42552677791022836,"score_spread":0.10378757154401397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974743586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911591,0.0023387326,0.00076434197,0.001314379,0.00029131144,0.0038574054,0.00005858802,0.00008501338,0.00013115766],"genre_scores_gemma":[0.99528277,0.0008344325,0.0009422828,0.0013935936,0.0007396151,0.00047194396,0.000019155079,0.00006236527,0.00025384407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972274,0.00032636483,0.0005420211,0.0005039174,0.0006796937,0.0007206444],"domain_scores_gemma":[0.99577856,0.0020862839,0.0001972449,0.0011972075,0.00046802862,0.00027269367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026157848,0.00029384228,0.00062557065,0.000052929066,0.00045837773,0.000046937064,0.0003773949,0.000106551044,0.00002872247],"category_scores_gemma":[0.0006982811,0.00016437615,0.00030418017,0.00025391718,0.00083732186,0.00017991451,0.00023684844,0.00069520646,0.000027310141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019574794,0.0030059936,0.97251135,0.000053652027,0.0014909557,0.0000022247655,0.0035768268,7.079425e-7,0.0010665435,0.0000134731545,0.00024309216,0.016077673],"study_design_scores_gemma":[0.006994021,0.002396695,0.9826338,0.00013936088,0.0005934532,0.0000037354462,0.0055557755,0.00025118774,0.00019226385,0.0000020375185,0.0010224045,0.00021526229],"about_ca_topic_score_codex":0.000009757166,"about_ca_topic_score_gemma":0.000030805142,"teacher_disagreement_score":0.01586241,"about_ca_system_score_codex":0.00014899771,"about_ca_system_score_gemma":0.000113440736,"threshold_uncertainty_score":0.6703065},"labels":[],"label_agreement":null},{"id":"W1975576130","doi":"10.1016/j.clinthera.2011.01.004","title":"Systematic Review and Meta-Analysis of the Efficacy and Tolerability of Nicotine Preparations in Active Ulcerative Colitis","year":2010,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Nicotinic Acetylcholine Receptors Study","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Calgary","keywords":"Tolerability; Medicine; Adverse effect; Placebo; Internal medicine; Meta-analysis; Clinical trial; Nicotine; Ulcerative colitis; Randomized controlled trial; Gastroenterology; Alternative medicine; Pathology","score_opus":0.13568506834466496,"score_gpt":0.45767074422543125,"score_spread":0.3219856758807663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975576130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009958417,0.9952626,0.000016473628,0.00008006302,0.000047419977,0.0032488815,0.0002911647,0.000002525003,0.000055000237],"genre_scores_gemma":[0.0021576574,0.9971299,0.000112998925,0.00020309296,0.000022957021,0.00016773344,0.000053200758,0.00002127567,0.00013117393],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99447906,0.0022134853,0.0024653815,0.0005391372,0.00015879948,0.00014414449],"domain_scores_gemma":[0.99551445,0.0013576653,0.0017119746,0.001139844,0.0002186522,0.00005741914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018890223,0.0003370149,0.006439011,0.0000562983,0.000036024743,0.000008521096,0.00036695832,0.00048288226,0.000020892501],"category_scores_gemma":[0.0014696891,0.00019075401,0.0017748249,0.0004914185,0.0005173043,0.0000030537922,0.00029321836,0.0005259496,3.7222807e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011027638,0.0021115951,0.00023091468,0.4783764,0.4940172,1.333403e-7,0.00027806312,0.00000385662,0.000025110729,0.0002453337,0.00005012298,0.02455097],"study_design_scores_gemma":[0.0003528689,0.00026299467,0.00022537327,0.0054122964,0.970844,0.00000410058,0.00001985485,0.000009737725,0.000064329935,0.000013465765,0.0225083,0.00028272875],"about_ca_topic_score_codex":0.0000053280473,"about_ca_topic_score_gemma":0.00016143061,"teacher_disagreement_score":0.47682673,"about_ca_system_score_codex":0.0000119004435,"about_ca_system_score_gemma":0.00019556117,"threshold_uncertainty_score":0.7778723},"labels":[],"label_agreement":null},{"id":"W1976350400","doi":"10.1016/s0149-2918(00)89027-x","title":"Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus","year":2000,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Sirolimus; Medicine; Pharmacokinetics; Therapeutic drug monitoring; Pharmacology; Dosing; Tacrolimus; Ciclosporin; Immunosuppressive drug; Immunosuppression; Urology; Transplantation; Internal medicine","score_opus":0.28015744838777035,"score_gpt":0.5272234146458807,"score_spread":0.2470659662581104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976350400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013046926,0.99618363,0.000017637713,0.000051450475,0.00087292364,0.00086159754,0.00005854045,0.00005198623,0.00059752207],"genre_scores_gemma":[0.0011723723,0.99548894,0.0011307066,0.00037991445,0.0007696665,0.000019692307,0.000050018127,0.000103872866,0.0008848361],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551445,0.0005357408,0.0027106926,0.0005744509,0.00034795373,0.00031669173],"domain_scores_gemma":[0.9959232,0.0024653797,0.00065597444,0.0005693485,0.00008495104,0.00030109932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007203375,0.0005278316,0.0033716054,0.00011905442,0.000049863902,0.000019884761,0.0002126568,0.00058156584,0.00008074031],"category_scores_gemma":[0.000021768768,0.00035866187,0.0014809443,0.00022193915,0.0003913392,0.000022808896,0.000035075856,0.00106129,0.000042889973],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014460375,0.0006197192,0.026687218,0.007370049,0.0027029926,0.000053570846,0.000028107335,2.4470947e-7,1.255313e-7,0.000015132536,0.0000050797667,0.96237314],"study_design_scores_gemma":[0.003174498,0.00061111664,0.005411702,0.012396681,0.015873037,0.00010439532,0.000009683717,0.000018148407,0.000002958553,0.00007169863,0.9619898,0.0003362588],"about_ca_topic_score_codex":0.0000017544762,"about_ca_topic_score_gemma":1.0185619e-7,"teacher_disagreement_score":0.9620369,"about_ca_system_score_codex":0.000026289106,"about_ca_system_score_gemma":0.0002218803,"threshold_uncertainty_score":0.9998865},"labels":[],"label_agreement":null},{"id":"W1977640666","doi":"10.1016/s0149-2918(00)87985-0","title":"Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Tobramycin; Cystic fibrosis; Placebo; Sputum; Clinical trial; Pseudomonas aeruginosa; Internal medicine; Emergency medicine; Intensive care medicine; Pathology","score_opus":0.08411197237564179,"score_gpt":0.38121898888889144,"score_spread":0.29710701651324967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977640666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966771,0.00019656762,0.0008359789,0.0011735234,0.00005986379,0.00093531335,0.00006354238,0.000015740061,0.000042365373],"genre_scores_gemma":[0.9927114,0.00023257987,0.005906542,0.00083866983,0.00007593632,0.000035396857,0.00012281058,0.000021967444,0.000054671444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791217,0.0002642815,0.0007365668,0.000240247,0.00058645976,0.000260299],"domain_scores_gemma":[0.99246925,0.0068742614,0.00011306936,0.00031286676,0.00012524758,0.00010531193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075278,0.00012210665,0.00040512852,0.000052921594,0.000030777584,0.000015533136,0.00013731235,0.0001764779,0.00015372594],"category_scores_gemma":[0.0023599993,0.000076525655,0.000082480416,0.0003005638,0.00029136235,0.00011390751,0.000027522816,0.00034850708,0.0000058357377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005413755,0.00065041985,0.6898443,0.0000208039,0.00004486446,0.000001596714,0.000106071064,0.00005656059,0.00008543736,0.000009366952,0.00010208398,0.30366474],"study_design_scores_gemma":[0.0054951264,0.0013179565,0.9726464,0.0006377459,0.000054272117,3.9535945e-7,0.000014582653,0.01338204,0.00006613079,0.00011607774,0.0061796783,0.00008960583],"about_ca_topic_score_codex":0.00022885736,"about_ca_topic_score_gemma":0.00040409414,"teacher_disagreement_score":0.30357513,"about_ca_system_score_codex":0.00011250727,"about_ca_system_score_gemma":0.00014286349,"threshold_uncertainty_score":0.31206256},"labels":[],"label_agreement":null},{"id":"W1978578638","doi":"10.1016/j.clinthera.2010.09.014","title":"Challenges and opportunities in establishing scientific and regulatory standards for determining therapeutic equivalence of modified-release products: Workshop summary report","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Drug Solubulity and Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Bioequivalence; Medicine; Regulatory science; Equivalence (formal languages); Food and drug administration; Pharmacology; Medical physics; Risk analysis (engineering); Drug; Immediate release; Pharmacokinetics; Management science; Mathematics; Engineering","score_opus":0.5046181438480937,"score_gpt":0.506426698833964,"score_spread":0.001808554985870292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978578638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702442,0.02268438,0.00017488466,0.0015453923,0.0034024513,0.0007048615,0.000087324326,0.000056897385,0.0010995882],"genre_scores_gemma":[0.98837894,0.009471953,0.00037873612,0.0007020311,0.00028087513,0.00004374444,0.000014971841,0.000031606694,0.0006971613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682194,0.00058843,0.0011640709,0.000690137,0.0002966397,0.00043876856],"domain_scores_gemma":[0.9950586,0.0032766247,0.0004553864,0.00054444995,0.00044418804,0.00022076572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011621045,0.00024966203,0.00058713846,0.00015569663,0.00023881815,0.00008543334,0.0002920433,0.0005729562,0.000011402543],"category_scores_gemma":[0.0009725439,0.00023569557,0.00009443584,0.00012221352,0.0018316857,0.00033351866,0.0001531425,0.0010412587,3.723771e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009295836,0.00062847586,0.015175124,0.0009884946,0.0002766129,0.00011009714,0.0036847778,0.000056990535,0.0067584664,0.0086012175,0.00024541456,0.96254474],"study_design_scores_gemma":[0.0128387185,0.0016990653,0.049922306,0.0013157019,0.0013926004,0.00058008166,0.0102754785,0.052838907,0.009078671,0.02709596,0.8304436,0.0025188837],"about_ca_topic_score_codex":0.0000029719765,"about_ca_topic_score_gemma":0.000053297746,"teacher_disagreement_score":0.96002585,"about_ca_system_score_codex":0.000025236923,"about_ca_system_score_gemma":0.00044223454,"threshold_uncertainty_score":0.9611386},"labels":[],"label_agreement":null},{"id":"W1978654244","doi":"10.1016/s0149-2918(02)80072-8","title":"Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Novartis","keywords":"Medicine; Nateglinide; Metformin; Glycemic; Population; Type 2 Diabetes Mellitus; Internal medicine; Diabetes mellitus; Type 2 diabetes; Cohort; Endocrinology; Environmental health","score_opus":0.05894874644330557,"score_gpt":0.3410450214186669,"score_spread":0.2820962749753613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978654244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931759,0.0047477633,0.00011335778,0.0007497776,0.00009879154,0.0010025477,0.000039851468,0.000009798481,0.00006218076],"genre_scores_gemma":[0.9943411,0.0024087445,0.0017393443,0.0014236282,0.000023402008,0.000010210276,0.0000052814357,0.000017300506,0.00003104305],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99852914,0.00009508016,0.0007965935,0.00023473617,0.00010450652,0.00023992301],"domain_scores_gemma":[0.99852216,0.00082721806,0.0001964293,0.00019516567,0.00004726387,0.00021177401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005523346,0.00015268412,0.0009383655,0.00014414509,0.000013542506,0.0000049814407,0.000056859888,0.000096320044,0.0000064907395],"category_scores_gemma":[0.00015012958,0.0001281622,0.00007782458,0.0001250601,0.00008601565,0.000038221388,0.000058346137,0.000105663006,0.0000026793236],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00913833,0.0026943935,0.096878976,0.0015545773,0.0024188785,0.000014172113,0.0029637276,0.001062052,0.011308568,0.0016211979,0.00007798954,0.87026715],"study_design_scores_gemma":[0.1255221,0.17316534,0.11821752,0.0047287582,0.003925931,0.0000075130297,0.00059587794,0.49767137,0.06646023,0.004624644,0.0033089384,0.0017717851],"about_ca_topic_score_codex":0.0000147997025,"about_ca_topic_score_gemma":0.000012539479,"teacher_disagreement_score":0.86849535,"about_ca_system_score_codex":0.000043307333,"about_ca_system_score_gemma":0.000050827624,"threshold_uncertainty_score":0.5226303},"labels":[],"label_agreement":null},{"id":"W1978827950","doi":"10.1016/j.clinthera.2011.11.025","title":"Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001–2006)","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pregnancy and Medication Impact","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Ministry of Health, British Columbia; Michael Smith Health Research BC","keywords":"Medicine; Medical prescription; Pregnancy; Population; Retrospective cohort study; Prescription drug; Family medicine; Obstetrics; Pediatrics; Environmental health; Internal medicine; Pharmacology","score_opus":0.11587946985230382,"score_gpt":0.3510047166709081,"score_spread":0.23512524681860428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978827950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721724,0.0003887456,0.00003917309,0.00014438418,0.0005458763,0.0013411884,0.00003504786,0.000045691362,0.00024266608],"genre_scores_gemma":[0.9960844,0.00015432284,0.000342886,0.001734418,0.000051608233,0.00007447083,0.000035473557,0.000027357843,0.0014950533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976366,0.00033255323,0.00091025064,0.0004041723,0.00036492542,0.0003515055],"domain_scores_gemma":[0.99876726,0.00025081518,0.00018531637,0.00047320148,0.00011274124,0.00021069434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006952496,0.000116292314,0.0004540817,0.000058966794,0.000046472353,0.000039648377,0.00013484355,0.00015438572,0.00013264774],"category_scores_gemma":[0.00082026445,0.00016022498,0.00007395776,0.0003823961,0.00005741941,0.00013620913,0.000020918445,0.00056577916,0.0000048570423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086052,0.0020667408,0.989945,0.000022255655,0.000040375548,0.00013495311,0.0002019416,0.0000020292423,0.0000025712359,0.0000028218662,0.00035489816,0.007140368],"study_design_scores_gemma":[0.004415588,0.00036190732,0.99309754,0.00092302274,0.00007189488,0.0000033027704,0.00016335899,0.0003511696,0.0000033228514,0.00016441854,0.00028924877,0.00015521873],"about_ca_topic_score_codex":0.91038936,"about_ca_topic_score_gemma":0.99534255,"teacher_disagreement_score":0.084953204,"about_ca_system_score_codex":0.0004138596,"about_ca_system_score_gemma":0.0009615564,"threshold_uncertainty_score":0.65337855},"labels":[],"label_agreement":null},{"id":"W1979161247","doi":"10.1016/j.clinthera.2007.08.018","title":"Interaction Between Warfarin and Cranberry Juice","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; CRANBERRY JUICE; Warfarin; Fruit juice; Pharmacology; Food science; Internal medicine; Atrial fibrillation","score_opus":0.3723215522173493,"score_gpt":0.5175486288675837,"score_spread":0.14522707665023438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979161247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792089,0.00018538123,0.0058055506,0.004945222,0.0006084155,0.00024159653,8.018617e-7,0.00008768992,0.008916443],"genre_scores_gemma":[0.99217707,0.00029241823,0.0014399212,0.0020803795,0.0018323205,1.7380242e-7,0.000007959448,0.000013480379,0.0021562881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990849,0.000036127676,0.00046039754,0.00015830129,0.000124481,0.00013580087],"domain_scores_gemma":[0.9987127,0.0009048134,0.00009130224,0.00015303979,0.000041254043,0.000096847514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091283384,0.000082579696,0.00024304043,0.000051750703,0.000044045413,0.00001543661,0.00003567833,0.00012164858,0.000054498156],"category_scores_gemma":[0.0001028101,0.000066544715,0.000111078996,0.00009531391,0.0000739848,0.000056436576,0.000038039077,0.0002047423,0.00004817024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018260781,0.000008529721,0.7643559,0.000011158533,0.0001186464,0.000003270162,0.00003581042,2.8802663e-7,0.00007050725,0.00034088333,0.00007261456,0.23479979],"study_design_scores_gemma":[0.00095627847,0.00016194017,0.732961,0.000013543888,0.00021051137,0.000002405443,0.00007587039,0.00008247747,0.00010941904,0.0003771732,0.26498386,0.00006554847],"about_ca_topic_score_codex":0.000002925315,"about_ca_topic_score_gemma":0.0000021988596,"teacher_disagreement_score":0.26491123,"about_ca_system_score_codex":0.000015290227,"about_ca_system_score_gemma":0.000010454478,"threshold_uncertainty_score":0.27136147},"labels":[],"label_agreement":null},{"id":"W1980121322","doi":"10.1016/j.clinthera.2013.05.020","title":"Insulin Pen Needles: Effects of Extra-Thin Wall Needle Technology on Preference, Confidence, and Other Patient Ratings","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Health Canada; Sanofi","keywords":"Medicine; Preference; Confidence interval; Internal medicine; Statistics","score_opus":0.09022198490551633,"score_gpt":0.36157302333624547,"score_spread":0.27135103843072916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980121322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859235,0.0007414833,0.00007478982,0.0014668019,0.00014783324,0.0012999958,0.0000012856964,0.00006256271,0.0102817],"genre_scores_gemma":[0.99233913,0.00040357138,0.0007246159,0.0045085144,0.00005389266,0.000056172117,0.0000023703476,0.00002578271,0.0018859396],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99847883,0.000115823095,0.00055056054,0.00028716715,0.00028240558,0.00028520523],"domain_scores_gemma":[0.9983089,0.00085228577,0.00016301741,0.0004065906,0.00014858514,0.000120638884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038067263,0.00015837279,0.0004406673,0.00018457862,0.000040494026,0.000027061242,0.00018126889,0.00026714892,0.00015693886],"category_scores_gemma":[0.00032152125,0.000109400346,0.00008542136,0.00026261524,0.0005121923,0.00004507981,0.00011613226,0.0004838236,0.00010694939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003564944,0.001979309,0.16169557,0.0006568988,0.0005817833,0.000011615933,0.0010660539,0.0000031712682,0.004449291,0.0077786422,0.0015659421,0.8198552],"study_design_scores_gemma":[0.034977775,0.07245003,0.42975572,0.0063322554,0.0015770306,0.000012834607,0.005955838,0.027164532,0.05265503,0.08826888,0.27854776,0.002302309],"about_ca_topic_score_codex":0.000011984428,"about_ca_topic_score_gemma":6.819818e-7,"teacher_disagreement_score":0.8175529,"about_ca_system_score_codex":0.0000115147595,"about_ca_system_score_gemma":0.00004073318,"threshold_uncertainty_score":0.44612166},"labels":[],"label_agreement":null},{"id":"W1980352630","doi":"10.1016/j.clinthera.2014.06.011","title":"Risk of Vascular Disease in Premenopausal Women With Diabetes Mellitus","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cardiac Imaging and Diagnostics","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Framingham Risk Score; Diabetes mellitus; Body mass index; Internal medicine; Stroke (engine); Blood pressure; Framingham Heart Study; Incidence (geometry); Disease; Endocrinology","score_opus":0.026534903253107485,"score_gpt":0.3250838365150239,"score_spread":0.29854893326191645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980352630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664694,0.0016147004,0.00063943624,0.00025154295,0.00014073697,0.0002179362,0.000011574392,0.000035506357,0.00044161238],"genre_scores_gemma":[0.99697155,0.0008391501,0.00081664626,0.0011001907,0.00019274573,0.00001667684,0.0000069160665,0.0000264378,0.000029674107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985337,0.0002480672,0.0004518873,0.00023372275,0.00025410648,0.00027848664],"domain_scores_gemma":[0.99762493,0.0013835073,0.00012258672,0.00052213273,0.00009977922,0.00024706908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012155209,0.00012997592,0.0005010883,0.000049369515,0.000019593543,0.000008945015,0.00007858714,0.00007360695,0.000016647056],"category_scores_gemma":[0.0008938002,0.00009482517,0.00010949615,0.00014852517,0.00025195425,0.000023632509,0.00002957011,0.00029879916,0.000011663267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037287522,0.0005129814,0.9745469,0.000063725005,0.0002602179,0.0000051529687,0.00010049767,0.000111052796,0.000031319745,0.00007853875,0.000021332988,0.023895392],"study_design_scores_gemma":[0.0028986237,0.001040167,0.98334306,0.00013536365,0.00056645373,2.376385e-7,0.000029129233,0.0014919152,0.00010107763,0.0010312151,0.009234084,0.00012865497],"about_ca_topic_score_codex":0.000005095719,"about_ca_topic_score_gemma":0.0000012046538,"teacher_disagreement_score":0.023766736,"about_ca_system_score_codex":0.000028897037,"about_ca_system_score_gemma":0.000092659604,"threshold_uncertainty_score":0.38668582},"labels":[],"label_agreement":null},{"id":"W1981145395","doi":"10.1016/j.clinthera.2014.01.008","title":"Economic Evaluation of Primary Prevention of Cardiovascular Diseases in Mild Hypertension: A Scenario Analysis for the Netherlands","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University College Cork","keywords":"Medicine; Losartan; Blood pressure; Hydrochlorothiazide; Internal medicine; Cardiology; Demography; Angiotensin II","score_opus":0.2286197789186631,"score_gpt":0.39840468482273705,"score_spread":0.16978490590407394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981145395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91549844,0.0779135,0.003599638,0.001289278,0.00028838124,0.0011304849,0.00001659124,0.000013924913,0.00024977355],"genre_scores_gemma":[0.9959781,0.0026010075,0.00032106394,0.000832001,0.00018229803,0.00002986909,0.000018768973,0.000009770759,0.00002712218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850583,0.00031545843,0.0006200946,0.00019280514,0.0002706706,0.000095134514],"domain_scores_gemma":[0.99776846,0.0012227371,0.00017334822,0.00049529347,0.0003090754,0.000031069067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028404125,0.000087613815,0.0009874621,0.0000746404,0.00003277592,0.0000031806037,0.00007797544,0.000097337506,0.000013605602],"category_scores_gemma":[0.00015888763,0.00005393952,0.00093745877,0.0001459825,0.00013149461,0.000019754596,0.000029394263,0.00009241222,8.415307e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001240105,0.001198444,0.5281348,0.00019201741,0.042652696,6.8647614e-7,0.00019925767,0.009894214,0.00010832169,0.00009659753,0.0005035971,0.41577923],"study_design_scores_gemma":[0.0045087873,0.00048212922,0.84538984,0.000071245595,0.07731727,0.0000011949035,0.000071944276,0.058678,0.00008218905,0.0005904715,0.0127242915,0.0000826251],"about_ca_topic_score_codex":0.000030347544,"about_ca_topic_score_gemma":0.000036618956,"teacher_disagreement_score":0.4156966,"about_ca_system_score_codex":0.00001166053,"about_ca_system_score_gemma":0.000105435145,"threshold_uncertainty_score":0.21995898},"labels":[],"label_agreement":null},{"id":"W1981398130","doi":"10.1016/s0149-2918(01)80012-6","title":"Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Centre for Addiction and Mental Health","funders":"","keywords":"Paroxetine; Sertraline; Fluoxetine; Fluvoxamine; Antidepressant; Medicine; Population; Defined daily dose; Psychiatry; Reuptake inhibitor; Drug; Pharmacology; Serotonin; Internal medicine; Environmental health","score_opus":0.3467348489353165,"score_gpt":0.5303455658047589,"score_spread":0.18361071686944241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981398130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519396,0.000203951,0.00085210154,0.00064943306,0.0005044629,0.002184769,0.000008397217,0.000009602058,0.00039333233],"genre_scores_gemma":[0.9974625,0.00003473305,0.0006790081,0.001421184,0.0001613155,0.00020103088,0.0000069710786,0.000016623195,0.00001661999],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986071,0.0003735367,0.00045550012,0.00019787853,0.00013513761,0.00023083798],"domain_scores_gemma":[0.9964732,0.002978739,0.00025139877,0.00022832351,0.000038256814,0.0000300927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074574084,0.00012565995,0.0002714677,0.000053983447,0.00012090173,0.0000093495,0.00020327848,0.0001213341,0.0000040742807],"category_scores_gemma":[0.000017179747,0.00007167362,0.00008762777,0.00015381204,0.00008163297,0.000030673153,0.000022160122,0.00018107827,0.0000011067472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0170745,0.009728232,0.08922588,0.0010071268,0.0011220892,0.000059819547,0.061067246,0.008982714,0.008250941,0.024517186,0.00088143174,0.77808285],"study_design_scores_gemma":[0.039021134,0.06274656,0.22907495,0.0076060146,0.0020580296,0.00013387042,0.015751546,0.27680868,0.23529509,0.12564401,0.003516329,0.002343777],"about_ca_topic_score_codex":0.000033195596,"about_ca_topic_score_gemma":0.000050207906,"teacher_disagreement_score":0.7757391,"about_ca_system_score_codex":0.000031582924,"about_ca_system_score_gemma":0.000009669014,"threshold_uncertainty_score":0.29227653},"labels":[],"label_agreement":null},{"id":"W1981972240","doi":"10.1016/j.clinthera.2007.09.001","title":"Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); Université de Montréal","funders":"","keywords":"Medicine; Verteporfin; Pegaptanib; Macular degeneration; Visual acuity; Quality-adjusted life year; Cost effectiveness; Ophthalmology; Choroidal neovascularization; Surgery; Bevacizumab; Chemotherapy","score_opus":0.07717141081480174,"score_gpt":0.39962613349727893,"score_spread":0.3224547226824772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981972240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965614,0.0010736253,0.00007214854,0.00009655835,0.00004577948,0.0020211758,0.00006440848,0.0000033367521,0.00006157048],"genre_scores_gemma":[0.9989261,0.00052580424,0.00016343054,0.00025532464,0.000008791502,0.00003964983,0.000063522544,0.000013840748,0.000003528824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986911,0.00020836742,0.00047475507,0.0002053515,0.00025266426,0.00016776145],"domain_scores_gemma":[0.9991112,0.00037535018,0.00008094853,0.0002250835,0.00009750204,0.00010992942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032469782,0.00014302721,0.00048512753,0.00005755971,0.0000186694,0.000005101149,0.000056730612,0.000054967568,0.0000043429523],"category_scores_gemma":[0.000011364286,0.000084908956,0.000060029215,0.00026393845,0.00005700973,0.000011292272,0.0000058558917,0.000074140546,2.2587811e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019750439,0.0010446442,0.9321141,0.000052397063,0.00026743408,0.0003530652,0.0014814736,0.0004435428,0.0018347559,0.00004118058,0.000001500895,0.04261542],"study_design_scores_gemma":[0.008968589,0.006648111,0.978013,0.00015927086,0.00013177637,0.000005611271,0.0010914326,0.00015161294,0.0042907484,0.000020373567,0.00042898513,0.0000904827],"about_ca_topic_score_codex":0.049207494,"about_ca_topic_score_gemma":0.39428553,"teacher_disagreement_score":0.34507805,"about_ca_system_score_codex":0.00044101803,"about_ca_system_score_gemma":0.0003829867,"threshold_uncertainty_score":0.95712394},"labels":[],"label_agreement":null},{"id":"W1982550015","doi":"10.1016/j.clinthera.2009.07.023","title":"Psychological interventions for reducing pain and distress during routine childhood immunizations: A systematic review","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Psychological intervention; Distress; Distraction; Randomized controlled trial; CINAHL; Physical therapy; PsycINFO; MEDLINE; Meta-analysis; Clinical psychology; Psychiatry; Internal medicine","score_opus":0.2241223208121907,"score_gpt":0.513148059693282,"score_spread":0.28902573888109134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982550015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000408215,0.9819334,0.008394652,0.00035619122,0.00009119426,0.008798837,0.0000389836,0.00029912184,0.00008355349],"genre_scores_gemma":[0.00003225759,0.9909038,0.005586777,0.0015659322,0.00031406188,0.00087589276,0.00034280258,0.00006860836,0.00030987218],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9940343,0.0016934893,0.003133187,0.00062537764,0.00020326239,0.00031036517],"domain_scores_gemma":[0.99525076,0.0021624896,0.0012201332,0.0011110747,0.00011766017,0.00013790764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005614686,0.00045221506,0.0041320645,0.00017345914,0.00012727108,0.000047617392,0.0003903922,0.00045544354,0.000012683644],"category_scores_gemma":[0.0046588746,0.00032602728,0.001837234,0.00044183712,0.00011778037,0.000039994644,0.00012917948,0.00074466463,0.0000056748904],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000043832433,0.0005701933,0.000013838995,0.7020611,0.0005005882,0.000005862275,0.000004930485,1.7474763e-8,1.1674426e-8,0.000040273902,0.00019977485,0.296599],"study_design_scores_gemma":[0.0005293723,0.0007404582,0.00020121921,0.9508938,0.021161452,0.00006747693,0.0000074344916,0.000021363332,1.1808161e-8,0.00017130953,0.025869463,0.00033660483],"about_ca_topic_score_codex":2.9524966e-7,"about_ca_topic_score_gemma":1.2917697e-7,"teacher_disagreement_score":0.2962624,"about_ca_system_score_codex":0.00008213231,"about_ca_system_score_gemma":0.00004085233,"threshold_uncertainty_score":0.9999192},"labels":[],"label_agreement":null},{"id":"W1983297225","doi":"10.1016/s0149-2918(02)85038-x","title":"Therapeutic drug monitoring of immunosuppressant drugs in clinical practice","year":2002,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Vancouver General Hospital; University Health Network; University of British Columbia","funders":"Novartis Pharmaceuticals Corporation","keywords":"Therapeutic drug monitoring; Medicine; Sirolimus; Tacrolimus; Everolimus; Dosing; Mycophenolate; Trough level; Pharmacology; Drug; Organ transplantation; Transplantation; Intensive care medicine; Internal medicine","score_opus":0.26763800362277324,"score_gpt":0.5240491652390866,"score_spread":0.2564111616163134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983297225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023431404,0.994994,0.000021508611,0.00014420583,0.0015550521,0.0012081836,0.000034063913,0.00004634418,0.0017623372],"genre_scores_gemma":[0.0010801981,0.99433845,0.0026161352,0.0003356875,0.00051171205,0.000047880283,0.000055863286,0.0001170622,0.0008970023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921556,0.0013932043,0.0047429735,0.00068408874,0.0005992469,0.00042487975],"domain_scores_gemma":[0.98877996,0.008325272,0.0014856546,0.0010131749,0.00019142745,0.0002044886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021105383,0.0005961691,0.0041756793,0.00020739766,0.000042568063,0.000026638183,0.00039215095,0.000820738,0.000074523756],"category_scores_gemma":[0.00024459924,0.00041492577,0.0021843978,0.00046017996,0.00029051237,0.00010460162,0.000059097074,0.0019219585,0.00012253855],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020592609,0.0023193273,0.018333701,0.0059458665,0.0029196427,0.00013410047,0.0001464595,2.959224e-7,7.887088e-8,0.00006867959,0.000009871892,0.96991605],"study_design_scores_gemma":[0.004017334,0.00063492276,0.0074571716,0.029354887,0.010640109,0.00012784018,0.00012489586,0.000016789538,0.0000021634714,0.000048067726,0.94714653,0.00042926832],"about_ca_topic_score_codex":0.000010951587,"about_ca_topic_score_gemma":3.4661525e-7,"teacher_disagreement_score":0.9694868,"about_ca_system_score_codex":0.00009723152,"about_ca_system_score_gemma":0.00030209526,"threshold_uncertainty_score":0.99983025},"labels":[],"label_agreement":null},{"id":"W1983560550","doi":"10.1016/j.clinthera.2006.09.020","title":"Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dosing; Kidney disease; Dialysis; Erythropoietin; Anemia; Internal medicine; Nephrology; Population; Retrospective cohort study; Intensive care medicine","score_opus":0.02617048378101648,"score_gpt":0.3224979688011131,"score_spread":0.2963274850200966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983560550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998119,0.00015295924,0.000036162237,0.0010212746,0.000063081636,0.00046213798,0.000042155374,0.000015980024,0.00008723311],"genre_scores_gemma":[0.9979467,0.0004637845,0.0001287065,0.0010942216,0.000045285044,0.000007838438,0.00021646416,0.000030360841,0.000066671615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871975,0.00010763795,0.00048418914,0.00028428898,0.00022109892,0.00018305215],"domain_scores_gemma":[0.9992262,0.00017112288,0.000109128385,0.00028470714,0.00008927973,0.00011955606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008619489,0.000156078,0.00035811862,0.00010003434,0.000037559497,0.000010696507,0.000053550848,0.00008628983,0.00006133465],"category_scores_gemma":[0.00007411164,0.00010883486,0.00005051157,0.0003332907,0.00015350139,0.000025318996,0.000030024696,0.00018643597,0.000003472533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066150946,0.0015016091,0.9891627,0.00010982697,0.000057434583,0.000041128238,0.0001443895,0.000048310638,0.000003904995,0.000028813445,0.000015372123,0.008225015],"study_design_scores_gemma":[0.0090629645,0.0009379711,0.9883272,0.000794528,0.00027037496,3.4227253e-7,0.00010340266,0.00016097902,0.00006752056,0.000011193648,0.00014560012,0.0001178945],"about_ca_topic_score_codex":0.00009294563,"about_ca_topic_score_gemma":0.00022082118,"teacher_disagreement_score":0.008401455,"about_ca_system_score_codex":0.00022508307,"about_ca_system_score_gemma":0.00014179513,"threshold_uncertainty_score":0.44381568},"labels":[],"label_agreement":null},{"id":"W1983686228","doi":"10.1016/s0149-2918(01)80047-3","title":"Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"American Thoracic Society","keywords":"Levofloxacin; Medicine; Streptococcus pneumoniae; Community-acquired pneumonia; Erythromycin; Pneumonia; Internal medicine; Broth microdilution; Clinical trial; Antimicrobial; Minimum inhibitory concentration; Antibiotics; Microbiology; Biology","score_opus":0.3516822832195693,"score_gpt":0.5214125733915022,"score_spread":0.16973029017193286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983686228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831002,0.0002095092,0.00278512,0.0018961979,0.001631594,0.0060376585,0.003985787,0.00018346001,0.00017049452],"genre_scores_gemma":[0.9920087,0.001295819,0.0003209391,0.004144285,0.00036249313,0.0003887349,0.0010562068,0.00013034053,0.00029247804],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97982466,0.011950889,0.0061140144,0.0009548249,0.0004530071,0.0007026215],"domain_scores_gemma":[0.960137,0.033368696,0.0020560094,0.0018649469,0.0019325481,0.0006407861],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.017609486,0.0006725029,0.0036774136,0.00015559715,0.00049531646,0.00012584623,0.0009605553,0.0010132489,0.00004053018],"category_scores_gemma":[0.016506834,0.00051878707,0.00094778166,0.00057011034,0.0008671943,0.00018823845,0.0002812038,0.001594239,0.000021424488],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107908644,0.026992027,0.013074948,0.00022829574,0.0040802252,0.00012435894,0.00022777708,0.0000062215786,0.7818334,0.000044024688,0.0014160696,0.06406402],"study_design_scores_gemma":[0.63882333,0.05450644,0.062229335,0.0042434493,0.007244567,0.000035140514,0.001606006,0.01117958,0.050532654,0.001242921,0.16613734,0.0022192579],"about_ca_topic_score_codex":0.00036658382,"about_ca_topic_score_gemma":0.00016963587,"teacher_disagreement_score":0.7313007,"about_ca_system_score_codex":0.00015366742,"about_ca_system_score_gemma":0.0005399131,"threshold_uncertainty_score":0.99972636},"labels":[],"label_agreement":null},{"id":"W1984862250","doi":"10.1016/j.clinthera.2009.08.003","title":"Long-term follow-up of the original interferon-β1b trial in multiple sclerosis: Design and lessons from a 16-year observational study","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Observational study; Multiple sclerosis; Placebo; Internal medicine; Clinical trial; Expanded Disability Status Scale; Physical therapy; Pediatrics; Immunology; Alternative medicine; Pathology","score_opus":0.6298683757513215,"score_gpt":0.48650142661736645,"score_spread":0.14336694913395504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984862250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390835,0.00035746806,0.00062887126,0.0024768258,0.0004094887,0.0021467183,0.000020988278,0.000024344894,0.000026920676],"genre_scores_gemma":[0.99671715,0.00090059784,0.001197957,0.00070403935,0.00030969008,0.000054773827,0.000008480071,0.000019452504,0.00008782467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694973,0.0007329021,0.00097446796,0.00044205025,0.0005899329,0.00031091872],"domain_scores_gemma":[0.9962595,0.002688845,0.00020671207,0.0005547506,0.00016734276,0.00012285469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015458982,0.00021478378,0.00070740096,0.00006950492,0.00010807361,0.000032258653,0.0003179886,0.00016153106,0.000045139754],"category_scores_gemma":[0.0012063186,0.0001423543,0.00022198608,0.0002786536,0.00037703852,0.00007137012,0.00015551847,0.00063601515,0.0000050496014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037786286,0.0029036454,0.9210293,0.00001132246,0.0003933363,0.000003391449,0.00066629174,0.00000677441,0.0014213284,0.00003234737,0.000114801674,0.03563115],"study_design_scores_gemma":[0.07625771,0.0030680152,0.91870177,0.0002580529,0.00016936653,4.248211e-7,0.0002979327,0.000591102,0.00024187204,0.00020190925,0.00009060515,0.00012125735],"about_ca_topic_score_codex":0.000048205286,"about_ca_topic_score_gemma":0.00015648713,"teacher_disagreement_score":0.03847143,"about_ca_system_score_codex":0.00008819005,"about_ca_system_score_gemma":0.00019851087,"threshold_uncertainty_score":0.58050394},"labels":[],"label_agreement":null},{"id":"W1985652007","doi":"10.1016/j.clinthera.2006.11.002","title":"Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Canadian Association of Radiation Oncology","funders":"","keywords":"Medicine; Medical prescription; Risperidone; Quetiapine; Antipsychotic; Retrospective cohort study; Cohort; Psychiatry; Olanzapine; Proportional hazards model; Schizophrenia (object-oriented programming); Pediatrics; Database; Internal medicine","score_opus":0.11194246009615434,"score_gpt":0.3936045367776961,"score_spread":0.28166207668154175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985652007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434876,0.0003426256,0.0010164371,0.00068153325,0.000018309285,0.0034920033,0.00008378575,0.0000136564295,0.0000029072037],"genre_scores_gemma":[0.99599475,0.00008132651,0.0033531873,0.00012999198,0.000042961805,0.00020504485,0.00008564943,0.000025470279,0.000081605234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986431,0.00011168281,0.00031547126,0.00041575212,0.00026316108,0.00025081163],"domain_scores_gemma":[0.9988038,0.00050655496,0.00014783746,0.00018995488,0.00026776796,0.00008410494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004638819,0.0001674243,0.0003503616,0.00006066044,0.0001358782,0.00005868909,0.000048726877,0.0000775429,8.5421937e-7],"category_scores_gemma":[0.00009809745,0.00009557265,0.000020521897,0.000201046,0.000089735244,0.00011098955,0.000021142789,0.00022851813,1.7206725e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02747726,0.0013570916,0.9696309,0.00003138539,0.00020241895,0.0000042568195,0.00020563882,0.00000938523,0.000001315695,0.00019126863,0.0000132387,0.00087582273],"study_design_scores_gemma":[0.030245582,0.00442899,0.9624223,0.00019511784,0.00025867575,0.0000012235218,0.0002728892,0.0017692179,0.000004639445,0.00026407544,0.000019853891,0.00011740522],"about_ca_topic_score_codex":0.0005140722,"about_ca_topic_score_gemma":0.03630281,"teacher_disagreement_score":0.035788737,"about_ca_system_score_codex":0.000119706645,"about_ca_system_score_gemma":0.0001109763,"threshold_uncertainty_score":0.9812822},"labels":[],"label_agreement":null},{"id":"W1985924058","doi":"10.1016/s0149-2918(00)83065-9","title":"A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Western University","funders":"Allergan","keywords":"Mometasone furoate; Medicine; Tazarotene; Tolerability; Psoriasis; Dermatology; Corticosteroid; Moisturizer; Calcipotriol; Erythema; Pharmacology; Adverse effect; Internal medicine","score_opus":0.15036461694942313,"score_gpt":0.39854128326357696,"score_spread":0.24817666631415383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985924058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810143,0.0150334425,0.00007520466,0.0005039957,0.0010604463,0.00089300796,0.00022768402,0.000050788713,0.0011411322],"genre_scores_gemma":[0.9843493,0.013230578,0.00064545363,0.00022683102,0.00014111011,0.00012179651,0.00020707215,0.000044893317,0.0010329747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99505126,0.0014135722,0.0019229364,0.00072142005,0.00021015556,0.00068062724],"domain_scores_gemma":[0.99458176,0.0034178824,0.0006507359,0.0011634933,0.000112706606,0.00007344987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095561973,0.0005586091,0.0016461429,0.00014776112,0.00018246524,0.000021031816,0.00074227777,0.00062430813,0.00050078303],"category_scores_gemma":[0.000079455116,0.0003913419,0.0006113445,0.00059969013,0.0006796868,0.000098113305,0.00005579991,0.00041204118,0.00018454064],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029804438,0.019668486,0.015317002,0.00006049466,0.0052030366,0.00005665677,0.010769816,0.00088830147,0.016561992,0.0004993172,0.00035221264,0.9008182],"study_design_scores_gemma":[0.13948214,0.088595234,0.11489336,0.0005132598,0.00977125,0.0000837664,0.008891162,0.0013595944,0.20871507,0.0006573716,0.42433503,0.0027027545],"about_ca_topic_score_codex":0.00033172854,"about_ca_topic_score_gemma":0.00014749482,"teacher_disagreement_score":0.8981155,"about_ca_system_score_codex":0.00020686131,"about_ca_system_score_gemma":0.00021489455,"threshold_uncertainty_score":0.99985385},"labels":[],"label_agreement":null},{"id":"W1986635261","doi":"10.1016/j.clinthera.2007.02.005","title":"Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Adverse effect; Adverse drug reaction; Audit; Drug; Psychiatry; Pharmacology","score_opus":0.17360845331881697,"score_gpt":0.37379915629465627,"score_spread":0.2001907029758393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986635261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402475,0.0000650237,0.004193701,0.00021474645,0.0003248639,0.00037737837,0.00022894113,0.0000075044754,0.0005631108],"genre_scores_gemma":[0.99882895,0.00023302158,0.0002188542,0.00056396006,0.000055428667,0.00000776204,0.00003394905,0.000013775116,0.000044280663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833256,0.000016193679,0.0012123729,0.00022661343,0.000032218213,0.00018003157],"domain_scores_gemma":[0.9985695,0.00033581245,0.0007215689,0.0002530489,0.000058074704,0.00006202826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011372836,0.00009810849,0.00036149216,0.00017711266,0.000027989281,0.0000042032407,0.00012825317,0.00011860979,0.000016026079],"category_scores_gemma":[0.000084797524,0.00009851539,0.0001246019,0.00019121957,0.00012910276,0.00006586869,0.000010325562,0.00013364344,0.000009097356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078278786,0.00082853046,0.9132987,0.0000441318,0.000092201655,1.5583515e-7,0.000059090387,0.0004114707,0.000046948076,0.08135929,0.000013554292,0.0030631404],"study_design_scores_gemma":[0.0040144594,0.00038368307,0.9718198,0.000021708878,0.000024927036,1.18826414e-7,0.000011247866,0.002750514,0.0015403903,0.0073900428,0.011880098,0.00016300888],"about_ca_topic_score_codex":0.000019301364,"about_ca_topic_score_gemma":0.000032944838,"teacher_disagreement_score":0.073969245,"about_ca_system_score_codex":0.00006549691,"about_ca_system_score_gemma":0.000027711843,"threshold_uncertainty_score":0.4017341},"labels":[],"label_agreement":null},{"id":"W1987489604","doi":"10.1016/j.clinthera.2013.01.011","title":"Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nature Conservancy of Canada","funders":"AstraZeneca","keywords":"Anastrozole; Medicine; Letrozole; Fulvestrant; Breast cancer; Oncology; Exemestane; Internal medicine; Aromatase inhibitor; Quality-adjusted life year; Aromatase; Cost effectiveness; Gynecology; Tamoxifen; Cancer; Risk analysis (engineering)","score_opus":0.04463607061786089,"score_gpt":0.3453188005657892,"score_spread":0.3006827299479283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987489604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987923,0.00026413272,0.0000048989596,0.000114352995,0.0002298911,0.0005289079,0.000033663622,0.0000029997423,0.000028887489],"genre_scores_gemma":[0.99934304,0.00018961761,0.000050617953,0.00014118249,0.000066850596,0.00004424672,0.00014910902,0.00001419479,0.0000011213001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987598,0.0003236616,0.00038453963,0.00021768412,0.00014683382,0.0001674728],"domain_scores_gemma":[0.99939716,0.00007375533,0.00014911262,0.00026475676,0.0000774293,0.000037762908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046378776,0.00012555547,0.00015911505,0.000047754947,0.000020651994,0.000011198221,0.00015607475,0.00017851162,0.000011847492],"category_scores_gemma":[0.000014475474,0.000081819795,0.000058002206,0.00012567836,0.00012983264,0.00000746764,0.000026128222,0.0001822679,0.0000052797163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040324335,0.0013513124,0.8402131,0.000022820497,0.00041213052,0.000002123466,0.0001578291,0.016674515,0.021481125,0.000025000045,0.000091258844,0.115536354],"study_design_scores_gemma":[0.0140076205,0.0016605114,0.9745129,0.00006793057,0.00015120748,0.0000020060513,0.00009726808,0.0060080574,0.0028831852,0.000027470336,0.0003207297,0.0002611398],"about_ca_topic_score_codex":0.000069479785,"about_ca_topic_score_gemma":0.00005711605,"teacher_disagreement_score":0.13429977,"about_ca_system_score_codex":0.000027839185,"about_ca_system_score_gemma":0.000114238166,"threshold_uncertainty_score":0.33365142},"labels":[],"label_agreement":null},{"id":"W1988586951","doi":"10.1016/j.clinthera.2013.07.005","title":"OC004—Fetal Exposure To Nonsteroidal Antiinflammatory Drugs (Nsaid) And Spontaneous Abortions","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pregnancy and Medication Impact","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Abortion; Pregnancy; Retrospective cohort study; Hazard ratio; Obstetrics; Confidence interval; Population; Cohort study; Proportional hazards model; Relative risk; Cohort; Internal medicine","score_opus":0.042593806648406424,"score_gpt":0.3642542367614284,"score_spread":0.3216604301130219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988586951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882245,0.0010766359,0.0006320399,0.0061385306,0.0005567739,0.00067822356,0.000010274458,0.00012091574,0.002562103],"genre_scores_gemma":[0.9836784,0.00084356545,0.0016937484,0.011108002,0.00042571747,0.000034148023,0.000009509193,0.000027711867,0.0021792257],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843985,0.000091209244,0.00062409346,0.0003004317,0.00024459636,0.00029981998],"domain_scores_gemma":[0.9983552,0.00035365988,0.000102137914,0.00047870702,0.00012746023,0.00058284873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038713223,0.00016584327,0.00036562377,0.00006527864,0.00008659219,0.000031087904,0.000115012685,0.00021521602,0.00031365672],"category_scores_gemma":[0.00019834188,0.00013243516,0.00012872732,0.000119904085,0.00023627575,0.00009275551,0.00005032931,0.00037855728,0.00039249213],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046864204,0.0010094316,0.11044059,0.00012718377,0.00057240325,0.00036937153,0.0024780054,0.000003866785,0.0069307233,0.00046061922,0.0032414407,0.87389773],"study_design_scores_gemma":[0.0071084094,0.0033607339,0.7614532,0.0007681795,0.0006739601,0.0016234621,0.00088068657,0.00078668725,0.0010841531,0.00078611355,0.2207255,0.00074887864],"about_ca_topic_score_codex":0.000005066566,"about_ca_topic_score_gemma":0.000002521467,"teacher_disagreement_score":0.87314886,"about_ca_system_score_codex":0.000019573376,"about_ca_system_score_gemma":0.00015570098,"threshold_uncertainty_score":0.54005486},"labels":[],"label_agreement":null},{"id":"W1989801881","doi":"10.1016/j.clinthera.2010.01.022","title":"Aripiprazole for the maintenance treatment of bipolar I disorder: A review","year":2010,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Aripiprazole; Medicine; Bipolar disorder; Bipolar I disorder; Tolerability; Comorbidity; Placebo; Internal medicine; Treatment of bipolar disorder; Metabolic syndrome; Randomized controlled trial; Psychiatry; Adverse effect; Pediatrics; Schizophrenia (object-oriented programming); Obesity; Lithium (medication); Mania","score_opus":0.20755194674908928,"score_gpt":0.4797742077705517,"score_spread":0.2722222610214624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989801881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.4409865e-7,0.99202496,0.0005838201,0.001184664,0.00059559644,0.005225418,0.00021014357,0.000034316545,0.00014072955],"genre_scores_gemma":[0.0000014727945,0.99620646,0.00065901404,0.0007104494,0.0003594409,0.0007281585,0.00018200777,0.000097225515,0.0010557537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970717,0.00017064612,0.0017300664,0.00047233203,0.000209737,0.00034555685],"domain_scores_gemma":[0.99534,0.0021896453,0.0007665397,0.0014142474,0.00015670955,0.00013288803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000653707,0.00052913884,0.0033026484,0.000043855387,0.000097991295,0.000010409549,0.00030235876,0.00057088246,0.000059018977],"category_scores_gemma":[0.00016032041,0.0002445741,0.0030121738,0.000222728,0.00034863778,0.000014803374,0.000038143688,0.00055024,0.000039286464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003572393,0.0014812677,0.00025330193,0.013860086,0.0019462986,0.0000014374084,0.000011106953,1.1346509e-8,4.406539e-8,0.00021492051,0.00015158829,0.9820442],"study_design_scores_gemma":[0.0014567437,0.0017058149,0.000056594894,0.012429216,0.021667382,0.000044806042,0.0000042969677,0.000011476333,3.5534615e-7,0.00006886782,0.96234745,0.00020700571],"about_ca_topic_score_codex":0.000010586699,"about_ca_topic_score_gemma":0.00003305604,"teacher_disagreement_score":0.9818372,"about_ca_system_score_codex":0.0000623711,"about_ca_system_score_gemma":0.00050450646,"threshold_uncertainty_score":0.9973442},"labels":[],"label_agreement":null},{"id":"W1991056746","doi":"10.1016/j.clinthera.2014.12.014","title":"Limited Impact of Drug Exposure Misclassification From Non-Benefit Thiazolidinedione Drug Use on Mortality and Hospitalizations From Saskatchewan, Canada: A Cohort Study","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian VIGOUR Centre; Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Drug; Hazard ratio; Medical prescription; Cohort; Pharmacoepidemiology; Population; Cohort study; Prescription drug; Emergency medicine; Internal medicine; Pharmacology; Environmental health; Confidence interval","score_opus":0.19000870755377947,"score_gpt":0.4048824680940676,"score_spread":0.21487376054028812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991056746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970987,0.0002169536,0.00029790503,0.00086876925,0.00030758514,0.0009022617,0.0001489823,0.00003537685,0.0001234548],"genre_scores_gemma":[0.99666476,0.00014659726,0.00029521616,0.001273465,0.00022219379,0.000038656326,0.00032269236,0.000023517743,0.0010129192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997683,0.00016742715,0.0009014718,0.00045917885,0.00061650947,0.00017244325],"domain_scores_gemma":[0.99699944,0.0007658116,0.00040773046,0.0009195222,0.00048684693,0.00042064488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005477807,0.00021161177,0.0006105657,0.000036748737,0.000054272587,0.000026261245,0.00017630256,0.00012937335,0.00009605677],"category_scores_gemma":[0.00034348934,0.00016466937,0.00011060001,0.00023274767,0.00014464755,0.000079139696,0.00003714289,0.00033408994,0.000015333859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019577974,0.001103043,0.99186033,0.000004876227,0.0006541398,0.0000050146805,0.0010752694,0.000027892058,0.00008983698,0.000008701648,0.0040573673,0.00091772515],"study_design_scores_gemma":[0.0023575346,0.0005105991,0.98976135,0.00008593411,0.00049573835,4.566393e-7,0.0029576782,0.003046515,0.000101452446,0.00022648212,0.00030097528,0.00015525863],"about_ca_topic_score_codex":0.22864152,"about_ca_topic_score_gemma":0.106757544,"teacher_disagreement_score":0.12188398,"about_ca_system_score_codex":0.00014137787,"about_ca_system_score_gemma":0.0012049945,"threshold_uncertainty_score":0.9095418},"labels":[],"label_agreement":null},{"id":"W1991230852","doi":"10.1016/j.clinthera.2013.07.331","title":"Analysis of Inpatient Use of Fresh Frozen Plasma and Other Therapies and Associated Outcomes in Patients with Major Bleeds from Vitamin K Antagonism","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Trauma, Hemostasis, Coagulopathy, Resuscitation","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"American Stroke Association; Stroke Association; Heart and Stroke Foundation of Canada; American Heart Association","keywords":"Medicine; Fresh frozen plasma; Cryoprecipitate; Intensive care unit; Blood transfusion; Warfarin; Emergency medicine; Internal medicine; Platelet","score_opus":0.05784814040604972,"score_gpt":0.3234521128109009,"score_spread":0.2656039724048512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991230852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986927,0.00011474496,0.000038177914,0.00023546707,0.00006480958,0.00055032613,0.0002714019,0.00001694387,0.000015443447],"genre_scores_gemma":[0.9972289,0.00011938264,0.0017912998,0.00069994485,0.00000936994,0.000010947094,0.00008749473,0.000028403836,0.000024242832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808216,0.00020902506,0.00089602295,0.00029226387,0.00034270636,0.00017779238],"domain_scores_gemma":[0.9974632,0.0014347283,0.00044963646,0.0003205756,0.00024110991,0.00009071895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027024324,0.00018961268,0.0009326087,0.00024483335,0.000023394556,0.000022521306,0.00007262145,0.00021253881,0.000043704345],"category_scores_gemma":[0.0001556751,0.00013354167,0.000110216795,0.00039863237,0.000323135,0.000112690606,0.000041209747,0.00019968628,0.0000011782785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004575556,0.0010132192,0.97657365,0.000015015892,0.0036680815,6.8317553e-7,0.0012941504,0.000005383004,0.0003008825,0.000010530024,0.0000050816316,0.016655775],"study_design_scores_gemma":[0.005885548,0.0009476636,0.9891833,0.000069111265,0.00175385,5.040935e-8,0.00033246932,0.0012155382,0.00034387526,0.000091274116,0.000043322158,0.00013401214],"about_ca_topic_score_codex":0.00042367715,"about_ca_topic_score_gemma":0.0003369209,"teacher_disagreement_score":0.016521763,"about_ca_system_score_codex":0.000029106688,"about_ca_system_score_gemma":0.000030645977,"threshold_uncertainty_score":0.54456717},"labels":[],"label_agreement":null},{"id":"W1991474123","doi":"10.1016/j.clinthera.2006.08.008","title":"A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antimicrobial Resistance in Staphylococcus","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Imipenem/cilastatin; Cilastatin; Meropenem; Tolerability; Internal medicine; Randomized controlled trial; Imipenem; Population; Post-hoc analysis; Subgroup analysis; Clinical trial; Surgery; Adverse effect; Antibiotics; Antibiotic resistance; Meta-analysis","score_opus":0.03495167743152463,"score_gpt":0.3450587925581699,"score_spread":0.3101071151266453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991474123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704725,0.00027612582,0.000040070598,0.000058369744,0.00006737771,0.0023884485,0.00007826739,0.000013368701,0.00003073218],"genre_scores_gemma":[0.9990568,0.00012208826,0.0005432957,0.000076370176,0.000014807001,0.000033005734,0.000120397985,0.00002787519,0.0000053182607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968843,0.00044813345,0.0016298757,0.00043426632,0.0003220782,0.00028134984],"domain_scores_gemma":[0.9967534,0.0016702047,0.00063538784,0.00044111602,0.0004259635,0.00007394193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005879839,0.00026374075,0.0018543875,0.0004997024,0.00003631031,0.000016128883,0.00014144236,0.00017253893,0.000019688072],"category_scores_gemma":[0.00012242836,0.00019630417,0.00023486157,0.0014920543,0.0005480698,0.000056540786,0.00006284562,0.0003727327,4.742086e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29407448,0.0054606306,0.69590783,0.00004272241,0.0017884512,0.000002495738,0.00040850986,0.00025552622,0.00030660818,0.000018493512,8.1077275e-7,0.0017334599],"study_design_scores_gemma":[0.3965241,0.0017169998,0.59834844,0.00007343435,0.002167376,6.35714e-8,0.0002461438,0.0005567015,0.00021971122,0.000008520714,0.00000988054,0.00012861092],"about_ca_topic_score_codex":0.0005036115,"about_ca_topic_score_gemma":0.0076163323,"teacher_disagreement_score":0.10244962,"about_ca_system_score_codex":0.00005550496,"about_ca_system_score_gemma":0.0000532528,"threshold_uncertainty_score":0.80050516},"labels":[],"label_agreement":null},{"id":"W1994199470","doi":"10.1016/j.clinthera.2008.11.006","title":"Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Tigecycline; Medicine; Acinetobacter baumannii; Enterococcus faecalis; Enterococcus faecium; Microbiology; Klebsiella oxytoca; Enterococcus; Antimicrobial; Vancomycin; Klebsiella pneumoniae; Vancomycin-resistant Enterococcus; Linezolid; Meropenem; Staphylococcus aureus; Antibiotics; Antibiotic resistance; Biology; Escherichia coli; Bacteria; Pseudomonas aeruginosa","score_opus":0.057998809316546995,"score_gpt":0.36692143464400934,"score_spread":0.30892262532746234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994199470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956953,0.000087076376,0.00015749213,0.002308886,0.00023010206,0.0011150526,0.00037248086,0.00000846523,0.000025146926],"genre_scores_gemma":[0.99174917,0.0023867015,0.00034756612,0.0042952592,0.00037858915,0.000006719982,0.00078464375,0.000020060706,0.000031283358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969102,0.0013559022,0.0006832755,0.00058085757,0.00020742281,0.0002623399],"domain_scores_gemma":[0.9965132,0.0024364253,0.00023402921,0.0005411465,0.00020265706,0.00007255358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002883115,0.00021833992,0.00028175072,0.000023946382,0.0001762959,0.00006197334,0.0002633121,0.00023170037,0.000008309192],"category_scores_gemma":[0.0020757962,0.00013604616,0.000060187165,0.00018184388,0.0008104938,0.0000072216453,0.00008814585,0.00029934707,0.000005162405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082325175,0.0019384573,0.87177944,0.000012032344,0.00049753935,0.00002871391,0.0035253132,0.00033958623,0.025791146,0.000035778783,0.008536276,0.005190546],"study_design_scores_gemma":[0.015846705,0.0014126837,0.9730174,0.000036114252,0.00005005936,0.0000035180797,0.00040655612,0.00081726216,0.005553645,0.00038442056,0.0021812345,0.00029039668],"about_ca_topic_score_codex":0.00014617863,"about_ca_topic_score_gemma":0.00074304384,"teacher_disagreement_score":0.101237975,"about_ca_system_score_codex":0.000021523298,"about_ca_system_score_gemma":0.0000826697,"threshold_uncertainty_score":0.5547801},"labels":[],"label_agreement":null},{"id":"W1995627580","doi":"10.1016/j.clinthera.2009.02.012","title":"Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Hôpital Saint-Luc","funders":"Hologic; Procter and Gamble","keywords":"Medicine; Dose-ranging study; Osteoporosis; Randomized controlled trial; Etidronic acid; Postmenopausal osteoporosis; Internal medicine; Double blind; Placebo; Bone mineral","score_opus":0.11313435884602921,"score_gpt":0.4842734203304222,"score_spread":0.371139061484393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995627580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815887,0.0039269747,0.0000074633563,0.0012609401,0.0010836219,0.011389945,0.0000146523635,0.00003986206,0.00068779784],"genre_scores_gemma":[0.9980675,0.0004729564,0.0002081134,0.0006585618,0.00015958061,0.0002362191,0.000013413626,0.000041159325,0.00014249916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928158,0.0017477276,0.002976073,0.0005981059,0.0010966633,0.0007656656],"domain_scores_gemma":[0.99103045,0.0061444906,0.0011124877,0.0009592345,0.00040607716,0.0003472342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035306385,0.00043687475,0.003394243,0.00024314184,0.00019446663,0.000021362981,0.00051282934,0.00037683165,0.000020767426],"category_scores_gemma":[0.0013935347,0.0002823621,0.0007826129,0.0006394755,0.00060846604,0.0001158948,0.00014720045,0.0014687971,0.0000048691245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8904154,0.02711494,0.009182848,0.00017385064,0.0007758486,0.00002303069,0.004628916,0.0000356707,0.001836622,0.000025372296,0.00001546167,0.06577208],"study_design_scores_gemma":[0.9386801,0.03193979,0.016739026,0.0005160514,0.0014230775,0.0000010967279,0.0018474477,0.005631811,0.0027930238,0.00003318908,0.00017029488,0.00022510263],"about_ca_topic_score_codex":0.0001543217,"about_ca_topic_score_gemma":0.00015024854,"teacher_disagreement_score":0.065546975,"about_ca_system_score_codex":0.00019208068,"about_ca_system_score_gemma":0.0006507707,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W1998267695","doi":"10.1016/s0149-2918(04)90040-9","title":"Underuse of aspirin in type 2 diabetes mellitus: Prevalence and correlates of therapy in rural Canada","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Aspirin; Thienopyridine; Internal medicine; Population; Diabetes mellitus; Cohort; Type 2 Diabetes Mellitus; Type 2 diabetes; Logistic regression; Cohort study; Guideline; Clopidogrel; Environmental health","score_opus":0.0452454638835269,"score_gpt":0.3249693867348366,"score_spread":0.2797239228513097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998267695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94780785,0.051640034,0.00000853078,0.00015073863,0.00010818716,0.000235907,0.000005586894,0.0000063632906,0.000036791203],"genre_scores_gemma":[0.93566,0.063728936,0.00007043951,0.0004898381,0.000022522247,0.0000024509309,0.0000040402583,0.000012642101,0.000009113155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988083,0.000111751215,0.0005663055,0.00015314741,0.00019296123,0.00016749538],"domain_scores_gemma":[0.999231,0.00028690952,0.00010413033,0.00024649542,0.000065430366,0.00006604159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041309375,0.00011476437,0.000511599,0.00004669668,0.000009614689,0.0000026029188,0.00008627562,0.000119207616,0.0000161966],"category_scores_gemma":[0.00005721897,0.00009256874,0.00012236334,0.0002129093,0.00024702228,0.000031914424,0.000018018172,0.00020264399,4.9953434e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005102683,0.00035517584,0.9399126,0.00013030645,0.00025352105,0.00001438663,0.00010571003,0.00008782889,0.0002502438,0.000165412,0.0000013209615,0.05821318],"study_design_scores_gemma":[0.005649048,0.00095247704,0.9875212,0.00060412474,0.00010286296,0.000003650565,0.00018384721,0.00009270342,0.0029465724,0.0014397202,0.0003720958,0.00013172033],"about_ca_topic_score_codex":0.0028436752,"about_ca_topic_score_gemma":0.0041556796,"teacher_disagreement_score":0.05808146,"about_ca_system_score_codex":0.000034233846,"about_ca_system_score_gemma":0.00039444622,"threshold_uncertainty_score":0.42988053},"labels":[],"label_agreement":null},{"id":"W1998479580","doi":"10.1016/j.clinthera.2013.07.332","title":"Targeting the Unstable Plaque in Acute Coronary Syndromes","year":2013,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Canakinumab; Fibrous cap; Clinical trial; Acute coronary syndrome; Vulnerable plaque; Unstable angina; Coronary artery disease; Inflammation; Randomized controlled trial; Cardiology; Pathology; Internal medicine; Myocardial infarction; Disease","score_opus":0.24100280342753128,"score_gpt":0.47462687540887655,"score_spread":0.23362407198134527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998479580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019022539,0.99591434,0.00010613806,0.00057974213,0.00094898633,0.001585139,0.00005251569,0.000055076278,0.0005678125],"genre_scores_gemma":[0.00012737873,0.9940848,0.00056148676,0.0010603954,0.00030441646,0.00017091937,0.00022354788,0.00008472123,0.0033823433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965308,0.00045530385,0.0019009605,0.00045142972,0.00023800065,0.0004235239],"domain_scores_gemma":[0.99483454,0.003704566,0.00044238498,0.00077810115,0.000098583885,0.00014184102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091776415,0.0004233687,0.0020339482,0.00010566185,0.00008928763,0.000049457652,0.0004228969,0.00062983524,0.00074117194],"category_scores_gemma":[0.00024723128,0.00024469677,0.0011458802,0.00032796105,0.0002625288,0.000054682045,0.00020632044,0.0016416871,0.00050863886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021002095,0.00056837883,0.0011224124,0.0019350091,0.0009919802,0.00027099694,0.000017488297,0.0000010262611,7.541398e-8,0.00034872742,0.0030047242,0.9917182],"study_design_scores_gemma":[0.000563756,0.0004999999,0.00034363626,0.0087810615,0.0028791772,0.0003376629,0.000046549732,0.00012076529,7.176649e-8,0.00026076357,0.9859064,0.00026012427],"about_ca_topic_score_codex":0.0000125283605,"about_ca_topic_score_gemma":0.00000421254,"teacher_disagreement_score":0.99145806,"about_ca_system_score_codex":0.00011306667,"about_ca_system_score_gemma":0.00041360504,"threshold_uncertainty_score":0.99784446},"labels":[],"label_agreement":null},{"id":"W1998688570","doi":"10.1016/j.clinthera.2015.03.021","title":"Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Pfizer","keywords":"Medicine; Caspofungin; Voriconazole; Incidence (geometry); Aspergillosis; Adverse effect; Neutropenia; Cumulative incidence; Amphotericin B; Internal medicine; Intensive care medicine; Immunology; Antifungal; Chemotherapy; Transplantation","score_opus":0.28544044083264086,"score_gpt":0.49307230655877554,"score_spread":0.20763186572613468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998688570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818224,0.00024525955,0.00007766412,0.0001081626,0.0002794166,0.000843989,0.00006665235,0.000019726815,0.00017688672],"genre_scores_gemma":[0.99863446,0.000060315742,0.0008118096,0.00014828304,0.00014564289,0.000027782615,0.00012887586,0.000022059521,0.00002076573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980521,0.00020046053,0.0009844244,0.00035138687,0.0001660948,0.0002454957],"domain_scores_gemma":[0.995689,0.003137601,0.00023498808,0.00040656116,0.00018848258,0.00034342188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045543342,0.00016033312,0.0006516739,0.000039488335,0.00003405309,0.000013364887,0.00014540221,0.0001580475,0.000014366592],"category_scores_gemma":[0.0016490823,0.00013840977,0.00020752577,0.00006379826,0.00022075132,0.00008421728,0.000034129615,0.00024852966,0.000009140691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012562496,0.0021880157,0.96708643,0.000050053328,0.000086065,0.000004833971,0.00028244752,0.00030585928,0.00003205381,0.000031491556,0.00004302241,0.01732724],"study_design_scores_gemma":[0.015737658,0.0051790997,0.9617294,0.00007998281,0.0002125316,9.489506e-8,0.00059099,0.015606751,0.0002139282,0.00030362033,0.00019138795,0.00015456483],"about_ca_topic_score_codex":0.000018471888,"about_ca_topic_score_gemma":0.00018883537,"teacher_disagreement_score":0.017172676,"about_ca_system_score_codex":0.00014696988,"about_ca_system_score_gemma":0.000628955,"threshold_uncertainty_score":0.5644187},"labels":[],"label_agreement":null},{"id":"W2000645923","doi":"10.1016/j.clinthera.2014.10.013","title":"Opioid Interruptions, Pain, and Withdrawal Symptoms in Nursing Home Residents","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; Greenwall Foundation; Health Services Research and Development; U.S. Department of Veterans Affairs","keywords":"Medicine; Discontinuation; Opioid; Dosing; Odds ratio; Anesthesia; Emergency medicine; Internal medicine","score_opus":0.041372503302005814,"score_gpt":0.38700574538883414,"score_spread":0.34563324208682833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000645923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070305,0.0006140895,0.003919288,0.0021287156,0.00034862003,0.00027807525,6.372001e-7,0.00006723371,0.0019402703],"genre_scores_gemma":[0.99031323,0.00068065285,0.0010300577,0.0069851335,0.0003241751,0.000006062311,0.000008757294,0.000021901024,0.00063003827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985496,0.00031978165,0.0004777342,0.00026553357,0.0001615969,0.0002257604],"domain_scores_gemma":[0.99889326,0.000575402,0.00007585024,0.000304741,0.0000355225,0.000115206414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017953652,0.00012604901,0.00031253757,0.00010433445,0.000044172622,0.000031668405,0.000102539416,0.00013721493,0.000020377183],"category_scores_gemma":[0.00026350832,0.00010739237,0.000074878495,0.00013373116,0.00022084442,0.000049876126,0.0000407736,0.00032781524,0.000022714787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001492408,0.00023085564,0.78845865,0.000031346044,0.0000462239,0.0000054495267,0.00020740188,8.50909e-7,0.000025002573,0.0009955015,0.00027705886,0.20957243],"study_design_scores_gemma":[0.0023886974,0.00071586337,0.97311574,0.00055677624,0.00009759617,0.0000015474476,0.00011037126,0.0077808653,0.0000053796316,0.0058470923,0.009238959,0.00014108195],"about_ca_topic_score_codex":0.0000047890076,"about_ca_topic_score_gemma":0.000005256849,"teacher_disagreement_score":0.20943135,"about_ca_system_score_codex":0.000035066827,"about_ca_system_score_gemma":0.000020583662,"threshold_uncertainty_score":0.4379334},"labels":[],"label_agreement":null},{"id":"W2001067466","doi":"10.1016/j.clinthera.2008.12.023","title":"Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; University of Ottawa","funders":"Pfizer Canada","keywords":"Atorvastatin; Medicine; C-reactive protein; Coronary artery disease; Internal medicine; Triglyceride; National Cholesterol Education Program; Gastroenterology; Statin; Clinical endpoint; Lipoprotein; Cholesterol; Endocrinology; Inflammation; Cardiology; Randomized controlled trial; Metabolic syndrome; Obesity","score_opus":0.06857215870727022,"score_gpt":0.3439261744786169,"score_spread":0.27535401577134666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001067466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236465,0.00015567691,0.000051699615,0.00006533994,0.00030645932,0.0068339114,0.00012309237,0.000027391909,0.00007180964],"genre_scores_gemma":[0.99920243,0.000014717663,0.00025478553,0.00012530043,0.00010568015,0.00014736492,0.000046998583,0.000038129623,0.000064572654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99385,0.0028374458,0.0010776399,0.00065233925,0.0011677128,0.00041486084],"domain_scores_gemma":[0.9943813,0.002956651,0.0008461712,0.0011276257,0.00044755993,0.0002406648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009132398,0.00041572517,0.001753683,0.0000904592,0.00013435817,0.000007145896,0.00016628044,0.0001393757,0.0000056872786],"category_scores_gemma":[0.0004224844,0.00026518173,0.00033688731,0.00046569048,0.0006281428,0.00009066623,0.000090685426,0.00074227125,0.000009205266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1545165,0.028761946,0.79599243,0.00094603427,0.005678362,0.0004886724,0.00779801,0.00032051574,0.00091685005,0.00011297543,0.0001637456,0.0043039653],"study_design_scores_gemma":[0.035989948,0.014309369,0.9432295,0.00064162875,0.00048119112,0.0000015802202,0.00036917214,0.00013779433,0.004508748,0.000019746803,0.00007318687,0.00023815627],"about_ca_topic_score_codex":0.00019049496,"about_ca_topic_score_gemma":0.00012244262,"teacher_disagreement_score":0.14723705,"about_ca_system_score_codex":0.00018986572,"about_ca_system_score_gemma":0.00054502574,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W2001129294","doi":"10.1016/j.clinthera.2005.08.001","title":"Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Mesylate; Placebo; Peripheral neuropathy; Double blind; Protein kinase C; Peripheral; Clinical trial; Randomized controlled trial; Internal medicine; Pharmacology; Kinase; Diabetes mellitus; Endocrinology; Pathology","score_opus":0.07598269146664982,"score_gpt":0.37383588489610886,"score_spread":0.29785319342945904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001129294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436296,0.00073395076,0.00019712537,0.0023823108,0.00036204388,0.011515016,0.000007986033,0.00009685406,0.00034178144],"genre_scores_gemma":[0.9924217,0.00058492343,0.001982782,0.00040317903,0.0013803589,0.0011983039,0.000010367333,0.0000922106,0.0019262126],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941664,0.0017373314,0.002298967,0.00065367034,0.00059592584,0.0005477398],"domain_scores_gemma":[0.99554104,0.0021607836,0.0008252798,0.0009826788,0.00016211004,0.0003281186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024233297,0.00055735675,0.002795499,0.00008317967,0.00017964967,0.000060050264,0.0002246197,0.00031078013,0.00009444095],"category_scores_gemma":[0.00023350169,0.00026926846,0.0014903574,0.00019183168,0.0006687183,0.00007014803,0.00004994475,0.0004676173,0.000040599494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9799344,0.0057384707,0.0008874887,0.000047651665,0.0025750832,0.00010500318,0.00023299178,0.000018957668,0.00025298263,0.00024169976,0.0000035532057,0.009961695],"study_design_scores_gemma":[0.980438,0.01110608,0.00035294652,0.000151749,0.0030193669,0.000024924104,0.00007820411,0.0022535704,0.0015969144,0.00008734563,0.0006262334,0.00026466488],"about_ca_topic_score_codex":0.0000070175442,"about_ca_topic_score_gemma":0.000008280865,"teacher_disagreement_score":0.010316712,"about_ca_system_score_codex":0.00012643205,"about_ca_system_score_gemma":0.0002758579,"threshold_uncertainty_score":0.999976},"labels":[],"label_agreement":null},{"id":"W2001157930","doi":"10.1016/s0149-2918(02)80022-4","title":"Efficacy and tolerability of a “suprabioavailable” formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Fenofibrate; Medicine; Tolerability; Dyslipidemia; Internal medicine; Gastroenterology; Adverse effect; Triglyceride; Cholesterol; Endocrinology; Obesity","score_opus":0.2215697994329045,"score_gpt":0.4352190506748764,"score_spread":0.21364925124197187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001157930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997308,0.00060457294,0.0003018255,0.00016009464,0.000031879386,0.0014294487,0.000027190685,0.000005709278,0.00013125507],"genre_scores_gemma":[0.9966551,0.00027209258,0.0027977931,0.00018711733,0.000028344744,0.000008860929,0.000020207417,0.0000129629025,0.000017500523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963197,0.0007667396,0.0020885018,0.00029584792,0.00036858016,0.0001606337],"domain_scores_gemma":[0.9970414,0.0010267714,0.00083759194,0.00067378586,0.0003238295,0.00009662174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054395837,0.00013596535,0.0023536335,0.00015593448,0.000019435625,0.0000067152855,0.0001204499,0.00016653306,0.0000613998],"category_scores_gemma":[0.00072894426,0.00009187704,0.00024515323,0.00087427406,0.00016050243,0.00007850519,0.00006307546,0.0001987148,4.9076556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003953738,0.004457175,0.88437057,0.00021024478,0.00525544,6.3222944e-7,0.00018953881,0.000067859706,0.00024868702,0.00013964169,0.0000046354403,0.101101816],"study_design_scores_gemma":[0.03726061,0.0029975555,0.94609404,0.0001684385,0.006380374,2.3419325e-7,0.000019774121,0.0063783927,0.00040770503,0.00011264989,0.000072590505,0.000107635016],"about_ca_topic_score_codex":0.00008971711,"about_ca_topic_score_gemma":0.000028281995,"teacher_disagreement_score":0.10099418,"about_ca_system_score_codex":0.000026588765,"about_ca_system_score_gemma":0.000070531845,"threshold_uncertainty_score":0.37466368},"labels":[],"label_agreement":null},{"id":"W2003147202","doi":"10.1016/j.clinthera.2015.03.005","title":"Polarized Stakeholders and Institutional Vulnerabilities: The Enduring Politics of the Patient Protection and Affordable Care Act","year":2015,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Healthcare Policy and Management","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canada Research Chairs; Commonwealth Fund","keywords":"Veto; Politics; Public administration; Medicaid; Legislation; Health care reform; Patient Protection and Affordable Care Act; Incentive; Public economics; Medicine; State (computer science); Public policy; Public opinion; Health policy; Public health; Health care; Economic growth; Political science; Economics; Nursing; Law; Market economy","score_opus":0.48240586748549996,"score_gpt":0.40322666741594804,"score_spread":0.07917920006955192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003147202","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008348548,0.9945869,0.0001747387,0.0008191743,0.0006842513,0.0014290115,0.00032401818,0.000013515455,0.001133571],"genre_scores_gemma":[0.015123224,0.9838368,0.00010914792,0.00048676247,0.00018795747,0.00008165953,0.000010607328,0.000026112164,0.00013771566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978386,0.0002447018,0.0012654748,0.00032784502,0.0000737656,0.00024962547],"domain_scores_gemma":[0.9983596,0.00029980973,0.00070455286,0.00048563533,0.00006141887,0.0000889553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012391966,0.00021800192,0.0009272906,0.00007390047,0.00029442256,0.00005148865,0.00023190981,0.00028953896,0.0000065249037],"category_scores_gemma":[0.00024653497,0.00013790462,0.00025608332,0.00015090122,0.00046580657,0.000058348003,0.00021015533,0.0006141712,0.000003850813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007937418,0.000069565256,0.00024050282,0.00593468,0.000282719,3.6587255e-7,0.001364612,0.000004428202,1.98366e-8,0.12807064,0.00001948655,0.864005],"study_design_scores_gemma":[0.00024218498,0.0001054539,0.00008616248,0.00056536746,0.00010184962,0.0000037605942,0.000357874,0.00005538486,1.987548e-7,0.007149219,0.9911826,0.00014989213],"about_ca_topic_score_codex":0.0005170065,"about_ca_topic_score_gemma":0.00003381303,"teacher_disagreement_score":0.9911632,"about_ca_system_score_codex":0.00017229856,"about_ca_system_score_gemma":0.00027513786,"threshold_uncertainty_score":0.5623587},"labels":[],"label_agreement":null},{"id":"W2004518311","doi":"10.1016/s0149-2918(00)80069-7","title":"Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Sumatriptan; Medicine; Migraine; Anesthesia; Aura; Agonist; Crossover study; Internal medicine; Placebo","score_opus":0.17747577325892122,"score_gpt":0.4761091663867683,"score_spread":0.2986333931278471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004518311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018264,0.004676823,0.0000039701663,0.00086206826,0.000041127823,0.0003086152,0.000008512894,0.000016493153,0.0038997678],"genre_scores_gemma":[0.9930441,0.0042416165,0.0005800333,0.0005624782,0.00008757473,0.000004530411,0.000011785775,0.000011840565,0.0014560331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984148,0.00009381167,0.00088647654,0.00022476267,0.00018165221,0.00019845307],"domain_scores_gemma":[0.9992532,0.00023550264,0.00011051313,0.00022251144,0.000088393805,0.00008988429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040564834,0.00013215616,0.000679686,0.000057052857,0.000034100634,0.000004364474,0.00006599584,0.00013886041,0.0001839887],"category_scores_gemma":[0.000113161084,0.00010479514,0.000120512275,0.0002059633,0.00026239848,0.000026260894,0.000023364679,0.00033832164,0.000010583087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037788754,0.0009449748,0.8759871,0.000052029543,0.00006623796,0.000001592615,0.00083751837,2.3847286e-7,0.000016687523,0.00004402731,0.0018811107,0.11979057],"study_design_scores_gemma":[0.0033512495,0.0017861924,0.91456443,0.0001405372,0.00012162148,0.0000013180213,0.00030587273,0.00042522262,0.000058589063,0.00022106986,0.07889868,0.00012524439],"about_ca_topic_score_codex":0.000016712314,"about_ca_topic_score_gemma":0.00005341135,"teacher_disagreement_score":0.119665325,"about_ca_system_score_codex":0.000014675088,"about_ca_system_score_gemma":0.00003767917,"threshold_uncertainty_score":0.42734218},"labels":[],"label_agreement":null},{"id":"W2004646022","doi":"10.1016/j.clinthera.2006.11.007","title":"Measurable outcomes in psychiatric disorders: Remission as a marker of wellness","year":2006,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; University of Toronto; University Health Network","funders":"","keywords":"Psychiatry; Bipolar disorder; Medicine; Anxiety; Schizophrenia (object-oriented programming); Major depressive disorder; Attention deficit hyperactivity disorder; Mood disorders; Mood; Clinical psychology","score_opus":0.12953490970203216,"score_gpt":0.4592544337710731,"score_spread":0.3297195240690409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004646022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009432463,0.98888,0.000020996664,0.00033384014,0.00047463833,0.0011761669,0.000018944686,0.000035392197,0.008965746],"genre_scores_gemma":[0.00048627515,0.996644,0.000288391,0.00012247749,0.00009285024,0.000043760167,0.00008632619,0.00008508784,0.0021508336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964514,0.00043778025,0.001909499,0.00051124097,0.0003706814,0.00031943907],"domain_scores_gemma":[0.99771976,0.00078996154,0.0005305217,0.0007861423,0.000047898837,0.00012568766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007659481,0.0004719828,0.003070955,0.00021770275,0.00003543965,0.000009993479,0.00022208907,0.00083221553,0.00010441608],"category_scores_gemma":[0.00010336844,0.00030322198,0.0014559244,0.00053130544,0.00012848017,0.00002535113,0.00005463218,0.00083867036,0.00006493967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066567554,0.0026591432,0.09715206,0.0043383553,0.0005551313,0.0000039899232,0.000007691597,1.05871514e-7,2.0871239e-8,0.00006136107,0.00007045664,0.8950851],"study_design_scores_gemma":[0.0019450239,0.00043368767,0.011205615,0.0035652118,0.0032758734,0.00001282093,0.000008795267,0.0000051309726,1.9847012e-7,0.0011309835,0.9781402,0.00027649436],"about_ca_topic_score_codex":0.00007127259,"about_ca_topic_score_gemma":0.00007544759,"teacher_disagreement_score":0.9780697,"about_ca_system_score_codex":0.000076752855,"about_ca_system_score_gemma":0.0004564113,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W2005819950","doi":"10.1016/j.clinthera.2005.03.006","title":"The CONCEPT trial: A 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Vancouver General Hospital","funders":"","keywords":"Medicine; Formoterol; Salmeterol; Regimen; Dosing; Budesonide/formoterol; Fluticasone propionate; Budesonide; Randomized controlled trial; Double blind; Fluticasone; Pharmacology; Internal medicine; Corticosteroid; Asthma; Alternative medicine","score_opus":0.08122762669967477,"score_gpt":0.3774367020759708,"score_spread":0.29620907537629604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005819950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99015385,0.0037350105,0.0008626398,0.0006230111,0.00010521468,0.0042412053,0.000015384992,0.00003632878,0.00022734748],"genre_scores_gemma":[0.9931086,0.000521171,0.005623221,0.00023477714,0.00012631032,0.00009349347,0.000016670208,0.00006728719,0.00020849943],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99536216,0.0005743096,0.0021636914,0.00053867715,0.0007591081,0.0006020511],"domain_scores_gemma":[0.99581486,0.0009555919,0.0014974758,0.000850977,0.000621185,0.0002598837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019666909,0.00038368185,0.0019702227,0.00013114492,0.00012119544,0.000035942838,0.0003540755,0.00023500164,0.000014603919],"category_scores_gemma":[0.000102935315,0.00021141411,0.00045185295,0.00037363396,0.0016052299,0.00024358155,0.00008077101,0.0005490846,0.0000012053225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9692908,0.0032154832,0.008466094,0.00023846055,0.0006815261,0.000008461849,0.0018588364,0.0006653684,0.0002035395,0.00018364032,0.00001935799,0.015168443],"study_design_scores_gemma":[0.95485044,0.010799356,0.0006334772,0.0030027626,0.0009740106,0.000011632403,0.0063526738,0.016929137,0.0041328156,0.000013241162,0.0019845653,0.00031587423],"about_ca_topic_score_codex":0.000088996996,"about_ca_topic_score_gemma":0.00013233273,"teacher_disagreement_score":0.016263768,"about_ca_system_score_codex":0.00010685645,"about_ca_system_score_gemma":0.00039476424,"threshold_uncertainty_score":0.8621217},"labels":[],"label_agreement":null},{"id":"W2006000651","doi":"10.1016/s0149-2918(02)80063-7","title":"Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Drug; Intensive care medicine; Family medicine; Pharmacology","score_opus":0.2682794857251483,"score_gpt":0.47529223269279236,"score_spread":0.20701274696764405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006000651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590033,0.0007835894,0.00001781047,0.0005537858,0.00034434017,0.0007264715,0.0000129002465,0.000016529457,0.0016442229],"genre_scores_gemma":[0.994072,0.00092583324,0.004050636,0.00056670496,0.00003296841,0.0000062277045,0.000009604355,0.000021428166,0.00031459093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952339,0.0004646466,0.003332676,0.00032120728,0.00039146733,0.00025612095],"domain_scores_gemma":[0.99547654,0.0025979108,0.001175196,0.00041049588,0.00014144936,0.0001983974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022583886,0.0001808263,0.0010688588,0.00012562229,0.000021620219,0.0000024277963,0.00018971143,0.00030561924,0.00041391051],"category_scores_gemma":[0.0008031284,0.00014607569,0.00032973816,0.0004343038,0.0005602508,0.000039177987,0.00009339655,0.00074137695,0.000010875767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011869989,0.0074861976,0.92003304,0.0004159434,0.0004963306,0.000007252543,0.0012475902,0.0000018918231,0.00016008643,0.000073844654,0.00017690759,0.06871393],"study_design_scores_gemma":[0.021853987,0.0010842504,0.93291175,0.0012705432,0.00074821967,0.000006952061,0.0007082214,0.008680826,0.007362192,0.00013084886,0.024861228,0.00038094888],"about_ca_topic_score_codex":0.000015568732,"about_ca_topic_score_gemma":0.000013109452,"teacher_disagreement_score":0.068332985,"about_ca_system_score_codex":0.000026282312,"about_ca_system_score_gemma":0.00016127415,"threshold_uncertainty_score":0.5956794},"labels":[],"label_agreement":null},{"id":"W2006329028","doi":"10.1016/j.clinthera.2008.03.015","title":"Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the Abatacept in Inadequate Responders to Methotrexate (AIM) trial","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Medicine; Abatacept; Internal medicine; Rheumatoid arthritis; Physical therapy; Placebo; Visual analogue scale; Randomized controlled trial; Quality of life (healthcare); Rheumatology; Family medicine; Alternative medicine; Rituximab; Nursing","score_opus":0.14534338236981523,"score_gpt":0.4034191662231987,"score_spread":0.2580757838533835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006329028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948786,0.0022687681,0.00066189386,0.00040099255,0.0002533419,0.001411784,0.00006624872,0.000044351596,0.0000140431675],"genre_scores_gemma":[0.9360762,0.060167678,0.0022146602,0.001262123,0.00007299268,0.00008227026,0.000021700436,0.000061076484,0.000041275336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917441,0.0033106245,0.002511541,0.0007775606,0.0008282185,0.00082797057],"domain_scores_gemma":[0.9944132,0.0027632508,0.00045312083,0.0013124566,0.00029114573,0.00076682545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045258254,0.00036871535,0.001831616,0.00071443414,0.000110078014,0.00005530662,0.00046272847,0.0003240935,0.0000852987],"category_scores_gemma":[0.001831763,0.00024945848,0.00063108926,0.0022418967,0.0010652046,0.0003393838,0.0001358674,0.0012283501,0.0000084353505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13116604,0.0028582884,0.77835447,0.0000104728,0.0014044035,0.00023149265,0.0021803307,0.00009861231,0.00072480715,0.00006231723,0.000017603847,0.082891144],"study_design_scores_gemma":[0.09609531,0.0074259033,0.887766,0.00058015727,0.00010076968,0.000024230214,0.0013336607,0.003829059,0.00043388354,0.00019085423,0.0017662186,0.00045392296],"about_ca_topic_score_codex":0.00028651833,"about_ca_topic_score_gemma":0.0037994718,"teacher_disagreement_score":0.10941155,"about_ca_system_score_codex":0.00009711687,"about_ca_system_score_gemma":0.0010513514,"threshold_uncertainty_score":0.99999577},"labels":[],"label_agreement":null},{"id":"W2007038546","doi":"10.1016/j.clinthera.2012.06.006","title":"Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Queen's University; Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Toronto","funders":"Microsoft","keywords":"Hyperphosphatemia; Medicine; Lanthanum carbonate; Dialysis; Regimen; Internal medicine; Phosphate binder; Kidney disease; Randomized controlled trial; Quality of life (healthcare); Sevelamer; Cost effectiveness; Intensive care medicine","score_opus":0.14983740060457254,"score_gpt":0.4346689814612225,"score_spread":0.28483158085664995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007038546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019223,0.006621121,0.0000019353872,0.00013124399,0.00011473205,0.00095667,0.00003737061,0.0000029814667,0.0019416922],"genre_scores_gemma":[0.99786854,0.0017773778,0.00002256031,0.00017107323,0.000026093612,0.00008175432,0.00002476321,0.000011735427,0.000016130942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863946,0.00037605787,0.00041360155,0.00015679469,0.00014513152,0.00026897003],"domain_scores_gemma":[0.99875677,0.00067575567,0.000101352896,0.00026541093,0.00009448418,0.000106256564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049184926,0.00013612093,0.00051965367,0.00010431651,0.000016110305,0.0000024562398,0.000073677635,0.000120176206,0.000006363609],"category_scores_gemma":[0.00006345885,0.00008178002,0.00017620531,0.00029780515,0.00011483256,0.00003256854,0.0000060796287,0.000105851715,0.0000043552245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049202325,0.0052294466,0.9871661,0.000006567894,0.00026233942,0.0000083771265,0.0030773152,0.000005572319,0.000016568025,0.0001842662,0.000003557117,0.0035478333],"study_design_scores_gemma":[0.006912704,0.0011820208,0.9888157,0.000026646823,0.00026770163,7.9139664e-7,0.0010772747,0.000054593776,0.00029639972,0.00017748866,0.0011142545,0.00007441872],"about_ca_topic_score_codex":0.025442157,"about_ca_topic_score_gemma":0.012310551,"teacher_disagreement_score":0.013131606,"about_ca_system_score_codex":0.00032655604,"about_ca_system_score_gemma":0.00014715792,"threshold_uncertainty_score":0.9810475},"labels":[],"label_agreement":null},{"id":"W2007106795","doi":"10.1016/s0149-2918(01)80156-9","title":"Cost-effectiveness to tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: A Canadian perspective","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph's Hospital","funders":"","keywords":"Tolterodine; Oxybutynin; Medicine; Overactive bladder; Discontinuation; Urinary incontinence; Cost effectiveness; Urology; Internal medicine","score_opus":0.1886520086421757,"score_gpt":0.46780211957990764,"score_spread":0.2791501109377319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007106795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98587614,0.000226418,0.0023946208,0.0044393167,0.00013758476,0.0050895256,0.0001389287,0.000045243338,0.0016522403],"genre_scores_gemma":[0.9945592,0.00035301768,0.0007260084,0.0030580868,0.00033245303,0.00040731503,0.00006937372,0.000070999675,0.00042353955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977926,0.0002331612,0.00036317206,0.00057143153,0.00035520317,0.00068445323],"domain_scores_gemma":[0.99701554,0.0008210832,0.00007816469,0.00041484652,0.000956594,0.00071374886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006890346,0.00028378356,0.00060146744,0.00015308437,0.00018284794,0.00004870603,0.00020004778,0.00014726508,0.000066892266],"category_scores_gemma":[0.00014842291,0.0001845583,0.00012457222,0.00042161255,0.0002707548,0.000119658536,0.000034000208,0.00043731605,0.000013504185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035675816,0.0015598834,0.88214207,0.00003225717,0.0006810202,0.0001295242,0.0011986158,0.0000068248864,0.000035455265,0.00018189779,0.00022650989,0.07813012],"study_design_scores_gemma":[0.020102965,0.031702146,0.8477456,0.00033474262,0.00016743041,0.000040065443,0.00051214045,0.00014576089,0.00030517593,0.00028513887,0.09813802,0.0005208113],"about_ca_topic_score_codex":0.0026150472,"about_ca_topic_score_gemma":0.0064722565,"teacher_disagreement_score":0.097911514,"about_ca_system_score_codex":0.00019383909,"about_ca_system_score_gemma":0.0006675903,"threshold_uncertainty_score":0.7526069},"labels":[],"label_agreement":null},{"id":"W2007908610","doi":"10.1016/s0149-2918(02)85104-9","title":"Confirmatory factor analysis and clinical significance of the illness intrusiveness ratings scale in men and women with common cancer diagnoses","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Health and Wellbeing Research","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Confirmatory factor analysis; Intrusiveness; Medical diagnosis; Clinical psychology; Scale (ratio); Psychiatry; Pathology; Psychotherapist; Statistics; Structural equation modeling","score_opus":0.13823340477401017,"score_gpt":0.5037623624326669,"score_spread":0.3655289576586568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007908610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958161,0.0006526463,0.000032719767,0.0021499773,0.00016243072,0.00081947685,0.000042020372,0.000015452624,0.00030917305],"genre_scores_gemma":[0.98957455,0.0070518814,0.000037771882,0.0028455576,0.00011347215,0.00014992835,9.739201e-7,0.000018467617,0.00020739758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951396,0.0024444915,0.0012710621,0.0003576005,0.00027761594,0.0005096535],"domain_scores_gemma":[0.99046755,0.008280637,0.00042156552,0.00040294655,0.00014333917,0.00028399067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025107723,0.00015084015,0.0007962812,0.00007776629,0.00034638174,0.000011850795,0.00024839965,0.00030678767,0.00023769149],"category_scores_gemma":[0.00033735676,0.00009194413,0.0000670723,0.000568947,0.00096652005,0.000056829296,0.00014914002,0.0012098984,0.0000034491845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020905587,0.0001664022,0.94257724,0.0001637453,0.00017236026,0.0000013527667,0.0037260754,0.0000034196287,0.00001212615,0.000019777175,0.000046590812,0.052901853],"study_design_scores_gemma":[0.0015826952,0.00021891724,0.9904476,0.00016934387,0.000095553274,1.8509989e-7,0.0021483905,0.0015111418,0.000027448423,0.00009513938,0.0035730626,0.00013051901],"about_ca_topic_score_codex":0.0004972102,"about_ca_topic_score_gemma":0.0015253939,"teacher_disagreement_score":0.052771334,"about_ca_system_score_codex":0.000071095965,"about_ca_system_score_gemma":0.00025774597,"threshold_uncertainty_score":0.52564734},"labels":[],"label_agreement":null},{"id":"W2008610508","doi":"10.1016/j.clinthera.2012.02.010","title":"Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vale (Canada); University of Toronto","funders":"Janssen Canada","keywords":"Bioequivalence; Cmax; Pharmacokinetics; Medicine; Pharmacology; Tolerability; Crossover study; In vivo; Adverse effect; Placebo; Biotechnology","score_opus":0.24557169644029217,"score_gpt":0.44398341118880796,"score_spread":0.1984117147485158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008610508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749786,0.0013302398,0.000118455144,0.00037571788,0.00012241356,0.0004882112,0.000023460256,0.0000026757084,0.000040967476],"genre_scores_gemma":[0.9988709,0.00081045,0.000121197714,0.00012667137,0.000021190543,0.00002996628,0.000007020107,0.000007690906,0.000004921452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981202,0.0004895481,0.0007934852,0.00015565667,0.00024035785,0.00020076512],"domain_scores_gemma":[0.99845684,0.0010895277,0.00019248639,0.00016514485,0.000053502754,0.000042502583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009982657,0.00011066519,0.00038665032,0.00015442613,0.000010292324,0.0000039477914,0.00010276045,0.000063381376,0.000023849734],"category_scores_gemma":[0.0002378375,0.00008269982,0.000037404632,0.00037324795,0.0001253107,0.00012190242,0.000031657255,0.00033133055,2.649416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021143445,0.0011857372,0.9309731,0.00013527452,0.000013767837,0.0000020605507,0.0010358529,0.000026593998,0.015978063,0.00008568182,0.0000016529846,0.050350737],"study_design_scores_gemma":[0.0018906354,0.000057343022,0.97520983,0.00013666977,0.00004709684,0.0000011319931,0.0010892254,0.019271815,0.0021139989,0.000074488955,0.000027409644,0.00008038061],"about_ca_topic_score_codex":0.008487135,"about_ca_topic_score_gemma":0.02121472,"teacher_disagreement_score":0.050270356,"about_ca_system_score_codex":0.000077789526,"about_ca_system_score_gemma":0.00019657711,"threshold_uncertainty_score":0.9981154},"labels":[],"label_agreement":null},{"id":"W2009222272","doi":"10.1016/s0149-2918(04)90174-9","title":"A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pelvic floor disorders treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada); Toronto Western Hospital; Jewish General Hospital; University of Toronto","funders":"Purdue Pharma","keywords":"Tolerability; Medicine; Oxybutynin; Adverse effect; Randomized controlled trial; Urology; Urinary incontinence; Urinary system; Anesthesia; Urination; Surgery; Overactive bladder; Internal medicine","score_opus":0.09302073076588048,"score_gpt":0.4021076919243689,"score_spread":0.30908696115848844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009222272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870114,0.0067786584,0.000518658,0.0021857864,0.00026910513,0.0025755656,0.000005607661,0.000048364214,0.0006068999],"genre_scores_gemma":[0.99353194,0.0036457612,0.0012890368,0.001032079,0.000114781455,0.00019915748,0.00003350822,0.000036822694,0.00011692927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964962,0.00026494273,0.0019935654,0.00047902457,0.00036155572,0.00040470148],"domain_scores_gemma":[0.997027,0.0016155218,0.0005142298,0.00047462652,0.00010266481,0.00026598098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015097428,0.00033509033,0.002593077,0.00016333598,0.00004306743,0.000015045365,0.00017573586,0.0003307524,0.000025903219],"category_scores_gemma":[0.000388249,0.0002527897,0.0004590814,0.00025466998,0.0007713532,0.00008594229,0.00008868436,0.00058512,0.00002019752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85306144,0.006183803,0.13535084,0.00007192193,0.0007831995,0.0000900438,0.0004431032,0.000076453915,0.00007671416,0.000799749,0.000009508262,0.003053231],"study_design_scores_gemma":[0.9800217,0.001427873,0.012954571,0.00024023141,0.0008096508,0.000019440587,0.00019810403,0.001721418,0.00017365739,0.001949829,0.0002529934,0.00023050871],"about_ca_topic_score_codex":0.00014159514,"about_ca_topic_score_gemma":0.000054975026,"teacher_disagreement_score":0.12696029,"about_ca_system_score_codex":0.000065404325,"about_ca_system_score_gemma":0.00017871356,"threshold_uncertainty_score":0.99999243},"labels":[],"label_agreement":null},{"id":"W2010613696","doi":"10.1016/j.clinthera.2013.07.012","title":"Oc013 — A Simplified Method For Busulfan Therapeutic Drug Monitoring Using Dried Blood Spot Sampling In Pediatric Patient Undergoing Stem Cell Transplantation","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood disorders and treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Busulfan; Therapeutic drug monitoring; Dried blood spot; Hematopoietic stem cell transplantation; Pharmacokinetics; Therapeutic window; Stem cell; Hematopoietic stem cell; Therapeutic index; Blood sampling; Drug; Transplantation; Therapeutic effect; Pharmacology; Haematopoiesis; Surgery; Internal medicine; Chromatography","score_opus":0.0800214425348415,"score_gpt":0.36916108506302103,"score_spread":0.28913964252817953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010613696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592351,0.0023862785,0.037126716,0.000059514867,0.00032035075,0.00078654493,0.000011393795,0.000020109212,0.000054046148],"genre_scores_gemma":[0.9733346,0.0028463216,0.023019912,0.0003257969,0.00024989285,0.00008186002,0.000042316933,0.00005817376,0.00004111089],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806243,0.00020297956,0.0006902996,0.00051062123,0.00013417222,0.00039946815],"domain_scores_gemma":[0.99886304,0.00041931903,0.00022399263,0.00030047205,0.00009552111,0.00009762462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032704507,0.0002565314,0.0003084645,0.00006261797,0.00012360049,0.00005966011,0.00016693767,0.0002583641,0.0000031157927],"category_scores_gemma":[0.000011207625,0.00024193618,0.00021750294,0.00014516938,0.000031751537,0.000012547645,0.00003563987,0.00017229177,0.000002847776],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064286054,0.0029152168,0.5921516,0.00042644647,0.0008025444,0.000008373043,0.001245895,0.0038010045,0.118297376,0.00009388093,0.000010533417,0.27960432],"study_design_scores_gemma":[0.039960425,0.00542012,0.20057309,0.00030290493,0.0056446427,0.0000424686,0.0048991507,0.016545545,0.71275765,0.008645807,0.0015801254,0.0036280728],"about_ca_topic_score_codex":0.000029121207,"about_ca_topic_score_gemma":0.000019745348,"teacher_disagreement_score":0.59446025,"about_ca_system_score_codex":0.000017595834,"about_ca_system_score_gemma":0.000100390746,"threshold_uncertainty_score":0.98658717},"labels":[],"label_agreement":null},{"id":"W2010788192","doi":"10.1016/j.clinthera.2005.11.020","title":"Postprandial glucose regulation: New data andnew implications","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Takeda Pharmaceuticals North America; Novartis Pharmaceuticals Corporation; Unilever; Amylin Pharmaceuticals; Bayer; AstraZeneca; Novo Nordisk; Sanofi","keywords":"Postprandial; Medicine; Internal medicine; Glycemic; Endocrinology; Type 2 diabetes; Diabetes mellitus; Insulin; Basal (medicine); Insulin glargine","score_opus":0.5155880908997695,"score_gpt":0.5286185095723552,"score_spread":0.013030418672585697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010788192","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003012616,0.9922548,0.0010829169,0.0011602484,0.0010760581,0.0019018796,0.00025787804,0.00017663818,0.0020865912],"genre_scores_gemma":[0.0000068181344,0.97426146,0.003895873,0.001532991,0.014843386,0.00003688502,0.003320782,0.00015182926,0.0019499642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956515,0.00043712396,0.0018927323,0.0010898323,0.00046987017,0.0004589529],"domain_scores_gemma":[0.9930643,0.00078116823,0.00054841983,0.0049016946,0.00014762838,0.0005568196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001589584,0.00056208955,0.0033956512,0.00013162373,0.00012233588,0.00008956034,0.0009891464,0.0010634245,0.00033525605],"category_scores_gemma":[0.00038882057,0.00043846478,0.002029562,0.0004611885,0.00024024512,0.00013170204,0.0003431672,0.0011704307,0.00057679036],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051273186,0.0002488419,0.0000125406905,0.0008741764,0.0021548609,0.000004167502,0.000009215972,1.9377774e-7,2.7022045e-8,0.00007623314,0.006199446,0.990369],"study_design_scores_gemma":[0.0015554883,0.00034376184,0.000825347,0.0025951995,0.011929656,0.00010699876,0.0000023617213,0.000017910404,1.408276e-7,0.00021758712,0.98197293,0.0004326297],"about_ca_topic_score_codex":0.00007139515,"about_ca_topic_score_gemma":0.000048566166,"teacher_disagreement_score":0.9899364,"about_ca_system_score_codex":0.00009316446,"about_ca_system_score_gemma":0.0017330288,"threshold_uncertainty_score":0.9998067},"labels":[],"label_agreement":null},{"id":"W2012199712","doi":"10.1016/j.clinthera.2011.09.015","title":"Pharmacokinetics of Prednisolone at Steady State in Young Patients With Systemic Lupus Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Prednisone; Medicine; Prednisolone; Dosing; Corticosteroid; Internal medicine; Pharmacokinetics; Gastroenterology; Systemic lupus erythematosus; Pharmacology; Disease","score_opus":0.23142160991511834,"score_gpt":0.4156275607950722,"score_spread":0.18420595087995384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012199712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902246,0.0005014544,0.000051949366,0.000022751903,0.0005641273,0.0073098834,0.000055838063,0.00009962073,0.0011697476],"genre_scores_gemma":[0.9970837,0.0005295577,0.00073391735,0.00019674092,0.00007961468,0.00019167602,0.000033732027,0.00019926962,0.0009517496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99326056,0.0013869444,0.0022386778,0.0010360483,0.0012937746,0.00078401854],"domain_scores_gemma":[0.9956094,0.00069649005,0.0008326658,0.0017837401,0.0006594022,0.00041832658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022926643,0.0005635088,0.0016837765,0.00028154138,0.000095416144,0.000051280556,0.0010676736,0.00027821137,0.000084551386],"category_scores_gemma":[0.00010287764,0.0004000577,0.00009339077,0.0006178335,0.00043424097,0.00024061599,0.00043255716,0.0007274074,0.000042516782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027111638,0.04260939,0.9095402,0.00028550936,0.0008784236,0.000106740845,0.011506047,0.0000059152553,0.0014788518,0.000011479591,0.000027426102,0.006438427],"study_design_scores_gemma":[0.36558333,0.22956991,0.375117,0.0056179687,0.0012971221,0.0033360915,0.009810707,0.001949444,0.0049617304,0.00038312844,0.00026031176,0.0021132445],"about_ca_topic_score_codex":0.00009091416,"about_ca_topic_score_gemma":0.00013019187,"teacher_disagreement_score":0.5344231,"about_ca_system_score_codex":0.00032555504,"about_ca_system_score_gemma":0.00024206565,"threshold_uncertainty_score":0.99984515},"labels":[],"label_agreement":null},{"id":"W2012729846","doi":"10.1016/s0149-2918(04)90039-2","title":"Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Tolterodine; Oxybutynin; Overactive bladder; Medicine; Urology; Population; Pharmacotherapy; Internal medicine; Alternative medicine","score_opus":0.11173355992120088,"score_gpt":0.4425396663932687,"score_spread":0.3308061064720678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012729846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337095,0.0021877778,0.000009287078,0.0030605658,0.00008214124,0.0005451174,0.00007150869,0.0000046445907,0.0006680118],"genre_scores_gemma":[0.9941835,0.005079791,0.000104830586,0.00041592866,0.00009747909,0.000014015389,0.000028696917,0.000015087626,0.000060707032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985234,0.00017138013,0.00064621324,0.00022916502,0.00015356268,0.00027626142],"domain_scores_gemma":[0.9986259,0.00063732185,0.0001233361,0.00032087514,0.000054396394,0.00023817364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038600102,0.00014648947,0.0005242742,0.000113084156,0.000036908183,0.0000089890045,0.00010287377,0.0001242958,0.00007124549],"category_scores_gemma":[0.000036162164,0.00009741958,0.00013024539,0.00009933078,0.00027979395,0.000040566592,0.000013633712,0.00026017166,0.000010920395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006348118,0.014052524,0.6785863,0.00015883235,0.0015454072,0.00031374735,0.014854785,0.00043644442,0.0011683943,0.0013380862,0.00022501813,0.28097236],"study_design_scores_gemma":[0.01917361,0.022331413,0.9284393,0.00012526996,0.0005815096,0.000052478117,0.0036089013,0.0023474244,0.0074311686,0.0024556753,0.013108094,0.00034513403],"about_ca_topic_score_codex":0.01587435,"about_ca_topic_score_gemma":0.013488477,"teacher_disagreement_score":0.28062722,"about_ca_system_score_codex":0.00019794762,"about_ca_system_score_gemma":0.0006634996,"threshold_uncertainty_score":0.990679},"labels":[],"label_agreement":null},{"id":"W2013209414","doi":"10.1016/j.clinthera.2004.09.015","title":"A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Drug Solubulity and Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Fenofibrate; Bioavailability; Medicine; Pharmacokinetics; Tolerability; Pharmacology; Bioequivalence; Area under the curve; Absorption (acoustics); Adverse effect","score_opus":0.5869144921197285,"score_gpt":0.5656751994212865,"score_spread":0.021239292698441936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013209414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907747,0.0018527784,0.0011558671,0.0024232552,0.0018380645,0.00052422704,0.0001689786,0.0000694891,0.0011926414],"genre_scores_gemma":[0.9949562,0.0010003306,0.0018609182,0.0014707989,0.00036989446,0.000004167587,0.000023161883,0.000017744362,0.00029678267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954769,0.0010568476,0.002545233,0.00043782452,0.00018844442,0.00029476522],"domain_scores_gemma":[0.99140716,0.006693979,0.0008954224,0.0003655289,0.00039578823,0.00024210525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003505073,0.00022509812,0.00086899777,0.000060491053,0.00018149582,0.000013916892,0.0002058066,0.0005819049,0.00004426714],"category_scores_gemma":[0.00093408924,0.00019912199,0.00028647605,0.00026815222,0.0012601027,0.00013985737,0.00013614562,0.00064928527,0.000018560286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025878048,0.015565233,0.60218877,0.0017810621,0.014092015,0.000051680872,0.0117128,0.012214872,0.030351376,0.048959278,0.005167183,0.23203766],"study_design_scores_gemma":[0.123707496,0.0228745,0.44215602,0.0016224321,0.0066433754,0.00011409607,0.011579787,0.013075421,0.046081588,0.19096653,0.13779905,0.0033796849],"about_ca_topic_score_codex":0.00002468142,"about_ca_topic_score_gemma":0.000057094265,"teacher_disagreement_score":0.22865798,"about_ca_system_score_codex":0.00004211539,"about_ca_system_score_gemma":0.00026187956,"threshold_uncertainty_score":0.8119959},"labels":[],"label_agreement":null},{"id":"W2013447731","doi":"10.1016/j.clinthera.2009.07.006","title":"Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Post-hoc analysis; Double blind; Placebo; Post hoc; Major depressive disorder; Internal medicine; Psychiatry; Pathology; Alternative medicine","score_opus":0.1276188551707093,"score_gpt":0.4377679477550525,"score_spread":0.3101490925843432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013447731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526108,0.038899254,0.0003125859,0.0012869008,0.00009577929,0.006716901,0.000028398192,0.000023749888,0.000025656613],"genre_scores_gemma":[0.97190696,0.0262413,0.00093527837,0.00034479116,0.00011691937,0.00031908954,0.00007826404,0.000021296444,0.000036125795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99592936,0.0009164327,0.001863952,0.0005642831,0.00042237982,0.00030361576],"domain_scores_gemma":[0.9935668,0.0045929076,0.0008113381,0.00070282986,0.00017416639,0.00015195196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015972126,0.0004302468,0.0035098013,0.00032872206,0.00009524815,0.000027746302,0.00017745097,0.00024528772,0.000015966734],"category_scores_gemma":[0.00023336642,0.00022475689,0.00080646767,0.00034377843,0.0006259874,0.00010201695,0.000036944177,0.00022011514,4.212869e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8961471,0.021653153,0.007323273,0.000021673115,0.014586402,0.00003047566,0.0015174176,0.000027618498,0.00024851758,0.000062013234,0.000001665708,0.058380723],"study_design_scores_gemma":[0.9302452,0.022566203,0.006133538,0.00009357512,0.035164084,0.000004650521,0.0006968957,0.0046009133,0.000051464453,0.00020821248,0.000059234888,0.00017603565],"about_ca_topic_score_codex":0.000088261055,"about_ca_topic_score_gemma":0.00044345495,"teacher_disagreement_score":0.058204688,"about_ca_system_score_codex":0.000041510724,"about_ca_system_score_gemma":0.000047245132,"threshold_uncertainty_score":0.916532},"labels":[],"label_agreement":null},{"id":"W2013547083","doi":"10.1016/j.clinthera.2009.07.024","title":"Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: Systematic review of randomized controlled trials and quasi-randomized controlled trials","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Intramuscular injections and effects","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Sanofi Pasteur","keywords":"Medicine; Randomized controlled trial; Psychological intervention; Placebo; Physical therapy; Intramuscular injection; CINAHL; Subcutaneous injection; Clinical trial; Vaccine efficacy; Injection site; Vaccination; Anesthesia; Surgery; Internal medicine; Alternative medicine; Nursing","score_opus":0.10631784320502378,"score_gpt":0.46884743610802276,"score_spread":0.36252959290299896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013547083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052141706,0.8888954,0.023747582,0.000187304,0.00043208318,0.08647983,0.000029162877,0.00014192298,0.00003456478],"genre_scores_gemma":[0.0007093869,0.9838027,0.0013997116,0.00021984903,0.0009531085,0.01248734,0.00016784821,0.00009645801,0.00016364775],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9130793,0.06775967,0.017783772,0.00064371945,0.0004174547,0.00031604696],"domain_scores_gemma":[0.82928234,0.15300795,0.015582091,0.00087728683,0.0010740969,0.0001762497],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.21469186,0.00089654094,0.09297648,0.0007239501,0.0002695362,0.00011911657,0.00015137043,0.0008040653,0.000012596118],"category_scores_gemma":[0.3173893,0.00046932077,0.026036587,0.000491031,0.00041795606,0.000091725764,0.00004897144,0.0008883284,8.0155297e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2090257,0.0013458652,1.501072e-7,0.65414244,0.03042842,0.0000010692962,0.00009444091,0.0000011230484,0.0000033012893,0.00048948824,0.000012948182,0.10445503],"study_design_scores_gemma":[0.4176602,0.0010554476,1.6958323e-7,0.43051863,0.14925086,0.000074625175,0.000026136457,0.0007738515,0.0000025146855,0.00032305278,0.00009557052,0.00021893541],"about_ca_topic_score_codex":0.0000087801145,"about_ca_topic_score_gemma":7.086838e-7,"teacher_disagreement_score":0.22362383,"about_ca_system_score_codex":0.0001173086,"about_ca_system_score_gemma":0.0002994437,"threshold_uncertainty_score":0.9997758},"labels":[],"label_agreement":null},{"id":"W2013803462","doi":"10.1016/j.clinthera.2009.10.014","title":"Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: A new simulation model","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"GlaxoSmithKline","keywords":"Medicine; Streptococcus pneumoniae; Haemophilus influenzae; Vaccination; Pneumococcal infections; Pneumococcal conjugate vaccine; Immunology; Pneumonia; Conjugate vaccine; Pneumococcal disease; Virology; Immunization; Microbiology; Internal medicine; Biology; Antibiotics","score_opus":0.1433132348477407,"score_gpt":0.4521680009138585,"score_spread":0.30885476606611784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013803462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831132,0.00036980378,0.012943138,0.0028375639,0.000063010266,0.0004139161,0.000006967257,0.000055483524,0.00019688474],"genre_scores_gemma":[0.9948619,0.00023648242,0.00010665727,0.0042261602,0.0003781224,0.0000016067829,0.0000035562166,0.000017872399,0.00016761813],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987593,0.00006201773,0.0005728424,0.00023139818,0.0001696545,0.00020474874],"domain_scores_gemma":[0.9987591,0.00030185044,0.00011039938,0.00041527813,0.00009339999,0.00032000092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019119476,0.0001797203,0.00041664147,0.00006337813,0.00009965794,0.000020425,0.00009044976,0.00017427413,0.0000122196125],"category_scores_gemma":[0.00016464709,0.00010379908,0.00031760742,0.0001770838,0.000043149128,0.00006828739,0.000021025726,0.0003798532,0.000005805813],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071636384,0.000469755,0.015481267,0.00000715317,0.00017246969,0.0000028246147,0.00015751863,0.94984806,0.0018246934,0.00011214029,0.000066558365,0.031141225],"study_design_scores_gemma":[0.0023242952,0.0018830434,0.06815036,0.00006467739,0.00029407258,0.000006829314,0.000010744541,0.9210262,0.000013407236,0.005857313,0.00026327386,0.00010581391],"about_ca_topic_score_codex":0.000026390804,"about_ca_topic_score_gemma":0.000002393634,"teacher_disagreement_score":0.05266909,"about_ca_system_score_codex":0.00003968509,"about_ca_system_score_gemma":0.00042443463,"threshold_uncertainty_score":0.42328036},"labels":[],"label_agreement":null},{"id":"W2013899794","doi":"10.1016/s0149-2918(02)80102-3","title":"An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme a reductase inhibitors on health care utilization: A Canadian population-based study","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Toronto Metropolitan University; University of Toronto; Bristol-Myers Squibb (Canada); PharmIdeas (Canada)","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Statin; Medical prescription; Atorvastatin; Drug; Drug interaction; Health care; Pharmacology; Population; Adverse effect; Internal medicine; Environmental health","score_opus":0.19452395590427193,"score_gpt":0.5057903588286968,"score_spread":0.31126640292442487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013899794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524236,0.0011789623,0.000014271653,0.0006300478,0.0011741924,0.0012697389,0.00028314863,0.000019229623,0.00018802636],"genre_scores_gemma":[0.9982708,0.00013318678,0.000052770036,0.0012084821,0.00019606747,0.000030525956,0.00005695503,0.00002996099,0.000021240337],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944878,0.0034368297,0.0011876685,0.00031815522,0.00029690785,0.00027261474],"domain_scores_gemma":[0.99698746,0.0012912479,0.00070874,0.0005175998,0.00021629798,0.00027867814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017273113,0.00023097993,0.0005705624,0.00023459615,0.00021434757,0.0000068671875,0.00038636368,0.0001530514,0.0002678075],"category_scores_gemma":[0.00015518005,0.00018169994,0.00024125271,0.00053834217,0.00020777773,0.000056328518,0.000030002477,0.00063817005,0.0000037675134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011566731,0.007822573,0.424453,0.0004673234,0.0011871109,0.00000933613,0.0153162265,0.01912801,0.014750995,0.00026470213,0.0009593085,0.51448476],"study_design_scores_gemma":[0.010538197,0.0060638827,0.7474264,0.00017095133,0.0015266072,0.000003597696,0.0012691437,0.053139996,0.1630053,0.000091115675,0.016150767,0.0006140451],"about_ca_topic_score_codex":0.0017528684,"about_ca_topic_score_gemma":0.0033949197,"teacher_disagreement_score":0.5138707,"about_ca_system_score_codex":0.00011288065,"about_ca_system_score_gemma":0.00018650094,"threshold_uncertainty_score":0.7409509},"labels":[],"label_agreement":null},{"id":"W2015078439","doi":"10.1016/j.clinthera.2010.10.011","title":"Safety profile of abatacept in rheumatoid arthritis: A review","year":2010,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Alberta; Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"","keywords":"Abatacept; Medicine; Rheumatoid arthritis; Adverse effect; Internal medicine; Rheumatology; Rheumatism; Placebo; Clinical trial; Methotrexate; Safety profile; Arthritis; Physical therapy; Alternative medicine; Rituximab; Pathology","score_opus":0.11986012295375029,"score_gpt":0.44744289692045824,"score_spread":0.327582773966708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015078439","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015957301,0.994117,0.000013159017,0.0002872856,0.00040110754,0.0029831366,0.00014497242,0.000057902675,0.0019794852],"genre_scores_gemma":[0.000007202872,0.99764186,0.00083163107,0.000569628,0.00015026948,0.00019821041,0.00025677794,0.00012145694,0.0002229875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99345684,0.0008473687,0.003849389,0.00064719387,0.0006041071,0.00059510046],"domain_scores_gemma":[0.9957966,0.001459454,0.00086685905,0.0013133594,0.0002382162,0.00032551814],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002951191,0.00054934534,0.0058657518,0.00023004312,0.000049649843,0.000020296357,0.0005031343,0.00093813677,0.00096473703],"category_scores_gemma":[0.001001885,0.00040870253,0.0015924866,0.0006319839,0.00070545496,0.00007194172,0.00015540967,0.0030631234,0.00027634835],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069080015,0.0005447415,0.00010676214,0.02059418,0.00033238437,0.00004691103,0.000018301647,3.914193e-9,4.6420092e-7,0.00023993052,0.00051159953,0.97753567],"study_design_scores_gemma":[0.0013499059,0.0003816276,0.000030420188,0.23078333,0.000057735106,0.0001696428,0.000006768772,0.0000027123415,9.060493e-7,0.00008095398,0.76687753,0.00025849644],"about_ca_topic_score_codex":0.00000667737,"about_ca_topic_score_gemma":0.000023964834,"teacher_disagreement_score":0.97727716,"about_ca_system_score_codex":0.00005117086,"about_ca_system_score_gemma":0.0012976939,"threshold_uncertainty_score":0.9999485},"labels":[],"label_agreement":null},{"id":"W2015788572","doi":"10.1016/s0149-2918(03)80171-6","title":"Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Canadian Association of Radiation Oncology","funders":"","keywords":"Galantamine; Medicine; Disease; Placebo; Clinical trial; Population; Economic evaluation; Pharmacoeconomics; Alzheimer's disease; Gerontology; Donepezil; Intensive care medicine; Dementia; Environmental health; Internal medicine; Alternative medicine","score_opus":0.197537456492979,"score_gpt":0.40990070971416415,"score_spread":0.21236325322118516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015788572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977623,0.0008323514,0.0000037651748,0.0006391953,0.000024183733,0.00019818667,0.00003731515,0.0000032850116,0.0004994016],"genre_scores_gemma":[0.9981675,0.0012199985,0.00003156852,0.00044826837,0.000036700687,0.00003923768,0.000039198636,0.000009113126,0.000008387404],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998573,0.0003402991,0.0005943246,0.00016748082,0.0001890294,0.0001358614],"domain_scores_gemma":[0.9979305,0.0014818975,0.00011663934,0.00039030303,0.000039402774,0.000041249026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011284726,0.000113673064,0.00024208469,0.000027784368,0.000016668355,0.000010594417,0.00020675463,0.00006575959,0.00012701222],"category_scores_gemma":[0.000079776684,0.000063066705,0.0001161122,0.00011833031,0.00008276664,0.000014101605,0.0000072704847,0.00009090981,0.000003568644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035605992,0.02473082,0.68830943,0.0001401273,0.0016030364,0.000016132572,0.014960615,0.06346236,0.014003397,0.0039192103,0.00032199116,0.1849723],"study_design_scores_gemma":[0.019587755,0.0015971047,0.16399962,0.00046602194,0.0041241227,0.0000033186632,0.0064238184,0.3061472,0.37652662,0.034682114,0.085052095,0.0013902122],"about_ca_topic_score_codex":0.00006990361,"about_ca_topic_score_gemma":0.000043993685,"teacher_disagreement_score":0.5243098,"about_ca_system_score_codex":0.000046373654,"about_ca_system_score_gemma":0.00005821351,"threshold_uncertainty_score":0.25717857},"labels":[],"label_agreement":null},{"id":"W2016111743","doi":"10.1016/j.clinthera.2014.10.002","title":"Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada","keywords":"Medicine; Pharmacokinetics; Cmax; Pharmacodynamics; Dosing; Placebo; Pharmacology; Gastroenterology; Oral administration; Hepatitis C virus; Hepatitis C; Internal medicine; Immunology; Virus","score_opus":0.10356200044011353,"score_gpt":0.4479772523695192,"score_spread":0.34441525192940564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016111743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432266,0.00017294324,0.002215364,0.0007038811,0.00041197753,0.0005341843,0.00015009337,0.000071587136,0.0014173154],"genre_scores_gemma":[0.9802796,0.0077245305,0.006593536,0.0044552223,0.000601247,0.000013009531,0.000089969755,0.00008733974,0.00015549951],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.996751,0.0004895973,0.00121234,0.0005273408,0.0005494285,0.0004702851],"domain_scores_gemma":[0.99736506,0.00071240554,0.00027193705,0.00065070647,0.0003757635,0.0006241572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013527506,0.0002916406,0.00083337975,0.00015585979,0.00008184051,0.000042562664,0.00028132068,0.00030687934,0.00013638697],"category_scores_gemma":[0.0003084893,0.00026681862,0.00019784152,0.000292311,0.0006606776,0.00012479982,0.00016130458,0.0007633219,0.000034976638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010772521,0.0014484088,0.51387316,0.00024734717,0.00049269793,0.000066997854,0.00022168877,0.000014314901,0.056160867,0.00015012053,0.00044837865,0.42579874],"study_design_scores_gemma":[0.017597916,0.01487569,0.36443517,0.0003725758,0.0014229032,0.00006238653,0.00006293998,0.42295653,0.036113497,0.0006626328,0.14030285,0.0011349166],"about_ca_topic_score_codex":0.00011184944,"about_ca_topic_score_gemma":0.00023744103,"teacher_disagreement_score":0.42466384,"about_ca_system_score_codex":0.0000440003,"about_ca_system_score_gemma":0.00019287765,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W2016152653","doi":"10.1016/j.clinthera.2011.09.025","title":"Economic Evaluation of Clodronate and Zoledronate in Patients Diagnosed With Metastatic Bone Disease From the Perspective of Public and Third Party Payors in Brazil","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Bone health and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Perspective (graphical); Bone disease; Disease; Oncology; Internal medicine; Osteoporosis","score_opus":0.17372663260397303,"score_gpt":0.4093388189380883,"score_spread":0.2356121863341153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016152653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690884,0.0016091723,0.000002177996,0.00054897653,0.000038482725,0.00073681504,0.000042404128,0.0000038611142,0.00010928896],"genre_scores_gemma":[0.99841446,0.00095443276,0.00015875525,0.00040313095,0.000006301819,0.000027848537,0.000019691848,0.000010701187,0.000004659237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853146,0.00040530367,0.0005296096,0.00021845447,0.00017481405,0.00014034807],"domain_scores_gemma":[0.9987977,0.00052389037,0.00022428967,0.00020849588,0.00011388695,0.00013172085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010289295,0.00010421531,0.00037264673,0.000046581295,0.000018012255,0.000003640799,0.000039465576,0.000047637488,0.000021651143],"category_scores_gemma":[0.0001739217,0.000062791805,0.000036566245,0.000071633185,0.00028285393,0.000064355256,0.000023401755,0.00015500211,0.0000010644198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001324882,0.0010307995,0.98006606,0.000016120019,0.00015406439,0.0000039867327,0.0011083526,0.000001059236,4.9777105e-7,0.00021836237,0.0000017038992,0.016074123],"study_design_scores_gemma":[0.012018389,0.000700926,0.98006016,0.000068961584,0.00044060044,3.0698158e-7,0.00036756916,0.0013795381,0.00000701598,0.004889471,0.0000122679385,0.000054779484],"about_ca_topic_score_codex":0.0005656932,"about_ca_topic_score_gemma":0.0011734605,"teacher_disagreement_score":0.016019344,"about_ca_system_score_codex":0.000067241665,"about_ca_system_score_gemma":0.00024878018,"threshold_uncertainty_score":0.25605753},"labels":[],"label_agreement":null},{"id":"W2016564058","doi":"10.1016/s0149-2918(02)80100-x","title":"An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Abbott Canada","keywords":"Medicine; Clarithromycin; Open label; Multicenter study; Randomized controlled trial; Pharmacology; Internal medicine","score_opus":0.11272284050426361,"score_gpt":0.3979798633208641,"score_spread":0.2852570228166005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016564058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917645,0.001384644,0.00021099628,0.00009119375,0.00016199057,0.008642946,0.00030188926,0.000006213597,0.000023698718],"genre_scores_gemma":[0.99569947,0.0036625622,0.00025523207,0.000022890079,0.00005805385,0.00017061191,0.000061786595,0.000033510485,0.000035909885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962461,0.0010770522,0.0014732428,0.00042177545,0.00050283317,0.00027896801],"domain_scores_gemma":[0.99436724,0.0028884665,0.0011575285,0.0008915149,0.0005555943,0.0001396832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060285325,0.0003373243,0.0017945592,0.000061930565,0.00013560336,0.000014229037,0.00032681497,0.0001955637,0.00006608019],"category_scores_gemma":[0.000051349587,0.0001589989,0.00015221341,0.0002609556,0.0012568849,0.00011903647,0.000059898437,0.00023365454,3.4175497e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82887954,0.0856315,0.010270245,0.0001654587,0.012765956,0.0000052899663,0.0038189625,0.0009921875,0.006088271,0.00008027722,0.000008854134,0.051293485],"study_design_scores_gemma":[0.73216534,0.18062398,0.06404161,0.00032326017,0.0062014624,0.0000014313325,0.0010648525,0.0076799467,0.0075169913,0.000008162217,0.00018685807,0.00018610139],"about_ca_topic_score_codex":0.0001929327,"about_ca_topic_score_gemma":0.00013506135,"teacher_disagreement_score":0.09671416,"about_ca_system_score_codex":0.00014693281,"about_ca_system_score_gemma":0.00031153855,"threshold_uncertainty_score":0.6483787},"labels":[],"label_agreement":null},{"id":"W2017030986","doi":"10.1016/j.clinthera.2005.05.005","title":"Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Dartmouth General Hospital","funders":"","keywords":"Medicine; Pioglitazone; Insulin; Glycemic; Internal medicine; Type 2 diabetes; Placebo; Diabetes mellitus; Type 2 Diabetes Mellitus; Clinical endpoint; Glycated hemoglobin; Endocrinology; Randomized controlled trial; Gastroenterology","score_opus":0.031599770645512774,"score_gpt":0.31556168110491983,"score_spread":0.28396191045940705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017030986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789229,0.00429727,0.000027360813,0.00041725574,0.00007373216,0.016137263,0.000014195342,0.0000361212,0.00007387835],"genre_scores_gemma":[0.99510646,0.002342755,0.0008710103,0.000657501,0.000035795416,0.0007828396,0.00007921912,0.00006107098,0.00006337768],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958626,0.0006743346,0.0016680124,0.0006372195,0.00074452756,0.00041332777],"domain_scores_gemma":[0.99641097,0.0014554382,0.00084411504,0.0006422646,0.00046829417,0.00017893869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013953048,0.00047179076,0.002479984,0.00033533692,0.000032072385,0.000023900788,0.00019279262,0.00012858669,0.0000054635807],"category_scores_gemma":[0.00020242414,0.00027004708,0.00020286263,0.0007201716,0.00037156604,0.00018348647,0.000050508963,0.00034416415,0.0000038300054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59087723,0.033710454,0.35714433,0.00008611034,0.002581371,0.000010869673,0.00089883676,0.00008522467,0.0000050920994,0.00007759329,0.0000013540671,0.014521544],"study_design_scores_gemma":[0.6138803,0.012683656,0.3702665,0.00033698225,0.0014137886,2.298104e-8,0.00006970924,0.0008386082,0.0002122131,0.000024227436,0.000082518935,0.00019152187],"about_ca_topic_score_codex":0.000046954337,"about_ca_topic_score_gemma":0.000119812496,"teacher_disagreement_score":0.023003032,"about_ca_system_score_codex":0.000075996795,"about_ca_system_score_gemma":0.00011297304,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W2017628719","doi":"10.1016/j.clinthera.2009.05.006","title":"Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; University of British Columbia; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Medicine; Prednisone; Thrombocytopenic purpura; Quality-adjusted life year; Cost–benefit analysis; Cost-effectiveness analysis; Pediatrics; Cost effectiveness; Internal medicine; Immunology; Immune system","score_opus":0.03971604369594409,"score_gpt":0.3745474140808868,"score_spread":0.3348313703849427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017628719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954581,0.00037850512,0.0018132675,0.0007498856,0.000014824997,0.0011998831,0.00019455163,0.0000073951446,0.00018355774],"genre_scores_gemma":[0.99541837,0.00037794095,0.0036684053,0.00032383282,0.0000049739047,0.000013998787,0.00017895471,0.000006012383,0.00000752],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985124,0.000029552188,0.00090084196,0.0001727455,0.00012479282,0.00025966542],"domain_scores_gemma":[0.9990251,0.00012073809,0.00021614754,0.00032529657,0.00016039425,0.00015229416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004926642,0.00013144633,0.000730308,0.0001797575,0.000029870585,0.000008746276,0.000088319815,0.00012970071,0.0000023614562],"category_scores_gemma":[0.00010275576,0.00010140116,0.00011495578,0.00042465536,0.00008402281,0.000081375576,0.000011872236,0.00012557255,8.325193e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034601483,0.0027222803,0.0982757,0.000334779,0.0045948518,0.000038402493,0.0039185463,0.024286445,0.0002795257,0.0008664275,0.000018545903,0.830063],"study_design_scores_gemma":[0.010751061,0.003931307,0.57396036,0.00016230589,0.0009834414,0.000006190279,0.00006327134,0.409129,0.00030118326,0.00042150915,0.00016494135,0.00012545571],"about_ca_topic_score_codex":0.011897134,"about_ca_topic_score_gemma":0.03677971,"teacher_disagreement_score":0.8299376,"about_ca_system_score_codex":0.000110139845,"about_ca_system_score_gemma":0.0004967838,"threshold_uncertainty_score":0.9946827},"labels":[],"label_agreement":null},{"id":"W2017801173","doi":"10.1016/j.clinthera.2011.09.001","title":"Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Tolerability; Medicine; Bioavailability; Adverse effect; Crossover study; Internal medicine; Population; Urinary system; Pharmacology; Placebo","score_opus":0.19891950271004039,"score_gpt":0.4303338162399595,"score_spread":0.2314143135299191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017801173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729365,0.0007406145,0.0000056567646,0.00022273211,0.000062532745,0.0008711117,0.0000144486075,0.000024588344,0.0007646889],"genre_scores_gemma":[0.9976163,0.0013962284,0.00039559972,0.0004663096,0.000028062559,0.0000106893185,0.00001157034,0.000016111158,0.00005915985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771285,0.00025302457,0.0010837927,0.00040568825,0.0002153417,0.00032932556],"domain_scores_gemma":[0.99859875,0.00034660203,0.00009108269,0.0005806102,0.00013224388,0.0002507346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013372792,0.00013907602,0.00063940155,0.00006881228,0.00002229733,0.0000039502142,0.00010439345,0.00025538905,0.00017109001],"category_scores_gemma":[0.00018462197,0.00010934105,0.00012291459,0.00021471384,0.00057712314,0.000040372328,0.00007672839,0.0005022237,0.000012915145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088348077,0.0011198976,0.93515915,0.00012158025,0.00005214193,0.0000048998872,0.00012069998,3.9749736e-8,0.00041640882,0.000021382548,0.0000033986007,0.0620969],"study_design_scores_gemma":[0.0016650602,0.0011824507,0.9949301,0.000052141077,0.000057913116,0.000009431854,0.000026222866,0.00015053536,0.0016022128,0.00015206651,0.00008062023,0.0000912773],"about_ca_topic_score_codex":0.00015507768,"about_ca_topic_score_gemma":0.0000577791,"teacher_disagreement_score":0.062005624,"about_ca_system_score_codex":0.000035874742,"about_ca_system_score_gemma":0.00016501831,"threshold_uncertainty_score":0.44587985},"labels":[],"label_agreement":null},{"id":"W2018295858","doi":"10.1016/j.clinthera.2010.01.021","title":"Aripiprazole in schizophrenia and schizoaffective disorder: A review","year":2010,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Université de Montréal; Hôpital Louis-H Lafontaine","funders":"Université de Montréal; Pfizer; AstraZeneca Canada; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Aripiprazole; Schizoaffective disorder; Tolerability; Medicine; Schizophrenia (object-oriented programming); Atypical antipsychotic; Psychiatry; Antipsychotic; Adverse effect; Tardive dyskinesia; Psychosis; Internal medicine","score_opus":0.1369497567409218,"score_gpt":0.4843338219404982,"score_spread":0.3473840651995764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018295858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007816989,0.9948127,0.0000070505994,0.00046249747,0.0001810093,0.0029335346,0.000018647861,0.000069676964,0.0014367044],"genre_scores_gemma":[0.000010625919,0.9959343,0.0021042742,0.00056312035,0.00027679224,0.00026161937,0.000055905213,0.00014971055,0.00064366753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967192,0.00051781436,0.0012671944,0.00074808946,0.00030745915,0.000440232],"domain_scores_gemma":[0.99718183,0.001145576,0.00033546888,0.0008627931,0.000058026628,0.00041628067],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011020884,0.00054130267,0.003228169,0.00022538612,0.00004951837,0.000029457855,0.0002114925,0.00075108325,0.00019533245],"category_scores_gemma":[0.00057324034,0.00035890852,0.00074635487,0.00048280743,0.000357348,0.000033607314,0.0001587272,0.00266141,0.0003272712],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040366795,0.00053328945,0.000403495,0.011019392,0.00042119608,0.00010826429,0.0000024006065,1.3659216e-9,3.4698274e-8,0.0003962349,0.000077584795,0.98663443],"study_design_scores_gemma":[0.0032768177,0.00055436435,0.0008607091,0.044903617,0.00211274,0.00015829015,0.0000016891703,0.000005618993,8.0517246e-8,0.0002952335,0.94754153,0.0002893106],"about_ca_topic_score_codex":0.00001013642,"about_ca_topic_score_gemma":0.00012682358,"teacher_disagreement_score":0.9863451,"about_ca_system_score_codex":0.00006290598,"about_ca_system_score_gemma":0.00081012154,"threshold_uncertainty_score":0.9998863},"labels":[],"label_agreement":null},{"id":"W2018680425","doi":"10.1016/j.clinthera.2006.08.013","title":"Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Credit Valley Hospital","funders":"","keywords":"Medicine; Levofloxacin; Exacerbation; Post-hoc analysis; Chronic bronchitis; Amoxicillin; Post hoc; Bronchitis; Internal medicine; Antibiotics; Microbiology","score_opus":0.1206712977328633,"score_gpt":0.40495823263159864,"score_spread":0.28428693489873536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018680425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623705,0.000238942,0.005011791,0.00029474063,0.00076500745,0.0019504298,0.029303685,0.000026951846,0.000037953334],"genre_scores_gemma":[0.97829527,0.00075390714,0.0019958098,0.0002842802,0.0007545135,0.0001387054,0.017548887,0.00006198171,0.00016661959],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99736285,0.000108838576,0.001447217,0.0005435987,0.0002251616,0.00031232674],"domain_scores_gemma":[0.9955728,0.001711306,0.00088153785,0.0009120678,0.00082222576,0.000100049736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002938908,0.0002831429,0.0012562111,0.00020968929,0.00009494713,0.000011902275,0.00025707245,0.00034991576,0.000045014607],"category_scores_gemma":[0.00016868571,0.00022406131,0.0008063794,0.0003033876,0.00022926928,0.000113573726,0.000055321892,0.00008414285,0.000001959199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12753588,0.038152747,0.114050604,0.0014193857,0.1401833,0.000009666177,0.0017606637,0.0020977268,0.37851518,0.00069185125,0.004364305,0.19121869],"study_design_scores_gemma":[0.13175678,0.09481604,0.41774532,0.00039687488,0.10186158,0.0000016853621,0.0003018504,0.115711465,0.017360197,0.00075692555,0.11805506,0.0012362282],"about_ca_topic_score_codex":0.00014692351,"about_ca_topic_score_gemma":0.0004633082,"teacher_disagreement_score":0.36115497,"about_ca_system_score_codex":0.000188199,"about_ca_system_score_gemma":0.00030648868,"threshold_uncertainty_score":0.9136955},"labels":[],"label_agreement":null},{"id":"W2019005588","doi":"10.1016/j.clinthera.2009.08.001","title":"Effectiveness and tolerability of pharmacologic and combined interventions for reducing injection pain during routine childhood immunizations: Systematic review and meta-analyses","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital","funders":"","keywords":"Medicine; Tolerability; Placebo; Analgesic; Psychological intervention; Systematic review; Acetaminophen; Meta-analysis; Randomized controlled trial; Clinical trial; MEDLINE; Adverse effect; Anesthesia; Physical therapy; Surgery; Internal medicine; Alternative medicine; Psychiatry","score_opus":0.33802041771310687,"score_gpt":0.5405198797280191,"score_spread":0.2024994620149122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019005588","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033210745,0.98631865,0.0039059932,0.00010416496,0.000028518905,0.009192886,0.000023442884,0.00008869683,0.0000055241235],"genre_scores_gemma":[0.0036420422,0.9939327,0.0013813068,0.0002250621,0.000032077198,0.0006818805,0.000047613015,0.000029531677,0.000027777445],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9929313,0.0039304993,0.0023921912,0.00046940878,0.00012598778,0.00015059588],"domain_scores_gemma":[0.99322075,0.0047085634,0.0013413767,0.00047288387,0.00018312517,0.00007328439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010363703,0.0003569792,0.005984561,0.00019432772,0.000098799894,0.000023102553,0.00012420492,0.00023933317,0.00000606742],"category_scores_gemma":[0.0035515537,0.00024302465,0.0011456755,0.00037560638,0.00015627654,0.000055943976,0.000111314854,0.00038045336,1.3408882e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018317403,0.00045485265,0.00009174566,0.9579932,0.009394742,7.399128e-7,0.000009680218,2.7616613e-7,0.0000013291542,0.000014340245,0.000006765275,0.032014016],"study_design_scores_gemma":[0.001265618,0.0018992379,0.0031885274,0.2864704,0.7058821,0.00003744642,0.000015593112,0.0000907624,0.000003070149,0.0004691687,0.00031238908,0.00036567767],"about_ca_topic_score_codex":0.0000020935402,"about_ca_topic_score_gemma":1.9237524e-7,"teacher_disagreement_score":0.69648737,"about_ca_system_score_codex":0.00006162015,"about_ca_system_score_gemma":0.00004899185,"threshold_uncertainty_score":0.99102575},"labels":[],"label_agreement":null},{"id":"W2019322941","doi":"10.1016/s0149-2918(02)85105-0","title":"Correlations between target scores and anchor ratings on a health transition questionnaire","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Adolescent and Pediatric Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical psychology; Family medicine","score_opus":0.3360833156149735,"score_gpt":0.5217275506866885,"score_spread":0.185644235071715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019322941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62647057,0.00997241,0.02988895,0.3222157,0.0036565969,0.004275339,0.00039463135,0.000798599,0.0023272336],"genre_scores_gemma":[0.9656928,0.003526886,0.0009219463,0.026918342,0.002420469,0.000024442723,0.000057734633,0.000030999432,0.00040635798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966813,0.0013181769,0.0010553027,0.00031437376,0.00020090467,0.00042996064],"domain_scores_gemma":[0.9974309,0.0015735357,0.0003204655,0.00023654882,0.00011121775,0.0003272885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012244309,0.00016023937,0.00038992675,0.00006546867,0.000970949,0.000009761429,0.00008794384,0.0003870683,0.00015741795],"category_scores_gemma":[0.00021451495,0.00013814471,0.00008470224,0.00019289755,0.00012012132,0.000075001015,0.000019769559,0.0013431346,0.00020079825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052718722,0.00017258948,0.86611277,0.00022700666,0.000030072893,0.000001430109,0.005074122,0.0000063273346,5.5721614e-7,0.0011850254,0.012657227,0.11448013],"study_design_scores_gemma":[0.003498873,0.0017749588,0.8425345,0.0012474249,0.00009921177,0.0000013744904,0.0010676272,0.007828735,6.5963854e-7,0.005855658,0.13561873,0.0004722809],"about_ca_topic_score_codex":0.00003493786,"about_ca_topic_score_gemma":0.000027849006,"teacher_disagreement_score":0.33922228,"about_ca_system_score_codex":0.000072609604,"about_ca_system_score_gemma":0.00015346319,"threshold_uncertainty_score":0.7467853},"labels":[],"label_agreement":null},{"id":"W2019621848","doi":"10.1016/j.clinthera.2014.10.023","title":"Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"Eisai","keywords":"Medicine; Vinorelbine; Eribulin; Internal medicine; Oncology; Gemcitabine; Capecitabine; Metastatic breast cancer; Breast cancer; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.17232625910111957,"score_gpt":0.5039678140005637,"score_spread":0.33164155489944414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019621848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982893,0.00015912544,0.0002942531,0.00024259074,0.000060248745,0.0007176972,0.00006676643,0.000011719465,0.00015831356],"genre_scores_gemma":[0.9984198,0.00026962926,0.00027184768,0.00085822365,0.000024867673,0.00009810069,0.000019703233,0.000014746202,0.000023065337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634874,0.0025081066,0.0005851344,0.00021160003,0.00014472402,0.00020171628],"domain_scores_gemma":[0.9955672,0.0037486989,0.0002609993,0.00025093547,0.00010260283,0.000069573296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014466644,0.00018075673,0.0013025673,0.00027273246,0.00003894121,0.0000051360907,0.000105828294,0.00007806292,0.00010699042],"category_scores_gemma":[0.000026815358,0.00013188014,0.00018120496,0.0011549898,0.00026366962,0.000040348266,0.000020908787,0.0005503703,0.000001220881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071377754,0.0028633978,0.96670085,0.00006898173,0.0060779867,0.000007812037,0.00314237,0.001898309,0.00093331037,0.000018838873,0.0000030055257,0.011147355],"study_design_scores_gemma":[0.013279904,0.0013298056,0.9595833,0.00017435879,0.0024036905,0.0000020820887,0.00034350384,0.021414062,0.0011803365,0.00013594331,0.00003264677,0.00012036843],"about_ca_topic_score_codex":0.0008984995,"about_ca_topic_score_gemma":0.0029597334,"teacher_disagreement_score":0.019515753,"about_ca_system_score_codex":0.0001655213,"about_ca_system_score_gemma":0.00012239696,"threshold_uncertainty_score":0.53779155},"labels":[],"label_agreement":null},{"id":"W2019834813","doi":"10.1016/j.clinthera.2005.02.011","title":"Long-term safety and, tolerability profiles andlipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Ezetimibe; Tolerability; Simvastatin; Statin; Placebo; Pharmacology; Cholesterol; Adverse effect; Internal medicine","score_opus":0.11742829436053269,"score_gpt":0.40376317560047476,"score_spread":0.28633488123994205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019834813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98193383,0.0019173046,0.0014950691,0.0005961867,0.00018196608,0.01359212,0.00001334977,0.000073360636,0.00019683925],"genre_scores_gemma":[0.99401206,0.0020244343,0.002560293,0.00043410299,0.00040002918,0.00024273213,0.000031193114,0.00006634039,0.00022879308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943638,0.0013424702,0.0022976522,0.00085562567,0.0006552435,0.00048523623],"domain_scores_gemma":[0.9947972,0.0026703742,0.0007101,0.0011219775,0.0003301634,0.00037018055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045586964,0.0005012664,0.0034571092,0.000105997926,0.00019112772,0.00005327747,0.00013873263,0.00023944842,0.000041574225],"category_scores_gemma":[0.0003253741,0.00030506065,0.0009082975,0.0001775537,0.0005300441,0.00010630968,0.00008102468,0.00046227901,0.000010438955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7858847,0.008511444,0.046431884,0.00018840679,0.0027934364,0.000037127877,0.001122881,0.000059915874,0.000033034325,0.0000115657,8.2631084e-7,0.15492482],"study_design_scores_gemma":[0.9480624,0.0056267404,0.037399437,0.00042157562,0.003840893,0.00004831719,0.00042769406,0.0034339773,0.00021200105,0.000003164302,0.00020993235,0.00031383778],"about_ca_topic_score_codex":0.000058112393,"about_ca_topic_score_gemma":0.00011171696,"teacher_disagreement_score":0.16217777,"about_ca_system_score_codex":0.000145527,"about_ca_system_score_gemma":0.00031528948,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W2021884927","doi":"10.1016/j.clinthera.2010.01.003","title":"Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Discontinuation; Olanzapine; Medicine; Risperidone; Antipsychotic; Medical prescription; Quetiapine; Atypical antipsychotic; Retrospective cohort study; Clozapine; Aripiprazole; Pediatrics; Psychiatry; Internal medicine; Schizophrenia (object-oriented programming); Pharmacology","score_opus":0.07018731493637761,"score_gpt":0.4099142443742175,"score_spread":0.3397269294378399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021884927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699587,0.00007756299,0.0014711127,0.00084289873,0.00006342882,0.000450546,0.00006874256,0.000004544338,0.000025284233],"genre_scores_gemma":[0.9980359,0.00022477092,0.0015320248,0.00006434406,0.00005745989,0.000007639149,0.00004412503,0.0000069601538,0.000026779846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984201,0.00019646857,0.00069210894,0.0001910762,0.0003781258,0.00012211649],"domain_scores_gemma":[0.9983906,0.0005056754,0.00027146077,0.00059729937,0.00018465117,0.000050280014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091999845,0.0000866803,0.00044215145,0.00010975353,0.0000137204015,0.0000045329143,0.00015647383,0.00010269377,0.00003898519],"category_scores_gemma":[0.0002668521,0.00005193252,0.0002410506,0.000351477,0.0002152715,0.000042591095,0.000027333834,0.00042605255,9.715123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078115272,0.0023159157,0.97767454,0.00003272777,0.0005809504,0.00000615965,0.00017123975,0.0000017488157,0.0021497281,0.001355522,0.000008344237,0.007891581],"study_design_scores_gemma":[0.0021839736,0.0010329336,0.9923025,0.000044530934,0.00076292886,0.0000013516676,0.0001059472,0.0013532288,0.0017333304,0.0004036164,0.000035017376,0.000040642917],"about_ca_topic_score_codex":0.0003430856,"about_ca_topic_score_gemma":0.013379628,"teacher_disagreement_score":0.014627943,"about_ca_system_score_codex":0.000018898496,"about_ca_system_score_gemma":0.0002169037,"threshold_uncertainty_score":0.74661463},"labels":[],"label_agreement":null},{"id":"W2022210442","doi":"10.1016/j.clinthera.2013.07.263","title":"PP222—Therapeutic drug monitoring of daptomycin: A retrospective monocentric analysis","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Daptomycin; Medicine; Lipopeptide; Drug; Therapeutic drug monitoring; Pharmacology; Antibiotics; Plasma concentration; Microbiology; Vancomycin; Bacteria; Staphylococcus aureus; Biology","score_opus":0.0772295150147761,"score_gpt":0.4048721682515044,"score_spread":0.3276426532367283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022210442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932632,0.0012764516,0.002125316,0.0005628854,0.0004367706,0.00051260623,0.0000062528247,0.000073158095,0.0017433525],"genre_scores_gemma":[0.9919074,0.00213991,0.0042960793,0.00061064766,0.0003371434,0.000005069618,0.0000069897037,0.000041666608,0.00065510446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769205,0.00011877938,0.0010037129,0.00041258676,0.00040182218,0.00037107916],"domain_scores_gemma":[0.9980356,0.0003144577,0.00032783058,0.0006074999,0.00046031643,0.00025430814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047158863,0.00023746237,0.00088983675,0.00024243075,0.000056307603,0.000023350964,0.00022553036,0.00017583532,0.00041836195],"category_scores_gemma":[0.00006216532,0.00019442252,0.0006796451,0.0012201812,0.00025133643,0.00005810645,0.00006994592,0.0005147443,0.00007746856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010980319,0.000845569,0.9772268,0.000029152821,0.0034126882,0.0000073720016,0.00025638987,0.00002022964,0.00092259905,0.00017321482,0.00007992812,0.01691624],"study_design_scores_gemma":[0.0015017212,0.0003516889,0.97940135,0.00003710679,0.003965727,0.0000029484709,0.00020666074,0.0098520275,0.0035288816,0.00048384583,0.00047148502,0.00019658357],"about_ca_topic_score_codex":0.00003373675,"about_ca_topic_score_gemma":4.24848e-7,"teacher_disagreement_score":0.016719656,"about_ca_system_score_codex":0.000056125537,"about_ca_system_score_gemma":0.000067831446,"threshold_uncertainty_score":0.7928321},"labels":[],"label_agreement":null},{"id":"W2023088935","doi":"10.1016/j.clinthera.2006.05.016","title":"Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus Oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 μg: A single-dose, randomized, open-label, three-period study in healthy adult volunteers","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carbon Engineering (Canada)","funders":"","keywords":"Medicine; Fentanyl; Buccal administration; Bioavailability; Anesthesia; Naltrexone; Crossover study; Placebo; Pharmacology; Opioid; Internal medicine","score_opus":0.13312735632988293,"score_gpt":0.40548873152078835,"score_spread":0.2723613751909054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023088935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985213,0.00042282577,0.00035167823,0.0051506558,0.00055238727,0.0079445345,0.000058649686,0.000036581652,0.00026970656],"genre_scores_gemma":[0.996505,0.00014676883,0.0016126741,0.0013275851,0.000099406,0.00009869109,0.000028923027,0.000041710864,0.00013921624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99347365,0.0017862215,0.0026038194,0.00082404894,0.00078680017,0.00052544824],"domain_scores_gemma":[0.9965375,0.0013580123,0.0006025444,0.0008630504,0.0003806436,0.00025824702],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0056779296,0.00043438052,0.001852984,0.000120658755,0.0001391106,0.00005446688,0.0005388583,0.00026580112,0.00006620774],"category_scores_gemma":[0.0008518498,0.00029753862,0.00032507893,0.0007877679,0.0012686265,0.00016656767,0.00026292092,0.00074084254,0.0000055516775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29417545,0.014407341,0.684692,0.0002676157,0.0007897073,0.000018456112,0.0010524723,0.000016560502,0.000532984,0.0014531078,0.00009788912,0.0024963755],"study_design_scores_gemma":[0.319241,0.006868623,0.6671399,0.0003113404,0.0010393955,0.0000015731468,0.00110774,0.0019584943,0.00015809064,0.0014800503,0.00031688943,0.00037694105],"about_ca_topic_score_codex":0.00085437775,"about_ca_topic_score_gemma":0.002990136,"teacher_disagreement_score":0.025065538,"about_ca_system_score_codex":0.0002323898,"about_ca_system_score_gemma":0.0003718113,"threshold_uncertainty_score":0.99994767},"labels":[],"label_agreement":null},{"id":"W2023622543","doi":"10.1016/j.clinthera.2005.01.002","title":"Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Tolerability; Celecoxib; Placebo; Osteoarthritis; Internal medicine; Visual analogue scale; Rheumatoid arthritis; Anesthesia; Adverse effect","score_opus":0.07528512727942918,"score_gpt":0.37152838101737373,"score_spread":0.2962432537379446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023622543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346995,0.0021892905,0.00001169022,0.001089158,0.00007778524,0.0027395517,0.000005021051,0.000009305069,0.00040827197],"genre_scores_gemma":[0.99872077,0.00040801978,0.00018782758,0.00044830822,0.000118667645,0.00006315788,0.0000028857137,0.000015259891,0.000035136225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99760485,0.00070365996,0.00096074294,0.0002466226,0.00028581033,0.00019830704],"domain_scores_gemma":[0.9958607,0.003184573,0.00034053897,0.00045648357,0.00007530492,0.00008240312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002189142,0.00019027831,0.0010903089,0.000040309063,0.00005358829,0.000012643191,0.000113300106,0.00017424082,0.000012800213],"category_scores_gemma":[0.0001598103,0.00009081448,0.00015247568,0.00016933338,0.0010518238,0.000039689116,0.000040244686,0.00041021444,0.0000018006326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5567268,0.0028866325,0.3225821,0.0002198205,0.00038323202,0.0000088053885,0.0043841694,0.000031129803,0.00028697125,0.00019888887,0.000031457734,0.112259984],"study_design_scores_gemma":[0.8481663,0.0037589099,0.13950846,0.00040944823,0.0009342178,0.00003995143,0.00039483968,0.0012177364,0.0033463922,0.00007728436,0.0019584799,0.00018799248],"about_ca_topic_score_codex":0.000016513244,"about_ca_topic_score_gemma":0.00014441727,"teacher_disagreement_score":0.29143947,"about_ca_system_score_codex":0.000017356655,"about_ca_system_score_gemma":0.0000768791,"threshold_uncertainty_score":0.38754886},"labels":[],"label_agreement":null},{"id":"W2026253267","doi":"10.1016/s0149-2918(02)85024-x","title":"Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Tramadol; Placebo; Osteoarthritis; Acetaminophen; Randomized controlled trial; Double blind; Anesthesia; Physical therapy; Analgesic; Internal medicine; Alternative medicine","score_opus":0.23805353866344967,"score_gpt":0.4155108502229706,"score_spread":0.1774573115595209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026253267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775727,0.0029988778,0.00088715885,0.0010206293,0.0008613311,0.016246973,0.0000411491,0.00009798694,0.0002732291],"genre_scores_gemma":[0.9920751,0.00162614,0.00021343936,0.0011227534,0.00028462248,0.0038308434,0.000038572933,0.000061046085,0.0007474957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99422437,0.002850729,0.0015879653,0.0005677352,0.00030791486,0.00046127723],"domain_scores_gemma":[0.98778087,0.010681213,0.0006447196,0.00062453805,0.00015267811,0.00011600893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028443327,0.00046680757,0.0015639191,0.000084156156,0.00034443656,0.000053137854,0.00041951577,0.0003192461,0.00028752585],"category_scores_gemma":[0.000120182,0.00029693762,0.0010256149,0.00011595153,0.0003914456,0.00010534731,0.000033632277,0.00032521904,0.000053242904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89699435,0.020296216,0.001422277,0.000033019795,0.0019562314,0.00008077804,0.0019369365,0.00007771693,0.000052247582,0.00016789668,0.00013158507,0.07685071],"study_design_scores_gemma":[0.8966319,0.06224935,0.0003022007,0.000044273656,0.001525002,0.00001971003,0.0007904585,0.025508305,0.00001679454,0.000077641875,0.012518565,0.000315795],"about_ca_topic_score_codex":0.000007981224,"about_ca_topic_score_gemma":0.000009702416,"teacher_disagreement_score":0.07653492,"about_ca_system_score_codex":0.0000624252,"about_ca_system_score_gemma":0.000016081825,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W2028860635","doi":"10.1016/s0149-2918(01)80094-1","title":"Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"McMaster University","keywords":"Medicine; Medroxyprogesterone acetate; Estrogen; Hormone replacement therapy (female-to-male); Medroxyprogesterone; Hormone therapy; Quality of life (healthcare); Menopause; Gynecology; Randomized controlled trial; Internal medicine; Breast cancer; Cancer","score_opus":0.14226910659633302,"score_gpt":0.4254504624263454,"score_spread":0.28318135583001236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028860635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903036,0.004745407,0.00004328776,0.0015087465,0.00005140939,0.0032286735,0.000042353593,0.000034533172,0.00004201399],"genre_scores_gemma":[0.9894455,0.0062354873,0.0010232901,0.0028058311,0.00003607639,0.00021078429,0.000043645116,0.000050106803,0.00014924988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970043,0.00042401758,0.001284691,0.00047394467,0.00026500892,0.0005480456],"domain_scores_gemma":[0.99733925,0.0011046474,0.0005690425,0.00036334587,0.00016583291,0.00045788113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002471138,0.00029620648,0.0012999628,0.00007919001,0.00006181668,0.00002552844,0.000068261914,0.00021494216,0.000010363531],"category_scores_gemma":[0.00025507057,0.00020180437,0.000020558253,0.00016355368,0.00025838317,0.00007525252,0.000037820508,0.00023883073,7.907959e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1605272,0.004627181,0.7556785,0.00021936401,0.0023165536,0.000024340072,0.0011372998,3.047334e-7,0.0127635915,0.000025339272,0.00001449986,0.062665835],"study_design_scores_gemma":[0.18051618,0.05001848,0.7675631,0.00025311456,0.00018228311,0.000025575888,0.00018100713,0.000101281235,0.00020775526,0.00009377065,0.00057777436,0.00027967457],"about_ca_topic_score_codex":0.000035193272,"about_ca_topic_score_gemma":0.000055151664,"teacher_disagreement_score":0.06238616,"about_ca_system_score_codex":0.00018752068,"about_ca_system_score_gemma":0.00022623605,"threshold_uncertainty_score":0.8229343},"labels":[],"label_agreement":null},{"id":"W2029503949","doi":"10.1016/s0149-2918(07)80080-4","title":"Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: Results of a Canadian multicenter, open-label trial","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Children's Hospital; McMaster University","funders":"","keywords":"Medicine; Desloratadine; Nasal congestion; Adverse effect; Allergy; Repeated measures design; Clinical trial; Randomized controlled trial; Internal medicine; Nose; Surgery","score_opus":0.07954413733668622,"score_gpt":0.36763202510965587,"score_spread":0.2880878877729697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029503949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970838,0.00009198129,0.0001975303,0.00006256542,0.00022329488,0.0012923813,0.00010647987,0.000005958626,0.0009360429],"genre_scores_gemma":[0.99817455,0.00014359716,0.0012002583,0.00020152898,0.00004772656,0.0000042860283,0.00018034346,0.000024668105,0.000023066374],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974424,0.00033298557,0.0013107876,0.00028680862,0.00036649755,0.00026050417],"domain_scores_gemma":[0.9970464,0.0013282514,0.00051053916,0.00033691016,0.0005772728,0.00020059227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021971103,0.00016428746,0.0007988957,0.00022029209,0.000025389776,0.000007160177,0.00019669447,0.00020470309,0.000009202653],"category_scores_gemma":[0.00042223342,0.00012816304,0.0000708253,0.0005350877,0.0002677722,0.000084171144,0.000046006673,0.00024942248,0.0000010380649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5597698,0.008766629,0.39390314,0.0003062546,0.0009391592,0.000086375,0.0007916886,0.00006727374,0.0005005931,0.0006134318,0.000027200102,0.034228425],"study_design_scores_gemma":[0.26869452,0.009389483,0.71828276,0.001300557,0.00014448585,0.0000020449156,0.00009555911,0.0010328057,0.0005841938,0.000039678573,0.0002743231,0.00015956412],"about_ca_topic_score_codex":0.0029848914,"about_ca_topic_score_gemma":0.005611141,"teacher_disagreement_score":0.32437965,"about_ca_system_score_codex":0.000070592876,"about_ca_system_score_gemma":0.0004196704,"threshold_uncertainty_score":0.5226337},"labels":[],"label_agreement":null},{"id":"W2030187973","doi":"10.1016/j.clinthera.2008.02.003","title":"The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine","year":2008,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Herd immunity; Medicine; Vaccination; Pneumococcal conjugate vaccine; Herd; Immunization; Pneumococcal polysaccharide vaccine; Incidence (geometry); Cost effectiveness; Pneumococcal disease; Conjugate vaccine; Serotype; Environmental health; Immunology; Streptococcus pneumoniae; Immune system; Veterinary medicine; Biology; Risk analysis (engineering); Antibiotics","score_opus":0.33469342281130365,"score_gpt":0.5030764512071305,"score_spread":0.16838302839582686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030187973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013286092,0.97493744,0.000058604564,0.0002270766,0.0009985566,0.009319056,0.00008298896,0.00007808548,0.0010121237],"genre_scores_gemma":[0.01576931,0.98330754,0.0000014283713,0.00008310613,0.00030508792,0.00038248414,0.000013421879,0.00006987495,0.00006772661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468476,0.0027574645,0.0015798113,0.00035840733,0.0003122249,0.00030730822],"domain_scores_gemma":[0.98932314,0.008130555,0.0011366411,0.0009922362,0.00029821342,0.00011922834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021415374,0.0004590957,0.0024383578,0.00011937741,0.00026072207,0.0000136032795,0.00032880367,0.00068140303,0.000021772623],"category_scores_gemma":[0.0007380783,0.00018680838,0.0024514177,0.0006028071,0.00054551184,0.000021749502,0.00006138863,0.001748509,0.000032126634],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005039154,0.0010328493,0.00093913253,0.0022099153,0.003632257,0.000009801622,0.000021638838,0.000009971106,0.00021063171,0.000104818086,0.00004762229,0.99127746],"study_design_scores_gemma":[0.001279956,0.0055745263,0.014500694,0.00882915,0.001840634,0.00022281436,0.000008576021,0.00004422591,0.0001233183,0.00012095588,0.9671751,0.00028004212],"about_ca_topic_score_codex":0.000010066672,"about_ca_topic_score_gemma":0.0000016561254,"teacher_disagreement_score":0.99099743,"about_ca_system_score_codex":0.00016409917,"about_ca_system_score_gemma":0.0008676779,"threshold_uncertainty_score":0.76178247},"labels":[],"label_agreement":null},{"id":"W2030812441","doi":"10.1016/j.clinthera.2005.11.014","title":"Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Hydrochlorothiazide; Morning; Tolerability; Fixed-dose combination; Losartan; Ambulatory blood pressure; Telmisartan; Clinical endpoint; Ambulatory; Blood pressure; Urology; Internal medicine; Adverse effect; Randomized controlled trial; Angiotensin II","score_opus":0.18770659114968835,"score_gpt":0.44962208006973875,"score_spread":0.2619154889200504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030812441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801219,0.009013068,0.0012875287,0.0035025491,0.00025505945,0.005191633,0.00012906991,0.00003796413,0.00046123358],"genre_scores_gemma":[0.98948026,0.0028444738,0.005551162,0.0016518753,0.000090469744,0.000119161814,0.00005117666,0.000060711965,0.00015073996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908982,0.0014750124,0.0052865515,0.00094282127,0.00092028844,0.00047710486],"domain_scores_gemma":[0.98975325,0.0056695906,0.0022336296,0.00091174187,0.0011271078,0.00030471126],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005499524,0.0006015743,0.0076187328,0.00086399174,0.0001615877,0.000054240747,0.0004014762,0.00040419758,0.000057343972],"category_scores_gemma":[0.002255396,0.00048946316,0.0006497934,0.0008522569,0.0011024585,0.00028260058,0.000499912,0.0006770498,0.000002925472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54114634,0.06830041,0.14163922,0.0012719117,0.049684912,0.000048409096,0.012816437,0.0013527592,0.1489521,0.0039411685,0.00097324594,0.02987312],"study_design_scores_gemma":[0.6528763,0.0043729255,0.07278648,0.0015609507,0.046220716,0.000019744764,0.0013012585,0.16953631,0.04734156,0.0025642992,0.00045767543,0.0009617634],"about_ca_topic_score_codex":0.0003248382,"about_ca_topic_score_gemma":0.0015054949,"teacher_disagreement_score":0.16818355,"about_ca_system_score_codex":0.000038059487,"about_ca_system_score_gemma":0.0001862216,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W2031244515","doi":"10.1016/j.clinthera.2006.11.017","title":"Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); University of Toronto; Mount Sinai Hospital; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Pregabalin; Medicine; Postherpetic neuralgia; Gabapentin; Neuropathic pain; Peripheral neuropathy; Brief Pain Inventory; Neuralgia; Anesthesia; Chronic pain; Diabetes mellitus; Internal medicine; Physical therapy","score_opus":0.06844249996525661,"score_gpt":0.3515527024553134,"score_spread":0.2831102024900568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031244515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988375,0.0012393573,0.006127935,0.0007609559,0.0001156661,0.0030717843,0.000058862755,0.000025279545,0.00022516916],"genre_scores_gemma":[0.9986982,0.0001689129,0.0003717266,0.00052291504,0.000025432786,0.000100211146,0.00001258072,0.00003872514,0.00006129354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977204,0.001199722,0.00036115106,0.0002831247,0.00017451556,0.00026105467],"domain_scores_gemma":[0.99649,0.0027096667,0.0001746582,0.0002819624,0.00024329219,0.000100390425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028207158,0.00017847869,0.00043230757,0.00004342069,0.000085787084,0.000011143814,0.00009982002,0.00009446686,0.000004751645],"category_scores_gemma":[0.0001678231,0.0001112874,0.00014021086,0.00017357162,0.00027204014,0.000019498306,0.000019939356,0.00018065848,2.7852656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077304114,0.0071771266,0.77059835,0.0017724974,0.0087921955,0.0007319207,0.0013173561,0.0005775824,0.0036162077,0.035600863,0.000028299968,0.1620572],"study_design_scores_gemma":[0.0063063167,0.005157128,0.9665233,0.0006600891,0.0021472888,0.00001469225,0.00056456594,0.014700856,0.00045158618,0.0031110193,0.00016266128,0.00020049994],"about_ca_topic_score_codex":0.0010758892,"about_ca_topic_score_gemma":0.00062885287,"teacher_disagreement_score":0.19592497,"about_ca_system_score_codex":0.00009004715,"about_ca_system_score_gemma":0.000107215215,"threshold_uncertainty_score":0.45381683},"labels":[],"label_agreement":null},{"id":"W2031543029","doi":"10.1016/j.clinthera.2009.06.004","title":"Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health; University of Toronto","funders":"H. Lundbeck A/S","keywords":"Medicine; Escitalopram; Generalized anxiety disorder; Anxiety; MEDLINE; Quality of life (healthcare); Psychiatry; Checklist; Population; Economic evaluation; Health care; Clinical psychology; Psychology; Environmental health; Nursing","score_opus":0.5233248457434514,"score_gpt":0.6402287132785927,"score_spread":0.11690386753514126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031543029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042950708,0.9930503,0.00028025158,0.00023657363,0.0006964235,0.004552147,0.0002444431,0.000042961394,0.00046740472],"genre_scores_gemma":[0.00033161367,0.9962753,0.0010730855,0.0010663146,0.000068823254,0.000564853,0.00007845393,0.00006866132,0.0004729147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98484457,0.0070353188,0.006343309,0.0010806161,0.00037207227,0.00032412462],"domain_scores_gemma":[0.9857858,0.00799556,0.0041506607,0.0012211835,0.0006122056,0.00023463344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00876184,0.0006860017,0.007967819,0.00027951185,0.00011221804,0.000026495876,0.00042257903,0.0006104268,0.00011800551],"category_scores_gemma":[0.003591141,0.0004970223,0.0008373794,0.0006991541,0.00045864916,0.00006881747,0.00019410797,0.0005572045,0.000028352622],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028792329,0.0008773541,0.0054989355,0.4301746,0.009514772,2.2495436e-7,0.0002834486,5.150058e-7,7.6718536e-8,0.0039041713,0.00019027297,0.5495269],"study_design_scores_gemma":[0.0072825477,0.001978463,0.020350402,0.40380022,0.07784561,0.000019078476,0.0013550457,0.0000148834215,2.3859653e-7,0.006419693,0.47813442,0.0027993936],"about_ca_topic_score_codex":0.000017860839,"about_ca_topic_score_gemma":0.000010933904,"teacher_disagreement_score":0.5467275,"about_ca_system_score_codex":0.000112075766,"about_ca_system_score_gemma":0.00032492203,"threshold_uncertainty_score":0.9997482},"labels":[],"label_agreement":null},{"id":"W2031699253","doi":"10.1016/j.clinthera.2007.02.016","title":"A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL)","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); Foothills Medical Centre; Hamilton Health Sciences","funders":"Abbott Laboratories","keywords":"Trandolapril; Medicine; Blood pressure; Regimen; Diuretic; Internal medicine; Prospective cohort study; Calcium channel blocker; ACE inhibitor; Angiotensin-converting enzyme","score_opus":0.1352168517517355,"score_gpt":0.4237829827254811,"score_spread":0.2885661309737456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031699253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679763,0.004010356,5.671729e-7,0.0005064626,0.00011412233,0.008406145,0.000018904178,0.000021918979,0.00012387933],"genre_scores_gemma":[0.99772775,0.00040115256,0.000058289716,0.0013998771,0.00011632267,0.0002102827,0.000003046465,0.000041102485,0.000042196876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966468,0.0010379544,0.001037322,0.00058824284,0.000339833,0.000349812],"domain_scores_gemma":[0.99569523,0.0029926253,0.00023803103,0.00051321316,0.00041308376,0.0001477872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020053783,0.00036237904,0.0019933954,0.00014890684,0.0000662408,0.000016888416,0.00019210136,0.00016252253,0.000003870945],"category_scores_gemma":[0.00044661187,0.00019958372,0.00011194981,0.0003510296,0.00022421336,0.000074404474,0.00009329266,0.00037983453,0.0000015563047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057586037,0.01882579,0.8737381,0.000085357264,0.0042056283,0.00015019116,0.011437492,0.0000028984896,0.0018684189,0.000009850323,0.000009412637,0.0320808],"study_design_scores_gemma":[0.15893868,0.07472832,0.7490611,0.00047532667,0.008596664,0.000008768642,0.0015776254,0.00067567645,0.005657815,0.000012563768,0.00005287099,0.00021456378],"about_ca_topic_score_codex":0.00068349554,"about_ca_topic_score_gemma":0.0014801193,"teacher_disagreement_score":0.12467699,"about_ca_system_score_codex":0.000014244181,"about_ca_system_score_gemma":0.000038593364,"threshold_uncertainty_score":0.8138788},"labels":[],"label_agreement":null},{"id":"W2032696644","doi":"10.1016/j.clinthera.2007.12.016","title":"Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Acute chest syndrome; Morphine; Confidence interval; Pediatrics; Crossover study; Narcotic; Chest pain; Anesthesia; Disease; Internal medicine; Sickle cell anemia","score_opus":0.02622493900361519,"score_gpt":0.3249527464453264,"score_spread":0.29872780744171124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032696644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973053,0.0004684386,0.000063535655,0.00053679594,0.00005878606,0.0012471606,0.00009626442,0.00005241629,0.00017135432],"genre_scores_gemma":[0.9974598,0.0002639651,0.00018953784,0.0015996977,0.00003854588,0.000009046263,0.000037251168,0.000070683476,0.00033143617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975639,0.00011385505,0.0008673774,0.0004961507,0.00049029215,0.00046844198],"domain_scores_gemma":[0.9982499,0.00028589377,0.00033825662,0.000586229,0.0002217462,0.00031800047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079215725,0.00031747128,0.00080359686,0.000111489215,0.00008325575,0.000017040264,0.0001550595,0.00032170353,0.00007911633],"category_scores_gemma":[0.00005321947,0.00021053324,0.00019023233,0.00066894025,0.00030189165,0.000061458646,0.00006670507,0.00079091423,0.000010370633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024358428,0.005770621,0.98261285,0.00002464004,0.002159354,0.0054004085,0.0011336632,0.000025348887,0.000013818987,0.0000039812967,0.000071751354,0.00034769936],"study_design_scores_gemma":[0.016559692,0.006269405,0.9708535,0.00013639903,0.0022682666,0.00049538736,0.0028759683,0.00007217093,0.000059369057,0.000029918128,0.00007420611,0.00030573516],"about_ca_topic_score_codex":0.00009115095,"about_ca_topic_score_gemma":0.000082643324,"teacher_disagreement_score":0.01412385,"about_ca_system_score_codex":0.00006876384,"about_ca_system_score_gemma":0.00020262561,"threshold_uncertainty_score":0.8585296},"labels":[],"label_agreement":null},{"id":"W2032702320","doi":"10.1016/j.clinthera.2012.03.060","title":"Efficacy and Tolerability of a 20-mg Dose of Methylphenidate for the Treatment of Daytime Sleepiness in Adult Patients With Myotonic Dystrophy Type 1: A 2-Center, Randomized, Double-Blind, Placebo-Controlled, 3-Week Crossover Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Jonquière; Hôpital de l'Enfant-Jésus; Centre hospitalier universitaire de Québec","funders":"Centre Hospitalier Universitaire de Québec","keywords":"Tolerability; Medicine; Epworth Sleepiness Scale; Methylphenidate; Placebo; Crossover study; Excessive daytime sleepiness; Physical therapy; Adverse effect; Internal medicine; Sleep disorder; Psychiatry; Attention deficit hyperactivity disorder; Polysomnography; Insomnia","score_opus":0.1306469501111931,"score_gpt":0.3884028703296902,"score_spread":0.2577559202184971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032702320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039656,0.0003724336,0.0001412089,0.00007965853,0.00046198053,0.008382706,0.00014213279,0.000007694664,0.000015602005],"genre_scores_gemma":[0.99857664,0.0005238655,0.000246688,0.00012849779,0.00007389117,0.0003896665,0.000008424985,0.000027323451,0.000024992725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964618,0.0009937697,0.0014608144,0.00042517067,0.00033695108,0.00032145818],"domain_scores_gemma":[0.9898576,0.008298354,0.0008242901,0.0005683627,0.00034019916,0.00011120846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081410055,0.00028576923,0.0014909175,0.00006120834,0.000055183707,0.000017708739,0.00026491116,0.000104087376,0.000013472884],"category_scores_gemma":[0.0010988881,0.00015252555,0.0003809566,0.00023817946,0.000982692,0.00007656461,0.000050997736,0.000113567774,9.607373e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9757815,0.012181053,0.0063749906,0.00003657441,0.0002710188,2.277747e-7,0.00033459804,0.00017289557,0.002077744,0.00011896527,0.0000010052611,0.0026494008],"study_design_scores_gemma":[0.9623644,0.005103487,0.0032993034,0.000025999387,0.0006349755,2.3616899e-7,0.000013110249,0.000945301,0.027336754,0.00006263145,0.00007411759,0.00013970272],"about_ca_topic_score_codex":0.000009631163,"about_ca_topic_score_gemma":0.0000054370817,"teacher_disagreement_score":0.02525901,"about_ca_system_score_codex":0.000022836464,"about_ca_system_score_gemma":0.00010742148,"threshold_uncertainty_score":0.62198114},"labels":[],"label_agreement":null},{"id":"W2033089190","doi":"10.1016/s0149-2918(01)80165-x","title":"Effects of washout and dose-escalation periods on theefficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Kelowna General Hospital; Interior Health","funders":"","keywords":"Medicine; Tolerability; Donepezil; Galantamine; Washout; Clinical trial; Pharmacology; Intensive care medicine; Adverse effect; Internal medicine; Dementia; Disease","score_opus":0.10176572572103756,"score_gpt":0.4324884654565914,"score_spread":0.3307227397355539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033089190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738187,0.0003887798,0.0000433789,0.0002178463,0.00006933896,0.0017275985,0.000006151919,0.000029196135,0.00013581594],"genre_scores_gemma":[0.9961645,0.0031301514,0.00038869912,0.0001576753,0.00006338603,0.000009562244,0.000022253023,0.000027858043,0.00003593437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955201,0.0014613959,0.0020451853,0.00045390025,0.00032159992,0.00019779192],"domain_scores_gemma":[0.99152535,0.0071381154,0.00066197757,0.00040039027,0.00011713181,0.00015706212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031953657,0.00023612502,0.0016319628,0.00008749998,0.000030979485,0.000008414457,0.00006803879,0.0003144797,0.000009207102],"category_scores_gemma":[0.0016570073,0.00014515953,0.00017056717,0.00016481288,0.00038330353,0.00004944723,0.000049970546,0.00034520248,8.122942e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018011006,0.0034579304,0.76931906,0.00013496184,0.00019019695,0.0000073459933,0.00010750408,0.0000036247664,0.0001685572,0.0000062038584,0.0000017116821,0.20859188],"study_design_scores_gemma":[0.029833999,0.010148707,0.95717394,0.0009088401,0.0006176833,0.0000032938897,0.000013833282,0.00038312568,0.0006619232,0.000022860519,0.000112965514,0.000118828604],"about_ca_topic_score_codex":0.00001237939,"about_ca_topic_score_gemma":0.000009017985,"teacher_disagreement_score":0.20847304,"about_ca_system_score_codex":0.000034950448,"about_ca_system_score_gemma":0.000050127805,"threshold_uncertainty_score":0.5919434},"labels":[],"label_agreement":null},{"id":"W2033163507","doi":"10.1016/j.clinthera.2013.12.011","title":"Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Pfizer","keywords":"Apixaban; Medicine; Rivaroxaban; Dabigatran; Atrial fibrillation; Stroke (engine); Discontinuation; Cost effectiveness; Randomized controlled trial; Quality-adjusted life year; Warfarin; Quality of life (healthcare); Internal medicine; Intensive care medicine; Cardiology; Anesthesia","score_opus":0.4687215229406663,"score_gpt":0.5252876808651197,"score_spread":0.05656615792445335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033163507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466023,0.00013875832,0.04868535,0.00043784312,0.0015127222,0.002163872,0.000009021941,0.000041663614,0.0004084569],"genre_scores_gemma":[0.9946026,0.000087083106,0.0026755226,0.000069949965,0.0018479618,0.000001402534,0.00003832199,0.00002329025,0.0006538236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985943,0.0003009428,0.00058929605,0.00019769713,0.00016662577,0.00015114549],"domain_scores_gemma":[0.9973349,0.0021353685,0.00020687793,0.00019694166,0.00006686379,0.000059055023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001521246,0.0001104915,0.0005387314,0.00008014901,0.00002142816,0.000010294208,0.000055800756,0.00016037928,0.000028476477],"category_scores_gemma":[0.0005033155,0.00009519599,0.00040435282,0.0001226132,0.000049307684,0.000057288777,0.000021047863,0.00008032144,0.000009682895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013662629,0.000021558104,0.73271716,0.00010476164,0.00037793186,1.7451433e-7,0.000028932842,0.0004776395,0.0004326343,0.0021375117,0.000027670303,0.25001138],"study_design_scores_gemma":[0.05589091,0.0030435803,0.80900145,0.00024306176,0.0010902308,5.2745304e-7,0.00004100072,0.02190297,0.0013195917,0.004054902,0.103120945,0.0002908074],"about_ca_topic_score_codex":0.000010282146,"about_ca_topic_score_gemma":0.000012864503,"teacher_disagreement_score":0.24972059,"about_ca_system_score_codex":0.000029666491,"about_ca_system_score_gemma":0.000059063328,"threshold_uncertainty_score":0.38819796},"labels":[],"label_agreement":null},{"id":"W2036061608","doi":"10.1016/j.clinthera.2009.07.022","title":"Inadequate pain management during routine childhood immunizations: The nerve of it","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Western University; MASSolutions (Canada); Hospital for Sick Children; Izaak Walton Killam Health Centre; Dalhousie University; University of Toronto","funders":"","keywords":"Medicine; CINAHL; Psychological intervention; PsycINFO; MEDLINE; Immunization; Cochrane Library; Physical therapy; Intensive care medicine; Pediatrics; Randomized controlled trial; Psychiatry; Surgery","score_opus":0.12442602584900106,"score_gpt":0.4316911133279372,"score_spread":0.3072650874789361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036061608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022240733,0.9902094,0.002356622,0.0013457322,0.00013194089,0.002839109,0.0000105550325,0.0002331385,0.0028512315],"genre_scores_gemma":[0.00022688636,0.99228483,0.0028440158,0.0027854275,0.0004655784,0.000097865355,0.00011600058,0.00008690448,0.0010924664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946879,0.0015744758,0.00240986,0.0004829516,0.00046227683,0.00038253414],"domain_scores_gemma":[0.99553585,0.0014107522,0.0011321193,0.00172098,0.000107324384,0.00009294842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0053363703,0.00047943732,0.0020643547,0.0002620427,0.00011336367,0.000028837941,0.0008788906,0.00045694926,0.000036002166],"category_scores_gemma":[0.00041998914,0.00031337616,0.0011019709,0.0009447302,0.00020926027,0.000038150603,0.00033408092,0.0010857207,0.000026793203],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000138420455,0.0005528404,0.0001396432,0.005158245,0.0012802252,0.000032473592,0.00002624591,7.4998974e-7,3.037987e-8,0.0003297909,0.00088628737,0.99157965],"study_design_scores_gemma":[0.00076052663,0.00036816928,0.0022375365,0.0083684875,0.0074597523,0.000013590331,0.00005721002,0.00004377927,3.3986038e-7,0.00059135613,0.97976094,0.00033828756],"about_ca_topic_score_codex":0.000002577802,"about_ca_topic_score_gemma":5.434292e-7,"teacher_disagreement_score":0.99124134,"about_ca_system_score_codex":0.00011394376,"about_ca_system_score_gemma":0.00012745828,"threshold_uncertainty_score":0.9999318},"labels":[],"label_agreement":null},{"id":"W2037423289","doi":"10.1016/j.clinthera.2013.02.017","title":"Single-Dose Pharmacokinetics of Fentanyl Sublingual Spray and Oral Transmucosal Fentanyl Citrate in Healthy Volunteers: A Randomized Crossover Study","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Medicine; Crossover study; Pharmacokinetics; Fentanyl; Anesthesia; Pharmacology","score_opus":0.09853510383459534,"score_gpt":0.4100276728572553,"score_spread":0.3114925690226599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037423289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993073,0.00086945726,0.00021730593,0.0019181377,0.00045766786,0.0031013496,0.0000058753603,0.000055594413,0.0003016047],"genre_scores_gemma":[0.9928086,0.0010299066,0.0010942476,0.0043993937,0.00023944574,0.00004758883,0.0000105854215,0.000046328136,0.00032389635],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99635094,0.00071053446,0.0016056751,0.00046331738,0.00041574799,0.00045376772],"domain_scores_gemma":[0.9978061,0.0011550365,0.0002598039,0.00037185222,0.00017118147,0.00023607918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024664197,0.0003027539,0.0013454066,0.0001787327,0.000048384805,0.00006719519,0.00018894652,0.00017707274,0.00019368478],"category_scores_gemma":[0.0002597276,0.000239594,0.00028709584,0.00034752308,0.0005790308,0.00012458109,0.00006612265,0.00056594436,0.000020110996],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20957175,0.013231911,0.73687303,0.00030930282,0.0017039259,0.00010892984,0.004353287,0.00001295719,0.0039399816,0.0001846592,0.0004452676,0.029264983],"study_design_scores_gemma":[0.77781975,0.0064757396,0.18756478,0.0002036871,0.0018043676,0.00000575847,0.0027306424,0.016939385,0.0005231547,0.0008511096,0.0044419416,0.00063967414],"about_ca_topic_score_codex":0.00008364252,"about_ca_topic_score_gemma":0.000054355896,"teacher_disagreement_score":0.56824803,"about_ca_system_score_codex":0.00004437673,"about_ca_system_score_gemma":0.000090024005,"threshold_uncertainty_score":0.977036},"labels":[],"label_agreement":null},{"id":"W2038494864","doi":"10.1016/j.clinthera.2005.07.010","title":"Antihypertensive Efficacy and Tolerability of Two Fixed-Dose Combinations of Valsartan and Hydrochlorothiazide Compared with Valsartan Monotherapy in Patients with Stage 2 or 3 Systolic Hypertension: An 8-Week, Randomized, Double-Blind, Parallel-Group Trial","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Valsartan; Medicine; Tolerability; Hydrochlorothiazide; Blood pressure; Combination therapy; Diuretic; Urology; Placebo; Internal medicine; Population; Adverse effect","score_opus":0.15365952237325772,"score_gpt":0.38808721179553135,"score_spread":0.23442768942227363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038494864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928449,0.0022323995,0.00008398437,0.00088337477,0.00008271381,0.0037635255,0.000020415267,0.00003594013,0.000052762505],"genre_scores_gemma":[0.9943998,0.0010976442,0.0023568366,0.0018588704,0.000097102995,0.000064471635,0.00003167163,0.000045859262,0.000047773905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99645054,0.00056497677,0.0015993639,0.0005968368,0.0004884297,0.00029987746],"domain_scores_gemma":[0.9956006,0.002187495,0.00059946,0.00064946734,0.00075065665,0.00021231525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011073133,0.00038695772,0.003489168,0.00015132932,0.00011281568,0.000022874392,0.000130394,0.00018162394,0.000014139836],"category_scores_gemma":[0.00011957252,0.0002206178,0.00014684633,0.00028108206,0.0012214676,0.00016300753,0.00005970726,0.00041112257,8.5307727e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92438906,0.010637813,0.059071463,0.000097028525,0.0015632948,0.00001571567,0.0007440801,0.000053095784,0.0000800855,0.00021808788,0.000014071016,0.0031161793],"study_design_scores_gemma":[0.9211527,0.0068542315,0.06678814,0.00029723096,0.0020673366,0.000017141107,0.00025982835,0.0016761218,0.00009787617,0.000060531995,0.00043560003,0.00029327974],"about_ca_topic_score_codex":0.00010397682,"about_ca_topic_score_gemma":0.00027733354,"teacher_disagreement_score":0.0077166697,"about_ca_system_score_codex":0.000011751119,"about_ca_system_score_gemma":0.000098844255,"threshold_uncertainty_score":0.89965326},"labels":[],"label_agreement":null},{"id":"W2039755216","doi":"10.1016/j.clinthera.2005.06.021","title":"Analgesia and anesthesia for neonates: Study design and ethical issues","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Population Health Research Institute; BC Children's Hospital; McGill University","funders":"","keywords":"Medicine; MEDLINE; Clinical trial; Population; Clinical study design; Informed consent; Intensive care medicine; Alternative medicine","score_opus":0.32915135622386593,"score_gpt":0.5332836885517359,"score_spread":0.20413233232786998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039755216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033461634,0.98460376,0.0068974206,0.0021808008,0.000036517413,0.0059696836,0.0000023830662,0.0002480387,0.000027960143],"genre_scores_gemma":[0.000033705823,0.9585294,0.0355947,0.0042840387,0.00081509707,0.00029688847,0.000018736242,0.000102472644,0.00032494383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960598,0.0011454237,0.0013666144,0.0007869331,0.00029640255,0.0003448586],"domain_scores_gemma":[0.9939363,0.004735961,0.00038839548,0.00061762,0.00010398464,0.00021775177],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005047343,0.00051198667,0.002684597,0.00019704184,0.00008714749,0.00006492573,0.00024947515,0.0013240208,0.000009450594],"category_scores_gemma":[0.0003807192,0.00038530934,0.00039138895,0.00022840912,0.0003122209,0.000026833663,0.000094520256,0.0013827696,0.000006215373],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084949555,0.00034810154,0.00057886686,0.0027286694,0.0006828819,0.00006010703,0.00004523087,3.6290494e-8,1.8540371e-8,0.00012356424,0.0018808655,0.99346673],"study_design_scores_gemma":[0.0009805158,0.002335098,0.00040356166,0.0013470466,0.008282477,0.000068189656,0.000032422544,0.00019538747,3.6004426e-8,0.0005186907,0.98547417,0.00036242724],"about_ca_topic_score_codex":0.0000015081866,"about_ca_topic_score_gemma":4.2418668e-7,"teacher_disagreement_score":0.9931043,"about_ca_system_score_codex":0.00004397508,"about_ca_system_score_gemma":0.00015580417,"threshold_uncertainty_score":0.99997246},"labels":[],"label_agreement":null},{"id":"W2040897701","doi":"10.1016/j.clinthera.2007.07.021","title":"Tolerability of a Salmeterol Xinafoate/Fluticasone Propionate Hydrofluoroalkane Metered-Dose Inhaler in Adolescent and Adult Patients with Persistent Asthma: A 52-Week, Open-Label, Stratified, Parallel-Group, Multicenter Study","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université Laval; South Health Campus; Institut Universitaire de Cardiologie et de Pneumologie de Québec; University of Calgary; Health Sciences Centre","funders":"","keywords":"Medicine; Tolerability; Fluticasone propionate; Fluticasone; Asthma; Salmeterol; Inhaler; Multicenter study; Metered-dose inhaler; Dry-powder inhaler; Anesthesia; Internal medicine; Randomized controlled trial; Adverse effect","score_opus":0.10870087893741076,"score_gpt":0.3820654086419896,"score_spread":0.27336452970457886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040897701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949655,0.00055992545,0.00014802565,0.00017205747,0.000094587456,0.0039490242,0.000024303692,0.000023816838,0.0000627532],"genre_scores_gemma":[0.9966558,0.00007656968,0.0016864502,0.001361142,0.000056617017,0.000054868684,0.00002498872,0.000044973556,0.00003857903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614555,0.00046104306,0.0015471956,0.0007693057,0.00058290403,0.00049397844],"domain_scores_gemma":[0.99781793,0.00030066597,0.0003796871,0.00067520107,0.0004115905,0.00041493945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011507635,0.00038618804,0.0010125865,0.000111074536,0.00008023089,0.000042990046,0.00027497258,0.00021722664,0.000032731496],"category_scores_gemma":[0.00013385282,0.0002608249,0.00014882316,0.00024711055,0.0004982066,0.00014626155,0.0002279203,0.0005812942,0.0000060072957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015455403,0.04634684,0.8591549,0.00017232027,0.0003637911,0.00009659697,0.00048738427,0.000003416282,0.00013523939,0.00000747493,0.000006545362,0.07777012],"study_design_scores_gemma":[0.03647991,0.017645517,0.9423614,0.00037602562,0.00037813585,0.000004662455,0.001347198,0.0006626495,0.00005553481,0.000009621284,0.00037537137,0.0003039656],"about_ca_topic_score_codex":0.000029316141,"about_ca_topic_score_gemma":0.00008583774,"teacher_disagreement_score":0.08320654,"about_ca_system_score_codex":0.00008174395,"about_ca_system_score_gemma":0.00010468117,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W2041932837","doi":"10.1016/j.clinthera.2013.04.003","title":"Chemical Sensitivity: Pathophysiology or Pathopsychology?","year":2013,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Fibromyalgia and Chronic Fatigue Syndrome Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Multiple chemical sensitivity; Toxicant; MEDLINE; Presentation (obstetrics); Intensive care medicine; Family medicine; Psychiatry; Surgery; Toxicity; Internal medicine","score_opus":0.3223596887544804,"score_gpt":0.5139793832305234,"score_spread":0.191619694476043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041932837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025991356,0.99641156,0.000057959878,0.0003270018,0.000757368,0.0015883564,0.00003669842,0.00013732266,0.0004238255],"genre_scores_gemma":[0.000019475041,0.99427575,0.0013587713,0.00045297045,0.0005894177,0.00013394216,0.00025239165,0.00016539752,0.002751885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99460524,0.0013950709,0.0016929867,0.0010588685,0.0003986412,0.0008491734],"domain_scores_gemma":[0.9942954,0.003147598,0.00040335383,0.0014446522,0.00024359861,0.00046540657],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0011527835,0.0006739741,0.004388831,0.0001421142,0.00006131637,0.000030177845,0.00031367672,0.002391578,0.0010507581],"category_scores_gemma":[0.00059883465,0.00040619067,0.0014602763,0.00053831417,0.0009001993,0.000034959674,0.00025493352,0.0029635269,0.0024221758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008539504,0.0005464463,0.000005930261,0.019674068,0.0008630752,0.00065046496,0.000012689305,7.2045143e-9,0.00004071479,0.000030342753,0.0024846655,0.9756062],"study_design_scores_gemma":[0.001146384,0.0011941807,0.000018766732,0.01068917,0.0018928208,0.0014024792,0.000015723519,0.00003993137,0.0000026227144,0.00014870391,0.9829345,0.0005147586],"about_ca_topic_score_codex":0.0000022907204,"about_ca_topic_score_gemma":9.517401e-8,"teacher_disagreement_score":0.9804498,"about_ca_system_score_codex":0.00015022799,"about_ca_system_score_gemma":0.0015966322,"threshold_uncertainty_score":0.99986243},"labels":[],"label_agreement":null},{"id":"W2042767008","doi":"10.1016/s0149-2918(08)80061-6","title":"Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Vancouver General Hospital","funders":"AstraZeneca Canada","keywords":"Pravastatin; Medicine; Rosuvastatin; Atorvastatin; Simvastatin; Perspective (graphical); Statin; Pharmacology; Internal medicine; Cholesterol","score_opus":0.1808289121573606,"score_gpt":0.43496613499180087,"score_spread":0.2541372228344403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042767008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846157,0.004168095,0.0071568675,0.0006896455,0.00034069622,0.0017845485,0.0007808502,0.00007334116,0.0003902942],"genre_scores_gemma":[0.9922202,0.0014217561,0.004992923,0.00092898833,0.00016180491,0.00005092965,0.0001572457,0.000047939437,0.000018164501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960427,0.0011787707,0.0010619287,0.0006394662,0.0005677786,0.00050932827],"domain_scores_gemma":[0.9957365,0.0016859149,0.00042835486,0.00071112585,0.00060392014,0.0008341935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021707916,0.00028165925,0.0017307318,0.00031240538,0.00023164747,0.000016467759,0.00011097187,0.00018691251,0.000027189459],"category_scores_gemma":[0.00034731792,0.00024757558,0.0006178575,0.0009753173,0.0003939323,0.000055518685,0.000037849684,0.00046725082,0.0000067740866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096414415,0.0017949658,0.48775238,0.0012674188,0.073357604,0.0008015275,0.023243492,0.0006479633,0.00019598592,0.0075946855,0.00041168288,0.39329085],"study_design_scores_gemma":[0.010280041,0.0026256794,0.9621945,0.0002889715,0.004482916,0.000036424233,0.010064403,0.006010258,0.00011484718,0.00006309372,0.003421891,0.00041698574],"about_ca_topic_score_codex":0.12586704,"about_ca_topic_score_gemma":0.021551603,"teacher_disagreement_score":0.47444212,"about_ca_system_score_codex":0.00059798494,"about_ca_system_score_gemma":0.0021077336,"threshold_uncertainty_score":0.9999977},"labels":[],"label_agreement":null},{"id":"W2042953923","doi":"10.1016/s0149-2918(02)85102-5","title":"Minimal important difference: Can we predict its magnitude?","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Scientific Measurement and Uncertainty Evaluation","field":"Decision Sciences","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Magnitude (astronomy); Statistics; Physics","score_opus":0.6847500435142605,"score_gpt":0.5048882643337423,"score_spread":0.17986177918051816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042953923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96287096,0.0028188888,0.00087728596,0.01559102,0.005903646,0.0007083731,0.00005935012,0.00014695268,0.011023558],"genre_scores_gemma":[0.9734618,0.00085843506,0.00038950276,0.0019070444,0.0005044643,0.000013192476,0.000006272809,0.000015918797,0.022843359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99291724,0.00071909814,0.0020522599,0.00080221624,0.0030773217,0.00043189168],"domain_scores_gemma":[0.99494666,0.0025070359,0.0005542925,0.0009320489,0.00078125455,0.00027872706],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.010413238,0.00021863778,0.00044952636,0.00015010349,0.0002260588,0.00036455182,0.0011595956,0.0002176234,0.0058937543],"category_scores_gemma":[0.004404209,0.0001451251,0.00031379584,0.0007292451,0.00028618894,0.00011727426,0.0001114822,0.00035542448,0.0008904772],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012747395,0.00086247927,0.24767144,0.000006439749,0.00013282862,0.000013301142,0.0013238403,0.000021868384,0.0014728829,0.001056269,0.028500557,0.7188106],"study_design_scores_gemma":[0.0041654743,0.0013882661,0.2409997,0.00007895437,0.00032787005,0.000012151259,0.0012241228,0.3310639,0.0008696201,0.060539782,0.35833246,0.0009977119],"about_ca_topic_score_codex":0.000001875675,"about_ca_topic_score_gemma":0.000038349404,"teacher_disagreement_score":0.7178129,"about_ca_system_score_codex":0.000039200524,"about_ca_system_score_gemma":0.000098455006,"threshold_uncertainty_score":0.99988747},"labels":[],"label_agreement":null},{"id":"W2043962964","doi":"10.1016/j.clinthera.2011.08.008","title":"Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure Management","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lawson Health Research Institute","funders":"","keywords":"Medicine; Valsartan; Irbesartan; Candesartan; Losartan; Blood pressure; Internal medicine; Cardiology; Calcium channel blocker; Angiotensin receptor; Myocardial infarction; Angiotensin II","score_opus":0.19506615408076922,"score_gpt":0.39758060657976513,"score_spread":0.2025144524989959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043962964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905669,0.0029104585,0.0000065867875,0.00035286514,0.00034058082,0.0005530229,0.000058911475,0.00002472485,0.005185962],"genre_scores_gemma":[0.99125624,0.0040341425,0.0035231865,0.00065255363,0.000052952957,0.0000036898036,0.0000076566685,0.000025877978,0.00044369948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976942,0.00016657477,0.0011545862,0.0003902491,0.0003726114,0.00022176912],"domain_scores_gemma":[0.99765325,0.00046664276,0.0005491221,0.0006614779,0.00059683464,0.00007269721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004473232,0.00020601286,0.0017963897,0.00044178046,0.00002132224,0.0000020265775,0.00016272983,0.00018785069,0.00016675063],"category_scores_gemma":[0.000110889894,0.00016214914,0.0005881399,0.0012077264,0.00044567304,0.00002714126,0.000105911895,0.00024320827,0.0000029050918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042385203,0.003867406,0.9007909,0.00011455929,0.08474443,0.000031119816,0.0010737384,0.0000078847015,0.0011549332,0.0005196446,0.0015324823,0.001924331],"study_design_scores_gemma":[0.006420216,0.0009679655,0.9189753,0.00017590364,0.06441858,4.3654458e-7,0.00036237141,0.00010418012,0.004931696,0.000033296583,0.0034671961,0.000142895],"about_ca_topic_score_codex":0.00026442812,"about_ca_topic_score_gemma":0.00012425319,"teacher_disagreement_score":0.020325854,"about_ca_system_score_codex":0.0000064591254,"about_ca_system_score_gemma":0.000031267948,"threshold_uncertainty_score":0.661225},"labels":[],"label_agreement":null},{"id":"W2044721275","doi":"10.1016/s0149-2918(00)89081-5","title":"Comparison of cisapride and metoclopramide for facilitating gastric emptying and improving tolerance to intragastric enteral nutrition in critically ill, mechanically ventilated adults","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Clinical Nutrition and Gastroenterology","field":"Nursing","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Health Sciences Centre Foundation; Health Sciences Centre Research Foundation","keywords":"Metoclopramide; Medicine; Gastric emptying; Cisapride; Cmax; Gastroenterology; Enteral administration; Antiemetic; Anesthesia; Internal medicine; Parenteral nutrition; Pharmacokinetics; Stomach; Vomiting","score_opus":0.07700206971764266,"score_gpt":0.41812018009579943,"score_spread":0.34111811037815676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044721275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617185,0.0004172613,0.027655939,0.008735296,0.00042337689,0.0009603473,0.000038293703,0.00004739831,0.000003559885],"genre_scores_gemma":[0.9557689,0.00017009488,0.0325352,0.01129671,0.0001268821,0.0000554477,0.000018280769,0.000026490121,0.0000019931072],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99652773,0.00031356196,0.0018888501,0.0005829121,0.0001814518,0.0005055059],"domain_scores_gemma":[0.9958028,0.0030564065,0.0002665541,0.00021997027,0.00041848375,0.000235741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010327171,0.00022777753,0.0008290947,0.00018856152,0.00008581163,0.00004531887,0.00017040914,0.00025190707,0.0000055158525],"category_scores_gemma":[0.0028665983,0.0002377321,0.0001640404,0.00031552708,0.0002107781,0.00011019848,0.00009433021,0.0005001515,8.4588845e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017296681,0.0032194934,0.3625849,0.000639557,0.00008816365,0.000013387598,0.000878923,0.00007740467,0.018467087,0.00008656478,0.00013731922,0.5965105],"study_design_scores_gemma":[0.056175068,0.04149686,0.47990274,0.004531578,0.000769772,0.00018331493,0.0051002246,0.383942,0.005242693,0.010403458,0.010500187,0.0017520777],"about_ca_topic_score_codex":0.000015368481,"about_ca_topic_score_gemma":0.000076214295,"teacher_disagreement_score":0.59475845,"about_ca_system_score_codex":0.000041563413,"about_ca_system_score_gemma":0.000008004519,"threshold_uncertainty_score":0.9694434},"labels":[],"label_agreement":null},{"id":"W2044804952","doi":"10.1016/j.clinthera.2004.09.010","title":"Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Nausea and vomiting management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Duloxetine; Nausea; Placebo; Medicine; Duloxetine Hydrochloride; Paroxetine; Antidepressant; Fluoxetine; Internal medicine; Major depressive disorder; Incidence (geometry); Reuptake inhibitor; Anesthesia; Serotonin","score_opus":0.09332992397978791,"score_gpt":0.38254932806403785,"score_spread":0.28921940408424995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044804952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506414,0.00038768662,0.0007482294,0.0029827054,0.00006122382,0.00043305947,0.0000027970282,0.00005029764,0.00026984228],"genre_scores_gemma":[0.993055,0.0010117274,0.004760867,0.0009625753,0.00012548281,0.000006022632,0.000009783177,0.000021117723,0.000047415768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985287,0.000070429,0.0006579681,0.00031852713,0.00023795842,0.00018636926],"domain_scores_gemma":[0.9988671,0.00027677655,0.00024937105,0.00030286371,0.00015730917,0.00014659748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006403319,0.0001628296,0.00048431312,0.000057646055,0.00006198991,0.000019062669,0.00006515481,0.000098597644,0.000009228321],"category_scores_gemma":[0.00016988956,0.000119385106,0.000044358887,0.00015464055,0.00028598408,0.000057668614,0.000074591284,0.00023626562,0.000002288767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028358463,0.001041231,0.9474492,0.0005328081,0.00051653525,0.0001159002,0.00035051937,0.000033187935,0.024645222,0.001461785,0.00003986188,0.020977883],"study_design_scores_gemma":[0.013834171,0.0028674826,0.96728545,0.0006432695,0.00060605427,0.00009097831,0.0002241688,0.0009975273,0.011551929,0.00058267993,0.0010329823,0.00028329543],"about_ca_topic_score_codex":0.000021227497,"about_ca_topic_score_gemma":0.000012537171,"teacher_disagreement_score":0.020694587,"about_ca_system_score_codex":0.000012436826,"about_ca_system_score_gemma":0.00005523605,"threshold_uncertainty_score":0.4868383},"labels":[],"label_agreement":null},{"id":"W2044832889","doi":"10.1016/j.clinthera.2007.07.001","title":"Health Care Costs and Mortality for Canadian Urban and Rural Patients with Diabetes: Population-Based Trends from 1993–2001","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Global Health Workforce Issues","field":"Health Professions","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"University of Alberta","keywords":"Medicine; Residence; Per capita; Rural area; Population; Demography; Environmental health; Health care; Medical prescription; Public health; Diabetes mellitus; Rural health; Gerontology; Economic growth; Nursing","score_opus":0.09260251319071314,"score_gpt":0.48299791608662784,"score_spread":0.3903954028959147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044832889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389946,0.0011408401,0.000043271433,0.0018205433,0.00061523385,0.0011599335,0.001000837,0.000060470713,0.00025939068],"genre_scores_gemma":[0.97682613,0.000043761993,0.0012565637,0.019947497,0.00031494576,0.00003330385,0.001481627,0.000040705294,0.000055489556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970076,0.0003599551,0.0010112469,0.00037164552,0.00021956328,0.0010299603],"domain_scores_gemma":[0.99595094,0.002063219,0.00036051715,0.00035599226,0.00023205452,0.001037259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010237155,0.00022475603,0.0005472025,0.00008877291,0.0008485339,0.000014751581,0.00011634632,0.00035707268,0.000037456262],"category_scores_gemma":[0.000099722936,0.00018435216,0.00005488673,0.00019014753,0.00012920289,0.000058296388,0.000024108771,0.00046673484,0.0000031345405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014810268,0.00004800693,0.9548117,0.000076588396,0.000042248314,3.6755756e-7,0.00061806064,0.0000011946987,3.5100598e-8,0.00008143439,0.0006502956,0.043522004],"study_design_scores_gemma":[0.0026756467,0.00058141287,0.9718225,0.00027885393,0.00005885164,1.1895014e-8,0.0009779799,0.00026214815,1.6402585e-7,0.00011523002,0.023038244,0.00018897305],"about_ca_topic_score_codex":0.096918836,"about_ca_topic_score_gemma":0.5130869,"teacher_disagreement_score":0.41616806,"about_ca_system_score_codex":0.0005750344,"about_ca_system_score_gemma":0.0005601471,"threshold_uncertainty_score":0.90909487},"labels":[],"label_agreement":null},{"id":"W2044867903","doi":"10.1016/s0149-2918(04)90069-0","title":"Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the assessment of treatment with lisinopril and survival (ATLAS) study","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Heart failure; Angiotensin-converting enzyme; Intensive care medicine; Internal medicine; Cardiology; Blood pressure","score_opus":0.0920809430383175,"score_gpt":0.36357612768059344,"score_spread":0.27149518464227596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044867903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212116,0.00014750578,0.00008469569,0.0044517037,0.00005729661,0.0029915255,0.00009830275,0.000032284228,0.000015523508],"genre_scores_gemma":[0.99046326,0.00005367179,0.008521323,0.0006970189,0.000047590143,0.0000727192,0.000090852234,0.0000380823,0.00001551314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970335,0.0003368922,0.00094247813,0.00066736754,0.00070542976,0.00031436654],"domain_scores_gemma":[0.99690264,0.0014211518,0.00041618836,0.00069678464,0.00035102537,0.00021217615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006267424,0.00041957753,0.0014004437,0.00018219391,0.00011796032,0.0000442375,0.00011559079,0.00010969662,0.0000343176],"category_scores_gemma":[0.00007565792,0.00022868405,0.00027036888,0.0005909218,0.00020620722,0.00013905029,0.000087736385,0.00020068191,0.0000018039433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011867516,0.004543476,0.9711318,0.000014920933,0.014405829,0.0000074253667,0.0009134124,0.00023222697,0.00010615468,0.000012870478,0.000007770829,0.007437341],"study_design_scores_gemma":[0.014200274,0.018038917,0.9536093,0.00057577563,0.011176105,2.2955656e-7,0.001214809,0.00007496838,0.00078486075,0.0000037961818,0.00010760573,0.00021336068],"about_ca_topic_score_codex":0.001263136,"about_ca_topic_score_gemma":0.0018979438,"teacher_disagreement_score":0.017522523,"about_ca_system_score_codex":0.0003607333,"about_ca_system_score_gemma":0.00042529992,"threshold_uncertainty_score":0.9325465},"labels":[],"label_agreement":null},{"id":"W2048285147","doi":"10.1016/j.clinthera.2009.11.012","title":"Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Medicine; Bortezomib; Pharmacokinetics; Ketoconazole; Pharmacology; Pharmacodynamics; Concomitant; Crossover study; Adverse effect; Internal medicine; Multiple myeloma; Placebo; Pathology","score_opus":0.01977489595929071,"score_gpt":0.37703235094745274,"score_spread":0.357257454988162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048285147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993971,0.00012197556,0.000018058658,0.000109558154,0.00021347638,0.0053470414,0.000035004512,0.0000057638144,0.00017810997],"genre_scores_gemma":[0.9988476,0.00013936729,0.000067687244,0.0006717871,0.00007232189,0.00012533105,0.000010189723,0.000024270139,0.000041441865],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99729097,0.0011419842,0.00075637194,0.00037770905,0.0002266046,0.0002063545],"domain_scores_gemma":[0.9982887,0.0005611363,0.0005342035,0.00040534296,0.00015982953,0.000050788873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015440112,0.00025600372,0.0005954047,0.000027626153,0.00007533233,0.000034866476,0.00041963567,0.00006513897,0.000005177529],"category_scores_gemma":[0.000179075,0.00013642297,0.000108109685,0.00012938994,0.00033423712,0.000015007741,0.00020191826,0.00039305052,5.9930744e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.564307,0.0148703465,0.26406658,0.000118820135,0.0010564203,0.0000037203724,0.0014003408,0.0005154245,0.09516547,0.000105925516,0.00006679119,0.05832319],"study_design_scores_gemma":[0.4400961,0.008980859,0.02784718,0.00031254024,0.00034701772,0.0000012081415,0.0001647565,0.0034816118,0.51805013,0.00009125201,0.0002486152,0.00037872294],"about_ca_topic_score_codex":0.00000531076,"about_ca_topic_score_gemma":0.000008765606,"teacher_disagreement_score":0.42288464,"about_ca_system_score_codex":0.000018973653,"about_ca_system_score_gemma":0.00003980744,"threshold_uncertainty_score":0.55631673},"labels":[],"label_agreement":null},{"id":"W2048362135","doi":"10.1016/j.clinthera.2015.03.019","title":"Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Tolerability; Medicine; Acetaminophen; Hydrocodone; Discontinuation; Anesthesia; Adverse effect; Analgesic; Dosing; Clinical endpoint; Osteoarthritis; Internal medicine; Opioid; Oxycodone; Clinical trial","score_opus":0.14359850445936834,"score_gpt":0.4098877593192153,"score_spread":0.26628925485984695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048362135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325293,0.0003865492,0.00032530792,0.0001480127,0.00020095379,0.005492646,0.00007190785,0.000034803543,0.00008687395],"genre_scores_gemma":[0.9963037,0.00006702728,0.001980836,0.0009219937,0.00007520251,0.00014612873,0.00010743221,0.00006373935,0.00033395886],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955954,0.0010135807,0.0015124207,0.000755247,0.00057713944,0.00054621685],"domain_scores_gemma":[0.9971417,0.0005723166,0.0004166318,0.0009892485,0.00037037625,0.00050970906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026147517,0.00042125254,0.0013759092,0.000094372044,0.00006240709,0.0000445303,0.00036720777,0.00022282597,0.00015480309],"category_scores_gemma":[0.0003070126,0.00029104887,0.00009614749,0.00043977404,0.00024504375,0.000204889,0.00017392005,0.00045431065,0.000042784894],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03572962,0.123047404,0.69465053,0.00016738089,0.0008581416,0.00034025358,0.00070040167,0.000017480106,0.00016366482,0.000005611795,0.00008216586,0.14423734],"study_design_scores_gemma":[0.7587634,0.15577377,0.071314394,0.0011992875,0.0008557882,0.0000076019187,0.0009091311,0.008536999,0.0006723427,0.00013545858,0.0010444534,0.00078743184],"about_ca_topic_score_codex":0.000094152776,"about_ca_topic_score_gemma":0.00040179765,"teacher_disagreement_score":0.7230337,"about_ca_system_score_codex":0.00025011343,"about_ca_system_score_gemma":0.0006110687,"threshold_uncertainty_score":0.99995416},"labels":[],"label_agreement":null},{"id":"W2050678883","doi":"10.1016/j.clinthera.2013.11.005","title":"Zopiclone’s Residual Effects on Actual Driving Performance in a Standardized Test: A Pooled Analysis of Age and Sex Effects in 4 Placebo-Controlled Studies","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Forensic Toxicology and Drug Analysis","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Zopiclone; Placebo; Residual; Meta-analysis; Internal medicine; Anesthesia; Hypnotic; Alternative medicine","score_opus":0.08639954341132566,"score_gpt":0.4523157813055958,"score_spread":0.36591623789427014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050678883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960447,0.0014783739,0.000020569983,0.0005888835,0.00034136872,0.0011521707,0.000008622738,0.00004113591,0.00032417075],"genre_scores_gemma":[0.9948114,0.0018447674,0.00021356106,0.0025315883,0.000100076795,0.00018817016,0.000007693996,0.000021823425,0.00028091526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99498934,0.0023703799,0.0013123741,0.0005453503,0.00023079224,0.00055174174],"domain_scores_gemma":[0.97109157,0.027948974,0.0003751188,0.00033207834,0.00009387811,0.00015837332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00332863,0.0003708742,0.0022534574,0.0006708527,0.00012550481,0.000019030425,0.00023907844,0.0006849512,0.0000803735],"category_scores_gemma":[0.0020859074,0.00029361236,0.00036168136,0.00095985585,0.00074550626,0.00009820503,0.00012283285,0.0013352035,0.000015264257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005985485,0.0013781381,0.8840742,0.00019275004,0.014340363,0.00016797917,0.0028332656,0.0018121436,0.0021077793,0.00019519676,0.00010670653,0.086805984],"study_design_scores_gemma":[0.059434425,0.0029784925,0.84529203,0.00022810728,0.012518223,0.0000030842575,0.0006430179,0.07014311,0.0065818913,0.0010000091,0.00051556376,0.0006620124],"about_ca_topic_score_codex":0.000012248134,"about_ca_topic_score_gemma":0.00027176205,"teacher_disagreement_score":0.08614397,"about_ca_system_score_codex":0.000090128684,"about_ca_system_score_gemma":0.000078303725,"threshold_uncertainty_score":0.9999516},"labels":[],"label_agreement":null},{"id":"W2050776171","doi":"10.1016/j.clinthera.2007.05.007","title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital","funders":"","keywords":"Deferasirox; Medicine; Deferoxamine; Thalassemia; Deferiprone; Beta thalassemia; Chelation therapy; Pediatrics; Internal medicine; Prospective cohort study; Adverse effect; Quality of life (healthcare); Surgery","score_opus":0.05687604124416545,"score_gpt":0.3762289759901872,"score_spread":0.3193529347460217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050776171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658227,0.00013159757,0.00007953808,0.000064786356,0.00008697256,0.0028251486,0.000008113338,0.000026986327,0.00019457459],"genre_scores_gemma":[0.9985559,0.00007828038,0.000999833,0.00011985033,0.000019862082,0.00006117577,0.000037044538,0.000037893584,0.00009016716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791354,0.00006337542,0.0008640703,0.00034303684,0.0005193613,0.00029664452],"domain_scores_gemma":[0.99839985,0.00033383936,0.00036148282,0.00031829014,0.00048421428,0.00010233044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056368165,0.00022641591,0.0005615957,0.00009591941,0.000046014662,0.000005743088,0.000042733467,0.00021641853,0.000015507998],"category_scores_gemma":[0.00015363621,0.00011992655,0.00011616363,0.00024366606,0.0001234877,0.000048867696,0.000011619407,0.00017934554,8.6305664e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012353015,0.0029808155,0.9527578,0.00004166086,0.00055197615,0.00001012737,0.00042076453,0.0000552219,0.00005051011,0.0000068100767,6.653227e-7,0.030770628],"study_design_scores_gemma":[0.035761233,0.012207427,0.9492146,0.00014855641,0.0010680557,0.000004587685,0.00041831337,0.0001525108,0.0007653418,0.000028490529,0.000073455354,0.00015744472],"about_ca_topic_score_codex":0.000010958197,"about_ca_topic_score_gemma":0.000101089354,"teacher_disagreement_score":0.030613182,"about_ca_system_score_codex":0.00031185566,"about_ca_system_score_gemma":0.00022337765,"threshold_uncertainty_score":0.4890463},"labels":[],"label_agreement":null},{"id":"W2051099017","doi":"10.1016/j.clinthera.2007.12.019","title":"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: A Monte Carlo simulation analysis","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Moxifloxacin; Gemifloxacin; Streptococcus pneumoniae; Medicine; Pharmacodynamics; Levofloxacin; Pneumonia; Pharmacology; Community-acquired pneumonia; Microbiology; Pharmacokinetics; Antibiotics; Internal medicine; Biology","score_opus":0.09618920936414552,"score_gpt":0.452283535848043,"score_spread":0.3560943264838975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051099017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945147,0.0007124101,0.0034153827,0.0001987534,0.000114433606,0.0007171377,0.00009068933,0.000049301874,0.00018720636],"genre_scores_gemma":[0.9978863,0.000927901,0.00022381858,0.000685465,0.000062307205,0.0000030558656,0.00007212172,0.000038877337,0.000100123616],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9966926,0.00044402387,0.0016448842,0.00040210914,0.00036779427,0.00044861107],"domain_scores_gemma":[0.9965331,0.0017956389,0.0004783824,0.0005657357,0.00032968,0.000297442],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018590658,0.00034993867,0.0013370988,0.00034947981,0.000113448856,0.000024476982,0.00021056866,0.00029619504,0.000022118666],"category_scores_gemma":[0.000085255306,0.00032690386,0.0003045062,0.0010758314,0.00048290397,0.00006907224,0.0001139148,0.0008686257,0.0000027343335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009899777,0.0029623618,0.8475543,0.00015541894,0.0028978619,0.00003959516,0.0028796839,0.028128726,0.10544268,0.000025687434,0.000046930316,0.008876743],"study_design_scores_gemma":[0.004521409,0.0007266578,0.46384326,0.00007274401,0.0021746668,0.0000011413655,0.00073159294,0.5226824,0.0042073005,0.000028096492,0.0006892663,0.00032146293],"about_ca_topic_score_codex":0.00007944647,"about_ca_topic_score_gemma":0.00017936324,"teacher_disagreement_score":0.4945537,"about_ca_system_score_codex":0.00007849831,"about_ca_system_score_gemma":0.00005546138,"threshold_uncertainty_score":0.9999183},"labels":[],"label_agreement":null},{"id":"W2051499477","doi":"10.1016/s0149-2918(02)80050-9","title":"How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Centre for Addiction and Mental Health; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Risperidone; Antipsychotic; Medicine; Olanzapine; Atypical antipsychotic; Quetiapine; Typical antipsychotic; Psychiatry; Population; Schizophrenia (object-oriented programming); Medical prescription; Pharmacology; Environmental health","score_opus":0.3496568085227026,"score_gpt":0.4277067110307701,"score_spread":0.07804990250806754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051499477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640256,0.0006363798,0.000025441579,0.033892784,0.0001727184,0.0005108378,0.000009372934,0.000032742322,0.00069409626],"genre_scores_gemma":[0.9951887,0.0010551497,0.00061081396,0.0020966758,0.00022759159,0.00002959757,0.000006389241,0.000025943524,0.0007591006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983756,0.00020090891,0.00030112328,0.0003412115,0.00032773855,0.00045344848],"domain_scores_gemma":[0.9983184,0.00039286626,0.00007347557,0.00059168146,0.00008074176,0.00054287136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030111516,0.00017392758,0.00030827854,0.000056921224,0.00032319667,0.0001478197,0.00018778411,0.00015893888,0.000108321125],"category_scores_gemma":[0.00023194282,0.0001042851,0.0001409721,0.00018495668,0.0002801014,0.00006431096,0.00003761068,0.00047534725,0.000038998685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058394775,0.00035176563,0.941531,0.000009517888,0.00023281258,0.00011507508,0.0018328786,3.596943e-7,0.000014635399,0.0052091666,0.00057915185,0.049539708],"study_design_scores_gemma":[0.00360203,0.0003391354,0.9720451,0.000104294675,0.00018662855,0.000088963214,0.0017717932,0.0025311606,0.000018949284,0.009556714,0.009565178,0.00019000088],"about_ca_topic_score_codex":0.0005355483,"about_ca_topic_score_gemma":0.0054151486,"teacher_disagreement_score":0.049349707,"about_ca_system_score_codex":0.00006595994,"about_ca_system_score_gemma":0.000066562665,"threshold_uncertainty_score":0.4252623},"labels":[],"label_agreement":null},{"id":"W2052455065","doi":"10.1016/s0149-2918(01)80021-7","title":"Tolerability of antihypertensive drugs in a community-based setting","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Tolerability; Losartan; Internal medicine; Incidence (geometry); Cumulative incidence; Prospective cohort study; Odds ratio; Cohort; Blood pressure; Angiotensin II; Adverse effect","score_opus":0.1786292144493821,"score_gpt":0.41770669114160397,"score_spread":0.23907747669222187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052455065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028915,0.0015581293,0.00004236616,0.006188635,0.00012973038,0.00022848214,0.0000038717308,0.000036496578,0.0015231199],"genre_scores_gemma":[0.9662375,0.0004258944,0.0011134287,0.03207476,0.00007936102,0.0000038940034,0.000006516256,0.000014088424,0.00004456163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982003,0.00050838303,0.000752889,0.00016564701,0.00018022867,0.00019252588],"domain_scores_gemma":[0.99683225,0.0021048614,0.00013302067,0.0005294082,0.00033243757,0.00006804897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014899127,0.00012317568,0.00083270547,0.000058881964,0.000074308606,0.0000043598047,0.00010624878,0.00016498289,0.000020725109],"category_scores_gemma":[0.0002461741,0.00009470518,0.00019629432,0.00022636166,0.00032097788,0.000022710716,0.000061925544,0.0007536251,0.000006802547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070248137,0.0020750372,0.9625069,0.00011477634,0.000346673,0.00003289,0.0009202798,0.0000062547497,0.0009008554,0.000031800395,0.00039636687,0.03196572],"study_design_scores_gemma":[0.0075601134,0.0013243936,0.92906016,0.00044841252,0.0011315891,0.00003138669,0.0025079374,0.0017907673,0.0013732127,0.0007461472,0.05375331,0.0002725706],"about_ca_topic_score_codex":0.00007917829,"about_ca_topic_score_gemma":0.000021279899,"teacher_disagreement_score":0.05335694,"about_ca_system_score_codex":0.0000065404247,"about_ca_system_score_gemma":0.00008016472,"threshold_uncertainty_score":0.38619652},"labels":[],"label_agreement":null},{"id":"W2054421884","doi":"10.1016/j.clinthera.2014.09.017","title":"Hypnotics in Insomnia: The Experience of Zolpidem","year":2014,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Sleep and related disorders","field":"Psychology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Université de Montréal; Université Laval; Institut Universitaire en Santé Mentale de Québec; Canadian Sleep & Circadian Network; University of Toronto","funders":"Servier; Canada Research Chairs; Valeant Pharmaceuticals International","keywords":"Zolpidem; Insomnia; Medicine; Bedtime; Anxiety; Primary Insomnia; Hypnotic; Psychiatry; Population; Sleep disorder","score_opus":0.2548751536100162,"score_gpt":0.5199757908516316,"score_spread":0.26510063724161537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054421884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116463714,0.9882345,0.00012612119,0.00009079509,0.0029720722,0.0005816898,0.000006294966,0.000029085744,0.007842979],"genre_scores_gemma":[0.00028385638,0.997737,0.000060095066,0.0010484006,0.0002564076,0.000057594447,0.000008195964,0.00006303206,0.00048541612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995239,0.001492821,0.002226885,0.00047330244,0.00019407821,0.00037387846],"domain_scores_gemma":[0.9930794,0.0048087826,0.0008065053,0.0011899888,0.000045656026,0.000069649825],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014194304,0.00035995626,0.0019807531,0.00010298231,0.00004449639,0.000012000675,0.0010265764,0.0014321068,0.00020111067],"category_scores_gemma":[0.00022103611,0.0002039402,0.0008821087,0.0005111834,0.0008106853,0.000015916934,0.00010727571,0.0016839346,0.00029885073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000134493985,0.00056178967,0.0002129402,0.00035647146,0.00067661295,0.0000051184097,0.00082100724,0.0000011246059,6.7631825e-9,0.002420289,0.00022834768,0.9947028],"study_design_scores_gemma":[0.0006910146,0.00012993418,0.000055817552,0.0012825018,0.0009707256,0.0000069971866,0.0003613622,0.0000173186,3.20011e-8,0.000422749,0.99582744,0.0002341165],"about_ca_topic_score_codex":0.000015967968,"about_ca_topic_score_gemma":0.000008480618,"teacher_disagreement_score":0.9955991,"about_ca_system_score_codex":0.000021536165,"about_ca_system_score_gemma":0.0001021779,"threshold_uncertainty_score":0.9998642},"labels":[],"label_agreement":null},{"id":"W2055695150","doi":"10.1016/j.clinthera.2009.03.013","title":"Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Medtronic (Canada)","funders":"","keywords":"Medicine; Life expectancy; Type 1 diabetes; Diabetes mellitus; Quality-adjusted life year; Insulin; Pediatrics; Quality of life (healthcare); Cost effectiveness; Internal medicine; Endocrinology; Environmental health; Population","score_opus":0.08166439137572463,"score_gpt":0.38843392464,"score_spread":0.30676953326427536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055695150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364424,0.0024076817,0.000012259376,0.0027936397,0.00014547221,0.0009078544,0.00004105161,0.000006939689,0.000040841547],"genre_scores_gemma":[0.99422455,0.004961972,0.00017516667,0.00044649816,0.000086923756,0.0000053591893,0.000031427535,0.000009648576,0.000058429396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867725,0.00008385476,0.00075114315,0.00016232021,0.00010751198,0.00021788765],"domain_scores_gemma":[0.99765575,0.0017423622,0.00021194668,0.0002218653,0.00008887041,0.000079188176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030208603,0.00010412753,0.0006305628,0.00006013531,0.000046767393,0.000006096366,0.00008726625,0.00006730062,0.0000048847955],"category_scores_gemma":[0.0000923454,0.000069137655,0.000073020456,0.000114943425,0.000109256456,0.000014215664,0.000017533097,0.0001309529,7.234754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028867243,0.00033732026,0.5783698,0.000030183995,0.0001171757,4.1238593e-7,0.00010477054,0.00004655214,0.000019947192,0.000014837722,0.00007538953,0.42059493],"study_design_scores_gemma":[0.00516093,0.012903799,0.9401414,0.0000873112,0.00015911867,2.5982067e-7,0.00034037477,0.02778316,0.0003169485,0.00013329629,0.012871894,0.00010150783],"about_ca_topic_score_codex":0.027318072,"about_ca_topic_score_gemma":0.101011604,"teacher_disagreement_score":0.42049342,"about_ca_system_score_codex":0.00016227865,"about_ca_system_score_gemma":0.0004361516,"threshold_uncertainty_score":0.9791591},"labels":[],"label_agreement":null},{"id":"W2055882466","doi":"10.1016/s0149-2918(02)85096-2","title":"Clinical benefit in patients with cancer of the pancreas: How does it compare with clinically significant changes in quality-of-life scores?","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Quality of life (healthcare); Physical therapy; Massage; Toileting; Family medicine; Activities of daily living; Alternative medicine; Nursing","score_opus":0.1645979465072582,"score_gpt":0.4017970300013916,"score_spread":0.2371990834941334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055882466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133193,0.0004227422,0.000012369203,0.006584219,0.0005094106,0.0008243143,0.00010502103,0.000017438635,0.00019256398],"genre_scores_gemma":[0.9919467,0.0021842185,0.00014032285,0.0052459976,0.00021612376,0.000041798117,0.000011114961,0.000042508796,0.00017121744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575424,0.00067408144,0.0019200225,0.0005405305,0.0007388677,0.0003722844],"domain_scores_gemma":[0.9952089,0.0022405728,0.00096736744,0.00092282926,0.00044572924,0.00021459204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017510012,0.00028132272,0.0015520876,0.00007912331,0.000031029937,0.00001305494,0.00040156904,0.00028309796,0.00014601463],"category_scores_gemma":[0.00045274833,0.00014184813,0.00027953586,0.000567843,0.00093792815,0.00004690627,0.00008908149,0.00092502317,0.0000016179572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050437236,0.0018270832,0.97263557,0.00017315483,0.00024061033,0.0000028587986,0.0005927331,0.00001502433,0.0000041648977,0.0000610432,0.000043351596,0.019360658],"study_design_scores_gemma":[0.008381357,0.0022061553,0.9855187,0.0011395254,0.00018806192,1.5573133e-7,0.0007888627,0.00012093204,0.000021954638,0.00004617443,0.001360105,0.000228021],"about_ca_topic_score_codex":0.0005403791,"about_ca_topic_score_gemma":0.02369217,"teacher_disagreement_score":0.02315179,"about_ca_system_score_codex":0.00005359653,"about_ca_system_score_gemma":0.0002143413,"threshold_uncertainty_score":0.9941229},"labels":[],"label_agreement":null},{"id":"W2056125033","doi":"10.1016/j.clinthera.2005.09.014","title":"Erectile response to vardenafil in men with a history of nonresponse to sildenafil: A time-from-dosing descriptive analysis","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Vardenafil; Tolerability; Medicine; Sildenafil; Dosing; Erectile dysfunction; Placebo; Sexual intercourse; Tadalafil; Adverse effect; Internal medicine; Population; Alternative medicine","score_opus":0.11813794857689912,"score_gpt":0.38242976801897793,"score_spread":0.2642918194420788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056125033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98380435,0.00070787873,0.0039539207,0.0038328525,0.0002408958,0.00056273333,0.000021822887,0.00009080349,0.006784729],"genre_scores_gemma":[0.9120168,0.00010591326,0.011718014,0.018030724,0.00034916258,0.0000638586,0.000012250839,0.00005323322,0.057650007],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755675,0.0005911774,0.0007632778,0.0004664095,0.0003699391,0.00025242724],"domain_scores_gemma":[0.9963093,0.0024738554,0.00013826277,0.00050183974,0.0002975083,0.0002792319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015716986,0.00020389768,0.0008248048,0.000548702,0.000034212117,0.00000872598,0.000101437276,0.00013780464,0.00083838037],"category_scores_gemma":[0.0010226159,0.00016196369,0.00021328434,0.0010760335,0.000112097405,0.000047317873,0.00006211471,0.00029104634,0.00033688327],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5266509,0.0039193267,0.2292434,0.000027721764,0.01020626,0.00012414214,0.027380267,0.0028567975,0.049388535,0.000033421627,0.08336922,0.0668],"study_design_scores_gemma":[0.004938789,0.00497564,0.33090463,0.00011277732,0.0022956457,0.000008885157,0.0021395287,0.0032606719,0.0007936872,0.00001146055,0.65017307,0.0003851935],"about_ca_topic_score_codex":0.000090661786,"about_ca_topic_score_gemma":0.00009599098,"teacher_disagreement_score":0.5668039,"about_ca_system_score_codex":0.00057959754,"about_ca_system_score_gemma":0.00032447383,"threshold_uncertainty_score":0.91796774},"labels":[],"label_agreement":null},{"id":"W2056574029","doi":"10.1016/j.clinthera.2012.04.009","title":"Restrictive Drug Coverage Policies can Induce Substantial Drug Exposure Misclassification in Pharmacoepidemiologic Studies","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Formulary; Medicine; Drug; Medical prescription; Confidence interval; Prescription drug; Pharmacoepidemiology; Family medicine; Actuarial science; Environmental health; Pharmacology; Internal medicine","score_opus":0.4229551031849782,"score_gpt":0.5130716424908232,"score_spread":0.09011653930584496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056574029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756818,0.007713817,0.0001455025,0.01342746,0.0008088485,0.00044071354,0.0000060064776,0.00006367002,0.001712189],"genre_scores_gemma":[0.97170144,0.013405069,0.00022671005,0.011707842,0.00075937156,0.00005195691,0.000017816183,0.000016064807,0.002113718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756217,0.00058973493,0.00089930353,0.0002913652,0.00025789774,0.0003995469],"domain_scores_gemma":[0.9974061,0.0014938449,0.00032473245,0.00039407634,0.00016369982,0.00021753793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018064439,0.0001864785,0.0005520192,0.000076944576,0.0000776027,0.000008441726,0.0001813298,0.00014321366,0.000082807775],"category_scores_gemma":[0.0008173361,0.00014223716,0.00012127326,0.00037283177,0.0003271336,0.00009063144,0.000042568907,0.000679045,0.00010883611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026137213,0.0008218264,0.9628606,0.000047827234,0.00021982139,0.0000060451816,0.0030288706,0.000004636093,0.0013419547,0.0011901119,0.007803197,0.022413777],"study_design_scores_gemma":[0.002850653,0.00020228869,0.9369144,0.00019311019,0.00021354435,0.000010209416,0.0049794028,0.00023682408,0.001416957,0.0013388114,0.051347714,0.00029611774],"about_ca_topic_score_codex":0.000027472612,"about_ca_topic_score_gemma":0.000010076477,"teacher_disagreement_score":0.043544516,"about_ca_system_score_codex":0.00010771046,"about_ca_system_score_gemma":0.00015191495,"threshold_uncertainty_score":0.58002627},"labels":[],"label_agreement":null},{"id":"W2057357532","doi":"10.1016/j.clinthera.2013.03.014","title":"Effects of Injectable HPβCD-Diclofenac on the Human Delayed Rectifier Potassium Channel Current In Vitro and on Proarrhythmic QTc In Vivo","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health and Social Services Centre University Institute of Geriatrics of Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Diclofenac; hERG; Pharmacology; Medicine; QT interval; In vivo; Potassium channel; Patch clamp; Proarrhythmia; Anesthesia; Internal medicine; Electrophysiology; Biology","score_opus":0.03951278087889062,"score_gpt":0.3405372061750166,"score_spread":0.301024425296126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057357532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946382,0.000876772,0.000004911465,0.0023591982,0.00038296962,0.0012923039,0.0000034291652,0.000021061318,0.0004211214],"genre_scores_gemma":[0.99584424,0.00071960775,0.000015994045,0.002778666,0.0003190859,0.00014603694,0.0000042751044,0.000026310712,0.00014576393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980647,0.00047853522,0.00057290384,0.00036699383,0.0001616651,0.0003551991],"domain_scores_gemma":[0.9977155,0.0016332108,0.00014598701,0.00036893412,0.000055526336,0.0000808811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000605105,0.00020807984,0.00061308284,0.00011719543,0.000061842984,0.000009179742,0.000085323074,0.00024228546,0.000026375612],"category_scores_gemma":[0.00020346443,0.00013316103,0.000160871,0.00024580373,0.00026328108,0.00003377583,0.000045947545,0.0011141123,0.000020307365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012170012,0.0064796973,0.009186358,0.00074196776,0.00095045293,0.00029644565,0.002004928,0.00009582616,0.7706339,0.0031609964,0.002624915,0.19165452],"study_design_scores_gemma":[0.02195501,0.017171003,0.41658488,0.0021243363,0.0005911049,0.00011644276,0.00027988682,0.004863975,0.5024759,0.027939854,0.004616177,0.0012813819],"about_ca_topic_score_codex":0.00002704414,"about_ca_topic_score_gemma":0.000004900895,"teacher_disagreement_score":0.40739852,"about_ca_system_score_codex":0.000050635354,"about_ca_system_score_gemma":0.000060578634,"threshold_uncertainty_score":0.5430149},"labels":[],"label_agreement":null},{"id":"W2058859951","doi":"10.1016/j.clinthera.2008.02.001","title":"Patterns of treatment for restless legs syndrome in primary care in the United Kingdom","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Restless Legs Syndrome Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Restless legs syndrome; Cohort; Medical prescription; Ropinirole; Pediatrics; Cohort study; Pramipexole; Physical therapy; Internal medicine; Levodopa; Neurology; Psychiatry; Disease","score_opus":0.3918408236238482,"score_gpt":0.4808492795010563,"score_spread":0.08900845587720813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058859951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967031,0.0004934129,0.00006632135,0.0010346806,0.00008140922,0.001293333,0.000030312794,0.000014957967,0.000282456],"genre_scores_gemma":[0.99686205,0.0017504736,0.0002601945,0.00066542195,0.000058697675,0.00010781863,0.000113225346,0.000034485092,0.00014763356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978123,0.00038001494,0.0008123596,0.00029694178,0.00034379418,0.00035459135],"domain_scores_gemma":[0.99722606,0.0018016786,0.00011477937,0.0006500079,0.00012883054,0.000078635734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073855656,0.00016783085,0.0006389844,0.00025372914,0.000041328134,0.000007534208,0.00028492062,0.00022257556,0.000010511857],"category_scores_gemma":[0.0000941399,0.00010671815,0.00022610073,0.00046254433,0.00019686435,0.000030775485,0.000039971485,0.00042207493,0.0000053965873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008436958,0.0012477719,0.98718154,0.00033318935,0.00011815142,0.0005953261,0.0012958238,0.000038225888,0.00010448001,0.00022512351,0.000011322214,0.008005348],"study_design_scores_gemma":[0.0070250477,0.0041027274,0.9766375,0.0003626362,0.00006754034,0.0002406563,0.00043259648,0.00024328918,0.000091841095,0.00006615455,0.010604292,0.00012574685],"about_ca_topic_score_codex":0.00024491645,"about_ca_topic_score_gemma":0.00007068475,"teacher_disagreement_score":0.01059297,"about_ca_system_score_codex":0.0002965844,"about_ca_system_score_gemma":0.00039573608,"threshold_uncertainty_score":0.435184},"labels":[],"label_agreement":null},{"id":"W2059265481","doi":"10.1016/s0149-2918(00)88480-5","title":"Improved postprandial glycemic control with humalog® mix75/25™ after a standard test meal in patients with type 2 diabetes mellitus","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Postprandial; Medicine; Insulin lispro; Internal medicine; Insulin; Glycemic; Endocrinology; Crossover study; Meal; Diabetes mellitus; Type 2 diabetes; Area under the curve; Type 2 Diabetes Mellitus; Placebo","score_opus":0.01941021928178088,"score_gpt":0.31364042115517365,"score_spread":0.29423020187339277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059265481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622947,0.0004958812,0.00001476542,0.00053759845,0.00010175997,0.0011303801,0.00003381178,0.000051407187,0.0014049028],"genre_scores_gemma":[0.9959632,0.00023185076,0.0003056969,0.002589799,0.00018374923,0.00003637934,0.00004545942,0.00005396528,0.00058986834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978066,0.00013048592,0.00052852905,0.00042038466,0.0004989311,0.0006150421],"domain_scores_gemma":[0.99851066,0.00053053995,0.00008464437,0.00043179153,0.00023926761,0.00020306864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005217194,0.00025108276,0.00062829646,0.00009570284,0.00005154043,0.00005035372,0.00016750881,0.00019216663,0.0006037605],"category_scores_gemma":[0.000078363926,0.00015385536,0.00009956477,0.0003278788,0.00040833058,0.00008173664,0.000027803142,0.000595619,0.000060872448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06949998,0.0010702236,0.8350424,0.000046081477,0.0003768377,0.000023177234,0.00004740404,0.0000025860347,0.000014625011,0.000004200029,0.000028489781,0.093843974],"study_design_scores_gemma":[0.048660263,0.05559004,0.87330943,0.00025118404,0.0005284231,3.4585537e-7,0.000017242886,0.0007466011,0.000025914247,0.00007503399,0.02041509,0.00038042918],"about_ca_topic_score_codex":0.0000030631165,"about_ca_topic_score_gemma":0.000020674266,"teacher_disagreement_score":0.09346355,"about_ca_system_score_codex":0.000056851193,"about_ca_system_score_gemma":0.0001320407,"threshold_uncertainty_score":0.6610754},"labels":[],"label_agreement":null},{"id":"W2063001046","doi":"10.1016/s0149-2918(02)85026-3","title":"Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis","year":2002,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Roche (Canada); PharmIdeas (Canada)","funders":"","keywords":"Dosing; Medicine; Pharmacotherapy; Internal medicine; Meta-analysis; Asymptomatic","score_opus":0.8496116408869574,"score_gpt":0.5824938469086183,"score_spread":0.2671177939783391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063001046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030449458,0.9948026,0.0013867687,0.0013912768,0.00017449894,0.0014863,0.00016398284,0.00008523667,0.00020484845],"genre_scores_gemma":[0.0019229734,0.982763,0.0050204354,0.0063851695,0.0005581679,0.00022446556,0.00011856576,0.000065994645,0.002941247],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944387,0.0009947278,0.0022873115,0.0012653247,0.00063360337,0.00038031506],"domain_scores_gemma":[0.98780936,0.00866923,0.00097135943,0.0015295981,0.000351867,0.0006685947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011169434,0.0006452445,0.0060950443,0.0002896697,0.00012296239,0.000072677074,0.0005916124,0.0006759798,0.0028665126],"category_scores_gemma":[0.0010131748,0.00044636786,0.0027796736,0.0016631711,0.00029735608,0.00011533736,0.00009346601,0.0013863029,0.001831434],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034125675,0.00020589618,0.032454293,0.0012054427,0.12582906,0.000044277334,0.00015250774,1.7251003e-7,0.0000017261515,0.000036141082,0.001437281,0.8385991],"study_design_scores_gemma":[0.00044511384,0.00043708642,0.0064929803,0.0015788481,0.5534257,0.000008473053,0.000015272093,0.000028093138,5.4493256e-7,0.00028728924,0.43679962,0.00048099083],"about_ca_topic_score_codex":0.00004664411,"about_ca_topic_score_gemma":0.000003600942,"teacher_disagreement_score":0.8381181,"about_ca_system_score_codex":0.000054869826,"about_ca_system_score_gemma":0.00034772992,"threshold_uncertainty_score":0.99979883},"labels":[],"label_agreement":null},{"id":"W2063790407","doi":"10.1016/j.clinthera.2012.02.004","title":"Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Royal Alexandra Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Amlodipine; Blood pressure; Diabetes mellitus; Randomized controlled trial; Telmisartan; Body mass index; Clinical endpoint; Internal medicine; Type 2 diabetes; Pill; Urology; Endocrinology; Pharmacology","score_opus":0.2593335191891657,"score_gpt":0.4009689819636401,"score_spread":0.14163546277447442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063790407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98392946,0.008287591,0.000118215685,0.0015691054,0.0023401193,0.0028746305,0.000010898173,0.00006728222,0.0008026897],"genre_scores_gemma":[0.9901611,0.002957568,0.0010037551,0.004726619,0.00080291164,0.00010631636,0.0000945607,0.000062498504,0.000084677085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99606264,0.0006962822,0.001778634,0.0004305447,0.00051608536,0.00051582564],"domain_scores_gemma":[0.9958245,0.0022479407,0.0005362134,0.0006017793,0.00052621565,0.00026332846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016273453,0.00038431687,0.002478423,0.00019077872,0.000078728415,0.00002012964,0.00017763644,0.00042551509,0.0000599746],"category_scores_gemma":[0.00044842658,0.00027997736,0.00049375236,0.00032534517,0.0005746025,0.00023054653,0.00006154402,0.0005275545,0.000018464774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9359351,0.015568012,0.008676501,0.000032843385,0.001627272,0.000004387701,0.0006855257,0.0000026530004,0.00025769134,0.0003681269,0.00013604187,0.03670586],"study_design_scores_gemma":[0.9709453,0.008587653,0.0076646027,0.00009197192,0.0023209734,0.0000023475893,0.00019954014,0.00024587763,0.00028361773,0.00023348941,0.009094639,0.00032996503],"about_ca_topic_score_codex":0.000033023374,"about_ca_topic_score_gemma":0.00001740826,"teacher_disagreement_score":0.036375895,"about_ca_system_score_codex":0.00003318605,"about_ca_system_score_gemma":0.000043266402,"threshold_uncertainty_score":0.99996525},"labels":[],"label_agreement":null},{"id":"W2064154338","doi":"10.1016/j.clinthera.2006.10.009","title":"Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Epoetin alfa; Observational study; Darbepoetin alfa; Anemia; Dosing; Retrospective cohort study; Erythropoietin; Internal medicine; Emergency medicine; Intensive care medicine","score_opus":0.18725864492591207,"score_gpt":0.4405692608878601,"score_spread":0.25331061596194804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064154338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700373,0.00029560004,0.00015359515,0.0016419481,0.00007020509,0.0006900366,0.00007847465,0.00002439534,0.000042024963],"genre_scores_gemma":[0.9918756,0.0008784308,0.005886965,0.00036703327,0.00013319918,0.00006843192,0.00048500867,0.000020154706,0.0002851675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984823,0.000096645526,0.0006878135,0.00036063412,0.0001989852,0.0001736123],"domain_scores_gemma":[0.998501,0.0004434184,0.00030805377,0.00024475437,0.00042268136,0.00008006496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016531198,0.00019151483,0.00064704346,0.000073708135,0.000097090684,0.000011311902,0.000042859414,0.000102062426,0.000020256959],"category_scores_gemma":[0.00003325089,0.00012894374,0.00016323716,0.00017616444,0.00020494884,0.00006409968,0.000013273341,0.000071272625,6.521359e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007859051,0.0035977839,0.9852138,0.00012187037,0.0029517205,0.000013867043,0.00032053774,0.000025466874,0.00006993903,0.000101702804,0.000011627857,0.006785791],"study_design_scores_gemma":[0.0060734423,0.008419934,0.9778555,0.00006917642,0.0055182483,0.0000045231286,0.000571809,0.00040979765,0.00023221917,0.00010358149,0.0006054652,0.00013628276],"about_ca_topic_score_codex":0.00006000103,"about_ca_topic_score_gemma":0.0005045074,"teacher_disagreement_score":0.007358267,"about_ca_system_score_codex":0.00018342923,"about_ca_system_score_gemma":0.00013222627,"threshold_uncertainty_score":0.52581733},"labels":[],"label_agreement":null},{"id":"W2064750161","doi":"10.1016/j.clinthera.2011.10.027","title":"Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile","year":2011,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Ziprasidone; Medicine; Quetiapine; Olanzapine; Tolerability; Antipsychotic; Risperidone; Atypical antipsychotic; Adverse effect; Internal medicine; Pharmacodynamics; Discontinuation; Pharmacology; Pharmacokinetics; Psychiatry; Schizophrenia (object-oriented programming)","score_opus":0.5311276252425429,"score_gpt":0.5636217574584395,"score_spread":0.03249413221589659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064750161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027145707,0.9887913,0.0003761202,0.0007386768,0.00013824039,0.009493863,0.0003841316,0.00002202837,0.000028503704],"genre_scores_gemma":[0.00046633923,0.9957193,0.002001195,0.00048386,0.0001569924,0.00062912767,0.00015810873,0.00007030645,0.00031473665],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9924954,0.0023608704,0.003718604,0.0007215641,0.00038506548,0.00031848953],"domain_scores_gemma":[0.98226315,0.014266709,0.0017227046,0.0011674403,0.000237571,0.0003424562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045252037,0.00052821694,0.008694255,0.00018080887,0.00009857716,0.000022133483,0.00037468193,0.00042643055,0.000064585256],"category_scores_gemma":[0.0022978715,0.00026575502,0.006273325,0.0007228807,0.000633637,0.000032927714,0.00014135533,0.0010478377,0.000008590831],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015366732,0.00049749884,0.009700545,0.66691804,0.25833142,0.0000010741046,0.0000067574765,5.373431e-9,3.0204796e-9,0.0002443946,0.000047319576,0.06409925],"study_design_scores_gemma":[0.0017070199,0.0005092914,0.0024985021,0.055227887,0.9278622,0.000008292118,0.0000029443663,0.000044043405,6.008588e-8,0.0006646812,0.011247933,0.00022709467],"about_ca_topic_score_codex":0.0000042019547,"about_ca_topic_score_gemma":0.00001175591,"teacher_disagreement_score":0.6695308,"about_ca_system_score_codex":0.000032715805,"about_ca_system_score_gemma":0.00033253725,"threshold_uncertainty_score":0.99997944},"labels":[],"label_agreement":null},{"id":"W2065216055","doi":"10.1016/s0149-2918(04)90022-7","title":"The KARTAN study: A postmarketing assessment of Irbesartan in patients with hypertension","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta; Bristol-Myers Squibb","keywords":"Irbesartan; Medicine; Postmarketing surveillance; Observational study; Clinical trial; Adverse effect; Internal medicine; Blood pressure; Angiotensin Receptor Blockers; Intensive care medicine; Renin–angiotensin system","score_opus":0.07715713618843272,"score_gpt":0.38665991334573196,"score_spread":0.30950277715729924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065216055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960344,0.000652106,0.000010212307,0.0019183046,0.00013736401,0.0006369475,0.0000017306235,0.000017417646,0.000591519],"genre_scores_gemma":[0.99617267,0.00021213527,0.0006920624,0.00280257,0.00005349089,0.000008051404,0.0000020619598,0.000018289647,0.000038660146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983765,0.00016964063,0.0006416343,0.0002269694,0.00038777743,0.00019750182],"domain_scores_gemma":[0.9982851,0.00077078823,0.00015616027,0.00040293016,0.00032540638,0.000059604972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010230768,0.00013078055,0.0005660479,0.000035524856,0.000115766,0.0000104816245,0.00009421447,0.00007705483,0.0000031920058],"category_scores_gemma":[0.00010793161,0.000067054185,0.00008755843,0.0001765021,0.0001796048,0.000025849888,0.000065249806,0.00035582823,0.0000018131334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007444501,0.0029031623,0.98434746,0.000009209789,0.0004956155,0.000017902059,0.00014038917,0.0000048527345,0.000026643493,0.000057883823,0.00003813134,0.011214278],"study_design_scores_gemma":[0.008194854,0.0031820782,0.98509705,0.00011881663,0.00061084074,0.0000024250025,0.00061138184,0.00003542096,0.000011985383,0.00007898345,0.0019719019,0.00008423322],"about_ca_topic_score_codex":0.000021923044,"about_ca_topic_score_gemma":0.00007521409,"teacher_disagreement_score":0.011130044,"about_ca_system_score_codex":0.000012830041,"about_ca_system_score_gemma":0.00009961988,"threshold_uncertainty_score":0.27343902},"labels":[],"label_agreement":null},{"id":"W2065380322","doi":"10.1016/j.clinthera.2005.12.007","title":"An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"IC Design Education Center; Biogen","keywords":"Medicine; Psoriasis; Tolerability; Clinical trial; Adverse effect; Incidence (geometry); Internal medicine; Plaque psoriasis; Population; Psoriasis Area and Severity Index; Dermatology; Surgery","score_opus":0.2201283353892288,"score_gpt":0.4562995894410747,"score_spread":0.23617125405184589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065380322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06379784,0.9300734,0.000052090672,0.000021053102,0.0010055725,0.0018760909,0.0030623546,0.000025455429,0.00008616149],"genre_scores_gemma":[0.008401055,0.9877394,0.00019407608,0.000069797185,0.00008059558,0.00004009933,0.0029794686,0.00006504637,0.00043049277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98729736,0.0060737585,0.005321535,0.0007366265,0.00014883289,0.00042186302],"domain_scores_gemma":[0.9896989,0.005250487,0.003361933,0.0011455928,0.00047506945,0.000068012494],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039176866,0.0007231442,0.008921754,0.00094408833,0.000055018216,0.000009787523,0.0008943398,0.0016410085,0.0005566054],"category_scores_gemma":[0.0005333433,0.00049342186,0.002584028,0.0013070402,0.00040107276,0.00006785769,0.00008287487,0.0005635391,0.000012053524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021610835,0.0015551465,0.028047165,0.00021143495,0.022200547,8.0861207e-7,0.00067872123,0.000011517816,0.000055785385,0.000010455621,0.000041138035,0.9450262],"study_design_scores_gemma":[0.01657335,0.005692661,0.075617455,0.008000521,0.060689125,0.0000017494797,0.0005805227,0.000022302565,0.0013872895,0.000022612334,0.82982004,0.0015923482],"about_ca_topic_score_codex":0.000080088794,"about_ca_topic_score_gemma":0.0001926175,"teacher_disagreement_score":0.9434338,"about_ca_system_score_codex":0.00009078832,"about_ca_system_score_gemma":0.00032253467,"threshold_uncertainty_score":0.99975175},"labels":[],"label_agreement":null},{"id":"W2065791589","doi":"10.1016/j.clinthera.2006.06.007","title":"Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"National Institute on Aging; Agency for Healthcare Research and Quality","keywords":"Medicine; Asthma; Pulmonary disease; Intensive care medicine; Drug; Cost sharing; Disease; Internal medicine; Pharmacology; Nursing","score_opus":0.08494535117893667,"score_gpt":0.3945263178454496,"score_spread":0.3095809666665129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065791589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849963,0.00018760555,0.000040929135,0.0002404017,0.00005606457,0.0007732685,0.00013040798,0.000015209507,0.00005650714],"genre_scores_gemma":[0.9991655,0.00004487821,0.000043821845,0.00035727213,0.00016258347,0.000027517875,0.000057150228,0.000025166695,0.000116114126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842304,0.0001639759,0.0006415212,0.00022667165,0.00033689325,0.00020789732],"domain_scores_gemma":[0.9982081,0.0006948177,0.00030393212,0.00046496768,0.00018404855,0.00014412212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014816134,0.00016526975,0.00035752176,0.0000876088,0.000050199444,0.000009199454,0.00014758937,0.00006376193,0.000106393025],"category_scores_gemma":[0.000118322656,0.00008275079,0.00021787966,0.00026937193,0.00062302506,0.000069343376,0.00005012659,0.0002570391,0.0000025240552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016974353,0.002152948,0.9867464,0.000036763628,0.00014099356,0.000027345068,0.000077043725,0.0005493433,0.000040639523,0.00016537249,0.000038178594,0.008327576],"study_design_scores_gemma":[0.002445745,0.00048816612,0.9949984,0.00024402038,0.00017975458,0.0000019327922,0.000030016277,0.0009284177,0.000046740053,0.000110525,0.0004310519,0.00009521061],"about_ca_topic_score_codex":0.0001220904,"about_ca_topic_score_gemma":0.000047855876,"teacher_disagreement_score":0.008252059,"about_ca_system_score_codex":0.00010182921,"about_ca_system_score_gemma":0.0005318011,"threshold_uncertainty_score":0.33744794},"labels":[],"label_agreement":null},{"id":"W2066077397","doi":"10.1016/s0149-2918(03)80244-8","title":"Quality of life III: Translating the science of quality-of-life assessment into clinical practice—an example-driven approach for practicing clinicians and clinical researchers","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia; McMaster University Medical Centre","funders":"","keywords":"Medicine; Clinical Practice; Quality of life (healthcare); Quality (philosophy); Medical physics; Medical education; Family medicine; Nursing; Epistemology","score_opus":0.6692807048451429,"score_gpt":0.6232561958343978,"score_spread":0.04602450901074506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066077397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256584,0.0009835294,0.057240263,0.010218819,0.00076455285,0.002806327,0.000032931683,0.000060021808,0.0022351511],"genre_scores_gemma":[0.80334157,0.0012257939,0.18949941,0.005296992,0.00050942646,0.000029307965,0.00001421096,0.00006346478,0.000019835947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9694536,0.014433947,0.011416608,0.0014682809,0.00245073,0.0007768503],"domain_scores_gemma":[0.86335534,0.12063086,0.008047446,0.0032731567,0.0031902404,0.0015029764],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.16021791,0.00042149815,0.0031381655,0.00015660615,0.0003750953,0.000061250736,0.0009350978,0.000701381,0.000017907409],"category_scores_gemma":[0.097840205,0.0003241547,0.0011305435,0.00085841346,0.0070115677,0.00047990622,0.00021675281,0.0024707615,7.962264e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012730817,0.017506707,0.81232053,0.0022635602,0.003725769,0.0000019288004,0.012922587,0.00015353889,0.00088400627,0.038553175,0.00013179351,0.0988056],"study_design_scores_gemma":[0.048456848,0.02323158,0.7366422,0.000924674,0.00342976,0.000017444529,0.13684747,0.029843282,0.00037942943,0.0075168116,0.010940904,0.001769596],"about_ca_topic_score_codex":0.0010567817,"about_ca_topic_score_gemma":0.00021455422,"teacher_disagreement_score":0.13225915,"about_ca_system_score_codex":0.00008271643,"about_ca_system_score_gemma":0.006084817,"threshold_uncertainty_score":0.999921},"labels":[],"label_agreement":null},{"id":"W2066302501","doi":"10.1016/j.clinthera.2011.01.012","title":"Impact of Prior Authorization on the Use and Costs of Lipid-Lowering Medications Among Michigan and Indiana Dual Enrollees in Medicaid and Medicare: Results of a Longitudinal, Population-Based Study","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Mental Health; Agency for Healthcare Research and Quality; National Institutes of Health; Canadian Institutes of Health Research; Harvard Medical School; American Australian Association; Zorginstituut Nederland; Eli Lilly and Company","keywords":"Medicaid; Medicine; Prior authorization; Medicare Part D; Population; Medical prescription; Pharmacy; Prescription drug; Cohort; Gerontology; Family medicine; Environmental health; Demography; Internal medicine; Health care; Pharmacology","score_opus":0.2411479810480585,"score_gpt":0.42534781828568,"score_spread":0.1841998372376215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066302501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840957,0.00013361542,0.00016687204,0.0005350613,0.000050918057,0.00063820573,0.000017528448,0.000008275307,0.00003994767],"genre_scores_gemma":[0.99911493,0.00036650413,0.00029461668,0.0001418178,0.000031477422,0.00001536466,0.000014544164,0.00000973124,0.000010995881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981065,0.00021543915,0.0009748773,0.00024140757,0.00035325138,0.00010856217],"domain_scores_gemma":[0.9969823,0.0018453068,0.00053330016,0.00034899736,0.00014419426,0.00014590302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013265655,0.00011789185,0.00042633238,0.0001232107,0.000040078725,0.0000052614078,0.000089900415,0.0001270654,0.00003334637],"category_scores_gemma":[0.0018865817,0.000076412776,0.000048637386,0.00027587012,0.00048423634,0.000053716456,0.00003325275,0.00024250559,3.3826922e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045341215,0.00066904264,0.9906069,0.000028675042,0.000154817,0.0000018716297,0.0017115079,0.0000013074357,0.00006158779,0.00008429018,0.000012060159,0.0062145097],"study_design_scores_gemma":[0.0028698258,0.0016190793,0.993241,0.00045202702,0.00010829561,0.0000014088131,0.0005279795,0.0009912249,0.00007577524,0.000047729478,0.000005845188,0.000059796675],"about_ca_topic_score_codex":0.0002983287,"about_ca_topic_score_gemma":0.00014487994,"teacher_disagreement_score":0.006154713,"about_ca_system_score_codex":0.000013316238,"about_ca_system_score_gemma":0.00015433179,"threshold_uncertainty_score":0.31160226},"labels":[],"label_agreement":null},{"id":"W2066749532","doi":"10.1016/s0149-2918(08)80049-5","title":"Risk of discontinuation of risperidone after exposure to potentially interacting drugs: A nested case-control study in patients with schizophrenia","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Risperidone; Discontinuation; Medicine; Cohort; Nested case-control study; Internal medicine; Schizophrenia (object-oriented programming); Antipsychotic; Cohort study; Psychiatry; Pediatrics","score_opus":0.03334888382373138,"score_gpt":0.34303748828907193,"score_spread":0.3096886044653406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066749532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976975,0.00009312124,0.00023701458,0.00010427519,0.00008289012,0.00171691,0.00004396022,0.000014271392,0.000010096003],"genre_scores_gemma":[0.9964623,0.000030158888,0.0032674249,0.00006992814,0.00006419984,0.000054838216,0.0000065671898,0.00002684426,0.000017768067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976196,0.00044529268,0.00094040134,0.00030946106,0.00045702187,0.00022817643],"domain_scores_gemma":[0.99804634,0.0006804967,0.00031051575,0.00044356193,0.00035788587,0.00016120197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005889805,0.00017822842,0.0006434019,0.00016233548,0.000040102932,0.000007684699,0.0000867484,0.00008571389,0.0000311981],"category_scores_gemma":[0.00035436646,0.000120356424,0.00014695522,0.00031884757,0.00011767111,0.00007581229,0.000042437758,0.00036829044,0.0000053965155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08434357,0.0059724133,0.8615527,0.00001045648,0.00071640505,0.0003605855,0.0012427969,0.00002721127,0.0000149714615,0.0000011915344,9.694902e-7,0.04575673],"study_design_scores_gemma":[0.03415591,0.012673039,0.9517574,0.0001288811,0.00043909295,0.000020406602,0.0005022045,0.00015550324,0.00005668343,0.0000075104726,0.0000025954332,0.00010077498],"about_ca_topic_score_codex":0.000102355945,"about_ca_topic_score_gemma":0.00040122055,"teacher_disagreement_score":0.09020469,"about_ca_system_score_codex":0.000040361632,"about_ca_system_score_gemma":0.00014740138,"threshold_uncertainty_score":0.49079925},"labels":[],"label_agreement":null},{"id":"W2067160101","doi":"10.1016/s0149-2918(01)80032-1","title":"Blood pressure control in patients with mild to moderate essential hypertension switched from nifedipine gastrointestinal therapeutic system (GITS) 30 mg to nifedipine GITS 20 mg","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer Canada","keywords":"Medicine; Nifedipine; Blood pressure; Adverse effect; Internal medicine; Anesthesia","score_opus":0.052774470317502896,"score_gpt":0.3047780477446789,"score_spread":0.25200357742717605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067160101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98035884,0.0040993155,0.003800753,0.00784898,0.00068088394,0.0025597126,0.00013639076,0.0002806798,0.00023446328],"genre_scores_gemma":[0.96726924,0.0001247215,0.0023311353,0.02853807,0.0011704781,0.000070835,0.000063731684,0.00011997358,0.00031180395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952355,0.00032733008,0.0014796685,0.0011496075,0.0009310123,0.0008768809],"domain_scores_gemma":[0.9962554,0.0007303578,0.00029037168,0.00097610184,0.0010861702,0.00066162524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059457327,0.0006712975,0.0020752281,0.00019926809,0.00019138237,0.00007654233,0.00033748258,0.00032142655,0.00008917352],"category_scores_gemma":[0.00015414612,0.00047891145,0.00026146582,0.00050588895,0.00015474026,0.00010915269,0.00017424996,0.00086949783,0.00013125493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040025838,0.008268298,0.9125745,0.0002508767,0.008844124,0.0009450252,0.0005138501,0.0008467864,0.014082897,0.000053516127,0.004548142,0.009046105],"study_design_scores_gemma":[0.061665382,0.011090053,0.87006557,0.0031064744,0.019020868,0.00024705392,0.0003440162,0.011327212,0.0005664583,0.00006376311,0.021056516,0.001446618],"about_ca_topic_score_codex":0.00010143847,"about_ca_topic_score_gemma":0.00006735988,"teacher_disagreement_score":0.04250896,"about_ca_system_score_codex":0.000021453592,"about_ca_system_score_gemma":0.0001427864,"threshold_uncertainty_score":0.99976623},"labels":[],"label_agreement":null},{"id":"W2067175073","doi":"10.1016/j.clinthera.2010.04.018","title":"Buprenorphine transdermal system in adults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; London Health Sciences Centre; University of Alberta; Hôpital Fleurimont","funders":"Purdue Pharma","keywords":"Medicine; Placebo; Buprenorphine; Visual analogue scale; Anesthesia; Crossover study; Tolerability; Opioid; Analgesic; Randomized controlled trial; Transdermal patch; Oxycodone; Randomization; Transdermal; Adverse effect; Surgery; Internal medicine; Pharmacology","score_opus":0.06105664667301164,"score_gpt":0.39338788889506493,"score_spread":0.3323312422220533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067175073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97442937,0.0011675482,0.0007124452,0.000776381,0.0005569659,0.021931507,0.000034457593,0.00013455313,0.0002567661],"genre_scores_gemma":[0.99545467,0.00020458587,0.0006526434,0.0010538028,0.00028010854,0.0015208888,0.00020565813,0.00014824748,0.00047941823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99397343,0.0014082912,0.0020951447,0.0011744811,0.0006425601,0.0007061005],"domain_scores_gemma":[0.99552315,0.0017712832,0.00049623137,0.0014374248,0.00029723922,0.0004746487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005628123,0.00068581966,0.0031218084,0.0001272623,0.00015474184,0.000176373,0.00057229993,0.00050673913,0.00016756676],"category_scores_gemma":[0.00015638313,0.00044371156,0.00031083435,0.00035426606,0.00039888843,0.00026702907,0.000089534675,0.0012167526,0.00006264777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9467447,0.03924536,0.0031524587,0.00025420458,0.0015231614,0.0002016493,0.0010944902,0.000017688946,0.0009745967,0.00002819387,0.00008479132,0.0066787056],"study_design_scores_gemma":[0.95186615,0.014424677,0.00020394474,0.000661651,0.0014285194,0.000026255468,0.000573391,0.029861232,0.00014653892,0.0000089573105,0.0003195484,0.00047911468],"about_ca_topic_score_codex":0.00018684716,"about_ca_topic_score_gemma":0.0007927712,"teacher_disagreement_score":0.029843543,"about_ca_system_score_codex":0.00015743276,"about_ca_system_score_gemma":0.00055639335,"threshold_uncertainty_score":0.99980146},"labels":[],"label_agreement":null},{"id":"W2067822742","doi":"10.1016/j.clinthera.2007.09.024","title":"Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Calgary; McMaster University","funders":"","keywords":"Medicine; Teriparatide; Osteoporosis; Tolerability; Internal medicine; Prospective cohort study; Adverse effect; Urology; Bone mineral","score_opus":0.2588330368175734,"score_gpt":0.5042437100223596,"score_spread":0.24541067320478616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067822742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988084,0.00019869392,0.000024438454,0.00013793878,0.000104161234,0.010790966,0.000085794025,0.000033857978,0.0005401077],"genre_scores_gemma":[0.996394,0.00023791604,0.0021534818,0.0006561413,0.00006638665,0.00022124534,0.00004118164,0.0000597776,0.00016986593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954162,0.00059909804,0.0015549543,0.001149877,0.0005774019,0.00070243125],"domain_scores_gemma":[0.99654,0.00096870743,0.00047866785,0.000894629,0.000514324,0.00060367136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010671772,0.0005272604,0.0018395359,0.00019034387,0.00020241356,0.00014008083,0.00026848254,0.00023313655,0.000044816043],"category_scores_gemma":[0.00013902997,0.00032506764,0.00007803814,0.0005492304,0.00035850555,0.00037052663,0.000121584235,0.0004674461,0.000004560072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044940248,0.03795535,0.7737629,0.000059690425,0.0002761872,0.00004186891,0.005425046,0.0000033801753,0.00005746937,0.0000021939472,0.000005537309,0.13747014],"study_design_scores_gemma":[0.040468756,0.09810741,0.8562577,0.0005992006,0.00018998762,0.0000014172668,0.0028751371,0.00024255257,0.0006735205,0.000006640573,0.00030250213,0.0002751707],"about_ca_topic_score_codex":0.00037377985,"about_ca_topic_score_gemma":0.002404935,"teacher_disagreement_score":0.13719498,"about_ca_system_score_codex":0.00062721904,"about_ca_system_score_gemma":0.00037609716,"threshold_uncertainty_score":0.9999201},"labels":[],"label_agreement":null},{"id":"W2067874068","doi":"10.1016/s0149-2918(03)80164-9","title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":299,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Abbott Laboratories","keywords":"Adalimumab; Medicine; Rheumatoid arthritis; Pharmacokinetics; Internal medicine; Placebo; Methotrexate; Pharmacology; Gastroenterology; Pathology","score_opus":0.07058524546251149,"score_gpt":0.41502992384413984,"score_spread":0.34444467838162834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067874068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229914,0.004474763,0.00030514394,0.00016977954,0.00012107724,0.0020558222,0.00004832164,0.00006593387,0.00046001578],"genre_scores_gemma":[0.94373196,0.0531733,0.0026813005,0.00021577104,0.00003202544,0.000049128514,0.000019744146,0.00007705779,0.000019698127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947305,0.0012642784,0.0017977423,0.0007602576,0.00076870265,0.00067856075],"domain_scores_gemma":[0.9968764,0.001424167,0.00043777155,0.0005680661,0.0002913478,0.00040221924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002153325,0.00045520952,0.0015782627,0.00021634175,0.00019232917,0.00007155663,0.00023153985,0.00010285577,0.00021398254],"category_scores_gemma":[0.00025708458,0.00036343074,0.00016037207,0.00044218844,0.0007111062,0.00014102802,0.00009841796,0.0009590387,0.000003005856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005063859,0.008201131,0.91573375,0.00010598965,0.00096191023,0.0002580565,0.0010731056,0.000008606089,0.014161803,0.0004127373,0.000007797322,0.054011244],"study_design_scores_gemma":[0.055119585,0.02501819,0.9130327,0.0020492764,0.00003894462,0.00015487785,0.0007984209,0.00052266393,0.0013461027,0.000118385535,0.0013248102,0.00047600325],"about_ca_topic_score_codex":0.00015348507,"about_ca_topic_score_gemma":0.00021686425,"teacher_disagreement_score":0.05353524,"about_ca_system_score_codex":0.000089900124,"about_ca_system_score_gemma":0.0005255703,"threshold_uncertainty_score":0.99988174},"labels":[],"label_agreement":null},{"id":"W2069718099","doi":"10.1016/s0149-2918(00)88483-0","title":"Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Ontario Institute for Cancer Research; Robarts Clinical Trials","funders":"","keywords":"Medicine; Levofloxacin; Community-acquired pneumonia; Pneumonia; Intensive care medicine; Intervention (counseling); Internal medicine; Nursing; Antibiotics; Microbiology","score_opus":0.15080335980512372,"score_gpt":0.46795402641240175,"score_spread":0.31715066660727803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069718099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936397,0.000032834145,0.000070449234,0.001221471,0.0010319352,0.0004865468,0.0000091561915,0.00004503689,0.0034628557],"genre_scores_gemma":[0.997126,0.0001544804,0.000058066722,0.0016069979,0.00027702592,0.000017443057,0.0000050064937,0.000019942909,0.0007350509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978216,0.00086720637,0.0008925329,0.00013696082,0.00012803254,0.00015362463],"domain_scores_gemma":[0.998608,0.00041681217,0.00020872016,0.0006553469,0.00004023641,0.00007087522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011090471,0.00012168795,0.00038702117,0.00003539786,0.00022139998,0.00001627707,0.00020490486,0.00016685607,0.00040288025],"category_scores_gemma":[0.000040467752,0.00008210879,0.0005649227,0.000097612814,0.00028398627,0.00004455043,0.000051181236,0.0005519845,0.00003259884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066792546,0.00850141,0.5574337,0.00017660132,0.0017876069,0.0000065338286,0.00062485016,0.00035128568,0.028670168,0.0008643924,0.00024726245,0.39465693],"study_design_scores_gemma":[0.041687172,0.0044671916,0.86278844,0.00027689565,0.00070365344,0.000025423431,0.00020847737,0.001956733,0.00075313053,0.0007653448,0.08612178,0.00024573697],"about_ca_topic_score_codex":0.000022369217,"about_ca_topic_score_gemma":0.000026876418,"teacher_disagreement_score":0.3944112,"about_ca_system_score_codex":0.000076662596,"about_ca_system_score_gemma":0.00013985904,"threshold_uncertainty_score":0.4411256},"labels":[],"label_agreement":null},{"id":"W2072296662","doi":"10.1016/j.clinthera.2005.04.004","title":"Best single time points as surrogates to the tacrolimus andmycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tacrolimus; Medicine; Liver transplantation; Therapeutic drug monitoring; Dosing; Transplantation; Area under the curve; Morning; Pharmacokinetics; Mycophenolic acid; Population; Urology; Trough level; Internal medicine; Immunosuppression; Kidney transplantation; Gastroenterology","score_opus":0.057443624185067765,"score_gpt":0.3380012689641093,"score_spread":0.28055764477904155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072296662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929347,0.0003128653,0.0002289495,0.003667483,0.00014042786,0.0008930006,0.0001861666,0.000021441849,0.0016149471],"genre_scores_gemma":[0.9911463,0.0025868423,0.0003184983,0.005393223,0.00008626555,0.00002373832,0.00015416878,0.000029274945,0.00026168834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804235,0.00021292131,0.000797589,0.00028110007,0.00038104638,0.00028498188],"domain_scores_gemma":[0.9984618,0.0007875563,0.00015431788,0.00032747016,0.000145586,0.00012330944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031942033,0.00023047211,0.00041735836,0.000066720684,0.00008334664,0.000020480797,0.00019517595,0.00015521052,0.00012237334],"category_scores_gemma":[0.00002324831,0.00012617058,0.00022225294,0.00020293995,0.00014065011,0.00008136522,0.000011935502,0.000270388,0.00025179406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01092492,0.011289443,0.84831196,0.00036238207,0.0020123564,0.00012386433,0.018414004,0.0013897399,0.0022464348,0.0006800928,0.000087354165,0.104157425],"study_design_scores_gemma":[0.024532484,0.005586134,0.9443673,0.0014358347,0.002512423,0.000107780324,0.00058486784,0.0032895089,0.014322758,0.000697813,0.001933441,0.00062964676],"about_ca_topic_score_codex":0.000057250032,"about_ca_topic_score_gemma":0.00029345075,"teacher_disagreement_score":0.103527784,"about_ca_system_score_codex":0.000045325454,"about_ca_system_score_gemma":0.00004931751,"threshold_uncertainty_score":0.51450866},"labels":[],"label_agreement":null},{"id":"W2072661042","doi":"10.1016/j.clinthera.2009.01.004","title":"Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"La Cité Médicale; Trillium Health Centre; Eli Lilly (Canada)","funders":"","keywords":"Medicine; Pioglitazone; Tolerability; Peripheral edema; Internal medicine; Edema; Adverse effect; Type 2 diabetes; Diabetes mellitus; Type 2 Diabetes Mellitus; Weight gain; Surgery; Endocrinology; Body weight","score_opus":0.08200695416127438,"score_gpt":0.376041522590259,"score_spread":0.2940345684289847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072661042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982078,0.00016824558,0.000018785537,0.000092070564,0.0000661698,0.0013831763,0.000043875003,0.0000101840305,0.00000969146],"genre_scores_gemma":[0.99767655,0.000059672326,0.001491291,0.0005226008,0.000024756328,0.000037990874,0.00013175483,0.00002331424,0.00003206739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841785,0.00020859258,0.00055153586,0.00042809578,0.00016357834,0.00023032168],"domain_scores_gemma":[0.9987793,0.00016205186,0.00021278969,0.0004347584,0.00034783222,0.00006325044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046707373,0.00018990418,0.0004788642,0.000027394182,0.000031594176,0.00002173292,0.00031823252,0.00012376251,0.0000036184363],"category_scores_gemma":[0.00014012665,0.00013623726,0.0000413795,0.0001974814,0.0001149582,0.000012072949,0.000056118613,0.00012553227,6.968954e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002601478,0.0058944137,0.9854493,0.0000074264594,0.00028945247,2.3668328e-7,0.000042930573,0.00001539891,0.0018134429,0.0000024393562,0.000016414388,0.0038670804],"study_design_scores_gemma":[0.010072082,0.006989417,0.9778542,0.000016198455,0.000037157784,2.6523068e-8,0.000035236637,0.000056956236,0.0042691613,0.000018051205,0.0004582831,0.00019325236],"about_ca_topic_score_codex":0.000006047528,"about_ca_topic_score_gemma":0.000030847812,"teacher_disagreement_score":0.0075951098,"about_ca_system_score_codex":0.000022288164,"about_ca_system_score_gemma":0.00007840596,"threshold_uncertainty_score":0.5555594},"labels":[],"label_agreement":null},{"id":"W2073097238","doi":"10.1016/s0149-2918(03)80161-3","title":"A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A","year":2003,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Bioequivalence; Pharmacokinetics; Dosing; Therapeutic drug monitoring; Bioavailability; Transplantation; Pharmacology; Clinical trial; Intensive care medicine; Trough level; Internal medicine; Tacrolimus","score_opus":0.32642736578202486,"score_gpt":0.5803530117450358,"score_spread":0.253925645963011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073097238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01191413,0.9852727,0.0001926275,0.000028446993,0.0005621462,0.0017402092,0.00019639528,0.0000067875862,0.00008652274],"genre_scores_gemma":[0.0048327344,0.99382156,0.00083765964,0.00021522366,0.0001393843,0.000006407708,0.0000515221,0.000045525354,0.00004997288],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99242145,0.0011911219,0.0054049813,0.00037861694,0.0003983778,0.00020547329],"domain_scores_gemma":[0.9943896,0.0018843919,0.0025873068,0.0007035606,0.00024069774,0.00019447143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013184936,0.00040546976,0.0045442428,0.000069859285,0.00003175524,0.0000038450135,0.00022279947,0.00047124966,0.00007676458],"category_scores_gemma":[0.0002053706,0.00020274863,0.005213486,0.00029700965,0.00054905575,0.0000228618,0.000063063,0.00076598587,0.0000012779246],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018785596,0.002423038,0.13055274,0.0681824,0.007292648,0.0000100662355,0.000006016784,0.0000012066185,9.678971e-7,0.00006766407,0.000009137833,0.79126626],"study_design_scores_gemma":[0.014229613,0.0045410627,0.29868305,0.45584026,0.14729343,0.00039371304,0.000006405602,0.0004882956,0.000004825138,0.00030900785,0.07741309,0.00079725607],"about_ca_topic_score_codex":0.000006782008,"about_ca_topic_score_gemma":4.895419e-7,"teacher_disagreement_score":0.790469,"about_ca_system_score_codex":0.000037963215,"about_ca_system_score_gemma":0.0005361847,"threshold_uncertainty_score":0.8267849},"labels":[],"label_agreement":null},{"id":"W2073722775","doi":"10.1016/s0149-2918(00)80079-x","title":"Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in Canada","year":2001,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Mount Sinai Hospital; University of Toronto; Centre Hospitalier de l’Université de Montréal; University of Alberta Hospital","funders":"","keywords":"Medicine; Infliximab; Rheumatoid arthritis; Disease; Intensive care medicine; Arthritis; Population; MEDLINE; Antirheumatic Agents; Physical therapy; Surgery; Internal medicine; Environmental health","score_opus":0.12134765707473184,"score_gpt":0.44760758735027584,"score_spread":0.326259930275544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073722775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025611894,0.9707843,0.000018042294,0.00024285457,0.00021985566,0.0027603917,0.00027562064,0.000019469053,0.000067537825],"genre_scores_gemma":[0.023716265,0.9754351,0.00014116241,0.00020353952,0.00013188337,0.00016726118,0.00008883139,0.00011026365,0.0000057023817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995293,0.0006255902,0.002195939,0.00073649455,0.0005218482,0.0006270956],"domain_scores_gemma":[0.99488956,0.0031847334,0.0006393582,0.00062887435,0.0002120875,0.00044537368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011760597,0.00065171765,0.0039510615,0.00024281515,0.00009457309,0.000049425937,0.00018630453,0.00032980097,0.000023612443],"category_scores_gemma":[0.00028478447,0.00041352556,0.0005690502,0.00026929606,0.0005788869,0.000050167233,0.00007549275,0.001553594,0.0000015758493],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016245055,0.00034761513,0.011256592,0.0019670646,0.00071180507,0.000049160928,0.00013972851,9.331956e-7,6.241234e-8,0.00012655476,0.0000946286,0.9836813],"study_design_scores_gemma":[0.008869419,0.008380694,0.0054313894,0.05352017,0.00008892111,0.0000828446,0.00037702947,0.00007016364,0.0000012653549,0.00016361673,0.9224957,0.000518749],"about_ca_topic_score_codex":0.0073312754,"about_ca_topic_score_gemma":0.0821142,"teacher_disagreement_score":0.9831626,"about_ca_system_score_codex":0.00024789848,"about_ca_system_score_gemma":0.002914067,"threshold_uncertainty_score":0.9998317},"labels":[],"label_agreement":null},{"id":"W2075000534","doi":"10.1016/j.clinthera.2013.08.007","title":"Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline","year":2013,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Medicine; KRAS; Epidermal growth factor receptor; EGFR inhibitors; T790M; Cetuximab; Colorectal cancer; Erlotinib; Oncology; Lung cancer; Panitumumab; Cancer; Cancer research; Internal medicine","score_opus":0.21777312751887434,"score_gpt":0.4774846052985893,"score_spread":0.259711477779715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075000534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037467787,0.9954804,0.000101479185,0.000759176,0.0007820016,0.0015291196,0.00020568259,0.00010090266,0.0010037296],"genre_scores_gemma":[0.000026823483,0.99015003,0.0017848811,0.0018130357,0.0010605153,0.00013676035,0.00033776028,0.000115898045,0.004574293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997323,0.00028960075,0.00126339,0.0005657397,0.00022128983,0.0003370172],"domain_scores_gemma":[0.99749875,0.0010603358,0.00042950964,0.00053195364,0.00017064305,0.00030878859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024959282,0.00051284157,0.0022209089,0.00008364414,0.00009280314,0.000053052383,0.0001513976,0.0006596077,0.00050532474],"category_scores_gemma":[0.0001022027,0.00031538808,0.0007060639,0.00015795052,0.00024212681,0.00006153077,0.000068748435,0.0007619894,0.00027972454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011794344,0.0002903646,0.00023523896,0.0020002348,0.001434389,0.000008663102,0.00006577908,2.8784186e-9,3.622341e-7,0.0001768603,0.002054774,0.99372154],"study_design_scores_gemma":[0.0010333739,0.0003971887,0.00008402427,0.0023322664,0.0029417325,0.000038315153,0.000017230088,0.0000052513715,8.939384e-7,0.00014609627,0.99270344,0.0003001688],"about_ca_topic_score_codex":0.000013936483,"about_ca_topic_score_gemma":0.0000014395487,"teacher_disagreement_score":0.9934214,"about_ca_system_score_codex":0.00010650476,"about_ca_system_score_gemma":0.0005767542,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W2075272700","doi":"10.1016/j.clinthera.2006.10.010","title":"Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); University of British Columbia; Vancouver Coastal Health; Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Irritable bowel syndrome; Constipation; Bloating; Quality of life (healthcare); Abdominal pain; Physical therapy; Internal medicine; Nursing","score_opus":0.12874909621588887,"score_gpt":0.3780033189623475,"score_spread":0.24925422274645864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075272700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994713,0.001261237,0.00008775055,0.0020489276,0.00004504694,0.0017043991,0.00010388434,0.000021299997,0.000014456812],"genre_scores_gemma":[0.9987091,0.0000073770075,0.0009596607,0.00016314357,0.000014610886,0.000007085373,0.000105977124,0.000021371641,0.000011702406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942991,0.0012642507,0.0027985764,0.00062123075,0.000666612,0.0003501946],"domain_scores_gemma":[0.9957691,0.0017049023,0.0013793204,0.0005673119,0.00039773938,0.00018164387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025658435,0.0002711827,0.0016470195,0.000115264564,0.00006259941,0.000006345964,0.00014144991,0.00005726194,0.0000030630672],"category_scores_gemma":[0.0016900736,0.00021272304,0.00007125064,0.00064898893,0.00027155262,0.00004228578,0.000070111615,0.00053958205,8.608104e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062612086,0.0051581576,0.9859998,0.00030893242,0.00013257917,0.000027244938,0.00066902133,0.00064140337,0.0000019022893,0.000010643247,0.000015691418,0.00077337056],"study_design_scores_gemma":[0.010419156,0.011705506,0.97027904,0.00067807,0.00013016854,0.000023389492,0.0064325323,0.000144753,0.0000011972535,0.000068220965,0.000001032121,0.0001169487],"about_ca_topic_score_codex":0.61252266,"about_ca_topic_score_gemma":0.8009525,"teacher_disagreement_score":0.18842985,"about_ca_system_score_codex":0.00019017121,"about_ca_system_score_gemma":0.0016420147,"threshold_uncertainty_score":0.86745936},"labels":[],"label_agreement":null},{"id":"W2075610799","doi":"10.1016/j.clinthera.2008.01.002","title":"Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: A two-way crossover study in healthy young adults","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Medicine; Bioavailability; Bead; Crossover study; Crossover; Pharmacology; Immediate release; Machine learning","score_opus":0.2718346021186047,"score_gpt":0.4690624820830536,"score_spread":0.1972278799644489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075610799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970483,0.000368093,0.0003630838,0.00012251765,0.00018469365,0.0017644438,0.000046630084,0.000064159,0.00003806256],"genre_scores_gemma":[0.9985427,0.000043206473,0.0009902045,0.00023420838,0.000080100464,0.000022744987,0.00004341832,0.000029986219,0.000013423883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965094,0.0008265999,0.0013764416,0.0006293834,0.0003865678,0.00027164535],"domain_scores_gemma":[0.9972342,0.0011207382,0.00045943144,0.0006279922,0.00035146938,0.0002061532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008312352,0.00025722192,0.00107199,0.000104233164,0.00010772716,0.00001710084,0.00010203747,0.00018556636,0.000022623128],"category_scores_gemma":[0.00026416563,0.00022453027,0.00014510758,0.0002947371,0.00032365683,0.00025070645,0.000061860286,0.00046217768,0.0000135486725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008856489,0.010028126,0.96993405,0.000095053634,0.00021239289,0.000026589758,0.0064074397,0.00007314353,0.0014106113,0.000011900052,0.0000012506724,0.0029429465],"study_design_scores_gemma":[0.018904343,0.003679558,0.9346582,0.00012745512,0.00027160192,0.000013902212,0.007658599,0.034316644,0.00011742064,0.00003198939,0.000014176785,0.00020608015],"about_ca_topic_score_codex":0.00086290506,"about_ca_topic_score_gemma":0.0010149396,"teacher_disagreement_score":0.035275828,"about_ca_system_score_codex":0.000118659234,"about_ca_system_score_gemma":0.000113613765,"threshold_uncertainty_score":0.9156079},"labels":[],"label_agreement":null},{"id":"W2076423044","doi":"10.1016/s0149-2918(00)80058-2","title":"Stages of change for adherence with medication regimens for chronic disease: Development and validation of a measure","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute on Drug Abuse; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Medication adherence; Construct validity; Psychological intervention; Predictive validity; Physical therapy; Clinical psychology; Psychometrics; Internal medicine; Psychiatry","score_opus":0.37221214354934246,"score_gpt":0.4488118181916646,"score_spread":0.07659967464232215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076423044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95554507,0.0052036447,0.03189972,0.00368887,0.000097602126,0.0032393113,0.00005084872,0.000036891666,0.00023805082],"genre_scores_gemma":[0.9866113,0.0012583705,0.010365632,0.0005640911,0.00010429166,0.00036188195,0.00007596299,0.0000121701505,0.0006462635],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99908435,0.000028079605,0.00042139986,0.00017343524,0.00019498746,0.00009774828],"domain_scores_gemma":[0.99903464,0.00024118628,0.00021684004,0.00021076394,0.00019722493,0.00009932763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003882962,0.00007508859,0.00023997642,0.000019989682,0.000028824104,0.0000024050814,0.000066163484,0.00006247176,0.00008814111],"category_scores_gemma":[0.00007041452,0.00005538001,0.000037991816,0.00007470286,0.00016540034,0.00003280794,0.00000471798,0.000055613596,0.0000025249003],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015350162,0.0003762892,0.033289794,0.00080434844,0.00019147932,2.8394797e-7,0.0003603826,0.0000011660374,0.000574817,0.00038104795,0.00016260355,0.9623228],"study_design_scores_gemma":[0.02329658,0.012187577,0.6767509,0.0052889558,0.0019125042,0.000008126296,0.00036892973,0.006967449,0.048387002,0.0016714294,0.22245984,0.0007007147],"about_ca_topic_score_codex":0.0000014663061,"about_ca_topic_score_gemma":0.0000012635699,"teacher_disagreement_score":0.96162206,"about_ca_system_score_codex":0.000012971079,"about_ca_system_score_gemma":0.00035581918,"threshold_uncertainty_score":0.22583312},"labels":[],"label_agreement":null},{"id":"W2076556555","doi":"10.1016/s0149-2918(03)90037-3","title":"Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria","funders":"Agency for Healthcare Research and Quality","keywords":"Medicine; Copayment; Family medicine; Medical prescription; Pharmacy; Logistic regression; Odds ratio; Drug class; Cost sharing; Multivariate analysis; Payment; Drug; Emergency medicine; Health care; Internal medicine; Finance; Nursing; Psychiatry","score_opus":0.15530392891948366,"score_gpt":0.41372693620273204,"score_spread":0.2584230072832484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076556555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976107,0.0007226066,0.00003831067,0.0003030756,0.000048144648,0.00031005242,0.0000019825877,0.0000053560934,0.00095977477],"genre_scores_gemma":[0.994591,0.0010632178,0.00022897357,0.0038289353,0.000027036387,0.000035619025,0.0000022300494,0.000006174356,0.00021679918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991125,0.00014195536,0.00034746516,0.00015431334,0.00012137472,0.00012239495],"domain_scores_gemma":[0.99951875,0.0001558321,0.00009702862,0.00015636954,0.00004036776,0.000031653875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058098655,0.000043759217,0.00017415344,0.000015044534,0.000019318888,0.000019445522,0.00005257964,0.000042846903,0.00014288741],"category_scores_gemma":[0.000037776495,0.00004669558,0.00001949196,0.00014162272,0.00009618912,0.000029217861,0.000014842589,0.00019842893,0.000003246609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016268958,0.0000955818,0.9232031,0.000041751788,0.00001443952,0.0000037493355,0.00058107445,1.6211509e-7,0.00017771692,0.00006478091,0.00008854166,0.07571284],"study_design_scores_gemma":[0.00095539336,0.0000678241,0.9916921,0.0001817172,0.00002277365,0.0000037793209,0.0030247283,0.00005526244,0.00013356806,0.0007219677,0.0030873404,0.000053496926],"about_ca_topic_score_codex":0.0005918905,"about_ca_topic_score_gemma":0.010736589,"teacher_disagreement_score":0.07565934,"about_ca_system_score_codex":0.000013473966,"about_ca_system_score_gemma":0.00005744548,"threshold_uncertainty_score":0.5991269},"labels":[],"label_agreement":null},{"id":"W2078566963","doi":"10.1016/s0149-2918(02)80004-2","title":"Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness","year":2002,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Institut Universitaire de Gériatrie de Montréal; Jewish General Hospital","funders":"","keywords":"Donepezil; Rivastigmine; Medicine; Dementia; Randomized controlled trial; MEDLINE; Clinical trial; Internal medicine; Disease; Psychiatry","score_opus":0.48674343857340263,"score_gpt":0.5216533915713597,"score_spread":0.03490995299795707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078566963","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008817679,0.98521817,0.000004128076,0.0006744187,0.00008268838,0.004849143,0.00024091556,0.0000065363683,0.000106330386],"genre_scores_gemma":[0.038115945,0.96125555,0.000013789875,0.00012530603,0.000097348355,0.00029564174,0.00003610886,0.000031392636,0.000028907747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951533,0.0024377785,0.00097281666,0.00066626567,0.0005025673,0.00026727928],"domain_scores_gemma":[0.9795985,0.017957037,0.00041895473,0.0017604158,0.00011651944,0.00014857887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025059325,0.00038651936,0.0018272221,0.00011745026,0.00006351379,0.00004620697,0.0006589535,0.00020875306,0.000032099706],"category_scores_gemma":[0.0015823066,0.00016510214,0.00036599298,0.00042880708,0.00091675436,0.000074807125,0.00025321546,0.00045960338,0.0000026399887],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004566702,0.0036045387,0.0070898104,0.002092335,0.0012006488,0.000015427897,0.000045553094,7.358967e-8,6.774145e-7,0.000014466186,0.00002098982,0.9854588],"study_design_scores_gemma":[0.005648636,0.006097322,0.19945455,0.051727965,0.030561842,0.00003601557,0.00009804042,0.00015155935,0.00004104964,0.000088565066,0.7056403,0.00045413512],"about_ca_topic_score_codex":0.000009894943,"about_ca_topic_score_gemma":0.00000273799,"teacher_disagreement_score":0.98500466,"about_ca_system_score_codex":0.000035069203,"about_ca_system_score_gemma":0.00024507573,"threshold_uncertainty_score":0.673267},"labels":[],"label_agreement":null},{"id":"W2079614274","doi":"10.1016/s0149-2918(03)80068-1","title":"A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; Ottawa Hospital","funders":"Eli Lilly and Company","keywords":"Pioglitazone; Medicine; Internal medicine; Placebo; Dyslipidemia; Glycemic; Diabetes mellitus; Thiazolidinedione; Glycated hemoglobin; Type 2 diabetes; Type 2 Diabetes Mellitus; Gastroenterology; Endocrinology; Insulin","score_opus":0.03897713012726592,"score_gpt":0.3408353580148224,"score_spread":0.30185822788755645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079614274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605245,0.004203166,0.00006359104,0.00016777593,0.0014668029,0.0077701584,0.0000071143522,0.00002008156,0.0002488425],"genre_scores_gemma":[0.99602526,0.0023186114,0.00020553647,0.0009240964,0.0002462646,0.00018881465,0.000010840574,0.0000461942,0.00003435968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933262,0.0027345454,0.0022955285,0.0005225123,0.00073351717,0.00038769565],"domain_scores_gemma":[0.9869539,0.010639068,0.000929779,0.00091544975,0.0003625013,0.00019926076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062762056,0.0003465529,0.0035579894,0.0001292623,0.000049633552,0.000011461729,0.00023548608,0.00051050517,0.00001013818],"category_scores_gemma":[0.006530134,0.00019220539,0.0010269012,0.00035886068,0.0013539976,0.00005081249,0.000036215497,0.00086083193,0.000004410259],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9094104,0.0018097413,0.0620446,0.00013793628,0.0029754443,0.0000018026183,0.00006585473,0.0000070519955,0.000008423077,0.00017536404,0.000013810083,0.02334953],"study_design_scores_gemma":[0.97330284,0.008022208,0.01366244,0.00050034135,0.003170871,6.944434e-7,0.000020599904,0.00016351891,0.00016434006,0.0002840532,0.00051032635,0.00019776197],"about_ca_topic_score_codex":0.000045114153,"about_ca_topic_score_gemma":0.000018037368,"teacher_disagreement_score":0.0638924,"about_ca_system_score_codex":0.00003689305,"about_ca_system_score_gemma":0.00033101937,"threshold_uncertainty_score":0.7837908},"labels":[],"label_agreement":null},{"id":"W2079816402","doi":"10.1016/j.clinthera.2006.07.009","title":"A cross-national study of prescription nonadherence due to cost: Data from the joint Canada-United States survey of health","year":2006,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Medical prescription; Family medicine; Cross-sectional study; National Health Interview Survey; Environmental health; Nursing","score_opus":0.5497007601702429,"score_gpt":0.5067636816724126,"score_spread":0.04293707849783035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079816402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181885,0.00026637997,0.0025101022,0.0031777387,0.00021783028,0.0009543688,0.00094295666,0.0000104357505,0.00010131971],"genre_scores_gemma":[0.9900643,0.00007772713,0.00035851044,0.00735759,0.000085422864,0.00001784032,0.0016255961,0.00000920567,0.00040380497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972417,0.0005112764,0.001163751,0.00027951773,0.0006611144,0.00014266724],"domain_scores_gemma":[0.99661136,0.0012622776,0.00047273896,0.0008068988,0.0007559888,0.000090710346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023708611,0.00009619536,0.0004001083,0.00002555507,0.000058877584,0.000011153077,0.00042811714,0.000047963757,0.00017109497],"category_scores_gemma":[0.0006987082,0.0000669383,0.000025305153,0.00034156596,0.00014703332,0.000031603395,0.000099103534,0.00020854962,0.000015889545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027586945,0.0015751594,0.955399,0.00002125091,0.0001405543,0.0000017035787,0.00014340636,0.000167498,0.00003896347,0.000037448983,0.033512067,0.008687095],"study_design_scores_gemma":[0.0011474614,0.00045194154,0.9807861,0.00007280567,0.00002695991,7.919688e-7,0.00024181519,0.006811499,0.00002363529,0.00015716374,0.010222301,0.000057534395],"about_ca_topic_score_codex":0.5826759,"about_ca_topic_score_gemma":0.2577114,"teacher_disagreement_score":0.32496446,"about_ca_system_score_codex":0.00004872316,"about_ca_system_score_gemma":0.0013845501,"threshold_uncertainty_score":0.75583345},"labels":[],"label_agreement":null},{"id":"W2079827356","doi":"10.1016/s0149-2918(08)00360-3","title":"Use of urinary globotriaosylceramide for fabry disease screening in Canada","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Globotriaosylceramide; Medicine; Fabry disease; Urinary system; Family medicine; Disease; Internal medicine","score_opus":0.3609747510201857,"score_gpt":0.42850058420405657,"score_spread":0.06752583318387084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079827356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484146,0.0009936133,0.0017983582,0.0014125906,0.00013293009,0.00069470314,0.00004714322,0.000015413982,0.00006380147],"genre_scores_gemma":[0.9937105,0.000914102,0.0027214093,0.0021189626,0.000109012806,0.000020729003,0.000025391417,0.000029805167,0.0003500413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821377,0.00012127973,0.0006788688,0.00026425143,0.00038999863,0.00033181332],"domain_scores_gemma":[0.9976502,0.0014059127,0.000101259764,0.00038704326,0.00017104029,0.00028454076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002982543,0.00012537416,0.00044644484,0.00005948431,0.00005049488,0.000004713791,0.00014510618,0.00008988816,0.00003309105],"category_scores_gemma":[0.00086786057,0.00011112247,0.00018992643,0.00023300729,0.0001933044,0.000059997386,0.00006342567,0.00031604705,0.0000016451456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031488168,0.0005606729,0.9594464,0.00008068553,0.00011943153,0.00034205907,0.000029595078,0.00012932533,0.000032855973,0.00004289531,0.00047176017,0.03559556],"study_design_scores_gemma":[0.003701199,0.0005192562,0.9600143,0.00010001173,0.00008038752,0.000019311223,0.00006912157,0.01708302,0.00005811628,0.00011892653,0.018076053,0.00016032044],"about_ca_topic_score_codex":0.08126777,"about_ca_topic_score_gemma":0.03290551,"teacher_disagreement_score":0.04836225,"about_ca_system_score_codex":0.00013250153,"about_ca_system_score_gemma":0.0020770086,"threshold_uncertainty_score":0.98474145},"labels":[],"label_agreement":null},{"id":"W2080391255","doi":"10.1016/j.clinthera.2007.01.001","title":"A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada); University of Manitoba; St. Michael's Hospital; McMaster University; Alberta Health Services; University of Calgary; University of Toronto; Université Laval","funders":"","keywords":"Tramadol; Medicine; Crossover study; Anesthesia; Chronic pain; Randomized controlled trial; Double blind; Immediate release; Controlled release; Pharmacology; Analgesic; Physical therapy; Internal medicine; Alternative medicine","score_opus":0.1309742844746246,"score_gpt":0.4343893811875262,"score_spread":0.30341509671290157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080391255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739954,0.0034784193,0.0019474368,0.0011536517,0.0016178113,0.016993944,0.00005305911,0.00013783277,0.0006224613],"genre_scores_gemma":[0.99260926,0.0010229517,0.00038620274,0.0024443266,0.0011830718,0.0012816489,0.0000936713,0.0001630889,0.00081577926],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99325466,0.0007736147,0.0031145941,0.00093186286,0.0009043935,0.0010208713],"domain_scores_gemma":[0.9856064,0.011054822,0.001010844,0.0011087088,0.0005856153,0.000633637],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0060479795,0.0007233478,0.0033574395,0.0002092659,0.00017326722,0.00006449627,0.00040353168,0.00060541707,0.00023104427],"category_scores_gemma":[0.0014953406,0.0005498686,0.0017813826,0.00043879153,0.0006941048,0.00010805434,0.000058375077,0.00080867246,0.00005991076],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92671305,0.017071696,0.0010483058,0.000169822,0.005569771,0.00006730981,0.0023987025,0.00010864248,0.00008451063,0.00012477215,0.00024351603,0.046399873],"study_design_scores_gemma":[0.9602424,0.019306976,0.0005922328,0.00014506791,0.0059165447,0.0000034561574,0.005989111,0.003992056,0.0004043143,0.00014416619,0.0027619998,0.0005016845],"about_ca_topic_score_codex":0.00038461233,"about_ca_topic_score_gemma":0.00026021316,"teacher_disagreement_score":0.045898188,"about_ca_system_score_codex":0.00035633155,"about_ca_system_score_gemma":0.0012301608,"threshold_uncertainty_score":0.9996953},"labels":[],"label_agreement":null},{"id":"W2081770159","doi":"10.1016/j.clinthera.2014.07.019","title":"Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Mellitus","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Medicine; Insulin glargine; Sitagliptin; Metformin; Type 2 Diabetes Mellitus; Hypoglycemia; Internal medicine; Insulin; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.0806538993218418,"score_gpt":0.36118291305526934,"score_spread":0.28052901373342753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081770159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996126,0.00072600355,0.00007460249,0.00008544072,0.00048697993,0.0010554643,0.0000067043948,0.000034002613,0.0014047914],"genre_scores_gemma":[0.99805397,0.0005155988,0.00076371216,0.00037890233,0.00007793941,0.000032395248,0.00009555062,0.00003411946,0.00004779876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.0002837569,0.00052162405,0.00031809078,0.00026388542,0.00030099475],"domain_scores_gemma":[0.99769336,0.0013909348,0.00016471707,0.00042596128,0.00021356152,0.00011146475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008469441,0.00020863111,0.0006564984,0.000095948395,0.000020799625,0.000009809027,0.00012387766,0.00014542497,0.0000315154],"category_scores_gemma":[0.00024228918,0.00015175468,0.00010505605,0.000343264,0.0001702347,0.000052353236,0.00006298041,0.00023034347,0.0000448831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005173511,0.0027838007,0.7951092,0.00016519192,0.000651018,0.000002947423,0.000046436315,0.00003296807,0.000037346446,0.00039222682,0.000012700003,0.19559264],"study_design_scores_gemma":[0.027414368,0.00820016,0.9468776,0.0003003135,0.0005476039,4.1011134e-8,0.000021255637,0.00056164415,0.0007572529,0.00021974684,0.014892349,0.00020767403],"about_ca_topic_score_codex":0.000003333555,"about_ca_topic_score_gemma":0.0000053584063,"teacher_disagreement_score":0.19538496,"about_ca_system_score_codex":0.00006394393,"about_ca_system_score_gemma":0.000042771495,"threshold_uncertainty_score":0.6188376},"labels":[],"label_agreement":null},{"id":"W2081920466","doi":"10.1016/s0149-2918(00)83044-1","title":"Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Nedocromil Sodium; Anesthesia; Dermatology; Ophthalmology; Placebo","score_opus":0.187318352998763,"score_gpt":0.4424597615847274,"score_spread":0.25514140858596435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081920466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944138,0.0018227504,0.00007417637,0.0019163856,0.00015850487,0.0007344373,0.000009604457,0.000016552327,0.00085378956],"genre_scores_gemma":[0.9963842,0.0026313593,0.00014606271,0.00050738925,0.00013715128,0.000006838475,0.000014198262,0.000026299249,0.00014648712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694514,0.000463599,0.0015257687,0.0003999033,0.00035661456,0.0003089441],"domain_scores_gemma":[0.99813825,0.00064261234,0.00035740115,0.0006839985,0.00007488352,0.00010287884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001687897,0.00024087643,0.0009356921,0.000044537817,0.0001366823,0.000011340109,0.00028513363,0.00035066254,0.00003077933],"category_scores_gemma":[0.000080092446,0.00015411973,0.0002758871,0.00014869937,0.0007975774,0.0000688243,0.00010353965,0.0008357269,0.0000031711052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034374634,0.005625106,0.94117707,0.00019866278,0.0006647739,0.000017705253,0.0020857814,0.00031898488,0.00784016,0.0008724945,0.00008143408,0.03768036],"study_design_scores_gemma":[0.011034917,0.003693141,0.8847103,0.00032803882,0.00075966347,0.000043449087,0.00041160992,0.09484249,0.0009584096,0.00144241,0.0014186504,0.00035691456],"about_ca_topic_score_codex":0.00004350955,"about_ca_topic_score_gemma":0.000033960416,"teacher_disagreement_score":0.09452351,"about_ca_system_score_codex":0.000023703,"about_ca_system_score_gemma":0.00011246383,"threshold_uncertainty_score":0.62848204},"labels":[],"label_agreement":null},{"id":"W2082220423","doi":"10.1016/j.clinthera.2007.09.022","title":"A population-based analysis of statin utilization in British Columbia","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of British Columbia; Health Sciences Centre","funders":"","keywords":"Rosuvastatin; Medicine; Statin; Atorvastatin; Simvastatin; Internal medicine; Medical prescription; Population; Diabetes mellitus; Pharmacology; Endocrinology; Environmental health","score_opus":0.10823144287888131,"score_gpt":0.41742397133131004,"score_spread":0.3091925284524287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082220423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867939,0.0003887391,0.012231669,0.000063529034,0.00007869602,0.0002906038,0.000012524029,0.000019386825,0.000120999764],"genre_scores_gemma":[0.99619323,0.00018730525,0.0020643065,0.0012860199,0.00006493756,0.0000030446597,0.00012610295,0.000012164945,0.000062898594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983798,0.00012578521,0.0008396378,0.00018544051,0.00030945247,0.0001598558],"domain_scores_gemma":[0.9990323,0.00027956543,0.00014681119,0.00031931247,0.00013645718,0.00008551443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002415828,0.000048699534,0.0005431741,0.00010112754,0.000024554969,0.000016505719,0.000045125395,0.00014438714,0.000110768655],"category_scores_gemma":[0.00018179229,0.00006765712,0.00037760028,0.0010526314,0.00004631995,0.000017513214,0.0000074130785,0.00016002331,9.20103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003910021,0.00026337977,0.7963748,0.000028244865,0.00040687795,0.000009660005,0.000014406916,0.000083676576,0.000006015595,0.00000804761,0.000006127961,0.2027597],"study_design_scores_gemma":[0.0013477915,0.0001731583,0.9883927,0.000048871952,0.00089199864,0.0000011051894,0.00004659276,0.007993592,0.000012251805,0.000068723944,0.0009627008,0.000060478626],"about_ca_topic_score_codex":0.009874501,"about_ca_topic_score_gemma":0.07883421,"teacher_disagreement_score":0.20269921,"about_ca_system_score_codex":0.000047470563,"about_ca_system_score_gemma":0.00011085008,"threshold_uncertainty_score":0.9967188},"labels":[],"label_agreement":null},{"id":"W2082986055","doi":"10.1016/j.clinthera.2009.04.021","title":"A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Hemostasis and retained surgical items","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Canadian Blood Services","funders":"Pfizer","keywords":"Medicine; Thrombin generation; Antibody; Pharmacology; Immunology; Thrombin","score_opus":0.35430822782105226,"score_gpt":0.4974353053195826,"score_spread":0.14312707749853032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082986055","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030138553,0.9930595,0.0002651135,0.0017755445,0.0003104008,0.0029901762,0.000057039542,0.000032709344,0.0012081116],"genre_scores_gemma":[0.0000845912,0.9939099,0.0017286821,0.0027373498,0.0007649984,0.000025522952,0.00020932822,0.000052465784,0.00048719332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99407506,0.0006565893,0.003839233,0.0005522857,0.00055237603,0.00032445716],"domain_scores_gemma":[0.99673736,0.0005513043,0.0009588366,0.0010057999,0.0004552173,0.00029148368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018041244,0.0004776869,0.005663241,0.00010542193,0.000042296193,0.000008185815,0.0002878451,0.0007492746,0.00014405877],"category_scores_gemma":[0.0009141271,0.00029505257,0.001738078,0.00055666344,0.0001786186,0.000025807007,0.000101465215,0.00079537136,0.00002223409],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008613318,0.0007516715,0.000024341374,0.045650315,0.0005047079,0.000015728994,0.000013666478,2.44671e-8,0.00010978291,0.00030023308,0.00040370607,0.9521397],"study_design_scores_gemma":[0.00054621947,0.0034944362,0.00008539388,0.09462883,0.0022749044,0.000034827783,0.0000030010217,0.000012527928,0.000098261604,0.000018356563,0.8985358,0.00026743277],"about_ca_topic_score_codex":0.00000387346,"about_ca_topic_score_gemma":0.0000017569179,"teacher_disagreement_score":0.9518722,"about_ca_system_score_codex":0.000072563824,"about_ca_system_score_gemma":0.0005511206,"threshold_uncertainty_score":0.9999502},"labels":[],"label_agreement":null},{"id":"W2082993446","doi":"10.1016/j.clinthera.2008.04.015","title":"Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Statin; Medical prescription; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Cardiology; Intensive care medicine; Internal medicine; Emergency medicine; Pharmacology","score_opus":0.2640612634101041,"score_gpt":0.43735099527588006,"score_spread":0.17328973186577595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082993446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95217395,0.00034243343,0.043166384,0.0028311405,0.00030882348,0.0007924865,0.000011955092,0.000021754613,0.00035109304],"genre_scores_gemma":[0.9923094,0.0006708491,0.003941944,0.0025436233,0.00021989801,0.00008384555,0.000021052314,0.0000108036675,0.00019859901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984902,0.00011230555,0.0007217131,0.0002071981,0.00031012957,0.00015841266],"domain_scores_gemma":[0.9987547,0.00043060593,0.00029304545,0.0002990521,0.00013967493,0.00008296987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007272123,0.0000858122,0.0002503426,0.000048169957,0.00007284076,0.000004392612,0.00018659572,0.0001359663,0.00008860646],"category_scores_gemma":[0.0002744142,0.00006041528,0.00012825939,0.00015300284,0.0004126666,0.000050307248,0.000018223589,0.00027600233,0.000030342793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00693877,0.004723339,0.67198694,0.0005730622,0.0009324222,0.00007637725,0.011071913,0.00011285264,0.009052976,0.0031259013,0.0061411657,0.2852643],"study_design_scores_gemma":[0.008710216,0.0027261297,0.91768783,0.00044628928,0.00038694462,0.000094908166,0.0009266791,0.04471173,0.0014839371,0.0021624886,0.020349992,0.00031286522],"about_ca_topic_score_codex":0.000009829066,"about_ca_topic_score_gemma":0.0000017988312,"teacher_disagreement_score":0.28495145,"about_ca_system_score_codex":0.000018497916,"about_ca_system_score_gemma":0.00025583108,"threshold_uncertainty_score":0.24636637},"labels":[],"label_agreement":null},{"id":"W2083760766","doi":"10.1016/j.clinthera.2007.04.009","title":"Prevalence and treatment of dyslipidemia in canadian primary care: A retrospective cohort analysis","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); Western University","funders":"","keywords":"Medicine; Dyslipidemia; Retrospective cohort study; Cohort; Internal medicine; Coronary artery disease; Cohort study; Hyperlipidemia; Risk factor; Medical prescription; Pediatrics; Disease; Diabetes mellitus; Endocrinology","score_opus":0.04291699522430418,"score_gpt":0.36856929925565995,"score_spread":0.32565230403135575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083760766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952067,0.0074181715,0.00010870961,0.00015683197,0.00007658341,0.00061738666,0.000016446776,0.0000098340215,0.0020753657],"genre_scores_gemma":[0.99296254,0.0055151423,0.0006093194,0.00063674024,0.00015793688,0.00000831347,0.000015766918,0.000010960381,0.0000832902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985046,0.00010001039,0.000572401,0.00029520533,0.00023405175,0.00029374933],"domain_scores_gemma":[0.99886036,0.00014661012,0.00008875178,0.00046112307,0.00011860164,0.0003245324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016738742,0.00011185303,0.00076408323,0.00017390799,0.000028683407,0.0000037410173,0.000044288772,0.00018651811,0.000012609758],"category_scores_gemma":[0.00005417181,0.0000874756,0.000334184,0.0004559298,0.00013853096,0.000016950025,0.000009731812,0.00016145282,0.0000011030149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010239418,0.00010913355,0.92753685,0.000067938585,0.0012579809,0.000026526553,0.00022559428,0.000001245575,0.0000063311145,0.000046124533,0.000001105248,0.0706188],"study_design_scores_gemma":[0.0012180582,0.0007703637,0.9933265,0.000035691166,0.0018932503,0.0000031718155,0.00005644469,0.000050605417,0.00004404078,0.000023027804,0.00250371,0.000075161624],"about_ca_topic_score_codex":0.025018942,"about_ca_topic_score_gemma":0.07728946,"teacher_disagreement_score":0.07054364,"about_ca_system_score_codex":0.00079494796,"about_ca_system_score_gemma":0.00048075616,"threshold_uncertainty_score":0.98147357},"labels":[],"label_agreement":null},{"id":"W2085309918","doi":"10.1016/j.clinthera.2005.08.002","title":"Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Korea Electrotechnology Research Institute; Eli Lilly and Company","keywords":"Medicine; Peripheral neuropathy; Construct validity; Cronbach's alpha; Convergent validity; Sensation; Intraclass correlation; Neuropathic pain; Diabetes mellitus; Diabetic neuropathy; Internal medicine; Physical therapy; Surgery; Patient satisfaction; Internal consistency; Psychometrics; Anesthesia; Clinical psychology; Endocrinology","score_opus":0.1494490140932621,"score_gpt":0.36216786054281347,"score_spread":0.21271884644955136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085309918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794614,0.00030470037,0.00032242783,0.00016221381,0.00023544743,0.0009882379,0.0000072014464,0.000016218943,0.000017421538],"genre_scores_gemma":[0.9973419,0.000033747776,0.002094606,0.00033445802,0.00010294828,0.000023070581,7.8101795e-7,0.000023960933,0.00004455031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822503,0.0003008655,0.00079550734,0.00023441557,0.00027602192,0.00016815531],"domain_scores_gemma":[0.9977314,0.0012227882,0.00036409093,0.00041730842,0.00020381951,0.000060612205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008525207,0.00016108976,0.00043054722,0.00002208796,0.000114926,0.0000062404374,0.00013823649,0.000070577255,0.000002454799],"category_scores_gemma":[0.00046539205,0.0000890008,0.0001345225,0.00012895683,0.00023609087,0.000023557106,0.000091574024,0.00018503811,3.3900895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020914998,0.0025401271,0.805911,0.000108292785,0.0003149352,0.000003275271,0.0014327802,0.000090547146,0.003412062,0.000090545785,0.0000013495634,0.18588595],"study_design_scores_gemma":[0.0031840606,0.003497044,0.9802413,0.00021059444,0.00069297355,0.000015897864,0.00031798828,0.006897141,0.004641681,0.000076429744,0.00012146181,0.000103403654],"about_ca_topic_score_codex":0.0000047817657,"about_ca_topic_score_gemma":0.000003818864,"teacher_disagreement_score":0.18578255,"about_ca_system_score_codex":0.000021050088,"about_ca_system_score_gemma":0.00010818875,"threshold_uncertainty_score":0.36293474},"labels":[],"label_agreement":null},{"id":"W2086440664","doi":"10.1016/s0149-2918(00)89012-8","title":"Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Rivastigmine; Medicine; Cholinesterase; Disease; Clinical trial; Dementia; Internal medicine; Donepezil","score_opus":0.08042570762440522,"score_gpt":0.38846438306793757,"score_spread":0.30803867544353236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086440664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986759,0.00009346494,0.000028624772,0.00016153985,0.000005744387,0.00089848525,0.000058100584,0.0000017601751,0.0000764021],"genre_scores_gemma":[0.9993116,0.0001111867,0.00008834241,0.00030119205,0.0000098608725,0.000056766985,0.000091078575,0.000008898125,0.000021022714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988781,0.000104276405,0.0003893624,0.00015898717,0.00028654817,0.00018270299],"domain_scores_gemma":[0.9990501,0.00040413367,0.00008000078,0.00024520975,0.00012227261,0.000098305165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026073641,0.00009707925,0.00038822202,0.00008698993,0.000016266767,0.0000040416403,0.000090734655,0.000022915514,0.000054831253],"category_scores_gemma":[0.00001520879,0.000051360752,0.00007636043,0.00042823076,0.000113561684,0.000026891616,0.000006206593,0.00008141045,1.206139e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029142168,0.0016037362,0.9187572,0.000009512118,0.0009972866,0.000007199998,0.00016696782,0.00015974778,0.0000015271512,0.0000035718908,6.9411027e-7,0.07537835],"study_design_scores_gemma":[0.0045314007,0.004101809,0.9841486,0.00005617722,0.0029817782,1.0658169e-7,0.00024838393,0.0036205237,0.000023764811,0.000004805862,0.00022562633,0.000057017194],"about_ca_topic_score_codex":0.06871392,"about_ca_topic_score_gemma":0.26534677,"teacher_disagreement_score":0.19663285,"about_ca_system_score_codex":0.00011188422,"about_ca_system_score_gemma":0.00067601766,"threshold_uncertainty_score":0.9374876},"labels":[],"label_agreement":null},{"id":"W2086969647","doi":"10.1016/s0149-2918(03)80282-5","title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Eplerenone; Medicine; Aldosterone; Spironolactone; Essential hypertension; Internal medicine; Pharmacology; Cardiology; Blood pressure","score_opus":0.042661481689849776,"score_gpt":0.31929515601366915,"score_spread":0.27663367432381936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086969647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99853206,0.0001914127,0.00007720244,0.00053388666,0.00009287367,0.00041256705,0.0000016997185,0.000007398553,0.00015091265],"genre_scores_gemma":[0.99848783,0.00014925728,0.00024228594,0.0009405316,0.000027837305,9.1299273e-7,0.000005509023,0.000016797734,0.0001290578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879974,0.00016198016,0.00043941045,0.00020828658,0.00025173696,0.00013887268],"domain_scores_gemma":[0.99909467,0.0002638386,0.00012181165,0.00024868906,0.00019742589,0.00007354738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024263759,0.00011522807,0.00037627624,0.000035086792,0.000046790876,0.0000046555015,0.00004442855,0.0001317016,0.00002493859],"category_scores_gemma":[0.0001289255,0.000063712454,0.000068978865,0.0001794504,0.00022412237,0.000024475266,0.000027874708,0.00025149636,0.0000028624388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025681704,0.0010368623,0.97547776,0.0000099167255,0.000110456574,0.0000048673824,0.0000632993,0.0000029906946,0.0005160347,0.000078638375,0.000009555159,0.020121468],"study_design_scores_gemma":[0.009842011,0.0006894022,0.9878419,0.0001061654,0.00017986243,0.000013228717,0.0000075112425,0.00011968251,0.0005407077,0.000019407715,0.0005623939,0.00007774991],"about_ca_topic_score_codex":0.0000017015344,"about_ca_topic_score_gemma":0.000007745919,"teacher_disagreement_score":0.020043718,"about_ca_system_score_codex":0.000020238384,"about_ca_system_score_gemma":0.000072216055,"threshold_uncertainty_score":0.25981185},"labels":[],"label_agreement":null},{"id":"W2087811094","doi":"10.1016/j.clinthera.2005.09.001","title":"Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label study","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital","funders":"Novo Nordisk","keywords":"Pioglitazone; Medicine; Glibenclamide; Internal medicine; Hypoglycemia; Type 2 diabetes; Glycated hemoglobin; Endocrinology; Glycemic; Diabetes mellitus; Combination therapy; Insulin","score_opus":0.15879567859381016,"score_gpt":0.432003724795728,"score_spread":0.27320804620191785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087811094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863573,0.0010101715,0.000023290973,0.0022710736,0.00012872246,0.009374419,0.0000038351222,0.00005941589,0.0007717741],"genre_scores_gemma":[0.98995584,0.004706272,0.00046680466,0.0026504043,0.00011887963,0.00017510545,0.000026898217,0.00007580039,0.0018240145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99518925,0.0015779907,0.0015570386,0.0006047189,0.00061177684,0.00045923793],"domain_scores_gemma":[0.99394846,0.004435855,0.0004156025,0.0006962096,0.00030407475,0.00019977655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052851713,0.00038528352,0.0023059077,0.0002938892,0.00010631038,0.00010745466,0.0004605078,0.00020085479,0.00025649453],"category_scores_gemma":[0.0005207446,0.00021073685,0.000101407706,0.0006601164,0.0005529796,0.00021761558,0.000111039386,0.00056905445,0.000014601352],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7416347,0.030335907,0.019600302,0.00003224111,0.0017457989,0.000016228072,0.00038380857,0.000020096923,0.00013151545,0.0005040989,0.000033257413,0.20556201],"study_design_scores_gemma":[0.8756663,0.065147355,0.04701596,0.00023034264,0.00036507848,3.7172958e-7,0.00018084476,0.009295254,0.00014817106,0.00039378065,0.0012551802,0.00030131152],"about_ca_topic_score_codex":0.000011283845,"about_ca_topic_score_gemma":0.000040455525,"teacher_disagreement_score":0.2052607,"about_ca_system_score_codex":0.00005650693,"about_ca_system_score_gemma":0.00017174828,"threshold_uncertainty_score":0.85936},"labels":[],"label_agreement":null},{"id":"W2089418176","doi":"10.1016/j.clinthera.2007.02.006","title":"Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review","year":2007,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Menopause; Hot flash; Randomized controlled trial; Internal medicine; Gabapentin; Oncology; Clinical trial; Cancer; Gynecology; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.58391020650909,"score_gpt":0.5827162318161314,"score_spread":0.001193974692958566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089418176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013661782,0.989405,0.00022816815,0.0024775285,0.0005395636,0.007069447,0.00018907695,0.00003077212,0.000046784175],"genre_scores_gemma":[0.000056628942,0.9901013,0.00087687164,0.0074299225,0.00030697024,0.0008398685,0.00008417651,0.00009974824,0.00020455489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953286,0.00061126414,0.002463712,0.0005797018,0.00045215382,0.0005645764],"domain_scores_gemma":[0.99334913,0.003905128,0.00091573776,0.0013165966,0.00023248025,0.00028094606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041997805,0.00053133874,0.002753637,0.00013781423,0.0000982967,0.000020031435,0.00045759874,0.00041195014,0.00014256565],"category_scores_gemma":[0.000042380594,0.0002849154,0.00037733468,0.00064054184,0.00024461234,0.00007042804,0.000042925876,0.0006463986,0.000013012302],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003118735,0.00085021346,0.00021083908,0.09743903,0.0016438267,0.000011747418,0.000007832656,0.0000011444927,8.2892825e-8,0.0001558191,0.000057827703,0.89930975],"study_design_scores_gemma":[0.0016094012,0.0014659179,0.0015188915,0.20864932,0.014488079,0.000014057918,0.000011005391,0.000048155493,1.5491328e-7,0.000036733112,0.7719277,0.00023060302],"about_ca_topic_score_codex":0.00010965726,"about_ca_topic_score_gemma":0.00008242879,"teacher_disagreement_score":0.89907914,"about_ca_system_score_codex":0.00023809704,"about_ca_system_score_gemma":0.00083458086,"threshold_uncertainty_score":0.9999603},"labels":[],"label_agreement":null},{"id":"W2090003551","doi":"10.1016/s0149-2918(04)90002-1","title":"Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment","year":2004,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of British Columbia; Western University; Osteoporosis Canada; McMaster University; University of Saskatchewan; Université Laval; University of Calgary","funders":"Merck Canada","keywords":"Medicine; Osteoporosis; Vitamin D and neurology; Epidemiology; Bone density; Hip fracture; FRAX; Internal medicine; Pediatrics; Physical therapy; Bone mineral; Osteoporotic fracture","score_opus":0.41335034293491074,"score_gpt":0.5670761980052973,"score_spread":0.15372585507038655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090003551","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001295312,0.9944369,0.000004547155,0.0019086578,0.000217916,0.002863694,0.000030772684,0.00004210348,0.00036583762],"genre_scores_gemma":[0.000022530732,0.99535763,0.0009872451,0.0011753339,0.00034679467,0.0008080859,0.00017862905,0.0000757688,0.001047992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939853,0.0015433782,0.0027345447,0.00083554315,0.00019821926,0.0007029978],"domain_scores_gemma":[0.9931198,0.0049872515,0.0005134014,0.0007226536,0.00007595538,0.0005809582],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003025973,0.0005062333,0.004283212,0.00021867512,0.00007719447,0.000013465679,0.0001562822,0.0013014979,0.0000991667],"category_scores_gemma":[0.00080573186,0.00034093496,0.00088930357,0.00035839505,0.0004308221,0.000032627155,0.00009226023,0.001193294,0.00008819275],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060917406,0.0010725881,0.0137119265,0.0064304653,0.00027324184,0.000028767367,0.000029642943,7.0485044e-8,6.918848e-9,0.00007160773,0.00018651858,0.9781343],"study_design_scores_gemma":[0.0026117493,0.003110579,0.0038923956,0.014006417,0.0012668791,0.000057127243,0.000023856566,0.000003995597,1.6272506e-7,0.000561529,0.9742162,0.00024908982],"about_ca_topic_score_codex":0.00008137825,"about_ca_topic_score_gemma":0.000067288354,"teacher_disagreement_score":0.9778852,"about_ca_system_score_codex":0.0005392914,"about_ca_system_score_gemma":0.0018491201,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W2090119792","doi":"10.1016/j.clinthera.2014.08.005","title":"Safety, Tolerability and Pharmacokinetics of Trimebutine 3-Thiocarbamoylbenzenesulfonate (GIC-1001) in a Randomized Phase I Integrated Design Study: Single and Multiple Ascending Doses and Effect of Food in Healthy Volunteers","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inversago Pharma (Canada); BioPhage Pharma (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Placebo; Adverse effect; Crossover study; Randomized controlled trial; Cmax; Anesthesia; Pharmacology; Internal medicine","score_opus":0.07788883207652543,"score_gpt":0.3927934260976332,"score_spread":0.31490459402110776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090119792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401706,0.0014130923,0.0020498978,0.0002747207,0.00006872874,0.002129471,0.000009839107,0.000019312716,0.000017888826],"genre_scores_gemma":[0.9978962,0.0005443544,0.001322253,0.0001816203,0.000016736398,0.000011919234,0.0000059517806,0.000019173094,0.0000018109306],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950969,0.0024707196,0.0015734895,0.00041816483,0.00018291426,0.00025781422],"domain_scores_gemma":[0.9880907,0.011120661,0.00029866683,0.00022756374,0.00010576316,0.00015666451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071529066,0.00025291258,0.0018587422,0.00016646952,0.000029174558,0.000009709584,0.0000719411,0.00013057844,0.0000037003203],"category_scores_gemma":[0.005524742,0.00019347528,0.0001134009,0.0002830135,0.0006511936,0.00004234319,0.000064684435,0.00045207984,9.763747e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37132278,0.004040897,0.579526,0.0004483398,0.00016726,0.000003906159,0.000721929,0.0000718885,0.0033550877,0.000017220675,6.513993e-7,0.04032402],"study_design_scores_gemma":[0.7156367,0.053318363,0.1218065,0.000602158,0.000701111,0.000016192482,0.00051954045,0.10412336,0.002572485,0.0004331984,0.00003524374,0.00023520025],"about_ca_topic_score_codex":0.00009747224,"about_ca_topic_score_gemma":0.00006934498,"teacher_disagreement_score":0.45771953,"about_ca_system_score_codex":0.000029006826,"about_ca_system_score_gemma":0.00005768589,"threshold_uncertainty_score":0.7889693},"labels":[],"label_agreement":null},{"id":"W2090827161","doi":"10.1016/j.clinthera.2010.06.022","title":"Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; AstraZeneca","keywords":"Medicine; COPD; Salmeterol; Formoterol; Fluticasone propionate; Budesonide; Exacerbation; Emergency department; Population; Inhaler; Budesonide/formoterol; Cohort; Internal medicine; Asthma; Physical therapy","score_opus":0.023409784193903632,"score_gpt":0.3405790098158872,"score_spread":0.3171692256219836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090827161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219894,0.0007520464,0.000104764054,0.000044200002,0.00010405996,0.0066504655,0.000107102656,0.000026080808,0.000012327709],"genre_scores_gemma":[0.99849224,0.0004006897,0.00013447768,0.000009294596,0.000017710589,0.0004343458,0.00045806763,0.00004163663,0.000011521404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996944,0.00071109104,0.00086822896,0.0006791317,0.0005636111,0.00023393142],"domain_scores_gemma":[0.9975696,0.0009491194,0.00038432615,0.00045646442,0.00037271093,0.00026773804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005953917,0.00032155606,0.0006825874,0.000205604,0.00011052685,0.000011598534,0.00008151991,0.00018015092,0.000035346122],"category_scores_gemma":[0.00029628817,0.00024413454,0.00006304341,0.00041196862,0.00034646728,0.00016032757,0.000054352593,0.00030080843,9.353968e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004599125,0.0033948726,0.9729975,0.0004897346,0.00041930875,0.000007469978,0.00013949486,0.00005100727,0.000045712328,0.00018470598,1.9426595e-7,0.017670903],"study_design_scores_gemma":[0.008857469,0.0072704,0.9751729,0.0003061602,0.00068821653,0.0000012086902,0.00006405948,0.0070657497,0.00005375515,0.00032841315,0.000003572964,0.00018812154],"about_ca_topic_score_codex":0.00008209478,"about_ca_topic_score_gemma":0.00007937864,"teacher_disagreement_score":0.017482782,"about_ca_system_score_codex":0.00027393628,"about_ca_system_score_gemma":0.00023166659,"threshold_uncertainty_score":0.99555176},"labels":[],"label_agreement":null},{"id":"W2091441695","doi":"10.1016/j.clinthera.2011.04.001","title":"Comparison of Preference for NovoPen® 4 With Previous Insulin Pen Treatments After 12 Weeks in Adult Patients With Type 1 and Type 2 Diabetes: A Multicenter Observational Study","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Clinique Neuro-Outaouais","funders":"Novo Nordisk","keywords":"Medicine; Observational study; Insulin pen; Diabetes mellitus; Type 2 diabetes; Insulin; Crossover study; Patient satisfaction; Randomized controlled trial; Adverse effect; Internal medicine; Type 1 diabetes; Clinical endpoint; Clinical trial; Surgery; Alternative medicine; Endocrinology","score_opus":0.40353163659496794,"score_gpt":0.44838655927344623,"score_spread":0.04485492267847829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091441695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722046,0.00010614887,0.0000113070855,0.000038225266,0.000052182462,0.0023557798,0.000007649267,0.000009050247,0.00019917962],"genre_scores_gemma":[0.9971742,0.000048347127,0.0020300485,0.00030432944,0.00001852534,0.00009017669,0.00004146835,0.000021143309,0.00027178746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878305,0.000080181526,0.00043166586,0.00025897718,0.00024618083,0.00019996297],"domain_scores_gemma":[0.99885917,0.00021536331,0.00012781595,0.0002358417,0.00049057376,0.00007121792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022802642,0.00013512693,0.00040908906,0.000054140255,0.000020295702,0.0000107938,0.00010115696,0.00006833382,0.00004042943],"category_scores_gemma":[0.0000856308,0.00008056288,0.000025731535,0.00016753288,0.00012976279,0.00006590703,0.000059602,0.00015667429,0.000004566862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076645343,0.0076196594,0.967799,0.00009855574,0.00051417365,0.0000013206068,0.00079834845,6.770478e-7,0.0000024050883,0.000004564471,0.00001552635,0.015481223],"study_design_scores_gemma":[0.01107115,0.016549567,0.9704587,0.00019264837,0.0003559368,1.476625e-8,0.00014770223,0.00082326814,0.000017864206,0.00001488116,0.00027332501,0.00009495305],"about_ca_topic_score_codex":0.000005515571,"about_ca_topic_score_gemma":0.000047089947,"teacher_disagreement_score":0.01538627,"about_ca_system_score_codex":0.00001638181,"about_ca_system_score_gemma":0.000051158357,"threshold_uncertainty_score":0.3285259},"labels":[],"label_agreement":null},{"id":"W2091547991","doi":"10.1016/j.clinthera.2007.06.002","title":"Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Merck KGaA","keywords":"Medicine; Tolerability; Immunogenicity; Interim; Interim analysis; Multiple sclerosis; Pharmacology; Internal medicine; Immunology; Adverse effect; Clinical trial; Immune system","score_opus":0.3748171886884401,"score_gpt":0.46086695992954513,"score_spread":0.08604977124110502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091547991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972561,0.00058255997,0.000678698,0.00007217934,0.000051570525,0.0012928577,0.000028668295,0.000011310305,0.000026061907],"genre_scores_gemma":[0.9957245,0.00022205673,0.003920199,0.00005062702,0.000030876527,0.000017391776,0.000013945548,0.000015808135,0.00000459385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968549,0.00033917863,0.0017646939,0.00036734826,0.00046286068,0.00021103279],"domain_scores_gemma":[0.9963449,0.0019241488,0.0005552234,0.00035941676,0.00065748644,0.00015877718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022595078,0.00019317465,0.0012253837,0.00018752937,0.00004020403,0.000007409702,0.00011504997,0.00012158805,0.0000104190085],"category_scores_gemma":[0.0017313744,0.00014168622,0.00012638881,0.00029554396,0.0008683562,0.00012011251,0.00010865954,0.00029927032,1.1389457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065585576,0.018901011,0.79855007,0.0002103348,0.0007861301,0.0000020477594,0.00243621,0.000011709383,0.08448318,0.00001030527,0.0000023089303,0.029021118],"study_design_scores_gemma":[0.056513894,0.024833232,0.9014545,0.000418446,0.00028615215,0.0000013780423,0.001661717,0.006705915,0.00792586,0.000056328274,0.0000070246992,0.00013556014],"about_ca_topic_score_codex":0.00024161603,"about_ca_topic_score_gemma":0.00057818554,"teacher_disagreement_score":0.10290442,"about_ca_system_score_codex":0.00009767493,"about_ca_system_score_gemma":0.00009188555,"threshold_uncertainty_score":0.57777965},"labels":[],"label_agreement":null},{"id":"W2093468331","doi":"10.1016/j.clinthera.2008.01.018","title":"Topical amethocaine gel 4% for intramuscular injection in term neonates: A double-blind, placebo-controlled, randomized trial","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Mount Sinai Hospital","funders":"","keywords":"Medicine; Anesthesia; Placebo; Randomized controlled trial; Tolerability; Visual analogue scale; Erythema; Adverse effect; Topical anesthetic; Local anesthetic; Intramuscular injection; Surgery; Anesthetic; Internal medicine","score_opus":0.15464061498712672,"score_gpt":0.4339777775669746,"score_spread":0.27933716257984786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093468331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86684155,0.0007082521,0.10986906,0.002853212,0.0009010127,0.017257124,0.000002452809,0.0003871556,0.0011801874],"genre_scores_gemma":[0.9548289,0.0045209685,0.027258497,0.0056716367,0.0030853928,0.0032059348,0.00005138483,0.00007833548,0.0012989147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960616,0.0008362145,0.0018147591,0.00051690877,0.00035775843,0.0004127462],"domain_scores_gemma":[0.9933925,0.005454491,0.00033876227,0.0005189098,0.00014824365,0.00014709066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064727603,0.00029310156,0.00197784,0.00029287668,0.00008155422,0.000023029379,0.00021947495,0.0005156154,0.000030202922],"category_scores_gemma":[0.0023201106,0.00022057217,0.0010600508,0.0003289901,0.00037537125,0.00007693268,0.00006195425,0.00069016503,0.000007820405],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9801742,0.0009753556,0.0026851713,0.0000445859,0.0005312476,0.000036192585,0.00010037983,0.0000076382385,0.000018109069,0.00038187104,0.00020947652,0.014835781],"study_design_scores_gemma":[0.9836327,0.0019533497,0.00042704344,0.00003888651,0.0008390438,0.000016360727,0.000021743035,0.0064179664,0.000025955595,0.0025380403,0.0038641093,0.00022479937],"about_ca_topic_score_codex":0.000014058338,"about_ca_topic_score_gemma":0.000005496859,"teacher_disagreement_score":0.08798739,"about_ca_system_score_codex":0.00011389127,"about_ca_system_score_gemma":0.00018190964,"threshold_uncertainty_score":0.8994672},"labels":[],"label_agreement":null},{"id":"W2094964401","doi":"10.1016/s0149-2918(01)80122-3","title":"Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: A one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Bayer Canada","keywords":"Medicine; Pravastatin; Cerivastatin; Randomization; Adverse effect; Randomized controlled trial; Internal medicine; Cholesterol; Pharmacology","score_opus":0.20848785641586248,"score_gpt":0.44190961746479573,"score_spread":0.23342176104893325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094964401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98526776,0.002897739,0.000029627001,0.00027296148,0.00008293741,0.010223392,0.00001936478,0.000003806877,0.0012023905],"genre_scores_gemma":[0.9911427,0.007598551,0.0004897406,0.00040890256,0.00002901856,0.00027087063,0.000037004684,0.000019550214,0.000003662869],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99225533,0.005209793,0.0013415574,0.00039481398,0.0005347807,0.00026372555],"domain_scores_gemma":[0.9896801,0.009168776,0.000354435,0.0005495821,0.00016377207,0.00008334806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040620305,0.00022916928,0.0022211226,0.00008593789,0.00003383544,0.000015110558,0.00020492922,0.000103990766,0.0000027457863],"category_scores_gemma":[0.0002655169,0.00015696167,0.00009625068,0.0004171027,0.00019044764,0.00008291044,0.00007287305,0.00043430287,3.150093e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5769469,0.017834963,0.08968961,0.00031979903,0.0011776013,0.00018243228,0.024008466,0.0001394397,0.000052644467,0.000024167888,0.0000012253903,0.28962275],"study_design_scores_gemma":[0.49554598,0.005627086,0.4813512,0.0002910983,0.00045764464,0.000009303899,0.01579698,0.00006129742,0.000021155882,0.000006841392,0.00070796127,0.00012343917],"about_ca_topic_score_codex":0.1879433,"about_ca_topic_score_gemma":0.30986327,"teacher_disagreement_score":0.39166158,"about_ca_system_score_codex":0.00087008276,"about_ca_system_score_gemma":0.0017691482,"threshold_uncertainty_score":0.8174643},"labels":[],"label_agreement":null},{"id":"W2098257709","doi":"10.1016/j.clinthera.2011.07.014","title":"The Need for Additional Metrics to Assess Therapeutic Equivalence of Some Multiphasic Modified-Release Products","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Bioequivalence; Food and drug administration; Equivalence (formal languages); Statement (logic); Metric (unit); Position statement; Advisory committee; Drug; Pharmacology; Actuarial science; Medical physics; Family medicine; Pharmacokinetics; Law; Operations management; Public administration; Mathematics","score_opus":0.8843704126214491,"score_gpt":0.6060957014774468,"score_spread":0.27827471114400226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098257709","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01548285,0.00079966855,0.9633731,0.0028286015,0.0065961187,0.005923423,0.003357428,0.00031425426,0.0013245399],"genre_scores_gemma":[0.12618297,0.0003706635,0.8681524,0.0030804942,0.0010841376,0.0004692656,0.000013112841,0.00012555951,0.000521408],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9934817,0.0015407623,0.0027767164,0.0007401764,0.0007644231,0.0006962546],"domain_scores_gemma":[0.7907345,0.20563622,0.00090807007,0.0013343698,0.0010739911,0.000312848],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009537883,0.0003875794,0.0011155441,0.000116678886,0.00025505314,0.000051172578,0.0012994289,0.0004004613,0.00026711772],"category_scores_gemma":[0.14978386,0.00026240628,0.0005599764,0.0007363116,0.0009077368,0.00011013078,0.00022358244,0.0006174122,0.00003643612],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018591004,0.00242682,0.0003014748,0.00023286484,0.0008776514,0.0000041388676,0.00017989142,0.0000071783297,0.00043504895,0.73265195,0.0052039237,0.25581998],"study_design_scores_gemma":[0.0018112441,0.0013152689,0.0010777318,0.0000892102,0.00048399344,0.0000017424566,0.00008274217,0.0019937898,0.0031689326,0.9804162,0.009175896,0.0003832547],"about_ca_topic_score_codex":0.0000021475328,"about_ca_topic_score_gemma":0.0000011007272,"teacher_disagreement_score":0.25543672,"about_ca_system_score_codex":0.000054026215,"about_ca_system_score_gemma":0.00028442772,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W2098903681","doi":"10.1016/j.clinthera.2005.06.018","title":"Analgesia and local anesthesia during invasive procedures in the neonate","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Hospital for Sick Children; Population Health Research Institute; SickKids Foundation; BC Children's Hospital; McGill University","funders":"","keywords":"Medicine; Venipuncture; Neonatal intensive care unit; MEDLINE; Intensive care medicine; Randomized controlled trial; Pain assessment; Cochrane Library; Clinical trial; Pediatrics; Anesthesia; Pain management; Surgery","score_opus":0.13155478369495083,"score_gpt":0.4365234261927203,"score_spread":0.30496864249776945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098903681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069573824,0.9959181,0.00006585427,0.0009982901,0.000025808014,0.00180776,0.0000015833451,0.00012334218,0.00036352253],"genre_scores_gemma":[0.0015356282,0.99305093,0.0005707935,0.0038551947,0.0006292108,0.00013237105,0.000016241542,0.00006356248,0.0001460811],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968332,0.00069081894,0.0012293585,0.00054601085,0.00033713924,0.0003634449],"domain_scores_gemma":[0.9967823,0.0020272518,0.00039177167,0.0006549098,0.000042207346,0.000101575526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017429263,0.00042519878,0.0016383203,0.00024350686,0.000058291917,0.0000425805,0.00045943563,0.00059086847,0.0000109056355],"category_scores_gemma":[0.0003231498,0.00026471744,0.00041922886,0.0004983963,0.0003609513,0.0000470577,0.000096831645,0.0012218177,0.000018331499],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003477397,0.0002057672,0.001707354,0.008630329,0.00021018244,0.0004810939,0.00005744199,1.8878812e-7,4.939996e-8,0.0000771722,0.00031194236,0.9882837],"study_design_scores_gemma":[0.00058207754,0.0002316356,0.0076286783,0.0058295233,0.0023110958,0.0004967522,0.000057310725,0.000014433784,1.5643131e-7,0.00019771037,0.9823185,0.00033210634],"about_ca_topic_score_codex":0.0000028406398,"about_ca_topic_score_gemma":0.000015407453,"teacher_disagreement_score":0.9879516,"about_ca_system_score_codex":0.00009009261,"about_ca_system_score_gemma":0.0004230143,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W2099867105","doi":"10.1016/s0149-2918(02)80088-1","title":"Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cefuroxime; Medicine; Ceftriaxone; Gemifloxacin; Community-acquired pneumonia; Pneumonia; Population; Antibacterial agent; Internal medicine; Randomized controlled trial; Concomitant; Antibiotics; Surgery","score_opus":0.2942405388694598,"score_gpt":0.45675434732795084,"score_spread":0.16251380845849106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099867105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917173,0.00007372848,0.000027852699,0.00025391334,0.00015879876,0.007643647,0.000024273182,0.000031121646,0.00006938579],"genre_scores_gemma":[0.9976708,0.00092786434,0.00048484385,0.0005677632,0.000054755194,0.00020152384,0.000014169269,0.000053504857,0.000024754252],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919445,0.0046874555,0.0019971048,0.00050773297,0.00048691715,0.0003763192],"domain_scores_gemma":[0.9946351,0.002944222,0.00080472435,0.0010969773,0.00033260125,0.00018635612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002216575,0.00046714948,0.002832266,0.00009290595,0.00020381405,0.000055755216,0.00039234437,0.00023461487,0.000028389148],"category_scores_gemma":[0.00016615678,0.00020642391,0.00016440458,0.0004100849,0.001687862,0.00011136835,0.00007256589,0.000645236,0.0000013883116],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36526015,0.0694799,0.5469606,0.00002622548,0.0018932305,0.000038491646,0.005289579,0.000007978334,0.00004270807,0.0000017836909,8.990494e-7,0.010998439],"study_design_scores_gemma":[0.58675057,0.12685187,0.28280905,0.00011703945,0.0014655222,0.000011867282,0.000859059,0.0005377617,0.000029036792,0.0000038633702,0.0003397184,0.00022467245],"about_ca_topic_score_codex":0.00032535565,"about_ca_topic_score_gemma":0.0006116241,"teacher_disagreement_score":0.26415157,"about_ca_system_score_codex":0.000059215625,"about_ca_system_score_gemma":0.00014721714,"threshold_uncertainty_score":0.8417723},"labels":[],"label_agreement":null},{"id":"W2101619662","doi":"10.1016/s0149-2918(01)80082-5","title":"Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach","year":2001,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Schizophrenia (object-oriented programming); Antipsychotic; Meta-analysis; Pharmacology; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.7396696450451444,"score_gpt":0.5672886461226634,"score_spread":0.17238099892248104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101619662","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001938236,0.9927577,0.00066119124,0.00041123593,0.00018316603,0.0054766517,0.00007255324,0.000039377006,0.00020429715],"genre_scores_gemma":[0.00061651086,0.9896945,0.006349456,0.00013651566,0.00060447474,0.001319528,0.00025579595,0.00009369379,0.0009295515],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941077,0.0013855901,0.0021935524,0.00084668084,0.00088501745,0.00058146013],"domain_scores_gemma":[0.982441,0.013863925,0.0010483807,0.0021505211,0.00028332527,0.0002128107],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0033341467,0.00074596336,0.0076100887,0.00025468392,0.00032064584,0.00007887697,0.00065501576,0.00041321584,0.00011081653],"category_scores_gemma":[0.00020097253,0.00028170238,0.013363534,0.0015913069,0.00047810565,0.000024064513,0.00006386606,0.00072263886,0.000019758827],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015484351,0.0013262767,0.00007343483,0.00043584342,0.39348498,0.0000026106543,0.00006796542,0.000017036487,1.5465682e-8,0.00008411987,0.00001879151,0.6029405],"study_design_scores_gemma":[0.0035182908,0.0022092997,0.00014105867,0.00015394749,0.7940876,0.000017754213,0.000047914382,0.0038061738,5.1332205e-7,0.00016960483,0.1956327,0.00021513535],"about_ca_topic_score_codex":0.000022754113,"about_ca_topic_score_gemma":0.000019781777,"teacher_disagreement_score":0.6027253,"about_ca_system_score_codex":0.0001606865,"about_ca_system_score_gemma":0.00067440857,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W2102906087","doi":"10.1016/j.clinthera.2010.06.017","title":"Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9–10, 2009","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"National Cancer Institute","keywords":"Session (web analytics); Library science; Medicine; Human papillomavirus; Field (mathematics); Medical education; Engineering ethics; Computer science; World Wide Web; Engineering","score_opus":0.3794184601936088,"score_gpt":0.5018382449413639,"score_spread":0.12241978474775506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102906087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855868,0.000613407,0.000052429194,0.005506224,0.00021457388,0.0005798351,0.0000020277325,0.000017256834,0.0074274438],"genre_scores_gemma":[0.99591106,0.0011115551,0.0003299519,0.0009932821,0.00022475558,0.000023465045,6.2155607e-7,0.000018642917,0.0013866355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979203,0.000062700594,0.00082952605,0.00035136705,0.00047494657,0.00036116262],"domain_scores_gemma":[0.9980737,0.000918669,0.00010426544,0.0003573764,0.00041357815,0.00013239596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021313874,0.00014072731,0.00043076812,0.000078773766,0.000034064975,0.000029584036,0.0004775153,0.00031974973,0.0014230752],"category_scores_gemma":[0.00168719,0.00009319998,0.00015161453,0.0005527005,0.00030002667,0.00009845262,0.000176109,0.0021318027,0.000013686734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002973399,0.0010227181,0.71575093,0.00035587902,0.000055991644,0.000007719527,0.0011218963,0.00013171606,0.004072759,0.0015467727,0.0002690089,0.2726912],"study_design_scores_gemma":[0.0025437498,0.00043794408,0.87517107,0.00056088564,0.000073256175,0.000008837682,0.00039397314,0.112715274,0.0010591212,0.004179715,0.0026113489,0.00024482879],"about_ca_topic_score_codex":0.000047615435,"about_ca_topic_score_gemma":0.00035485282,"teacher_disagreement_score":0.27244636,"about_ca_system_score_codex":0.000038968832,"about_ca_system_score_gemma":0.00029168013,"threshold_uncertainty_score":0.9994898},"labels":[],"label_agreement":null},{"id":"W2102912926","doi":"10.1016/j.clinthera.2013.07.261","title":"PP220—The risk of birth defects following exposure to nitrofurantoin during first trimester","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pregnancy and Medication Impact","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Nitrofurantoin; Medicine; Pregnancy; Obstetrics; First trimester; Retrospective cohort study; Cohort study; Gestation; Antibiotics; Surgery; Internal medicine","score_opus":0.05398706112869189,"score_gpt":0.3600774374560647,"score_spread":0.3060903763273728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102912926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930193,0.0013284779,0.00040807342,0.003338696,0.00052355096,0.00074926706,0.000005964279,0.000053353,0.00057333393],"genre_scores_gemma":[0.99335295,0.0008658391,0.00052425376,0.0036338675,0.00026949059,0.000040807216,0.0000023089149,0.000027313758,0.0012831945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983401,0.00018841233,0.00069181033,0.000224723,0.0002729874,0.0002819686],"domain_scores_gemma":[0.99779767,0.0010016102,0.0001973946,0.0006601227,0.00008463254,0.00025857126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007153431,0.00014853693,0.00042722936,0.00005485794,0.00010946146,0.000015273055,0.00019734635,0.00015983194,0.00012968155],"category_scores_gemma":[0.00083225296,0.00008974999,0.00041403866,0.00021282329,0.000110312285,0.00006664871,0.00005106396,0.00041371607,0.00016482364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035368768,0.0006352612,0.95075977,0.00016656364,0.0008483632,0.000012995076,0.0011589754,0.000014216763,0.004675311,0.000029420979,0.0007295623,0.040615853],"study_design_scores_gemma":[0.0034949395,0.0010302453,0.9785381,0.0005368324,0.00046963553,0.000010636716,0.00017994379,0.00007460404,0.0044029406,0.00025968597,0.010851357,0.00015110525],"about_ca_topic_score_codex":0.000015602227,"about_ca_topic_score_gemma":0.000004380544,"teacher_disagreement_score":0.040464748,"about_ca_system_score_codex":0.000021309539,"about_ca_system_score_gemma":0.00009792706,"threshold_uncertainty_score":0.36598986},"labels":[],"label_agreement":null},{"id":"W2104666672","doi":"10.1016/j.clinthera.2005.04.009","title":"Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia","year":2005,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Nova scotia; Medical prescription; Statin; Public health; Pharmaceutical Benefits Scheme; Environmental health; Family medicine; Internal medicine; Pharmacology; Geography; Nursing","score_opus":0.28831103401476077,"score_gpt":0.41656768573180314,"score_spread":0.12825665171704237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104666672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925423,0.0011925049,0.00029414988,0.0052149883,0.0001706133,0.0005098781,0.000052509524,0.000008543132,0.000014464508],"genre_scores_gemma":[0.9958733,0.00034340506,0.0009467563,0.002401488,0.00030584043,0.0000013250715,0.00000490703,0.000015733047,0.00010728905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826646,0.00029832678,0.0006295481,0.00021573866,0.00034693014,0.00024302478],"domain_scores_gemma":[0.99821466,0.00086469646,0.00018209466,0.0005143625,0.00009000371,0.00013416998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009722226,0.00014024561,0.0005372928,0.000014620825,0.00010010428,0.000024885405,0.000104878294,0.00011617254,0.000011211618],"category_scores_gemma":[0.00010630687,0.00007537474,0.00014012367,0.00010530621,0.0004173755,0.000036082383,0.00005714393,0.00050173845,0.0000012849348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058599562,0.000046378154,0.95188844,0.00006084736,0.00038945818,0.0000014643416,0.00017262391,0.000009913276,0.000048878665,0.00007070862,0.00093143753,0.04632124],"study_design_scores_gemma":[0.0014348682,0.0000969437,0.9442345,0.000112714144,0.00044308198,0.0000131651295,0.00016372705,0.0006064476,0.00024528382,0.00000870779,0.05254678,0.00009379449],"about_ca_topic_score_codex":0.14994216,"about_ca_topic_score_gemma":0.2907082,"teacher_disagreement_score":0.14076605,"about_ca_system_score_codex":0.000028022223,"about_ca_system_score_gemma":0.00029063158,"threshold_uncertainty_score":0.85571843},"labels":[],"label_agreement":null},{"id":"W2105175561","doi":"10.1016/s0149-2918(02)80033-9","title":"Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review","year":2002,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Piroxicam; Diclofenac; Rheumatoid arthritis; Adverse effect; Meloxicam; Tenoxicam; Internal medicine; MEDLINE; Osteoarthritis; Etodolac; Clinical trial; Ibuprofen; Alternative medicine; Pharmacology","score_opus":0.13708050951323972,"score_gpt":0.42853028175015867,"score_spread":0.2914497722369189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105175561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016634894,0.99368054,0.0000094480865,0.00007609286,0.0012608628,0.0035565225,0.000052652314,0.000120955185,0.0010766002],"genre_scores_gemma":[0.000054473367,0.99651283,0.00015205175,0.000842271,0.00142565,0.00013440051,0.00020697077,0.00017100414,0.0005003422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917726,0.0029898256,0.003356089,0.0007575028,0.00061729265,0.0005066889],"domain_scores_gemma":[0.9915825,0.004534086,0.0015986296,0.0016145683,0.0002718867,0.00039829066],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004666387,0.00089326716,0.0061599463,0.00026156957,0.000105099556,0.000029851368,0.0004224879,0.0018234315,0.00013142623],"category_scores_gemma":[0.0010560054,0.00060292275,0.0029342668,0.0008146889,0.00038699407,0.00008616719,0.00010785368,0.003649694,0.00037234707],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037439346,0.0002104052,0.0009128254,0.21200064,0.0008616935,0.00018138337,0.000060082442,4.8319595e-8,3.6539217e-7,0.000042837924,0.0016964127,0.78399587],"study_design_scores_gemma":[0.000954924,0.0005303884,0.000111712885,0.24681441,0.006674883,0.00018075995,0.000001943389,0.000017605229,0.0000012666527,0.000008419819,0.7443123,0.00039140036],"about_ca_topic_score_codex":1.5877555e-7,"about_ca_topic_score_gemma":1.7395408e-7,"teacher_disagreement_score":0.78360444,"about_ca_system_score_codex":0.00007760847,"about_ca_system_score_gemma":0.00036914911,"threshold_uncertainty_score":0.9996422},"labels":[],"label_agreement":null},{"id":"W2105482790","doi":"10.1016/s0149-2918(04)90171-3","title":"A treatment algorithm for neuropathic pain","year":2004,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre; Manitoba Health","funders":"","keywords":"Medicine; Neuropathic pain; Drug class; Pregabalin; Drug; Chronic pain; MEDLINE; Intensive care medicine; Anesthesia; Physical therapy; Psychiatry","score_opus":0.305997592243914,"score_gpt":0.495687724004519,"score_spread":0.189690131760605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105482790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7953731e-7,0.9408462,0.05536947,0.00010114175,0.00061134546,0.0027693848,0.00011941275,0.000102541126,0.0000803034],"genre_scores_gemma":[6.5386354e-7,0.9676107,0.028146375,0.001100519,0.00076931034,0.00046805493,0.00030436763,0.00015193998,0.0014480692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662465,0.0009621775,0.0011574711,0.00065895496,0.00018968633,0.0004070478],"domain_scores_gemma":[0.99575466,0.002818491,0.00037432995,0.00071575714,0.000078747085,0.00025800732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018504851,0.000591018,0.002792506,0.00008067499,0.00008545633,0.00002406173,0.0001503437,0.0007383496,0.000021427779],"category_scores_gemma":[0.00022279381,0.00036926795,0.0022890246,0.00014772723,0.00008911184,0.000013767202,0.000026944523,0.00040742086,0.00009933689],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016674283,0.001282207,0.000003043867,0.0026444106,0.0014711899,0.00015389196,0.000007820735,3.253574e-8,2.8520502e-8,0.00012724838,0.00001110997,0.99428236],"study_design_scores_gemma":[0.0026520542,0.0053046052,0.0000010992422,0.0059293634,0.008437996,0.000090799316,0.0000031433644,0.0005233141,3.7858504e-7,0.00067208265,0.9761112,0.00027398844],"about_ca_topic_score_codex":0.0000022461447,"about_ca_topic_score_gemma":3.2900195e-7,"teacher_disagreement_score":0.99400836,"about_ca_system_score_codex":0.00031735285,"about_ca_system_score_gemma":0.00089747354,"threshold_uncertainty_score":0.9998759},"labels":[],"label_agreement":null},{"id":"W2105534073","doi":"10.1016/s0149-2918(03)80071-1","title":"Tramadol/Acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double-blind, placebo-controlled outpatient study","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":187,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tramadol; Acetaminophen; Placebo; Discontinuation; Population; Analgesic; Randomized controlled trial; McGill Pain Questionnaire; Anesthesia; Visual analogue scale; Internal medicine; Alternative medicine","score_opus":0.20634434407819519,"score_gpt":0.4300767357906223,"score_spread":0.2237323917124271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105534073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782976,0.0019253693,0.0023279511,0.0004687213,0.001486241,0.015250875,0.000009562175,0.000045647015,0.00018805743],"genre_scores_gemma":[0.99494237,0.00085672986,0.00021836878,0.00057596614,0.00018479583,0.002212545,0.000012908096,0.0000509453,0.0009453592],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99398696,0.0033620796,0.0015252198,0.00047186247,0.00023097449,0.0004229122],"domain_scores_gemma":[0.98919636,0.009357251,0.00060473254,0.00057312933,0.00017356341,0.00009496728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047459807,0.0003960686,0.0014548784,0.00005838691,0.00022752286,0.000037121015,0.00032080594,0.0002636079,0.0003118968],"category_scores_gemma":[0.00013338278,0.00023880904,0.00095958414,0.00010645944,0.00039091846,0.000078375175,0.000021526976,0.00024740325,0.000047285357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95808536,0.027113732,0.0018227755,0.0000519891,0.0033297336,0.000034551664,0.0013026292,0.000119892364,0.00014311484,0.00025405784,0.000056760477,0.007685383],"study_design_scores_gemma":[0.9221777,0.040799987,0.0002488559,0.00002591282,0.001849603,0.000014273549,0.00043552948,0.016781608,0.000073429794,0.00010312016,0.017217563,0.0002724742],"about_ca_topic_score_codex":0.000006410007,"about_ca_topic_score_gemma":0.0000048804964,"teacher_disagreement_score":0.035907734,"about_ca_system_score_codex":0.0001243373,"about_ca_system_score_gemma":0.00009986966,"threshold_uncertainty_score":0.97383493},"labels":[],"label_agreement":null},{"id":"W2105923514","doi":"10.1016/j.clinthera.2008.09.001","title":"Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cardiovascular Syncope and Autonomic Disorders","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Midodrine; Crossover study; Blood pressure; Placebo; Atrial natriuretic peptide; Heart rate; Anesthesia; Internal medicine; Endocrinology","score_opus":0.024960748852310265,"score_gpt":0.31873510260042176,"score_spread":0.2937743537481115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105923514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97629917,0.012881428,0.000049824772,0.00015168745,0.00058664527,0.0087865405,0.000008604837,0.00009789799,0.0011381849],"genre_scores_gemma":[0.99617183,0.002238848,0.000074429416,0.0003639432,0.0002586148,0.00030337943,0.000003157847,0.000073741445,0.0005120284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622303,0.0009959334,0.0013156396,0.0006958394,0.00039789954,0.00037162803],"domain_scores_gemma":[0.9947803,0.0038555153,0.00045399024,0.0006042869,0.00012747517,0.0001784339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017832242,0.00046737902,0.0024457064,0.00012808875,0.0002003796,0.00005123093,0.00021035514,0.00015012412,0.00000989787],"category_scores_gemma":[0.00041787847,0.00030106926,0.00082341535,0.00017651964,0.0011530217,0.000058936585,0.00011751871,0.0006145832,0.000007888304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89409786,0.008222051,0.015983263,0.0011854322,0.046259493,0.00053641404,0.003073127,0.0017292068,0.0045899744,0.00027521158,0.000032188465,0.024015767],"study_design_scores_gemma":[0.9397462,0.0028592935,0.0036885913,0.00024746003,0.021115199,0.00038463922,0.00034932763,0.0301229,0.0006689111,0.000031115356,0.0004240814,0.0003622763],"about_ca_topic_score_codex":0.000024839292,"about_ca_topic_score_gemma":0.0000035536282,"teacher_disagreement_score":0.045648336,"about_ca_system_score_codex":0.000036707544,"about_ca_system_score_gemma":0.00015021513,"threshold_uncertainty_score":0.99994415},"labels":[],"label_agreement":null},{"id":"W2107264775","doi":"10.1016/j.clinthera.2009.02.021","title":"A framework for planning and critiquing medication compliance and persistence research using prospective study designs","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acadia University; Western University","funders":"","keywords":"Checklist; Medicine; CINAHL; MEDLINE; Research design; Clinical study design; Persistence (discontinuity); Prospective cohort study; Health care; Family medicine; Clinical trial; Psychological intervention; Nursing; Psychology; Surgery","score_opus":0.9158002955140738,"score_gpt":0.6840258787490402,"score_spread":0.23177441676503363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107264775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025674448,0.9669955,0.028417515,0.00031002256,0.00013556135,0.003721942,0.000005704456,0.0000386161,0.00011844293],"genre_scores_gemma":[0.0015777799,0.9668417,0.030021477,0.0006219059,0.000497391,0.00023289073,0.000010367793,0.000039538216,0.00015693618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694264,0.0005489672,0.00093976356,0.00076497765,0.00044932138,0.0003543089],"domain_scores_gemma":[0.9944906,0.003998425,0.00036497044,0.0005059911,0.00038755417,0.00025243356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003131493,0.00027159238,0.0014363843,0.00012049101,0.00031263535,0.000064176405,0.00022228851,0.0004500318,0.000013370992],"category_scores_gemma":[0.0014355032,0.00021882303,0.00015910546,0.00034411263,0.00056802336,0.00005195181,0.00007010229,0.0014372647,0.0000093966455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008524575,0.00042697377,0.002407571,0.003986337,0.00028212272,0.000011425097,0.0005328565,7.0491005e-8,6.267759e-7,0.00064038427,0.000053864314,0.9915725],"study_design_scores_gemma":[0.0039734165,0.00993959,0.0078199785,0.19238745,0.006981487,0.00034594224,0.007537724,0.0041953987,0.0000014632276,0.025063725,0.74045575,0.001298114],"about_ca_topic_score_codex":0.0000011422846,"about_ca_topic_score_gemma":1.6885468e-7,"teacher_disagreement_score":0.9902744,"about_ca_system_score_codex":0.00009085665,"about_ca_system_score_gemma":0.0004559384,"threshold_uncertainty_score":0.8923344},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"theoretical_or_conceptual","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2107506531","doi":"10.1016/s0149-2918(00)83048-9","title":"Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma","year":2000,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; PharmIdeas (Canada); London Health Sciences Centre; University of Toronto","funders":"","keywords":"Brimonidine; Latanoprost; Medicine; Intraocular pressure; Timolol; Randomized controlled trial; Glaucoma; Ophthalmology; Placebo; Dorzolamide; Bimatoprost; Anesthesia; Internal medicine","score_opus":0.17680194669116822,"score_gpt":0.4375386059977292,"score_spread":0.260736659306561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107506531","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034565207,0.9633221,5.881172e-7,0.00019046424,0.0000408291,0.0015934559,0.00009852801,0.000003273259,0.00018555463],"genre_scores_gemma":[0.012607627,0.9869817,0.000011537544,0.00010926189,0.000025746182,0.000038185466,0.000034080997,0.000022732413,0.00016915456],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99624246,0.0015066391,0.001436768,0.0003057163,0.0003605629,0.00014783545],"domain_scores_gemma":[0.9953173,0.0029090801,0.0006694786,0.0010273136,0.000037773618,0.000039046052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097230537,0.0003528031,0.0054976726,0.00013815564,0.000020909456,0.000004312544,0.00028740359,0.00037245412,0.00006129696],"category_scores_gemma":[0.000055573702,0.00012592779,0.0046421667,0.0007548572,0.00046590384,0.00000667474,0.000022107006,0.00035530978,8.4975323e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005374364,0.0019744677,0.026468514,0.006215666,0.33169758,0.000013562688,0.00016116558,0.0000016975644,0.0000018247251,0.00008968615,0.000014034862,0.63282436],"study_design_scores_gemma":[0.0006746109,0.0037460988,0.005928888,0.00047361344,0.58323634,0.000004580258,0.0000057311227,0.00002229246,0.000019262685,0.000011805711,0.4057999,0.00007691005],"about_ca_topic_score_codex":0.000038927927,"about_ca_topic_score_gemma":0.000014915273,"teacher_disagreement_score":0.6327474,"about_ca_system_score_codex":0.000012264594,"about_ca_system_score_gemma":0.000056941397,"threshold_uncertainty_score":0.51351863},"labels":[],"label_agreement":null},{"id":"W2108801909","doi":"10.1016/j.clinthera.2012.03.057","title":"P28—Metabolomic Studies in Fabry Disease","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Metabolomics; Fabry disease; Medicine; Urine; Glycosphingolipid; Biomarker; Disease; Biomarker discovery; Pathology; Internal medicine; Bioinformatics; Biochemistry; Biology; Proteomics","score_opus":0.4551680604342415,"score_gpt":0.5540879189859151,"score_spread":0.09891985855167362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108801909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525825,0.04317432,0.00006439796,0.0022374124,0.00065132306,0.00037713378,0.0000040757777,0.000051170005,0.0008576836],"genre_scores_gemma":[0.986821,0.0073092314,0.00030511257,0.0038860296,0.00057513866,0.000025373885,0.0000060411544,0.000030199291,0.0010418524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981845,0.00024311387,0.0005256802,0.0002317287,0.00031623416,0.0004987548],"domain_scores_gemma":[0.9983826,0.00065076136,0.00005910267,0.00041714357,0.00010046698,0.00038991382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011147851,0.00014546061,0.00046708735,0.00008242795,0.000042433414,0.00000809026,0.00013754165,0.00012686203,0.00010763102],"category_scores_gemma":[0.0009225591,0.00011013328,0.00019354046,0.0002627064,0.0004310374,0.00008912945,0.00011286966,0.00052433397,0.00026202976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000658691,0.001270802,0.94680035,0.000076695105,0.0002445374,0.000047176723,0.00040817115,8.4810944e-7,0.00007537629,0.0004295261,0.00045160527,0.0495362],"study_design_scores_gemma":[0.003202097,0.00024936482,0.9397161,0.00009126152,0.00023470368,0.000008235817,0.0009410141,0.00023722628,0.000060386228,0.0010495093,0.053983912,0.00022620693],"about_ca_topic_score_codex":0.0000031949842,"about_ca_topic_score_gemma":0.0000021758483,"teacher_disagreement_score":0.053532306,"about_ca_system_score_codex":0.0000756414,"about_ca_system_score_gemma":0.00010948368,"threshold_uncertainty_score":0.44911048},"labels":[],"label_agreement":null},{"id":"W2110145837","doi":"10.1016/j.clinthera.2006.11.006","title":"Remission versus response as the goal of therapy in ADHD: A new standard for the field?","year":2006,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Western University","funders":"","keywords":"Medicine; Field (mathematics); Psychotherapist; Clinical psychology","score_opus":0.4098878550077667,"score_gpt":0.5730810218029107,"score_spread":0.16319316679514395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110145837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016928106,0.98943704,0.00047596768,0.005230269,0.00062874693,0.0023013554,0.0000320216,0.000015518583,0.00018629062],"genre_scores_gemma":[0.00047202682,0.99656177,0.0002381986,0.0007183384,0.0003607101,0.000045709527,0.000017170478,0.000057278496,0.0015287787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969763,0.0007834488,0.001331282,0.00030604348,0.0003886349,0.00021426154],"domain_scores_gemma":[0.9656781,0.032384887,0.00078059634,0.00093019166,0.00016706044,0.00005916195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025515608,0.0002830238,0.0016624726,0.00008041117,0.000051286483,0.000011525843,0.00037926305,0.00059040665,0.000098632205],"category_scores_gemma":[0.002697265,0.00013693835,0.0012430314,0.00034982388,0.00021693404,0.000022624017,0.00005635232,0.00090036413,0.0000056677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014626601,0.00025350272,0.00006062454,0.00058315037,0.00043914045,0.0000024263902,0.000068703805,0.0000016006717,0.0000031086865,0.00006316509,0.0017956072,0.9821024],"study_design_scores_gemma":[0.0041202954,0.0027405093,0.000102179285,0.002294279,0.0011013512,0.0000059732433,0.00015850218,0.000020039488,0.000005192842,0.0001375355,0.9891843,0.00012980812],"about_ca_topic_score_codex":0.000027609956,"about_ca_topic_score_gemma":0.000008562191,"teacher_disagreement_score":0.98738873,"about_ca_system_score_codex":0.000050496565,"about_ca_system_score_gemma":0.0013203193,"threshold_uncertainty_score":0.5584184},"labels":[],"label_agreement":null},{"id":"W2111636346","doi":"10.1016/s0149-2918(00)83030-1","title":"Indirect cost of HIV infection in England","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pound Sterling; Medicine; Population; Pound (networking); Economic cost; Public health; Demography; Environmental health; Economics","score_opus":0.135650765985688,"score_gpt":0.46114938000938094,"score_spread":0.32549861402369296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111636346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778974,0.00018830347,0.00015933071,0.0004998897,0.000039802857,0.00024580376,0.000009395847,0.000019986624,0.020940082],"genre_scores_gemma":[0.9837349,0.0034390446,0.00012913428,0.00028669531,0.00013742218,0.000010165318,0.00001862898,0.000010391102,0.012233641],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989529,0.00016905465,0.00046884557,0.000120085875,0.00013696078,0.00015212646],"domain_scores_gemma":[0.99936384,0.00026522425,0.000040450985,0.00018455405,0.00005584717,0.00009010653],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006216568,0.00005943042,0.00024589407,0.000080541155,0.00001746379,0.00000547058,0.00004945044,0.00011157,0.0018433449],"category_scores_gemma":[0.0001772817,0.000047785048,0.0001673423,0.00021487546,0.00012493788,0.00003302757,0.00001026972,0.00034941378,0.0001456274],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025923055,0.00064708176,0.48944306,0.000020468864,0.000062475825,0.0000055557575,0.000092319766,0.0000027241956,0.00009975609,0.000021886526,0.00055104226,0.5087944],"study_design_scores_gemma":[0.0035518908,0.0027957135,0.59051484,0.00017731266,0.000048813137,0.00000892611,0.000011135011,0.0021416359,0.0007045123,0.00023873216,0.39973503,0.00007143326],"about_ca_topic_score_codex":0.00003290653,"about_ca_topic_score_gemma":0.000106817155,"teacher_disagreement_score":0.50872296,"about_ca_system_score_codex":0.000021196174,"about_ca_system_score_gemma":0.00005377814,"threshold_uncertainty_score":0.9990691},"labels":[],"label_agreement":null},{"id":"W2111916107","doi":"10.1016/s0149-2918(04)90179-8","title":"Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Medicine; Propensity score matching; Retrospective cohort study; Internal medicine; ACE inhibitor; Cohort; Medical prescription; Myocardial infarction; Angiotensin-converting enzyme; Cohort study; Population; Incidence (geometry); Blood pressure; Pharmacology","score_opus":0.06700490190089801,"score_gpt":0.31729247042393105,"score_spread":0.250287568523033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111916107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577045,0.0026035148,0.000013413883,0.0001756861,0.00022730081,0.001173656,8.499121e-7,0.000022118405,0.0000129994505],"genre_scores_gemma":[0.9992148,0.000115769755,0.000031581047,0.00048638196,0.00011551768,0.000008912756,0.0000015935711,0.000023362416,0.0000020622317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981439,0.00016404665,0.00050849596,0.0004865743,0.00046265268,0.00023433965],"domain_scores_gemma":[0.9987589,0.0003760421,0.00015089774,0.00039051494,0.00023871582,0.00008489734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085626077,0.0002258051,0.0011546534,0.00005625645,0.00014752777,0.000013680695,0.00004461962,0.00011601989,2.6022138e-7],"category_scores_gemma":[0.00018811028,0.00013685078,0.00015436616,0.00016950861,0.00032394085,0.00004447272,0.00011343105,0.0004925506,3.0304798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045823067,0.0008685787,0.9939867,0.000049729053,0.0032898474,0.00008408055,0.00059237325,0.000019094108,0.000025426078,0.000002986529,0.0000045216952,0.0006183915],"study_design_scores_gemma":[0.007145237,0.0023150702,0.98603225,0.00036424,0.0030548228,0.000015810614,0.00039053315,0.00012535395,0.00039051968,0.000011269712,0.0000036332399,0.00015124874],"about_ca_topic_score_codex":0.00024624594,"about_ca_topic_score_gemma":0.00003987569,"teacher_disagreement_score":0.00795448,"about_ca_system_score_codex":0.000021125805,"about_ca_system_score_gemma":0.000024938478,"threshold_uncertainty_score":0.55806124},"labels":[],"label_agreement":null},{"id":"W2114552474","doi":"10.1016/j.clinthera.2007.05.003","title":"Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors","year":2007,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto; Western University; SickKids Foundation; Hospital for Sick Children","funders":"Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Paroxetine; Medicine; Pregnancy; Confounding; Odds ratio; Obstetrics; Serotonin reuptake inhibitor; Depression (economics); Teratology; Pediatrics; Psychiatry; Gestation; Internal medicine; Antidepressant","score_opus":0.462211290833294,"score_gpt":0.5250928676859848,"score_spread":0.06288157685269086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114552474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004306759,0.99412346,0.0003489148,0.000061302286,0.00024776493,0.00069902634,0.00010503677,0.000017666986,0.000090060545],"genre_scores_gemma":[0.013184935,0.9854465,0.000526915,0.00029888368,0.00008912247,0.000011982226,0.00015298356,0.00001983754,0.00026881386],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997314,0.00027002243,0.0017500198,0.0002676899,0.00021240156,0.00018588886],"domain_scores_gemma":[0.99750704,0.0012199184,0.0007233595,0.00024563886,0.00011833277,0.00018569043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010208525,0.00027875404,0.0030347165,0.00021424964,0.00007927832,0.00002906775,0.00005048458,0.0003899788,0.00012622167],"category_scores_gemma":[0.00009250721,0.00018534665,0.00094654167,0.0002118555,0.00025880252,0.00005289156,0.00004716398,0.00043379224,0.000003324718],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040498652,0.0006395405,0.011117389,0.1164277,0.4490272,0.00008540339,0.00038536504,8.095764e-7,8.955313e-7,0.0015628659,0.000012398946,0.42033544],"study_design_scores_gemma":[0.0007699328,0.00055362476,0.0018630115,0.0025355215,0.8145972,0.00015298143,0.000050429517,0.00006670501,0.0000144195765,0.00009168674,0.17896283,0.00034164588],"about_ca_topic_score_codex":0.000012988458,"about_ca_topic_score_gemma":0.000005432679,"teacher_disagreement_score":0.4199938,"about_ca_system_score_codex":0.000015696352,"about_ca_system_score_gemma":0.00009458095,"threshold_uncertainty_score":0.7558217},"labels":[],"label_agreement":null},{"id":"W2115190836","doi":"10.1016/s0149-2918(00)89086-4","title":"Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seneca Polytechnic; University of Toronto","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Medicine; Stimulant; Impulsivity; Dextroamphetamine; Modafinil; Psychiatry; Amphetamine; Attention deficit; Pediatrics; Internal medicine","score_opus":0.16407610934884218,"score_gpt":0.4647215245034929,"score_spread":0.3006454151546507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115190836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222263,0.0011608509,0.07031252,0.00381534,0.000437268,0.0011696748,0.000045664598,0.0002386249,0.0005937346],"genre_scores_gemma":[0.98891675,0.0035600404,0.0018268119,0.0020268257,0.0004305816,0.00017923015,0.00016943963,0.00008687027,0.0028034218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997184,0.0002407857,0.00094564684,0.00070056686,0.0004161383,0.0005128842],"domain_scores_gemma":[0.9968753,0.0014285466,0.00034649632,0.00071590126,0.00041110456,0.0002226698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071511156,0.00035165367,0.000995375,0.0002739648,0.00026241323,0.000067196816,0.00019176737,0.00029828842,0.0008245699],"category_scores_gemma":[0.00025987322,0.00031438313,0.0014330911,0.0010994857,0.00022605955,0.0002286534,0.000044639022,0.0005393097,0.00012399004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008130989,0.0026211948,0.9156536,0.000023519033,0.0040414934,0.000011428559,0.000035706715,0.00009027173,0.0016221141,0.0000980257,0.00007147842,0.07491807],"study_design_scores_gemma":[0.008252475,0.0005543956,0.8085689,0.000029471967,0.0077532083,0.000043994693,0.0013428114,0.015935045,0.00002205829,0.0001123005,0.15676594,0.00061943266],"about_ca_topic_score_codex":0.000018130317,"about_ca_topic_score_gemma":0.000043163825,"teacher_disagreement_score":0.15669446,"about_ca_system_score_codex":0.00006348855,"about_ca_system_score_gemma":0.000092191854,"threshold_uncertainty_score":0.9999308},"labels":[],"label_agreement":null},{"id":"W2115323541","doi":"10.1016/j.clinthera.2011.05.057","title":"Does Impaired Cellular and Pulmonary Respiration Lead to Decreased Activity Tolerance in a Patient with Late-Onset Pompe Disease? — Application of the Ventilatory Threshold","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Glycogen Storage Diseases and Myoclonus","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Anaerobic exercise; Glycogen; Respiration; Internal medicine; Atrophy; Cardiology; Aerobic capacity; Myopathy; Athletes; Ventilation (architecture); Work rate; Endurance training; Physical therapy; Heart rate","score_opus":0.05105243208784062,"score_gpt":0.3087178747554974,"score_spread":0.2576654426676568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115323541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981386,0.00034309982,0.00021582787,0.00026771138,0.00007686648,0.0008737206,0.000020865811,0.000018256447,0.000045041],"genre_scores_gemma":[0.9983908,0.000044929773,0.0001573286,0.0012670748,0.000036246656,0.000054543383,0.000007517013,0.000017637154,0.000023933833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896777,0.00006847858,0.0003367895,0.0002851472,0.00019569106,0.00014613818],"domain_scores_gemma":[0.99904644,0.00005192538,0.0001498515,0.00049182895,0.00007773436,0.00018220859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019680125,0.00012474622,0.00024745392,0.000034053057,0.00004271298,0.0000054107977,0.000087250555,0.000068082656,0.0000068749223],"category_scores_gemma":[0.000024681416,0.00006695545,0.0001036604,0.00016270565,0.00014917405,0.00004284728,0.00004230075,0.00015129343,0.0000018581856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007639801,0.0014091232,0.9630907,0.000077963894,0.000055362812,0.0001631856,0.00023685544,0.000015428725,0.005935974,0.000027847535,0.0000051980323,0.021342514],"study_design_scores_gemma":[0.0008387516,0.00048769146,0.9895078,0.00012850422,0.00019192297,0.0000066070593,0.000044649598,0.003516265,0.004336475,0.00025545593,0.00056792016,0.000117957235],"about_ca_topic_score_codex":0.000040870982,"about_ca_topic_score_gemma":0.000024997315,"teacher_disagreement_score":0.026417056,"about_ca_system_score_codex":0.000023956369,"about_ca_system_score_gemma":0.000105920924,"threshold_uncertainty_score":0.2730364},"labels":[],"label_agreement":null},{"id":"W2115443135","doi":"10.1016/j.clinthera.2007.05.020","title":"Analyzing international prescribing patterns and medication use: An approach to assisting in the improvement of health care quality and patient outcomes","year":2007,"lang":"en","type":"editorial","venue":"Clinical Therapeutics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Quality management; Quality (philosophy); Health care; Medication adherence; Intensive care medicine; Family medicine; Emergency medicine; Internal medicine; Operations management","score_opus":0.41461194835279486,"score_gpt":0.5599310915030772,"score_spread":0.14531914315028233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115443135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.831649,0.0015950149,0.0027851777,0.006003577,0.15512559,0.0023152588,0.00026143304,0.00003648084,0.00022843918],"genre_scores_gemma":[0.9547117,0.0017827365,0.0024785555,0.010444808,0.029931637,0.000031812742,0.0005688405,0.000040549312,0.0000093927465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600524,0.0005968933,0.0017048424,0.00047722054,0.0009682607,0.00024752974],"domain_scores_gemma":[0.99308944,0.0052364143,0.0008613543,0.0003833002,0.0002444128,0.00018506113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004390202,0.0002248191,0.0007411339,0.00012062806,0.00006652088,0.00005882481,0.00020021347,0.00033103288,0.000002602937],"category_scores_gemma":[0.0023877162,0.00014917307,0.000107408814,0.000099454875,0.00012379147,0.000117650234,0.00014045878,0.0012030558,1.8234213e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034788487,0.00078296766,0.6832674,0.000500619,0.00029879488,0.0000018509114,0.005215829,0.0000023170128,0.000004456556,0.00003698752,0.0012691857,0.30827168],"study_design_scores_gemma":[0.003197844,0.0018736447,0.77786666,0.0005917492,0.0004526267,0.0000018038984,0.010195163,0.00078444346,0.00000842621,0.000029290028,0.20461929,0.00037907143],"about_ca_topic_score_codex":0.00035058503,"about_ca_topic_score_gemma":0.000041648822,"teacher_disagreement_score":0.30789262,"about_ca_system_score_codex":0.00011085145,"about_ca_system_score_gemma":0.00015785806,"threshold_uncertainty_score":0.6083101},"labels":[],"label_agreement":null},{"id":"W2120078448","doi":"10.1016/j.clinthera.2008.06.004","title":"A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in Southwestern Ontario, Canada","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Dyslipidemia; Medical record; Retrospective cohort study; Cohort; Population; Demographics; Disease; Internal medicine; Pediatrics; Demography; Environmental health","score_opus":0.1399332306864444,"score_gpt":0.3298713519038186,"score_spread":0.18993812121737422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120078448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951965,0.0039639687,7.1666074e-7,0.0005577352,0.00005514251,0.00014804874,0.000010891231,0.0000023631685,0.00006459541],"genre_scores_gemma":[0.9952076,0.0033624603,0.00005453984,0.0010166835,0.000017785955,0.000001994274,7.1366355e-7,0.0000042018237,0.00033402952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911803,0.00006872223,0.00040192637,0.00017764357,0.00014960422,0.00008410114],"domain_scores_gemma":[0.9991791,0.00031120566,0.00012524876,0.00023822405,0.00010491755,0.000041297142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012562332,0.000087025786,0.0007619964,0.000037618196,0.000035825527,9.252027e-7,0.000032493615,0.00007073533,0.00000982372],"category_scores_gemma":[0.000041851374,0.00004852659,0.00010061135,0.00018079938,0.00026641818,0.000009966073,0.000035210254,0.00010528083,4.2114262e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010329883,0.00016446326,0.996288,0.000015210829,0.0014828594,0.000011248222,0.00069008674,0.0000010949616,0.000093095354,0.000005189397,0.00002822716,0.0011171992],"study_design_scores_gemma":[0.0011009425,0.0003416945,0.992347,0.000041457566,0.004954574,0.000010400485,0.00006264243,0.00013484244,0.00006589045,0.000012593356,0.0008843353,0.000043651467],"about_ca_topic_score_codex":0.23151688,"about_ca_topic_score_gemma":0.7503414,"teacher_disagreement_score":0.5188245,"about_ca_system_score_codex":0.000028602677,"about_ca_system_score_gemma":0.00019475736,"threshold_uncertainty_score":0.7736005},"labels":[],"label_agreement":null},{"id":"W2121182609","doi":"10.1016/j.clinthera.2004.12.001","title":"Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Advanced Drug Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Generex Biotechnology (Canada)","funders":"Hebrew University of Jerusalem","keywords":"Medicine; Insulin; Pharmacokinetics; Pharmacodynamics; Cmax; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.31633814838680685,"score_gpt":0.5086585486587283,"score_spread":0.19232040027192143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121182609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845918,0.011518998,0.0012974273,0.00028928265,0.0007456085,0.001442755,0.000021700958,0.00005420996,0.00003824412],"genre_scores_gemma":[0.99446756,0.0035938818,0.0008855384,0.00084995816,0.000112795984,0.000031912157,0.0000040832074,0.00004622482,0.000008026217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957989,0.0014860937,0.0016609832,0.00043433177,0.00020734507,0.00041236964],"domain_scores_gemma":[0.9978414,0.0008557397,0.00074417767,0.00024917777,0.00016762446,0.00014185232],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018058821,0.00032357918,0.0008267844,0.00018227378,0.00014410676,0.000011837058,0.0002669161,0.00047821464,0.000010036586],"category_scores_gemma":[0.0001253044,0.00025858625,0.00009863028,0.00046610885,0.0012138444,0.00012028805,0.0001378624,0.0014131311,0.0000017202784],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010012543,0.0020357042,0.03623441,0.0004136543,0.0002498873,0.00002432115,0.0026614212,0.020732911,0.85248387,0.00008452161,0.0000024070391,0.07506437],"study_design_scores_gemma":[0.030925112,0.010709982,0.0039314083,0.0009295645,0.0013758291,0.0010439666,0.0031519488,0.16581447,0.77209187,0.0017354521,0.0067309397,0.0015594347],"about_ca_topic_score_codex":0.00007324558,"about_ca_topic_score_gemma":0.00006424627,"teacher_disagreement_score":0.14508156,"about_ca_system_score_codex":0.00014335783,"about_ca_system_score_gemma":0.0001885898,"threshold_uncertainty_score":0.99998665},"labels":[],"label_agreement":null},{"id":"W2123917199","doi":"10.1016/j.clinthera.2009.08.016","title":"Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: A 12-week, randomized, double-blind, placebo-controlled, exploratory study","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; St Mary's Hospital; McMaster University","funders":"","keywords":"Medicine; Tolerability; Placebo; Internal medicine; Adverse effect; Osteoporosis; Discontinuation; Alendronic acid; Bisphosphonate; Gastroenterology","score_opus":0.12602852028918107,"score_gpt":0.4143170142848349,"score_spread":0.2882884939956538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123917199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823005,0.0007306043,0.000068898844,0.002915627,0.00020278328,0.0066702706,0.0000102407685,0.00007332579,0.0010982191],"genre_scores_gemma":[0.9946144,0.0003031288,0.0007105232,0.002811143,0.00023872295,0.0005113885,0.000014095132,0.000046020916,0.0007505684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9917754,0.0020645442,0.003257535,0.0008492149,0.00091835216,0.0011349824],"domain_scores_gemma":[0.9942771,0.0029007366,0.00059640827,0.0009898485,0.00051148195,0.0007244186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0106216725,0.00046967473,0.0030822367,0.00028304756,0.00010915392,0.0000410431,0.0003777733,0.00027059126,0.0002703401],"category_scores_gemma":[0.0009835629,0.00035867133,0.00043743043,0.00042863714,0.00061088364,0.00016835047,0.00010876164,0.0015701026,0.000071282564],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9493966,0.010549363,0.030691313,0.00008955043,0.00022042319,0.00010755426,0.0012957547,0.00001993206,0.00071419624,0.000038567807,0.000039237377,0.0068374765],"study_design_scores_gemma":[0.95594764,0.02056611,0.017391512,0.00021010089,0.00025245902,0.000040257128,0.0021071273,0.002212092,0.00012204937,0.00048297655,0.0003328419,0.00033482382],"about_ca_topic_score_codex":0.000031275602,"about_ca_topic_score_gemma":0.00004696898,"teacher_disagreement_score":0.0132997995,"about_ca_system_score_codex":0.0002595865,"about_ca_system_score_gemma":0.00091775233,"threshold_uncertainty_score":0.9998865},"labels":[],"label_agreement":null},{"id":"W2124890015","doi":"10.1016/s0149-2918(03)80080-2","title":"Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made?","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Medicine; European union; Agency (philosophy); Drug approval; Family medicine; International trade; Drug; Business; Pharmacology","score_opus":0.1803435469890641,"score_gpt":0.38183239178521533,"score_spread":0.20148884479615123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124890015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7914912,0.1870734,0.00019889287,0.008586602,0.00061681005,0.00063815503,0.00052277127,0.000009652995,0.010862529],"genre_scores_gemma":[0.88058525,0.097553864,0.0032831596,0.018187325,0.00011810451,0.000007844943,0.0000114689665,0.00003478904,0.00021820578],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775165,0.000046964313,0.0015910737,0.00031927926,0.0000343326,0.0002566964],"domain_scores_gemma":[0.99873954,0.00029120332,0.0005230778,0.00029983246,0.000026329199,0.0001200074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069903955,0.00014743261,0.00091674237,0.000033392036,0.000016053902,0.000009106845,0.00021510111,0.00010852307,0.00034808353],"category_scores_gemma":[0.000095841395,0.00015686233,0.00011039735,0.00017473237,0.00013291491,0.00007095188,0.000047159487,0.00024308193,0.000011331871],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007758935,0.00047592015,0.8287239,0.0008628035,0.00059891504,0.000002836274,0.0009558712,0.000015374988,0.0000075927296,0.09647108,0.007618804,0.06418928],"study_design_scores_gemma":[0.0032284425,0.00012169344,0.034237586,0.0004246807,0.0001722513,0.0000020969965,0.00008896679,0.0039552376,0.00057017035,0.20914198,0.74737567,0.0006811948],"about_ca_topic_score_codex":0.0831066,"about_ca_topic_score_gemma":0.007247969,"teacher_disagreement_score":0.79448634,"about_ca_system_score_codex":0.00006723367,"about_ca_system_score_gemma":0.00037032686,"threshold_uncertainty_score":0.9229991},"labels":[],"label_agreement":null},{"id":"W2125923881","doi":"10.1016/s0149-2918(07)80089-0","title":"A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Pfizer (Canada); Université de Montréal","funders":"","keywords":"Atorvastatin; Medicine; Simvastatin; Statin; Dosing; Cohort; Internal medicine; Population; Cost effectiveness; Pharmacology; Cholesterol; Environmental health","score_opus":0.12112275625688401,"score_gpt":0.42868644523898336,"score_spread":0.30756368898209935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125923881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9053203,0.00051125616,0.09123107,0.00039795175,0.00009356863,0.0023603803,0.000013393261,0.000013041567,0.000059060818],"genre_scores_gemma":[0.9937682,0.000113370486,0.00442348,0.0014580985,0.0001287891,0.000053819946,0.00000930904,0.000033382516,0.000011536772],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99795777,0.00037884587,0.00068255037,0.0003077446,0.00024878982,0.00042429983],"domain_scores_gemma":[0.99770194,0.0012874566,0.00015754729,0.00041399235,0.00017970506,0.00025938434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00987561,0.00016207129,0.00059701095,0.00008517343,0.00012054537,0.00002610139,0.00009747067,0.0001943214,0.0000013508628],"category_scores_gemma":[0.00041407047,0.00011683138,0.00021805782,0.0001695097,0.00018820868,0.00006301926,0.000033368524,0.0004609588,5.311867e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061160506,0.00029594457,0.11939971,0.00084584224,0.00027414566,0.00002283594,0.0007067739,0.00030276255,0.0018216042,0.00025960445,0.0000038132353,0.8754554],"study_design_scores_gemma":[0.003990347,0.0002899716,0.93981653,0.00058490166,0.00016282192,0.000016916836,0.00032223732,0.051935665,0.0016433251,0.0005693569,0.0004855186,0.00018237683],"about_ca_topic_score_codex":0.00568983,"about_ca_topic_score_gemma":0.019065754,"teacher_disagreement_score":0.875273,"about_ca_system_score_codex":0.000120346944,"about_ca_system_score_gemma":0.00050759484,"threshold_uncertainty_score":0.9988337},"labels":[],"label_agreement":null},{"id":"W2128332307","doi":"10.1016/j.clinthera.2015.06.010","title":"“I Do My Best To Listen to Patients”: Qualitative Insights Into DAWN2 (Diabetes Psychosocial Care From the Perspective of Health Care Professionals in the Second Diabetes Attitudes, Wishes and Needs Study)","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Education","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health; Dalhousie University","funders":"Otsuka Pharmaceutical; Novo Nordisk; Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psychosocial; Medicine; Nursing; Qualitative research; Health care; Diabetes management; Health professionals; Family medicine; Medical education; Diabetes mellitus; Type 2 diabetes; Psychiatry","score_opus":0.1470765174994581,"score_gpt":0.49216777344993834,"score_spread":0.34509125595048024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128332307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97980034,0.005240488,0.0000014994599,0.011453614,0.0005363549,0.0022305034,0.000028102846,0.00001246307,0.0006966268],"genre_scores_gemma":[0.9862113,0.000024289273,0.00021032784,0.01294538,0.000327032,0.00012274267,0.000060727885,0.000021436723,0.00007678809],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99702865,0.0012418885,0.0006787483,0.0003549943,0.00044255136,0.00025318944],"domain_scores_gemma":[0.9970741,0.0014886874,0.00021761435,0.00042982222,0.0006315489,0.00015821359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013862294,0.0001941281,0.0005384004,0.000105050094,0.0001360267,0.00005410457,0.00030005228,0.00009643771,0.00001199389],"category_scores_gemma":[0.00047946748,0.00011316514,0.000081685204,0.0004951856,0.00017942,0.00008444011,0.0001344341,0.0003138517,0.0000097556185],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059893362,0.0008754795,0.49471247,0.00004373985,0.00015127262,8.8364736e-8,0.49399123,2.9006037e-7,0.0000012386699,0.00014113089,0.0010830039,0.00894016],"study_design_scores_gemma":[0.0010929982,0.0022718532,0.4114009,0.00016391155,0.000088309396,3.076265e-9,0.5799744,0.0000011664805,0.0000055828527,0.00067872833,0.0042295516,0.00009258266],"about_ca_topic_score_codex":0.0001643822,"about_ca_topic_score_gemma":0.0006975914,"teacher_disagreement_score":0.08598318,"about_ca_system_score_codex":0.00016886444,"about_ca_system_score_gemma":0.00021849008,"threshold_uncertainty_score":0.46147403},"labels":[],"label_agreement":null},{"id":"W2128662046","doi":"10.1016/j.clinthera.2012.10.007","title":"Comparative Effectiveness of Tiotropium and Ipratropium in Prevention of Hospital Readmission for COPD: A Population-Based Cohort Study","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of British Columbia","funders":"University of British Columbia","keywords":"Medicine; Ipratropium bromide; COPD; Ipratropium; Tiotropium bromide; Population; Cohort; Internal medicine; Logistic regression; Emergency medicine; Physical therapy; Bronchodilator; Asthma; Environmental health","score_opus":0.06751737707858567,"score_gpt":0.43483446403829884,"score_spread":0.36731708695971316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128662046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931374,0.0002519871,0.00062038493,0.0001141413,0.000125781,0.0056696585,0.00001815279,0.000011651874,0.00005084833],"genre_scores_gemma":[0.9989496,0.000026933667,0.00060371007,0.00002147777,0.00005029164,0.00022242288,0.000067683926,0.00001786155,0.000040041148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.000582472,0.0006977729,0.00033021191,0.00029235706,0.00017253857],"domain_scores_gemma":[0.99749655,0.001433488,0.00023324009,0.0002948381,0.0004238922,0.00011800606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000804717,0.00013928284,0.00073776377,0.00009795718,0.000029929251,0.0000074562195,0.00007849652,0.000120684956,0.000039828257],"category_scores_gemma":[0.00021657627,0.00011549651,0.00014714067,0.00018268282,0.00019251723,0.00007274338,0.000037856338,0.0001977553,0.0000017104848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013698047,0.0036652433,0.9897955,0.00053371006,0.00021266071,0.000001415134,0.00007302422,0.000022567907,0.0007478527,0.00007261046,0.0000075540056,0.0034980795],"study_design_scores_gemma":[0.0056166523,0.003831084,0.9827107,0.0002619296,0.00019894185,3.4515236e-7,0.00025753965,0.005510226,0.0005944768,0.000904647,0.000015992777,0.000097417134],"about_ca_topic_score_codex":0.0001266172,"about_ca_topic_score_gemma":0.00000983156,"teacher_disagreement_score":0.0070847287,"about_ca_system_score_codex":0.0001093783,"about_ca_system_score_gemma":0.00022683943,"threshold_uncertainty_score":0.4709811},"labels":[],"label_agreement":null},{"id":"W2129352405","doi":"10.1016/j.clinthera.2011.02.009","title":"Time Series Evaluation of an Intervention to Increase Statin Tablet Splitting by General Practitioners","year":2011,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria","funders":"National Institute on Aging; Canadian Institutes of Health Research; Agency for Healthcare Research and Quality","keywords":"Medicine; Statin; Series (stratigraphy); Intervention (counseling); Family medicine; Internal medicine; Nursing","score_opus":0.31847013350256037,"score_gpt":0.5199426217586675,"score_spread":0.20147248825610709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129352405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187475,0.00037220004,0.00040663834,0.0011609924,0.00017038322,0.00043733648,0.000033307573,0.000033187884,0.005511204],"genre_scores_gemma":[0.9742701,0.00044737716,0.019229738,0.0046686567,0.00028965008,0.000037707065,0.00012363182,0.000029745665,0.00090337306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979416,0.0006713289,0.00063110085,0.00021932354,0.00036685923,0.00016974976],"domain_scores_gemma":[0.998621,0.00032365834,0.00028363147,0.00020653049,0.00037542725,0.00018974631],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003926884,0.000108686814,0.00027951962,0.000028617622,0.00006408898,0.000012377881,0.000077526245,0.000086180145,0.0010857497],"category_scores_gemma":[0.0008942413,0.00009070175,0.00010115851,0.00013049434,0.00012850606,0.00025764576,0.000050287952,0.00022282165,0.000048487287],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008631273,0.005732142,0.013669497,0.00014996614,0.0014420899,0.000012009086,0.0022302915,0.000025193163,0.018116577,0.0005392791,0.0038412767,0.9456104],"study_design_scores_gemma":[0.025886703,0.02528882,0.13598996,0.00065858586,0.012012984,0.0000956967,0.0071517187,0.08566537,0.059008908,0.008708245,0.6379276,0.0016054143],"about_ca_topic_score_codex":0.000095468225,"about_ca_topic_score_gemma":0.0000073274778,"teacher_disagreement_score":0.944005,"about_ca_system_score_codex":0.000038194587,"about_ca_system_score_gemma":0.00005597277,"threshold_uncertainty_score":0.9998274},"labels":[],"label_agreement":null},{"id":"W2130331850","doi":"10.1016/j.clinthera.2015.05.495","title":"Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing","year":2015,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Children's & Women's Health Centre of British Columbia","funders":"World Health Organization","keywords":"Medicine; Dosing; Pharmacokinetics; Warfarin; Pharmacodynamics; Overweight; Population; Vancomycin; Therapeutic drug monitoring; Obesity; Intensive care medicine; Pediatrics; Pharmacology; Internal medicine","score_opus":0.5346818210259923,"score_gpt":0.5971420242447313,"score_spread":0.06246020321873902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130331850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029034922,0.99446845,0.00019325402,0.002176257,0.0006190868,0.0016195131,0.00012113257,0.00006522866,0.0007080378],"genre_scores_gemma":[0.000016204549,0.9927285,0.001618725,0.0025060931,0.0025733132,0.000100701014,0.00006605159,0.00007190149,0.00031856433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976843,0.00023315268,0.0010813762,0.0004922053,0.00015937287,0.00034957964],"domain_scores_gemma":[0.99434173,0.0041469242,0.00048757633,0.00036498412,0.00025000825,0.00040876932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014875829,0.00036345527,0.0018727956,0.00006550576,0.00016203825,0.000051513012,0.00018256727,0.00033713496,0.000014664159],"category_scores_gemma":[0.00033012862,0.00026174524,0.0005525932,0.00026754092,0.0001742346,0.000045728615,0.0001633066,0.0008795841,0.000023185086],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003745689,0.00028863907,0.00069818523,0.005639354,0.00057216355,0.0000019204192,0.000015217308,2.5212131e-8,7.0449595e-8,0.00013590387,0.003977276,0.9886338],"study_design_scores_gemma":[0.0010479155,0.00017742292,0.00011405574,0.0004576221,0.018986044,0.00003617521,0.000006910945,0.000032579635,1.12578604e-7,0.00053170096,0.9783417,0.00026774756],"about_ca_topic_score_codex":7.3453515e-7,"about_ca_topic_score_gemma":3.0757363e-7,"teacher_disagreement_score":0.98836607,"about_ca_system_score_codex":0.00005702059,"about_ca_system_score_gemma":0.00031402378,"threshold_uncertainty_score":0.9999835},"labels":[],"label_agreement":null},{"id":"W2130684080","doi":"10.1016/j.clinthera.2012.09.007","title":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Memorial Hospital","funders":"","keywords":"Exenatide; Medicine; Metformin; Pioglitazone; Internal medicine; Glycemic; Sitagliptin; Type 2 diabetes; Type 2 Diabetes Mellitus; Rosiglitazone; Thiazolidinedione; Population; Diabetes mellitus; Adverse effect; Endocrinology; Insulin","score_opus":0.05035296391707674,"score_gpt":0.3298384970012453,"score_spread":0.27948553308416857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130684080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780065,0.00030289261,0.00008938517,0.00015868006,0.000045414083,0.001382947,0.000007657882,0.000021438416,0.00019095748],"genre_scores_gemma":[0.9940253,0.000291255,0.0048527825,0.00032453495,0.000025849293,0.00005344601,0.00011868566,0.0000326691,0.00027550824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987096,0.000059557446,0.00048508658,0.00019158855,0.00024728331,0.0003068637],"domain_scores_gemma":[0.9989197,0.00043246162,0.00019511768,0.00023062127,0.00014139882,0.00008067711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051977613,0.00016345899,0.00054879737,0.000121163604,0.000016279426,0.000005937235,0.000067230474,0.000085617976,0.000012160059],"category_scores_gemma":[0.000049704813,0.00009321,0.000038604354,0.00043983114,0.000108251545,0.00012925886,0.00001776358,0.00012353389,0.000002365397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008600409,0.0034410716,0.94223326,0.000068822505,0.00043825188,0.0000032192652,0.00016117387,0.000008536931,0.000007964693,0.00017880533,0.000016406735,0.04484209],"study_design_scores_gemma":[0.02630255,0.012819824,0.95628285,0.00040873076,0.0005684901,2.274309e-7,0.0001068523,0.0002157972,0.0005654759,0.000039652306,0.0025160054,0.00017354541],"about_ca_topic_score_codex":0.000008205687,"about_ca_topic_score_gemma":0.00003430703,"teacher_disagreement_score":0.044668544,"about_ca_system_score_codex":0.00007991735,"about_ca_system_score_gemma":0.00005308995,"threshold_uncertainty_score":0.38009936},"labels":[],"label_agreement":null},{"id":"W2131678577","doi":"10.1016/j.clinthera.2014.02.009","title":"Onset of Response with Duloxetine Treatment in Patients with Osteoarthritis Knee Pain and Chronic Low Back Pain: A Post Hoc Analysis of Placebo-Controlled Trials","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Musculoskeletal pain and rehabilitation","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Fraser Health","funders":"Eli Lilly and Company","keywords":"Duloxetine; Medicine; Osteoarthritis; Placebo; Post-hoc analysis; Chronic pain; Physical therapy; Fibromyalgia; Tramadol; Brief Pain Inventory; Analgesic; Anesthesia; Internal medicine","score_opus":0.024070211407574166,"score_gpt":0.3298004672056637,"score_spread":0.30573025579808955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131678577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964028,0.0003861235,0.00032991325,0.00073203724,0.000024408013,0.0020567449,0.00003552848,0.000009777907,0.00002264148],"genre_scores_gemma":[0.9983795,0.00011048071,0.0007849644,0.0004472629,0.000036298166,0.000052758867,0.00008239048,0.000021180955,0.00008515684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904806,0.007239914,0.0014900817,0.0003107549,0.00028964668,0.00018902263],"domain_scores_gemma":[0.97933906,0.019234389,0.0006130393,0.0004322951,0.00026229766,0.000118922835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014887401,0.000218345,0.002344164,0.00027982218,0.00002204281,0.000006995639,0.000048522044,0.00017042854,0.00006896588],"category_scores_gemma":[0.0042350935,0.00011923342,0.00044717055,0.0004567779,0.00038379987,0.000025467563,0.000011127273,0.00013611547,0.0000012734206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32538557,0.0020067133,0.50966465,0.00033079679,0.0031632162,0.0000019990807,0.00034068184,0.000081227285,0.00025835674,0.000007425686,0.000003860199,0.15875551],"study_design_scores_gemma":[0.108559966,0.11440403,0.7699364,0.0006188923,0.0020041782,2.7680173e-7,0.00014167024,0.0039624195,0.000030674604,0.000012119426,0.00017607397,0.000153307],"about_ca_topic_score_codex":0.000012361667,"about_ca_topic_score_gemma":0.00017786337,"teacher_disagreement_score":0.26027176,"about_ca_system_score_codex":0.000065528795,"about_ca_system_score_gemma":0.00017768767,"threshold_uncertainty_score":0.5159706},"labels":[],"label_agreement":null},{"id":"W2131931738","doi":"10.1016/j.clinthera.2006.09.021","title":"Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization","year":2006,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Persistence (discontinuity); Medicine; Medical prescription; Terminology; MEDLINE; Ranking (information retrieval); Intensive care medicine; Pharmacology; Information retrieval; Computer science","score_opus":0.9320255751568463,"score_gpt":0.5942286578077858,"score_spread":0.3377969173490605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131931738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010949979,0.9831338,0.013484124,0.000066265675,0.00004452115,0.0015268578,0.00028554245,0.0001009345,0.00026295075],"genre_scores_gemma":[0.0016670134,0.96221906,0.03576398,0.00007736729,0.00005946412,0.000067121255,0.00005520157,0.00007950234,0.000011272196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99577975,0.0012131281,0.0011138794,0.0006353129,0.00097093673,0.00028700044],"domain_scores_gemma":[0.99173105,0.0058638765,0.00068167236,0.0005418019,0.0010972068,0.00008439696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002683847,0.00040978676,0.0017479501,0.00016014128,0.000103843086,0.000056592613,0.00021372936,0.00035438832,0.000008217701],"category_scores_gemma":[0.0005977614,0.00027503815,0.00015207683,0.00026764712,0.0008247433,0.00007065561,0.00008349863,0.0007766195,0.000001018718],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020445616,0.0002276804,0.00005229759,0.0020457942,0.0003065183,0.000007051502,0.00025854568,1.416237e-7,0.0000033030205,0.0071070236,0.0001355638,0.9896516],"study_design_scores_gemma":[0.0019392448,0.00499556,0.00012952376,0.034298494,0.0016396386,0.000016796846,0.0013355021,0.000037405734,0.00025741008,0.3115118,0.6426866,0.0011519816],"about_ca_topic_score_codex":0.000024897712,"about_ca_topic_score_gemma":0.000024040019,"teacher_disagreement_score":0.98849964,"about_ca_system_score_codex":0.000113042675,"about_ca_system_score_gemma":0.00029214527,"threshold_uncertainty_score":0.9999702},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2133494155","doi":"10.1016/j.clinthera.2010.01.006","title":"Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeurAxon (Canada)","funders":"","keywords":"Medicine; Tolerability; Placebo; Pharmacokinetics; Blood pressure; Orthostatic vital signs; Creatine kinase; Internal medicine; Pharmacology; Adverse effect; Gastroenterology; Pathology","score_opus":0.17024440998261145,"score_gpt":0.47557819310356375,"score_spread":0.3053337831209523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133494155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268205,0.0122269,0.0000374351,0.0035795819,0.00014353196,0.0011514805,0.000015915068,0.000015995682,0.00014708252],"genre_scores_gemma":[0.9516966,0.04360248,0.001460827,0.0027891109,0.00018037838,0.000041258496,0.000006518005,0.000020931873,0.000201944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977381,0.0001839281,0.0012651468,0.00034778463,0.00017108116,0.00029391615],"domain_scores_gemma":[0.9967694,0.0024701862,0.00018149271,0.00021957334,0.0002269288,0.0001324117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001273939,0.00023241439,0.0013917596,0.00013071709,0.00004094375,0.0000073804513,0.0000629665,0.00019379845,0.000014881011],"category_scores_gemma":[0.0007842077,0.00017129327,0.00015232984,0.00016756998,0.0012662271,0.000047030233,0.00009549938,0.00070990634,0.0000013618651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86220676,0.002599639,0.11806388,0.0004425491,0.000731065,0.000038221744,0.007911592,0.0000063656207,0.0004668851,0.00014114121,0.00018309051,0.007208783],"study_design_scores_gemma":[0.9732587,0.0019621474,0.010731064,0.0003122889,0.00060473895,0.000016337734,0.0030670364,0.0033967623,0.000185639,0.00034797983,0.0058169663,0.00030035572],"about_ca_topic_score_codex":0.0000898526,"about_ca_topic_score_gemma":0.0014149089,"teacher_disagreement_score":0.1110519,"about_ca_system_score_codex":0.00001818632,"about_ca_system_score_gemma":0.00005440707,"threshold_uncertainty_score":0.6985137},"labels":[],"label_agreement":null},{"id":"W2136589123","doi":"10.1016/j.clinthera.2012.06.007","title":"Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada, Italy, Sweden, and Switzerland","year":2012,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Sanofi","keywords":"Medicine; Dronedarone; Atrial fibrillation; Cardiology; Internal medicine; Amiodarone","score_opus":0.29979429542113706,"score_gpt":0.46790663045306075,"score_spread":0.1681123350319237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136589123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271816,0.00155445,0.00063819287,0.0018603215,0.00093669357,0.0016651412,0.00003760729,0.000015475576,0.0005739505],"genre_scores_gemma":[0.9971802,0.00027226954,0.0005073336,0.0001237745,0.0015823385,0.0000016912265,0.000046338406,0.000012830385,0.0002731955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868673,0.00013950659,0.0006562807,0.00015919161,0.00016463097,0.00019365895],"domain_scores_gemma":[0.9965127,0.0029744122,0.00017109764,0.00016908537,0.00007519433,0.00009748969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016585407,0.000104392646,0.00046172616,0.000045270855,0.00003062433,0.000006410053,0.00003632116,0.00011599743,0.0000052539526],"category_scores_gemma":[0.0004948333,0.000085990636,0.00014235894,0.00011825881,0.00006926427,0.00006190444,0.000030816056,0.00008269858,9.097664e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00537119,0.000010300501,0.9730586,0.00011534033,0.00017438518,7.556958e-7,0.000050503102,0.000057977923,0.00006401804,0.00063037325,0.00012767878,0.020338884],"study_design_scores_gemma":[0.009664045,0.00033699628,0.896409,0.00006495509,0.00022315019,0.0000018888496,0.000054868015,0.00059682154,0.00016995147,0.00020894392,0.092156775,0.00011260512],"about_ca_topic_score_codex":0.0011813123,"about_ca_topic_score_gemma":0.0027488635,"teacher_disagreement_score":0.0920291,"about_ca_system_score_codex":0.00005631105,"about_ca_system_score_gemma":0.00013789853,"threshold_uncertainty_score":0.35065964},"labels":[],"label_agreement":null},{"id":"W2137023766","doi":"10.1016/j.clinthera.2014.10.008","title":"Critical Appraisal of the SHARP Trial: The Results May Be Dull","year":2014,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; Vancouver General Hospital","funders":"","keywords":"Medicine; Ezetimibe; Kidney disease; Critical appraisal; Context (archaeology); Intensive care medicine; Clinical trial; Medical prescription; Statin; Disease; Dialysis; Alternative medicine; Internal medicine; Pharmacology; Pathology","score_opus":0.15218081481931708,"score_gpt":0.45601327067003666,"score_spread":0.3038324558507196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137023766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70468265,0.002322478,0.0028869573,0.2475066,0.011440844,0.003410227,0.00007997487,0.0001762988,0.027493965],"genre_scores_gemma":[0.9849068,0.00030008002,0.00040856109,0.011503733,0.0025024542,0.000019424333,0.0000047105273,0.000029690356,0.00032457217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677277,0.0010270347,0.0009804015,0.000294851,0.0006412006,0.0002837241],"domain_scores_gemma":[0.99380815,0.003911387,0.00017232794,0.0017389101,0.00021769729,0.0001515084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058363485,0.00014429732,0.0005592593,0.000015282345,0.000126814,0.000019226447,0.00035308648,0.00024812127,0.000029968038],"category_scores_gemma":[0.006903004,0.00006645839,0.000866443,0.00017516143,0.00072159956,0.000022984264,0.00010923088,0.0007020401,0.000016498592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07800665,0.004909172,0.010641,0.0006184732,0.0023419028,0.00001971857,0.0014041753,0.00001791554,0.000328219,0.11127735,0.017779617,0.7726558],"study_design_scores_gemma":[0.032922298,0.001974359,0.026973637,0.000105779596,0.00072050246,0.000025995238,0.00012242088,0.00056200946,0.0002833888,0.0010767401,0.9350858,0.0001470827],"about_ca_topic_score_codex":0.000021510261,"about_ca_topic_score_gemma":0.0000050857525,"teacher_disagreement_score":0.9173062,"about_ca_system_score_codex":0.000013655407,"about_ca_system_score_gemma":0.00018092133,"threshold_uncertainty_score":0.8264039},"labels":[],"label_agreement":null},{"id":"W2141327424","doi":"10.1016/s0149-2918(04)90062-8","title":"Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus*1","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Management and Education","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Outreach; Pharmacotherapy; Type 2 diabetes; Rural area; Family medicine; Disease management; Gerontology; Internal medicine; Endocrinology; Disease; Economic growth","score_opus":0.0633145700394942,"score_gpt":0.33720288779889146,"score_spread":0.27388831775939726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141327424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949617,0.0003019026,0.000011333371,0.001919697,0.00047737197,0.0010913968,0.0000036976114,0.000023428423,0.0012094772],"genre_scores_gemma":[0.99341416,0.00070379255,0.0019683018,0.0030994716,0.0001125589,0.000048164395,0.00019419826,0.000025626015,0.00043369576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905926,0.000018521045,0.0002834489,0.00019794359,0.00011337582,0.00032744632],"domain_scores_gemma":[0.9993872,0.00006507358,0.000050445968,0.0002444691,0.00009251143,0.000160299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013425345,0.0001345777,0.00025015752,0.00011205607,0.000045795157,0.000017209602,0.000060419115,0.00007536534,0.000016034064],"category_scores_gemma":[0.000014826036,0.000095158255,0.000068990994,0.00017601333,0.000048756443,0.000042493473,0.000009417355,0.00006865748,0.00003216322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032485247,0.0016229975,0.69871217,0.00005344772,0.00042504186,0.000006403364,0.00009705695,0.000026228365,0.00000462699,0.00062048255,0.00017892008,0.29792777],"study_design_scores_gemma":[0.010541537,0.003800402,0.8990492,0.00015230945,0.0005757627,2.0044418e-7,0.00017318914,0.00017314478,0.00004876631,0.0010645817,0.08421024,0.00021066787],"about_ca_topic_score_codex":0.0003255061,"about_ca_topic_score_gemma":0.001070389,"teacher_disagreement_score":0.2977171,"about_ca_system_score_codex":0.00026336606,"about_ca_system_score_gemma":0.00010065537,"threshold_uncertainty_score":0.3880441},"labels":[],"label_agreement":null},{"id":"W2142403091","doi":"10.1016/s0149-2918(00)83053-2","title":"Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Centre; Toronto Western Hospital; Hôpital de l'Enfant-Jésus; Sunnybrook Health Science Centre; Université de Montréal; Université Laval; Saint John Regional Hospital; Novartis (Canada)","funders":"Novartis Pharmaceuticals Canada; Novartis Pharmaceuticals Corporation","keywords":"Rivastigmine; Medicine; Clinical trial; Placebo; Cognition; Clinical Global Impression; Disease; Dementia; Physical therapy; Gerontology; Psychiatry; Clinical psychology; Internal medicine; Donepezil; Alternative medicine; Pathology","score_opus":0.18441508982824775,"score_gpt":0.46999788010826427,"score_spread":0.28558279028001654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142403091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791545,0.0019038892,0.0043409923,0.008825315,0.00021382388,0.0023518794,0.00030429926,0.000038183585,0.0028670907],"genre_scores_gemma":[0.99610674,0.00068952097,0.00023352461,0.0023217562,0.00010062109,0.00008416705,0.00007888828,0.000014628605,0.00037014906],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998974,0.000061359686,0.0004502435,0.00018583059,0.00012483406,0.00020371556],"domain_scores_gemma":[0.9987909,0.0003572831,0.00005509568,0.0001910631,0.00020641653,0.00039921733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043375554,0.00008853133,0.00022836897,0.00007100377,0.000053659798,0.000014813638,0.00007855644,0.00005927099,0.00020136214],"category_scores_gemma":[0.00017202916,0.00007332368,0.00011945611,0.000081264305,0.0002463393,0.00003774993,0.000012470919,0.00012270291,0.000011616954],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037816216,0.00011713589,0.49581823,0.00001729169,0.00018212324,7.974947e-7,0.000031376785,5.772904e-7,0.000027228054,0.00008413563,0.00011596107,0.503227],"study_design_scores_gemma":[0.0013872895,0.00043222934,0.96258044,0.000044456956,0.0005554159,0.0000017894507,0.000023811139,0.0017633952,0.000043232594,0.0006462138,0.032448217,0.0000735204],"about_ca_topic_score_codex":0.00013413416,"about_ca_topic_score_gemma":0.00048706614,"teacher_disagreement_score":0.50315344,"about_ca_system_score_codex":0.000019532528,"about_ca_system_score_gemma":0.00018797551,"threshold_uncertainty_score":0.2990053},"labels":[],"label_agreement":null},{"id":"W2143462158","doi":"10.1016/s0149-2918(03)80122-4","title":"Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Indirect costs; Emergency medicine; Intensive care medicine; Cost database; Microalbuminuria; Macrovascular disease; Complication; Type 2 diabetes; Health care; Surgery; Endocrinology; Database","score_opus":0.06930654272877787,"score_gpt":0.37471949241252256,"score_spread":0.30541294968374466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143462158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875876,0.009383669,0.00014797982,0.001661775,0.000067046276,0.00078744366,0.000014811098,0.00001766676,0.00033205052],"genre_scores_gemma":[0.9793381,0.010029321,0.0065040383,0.0035528527,0.000031424708,0.0000687858,0.00042559495,0.000026057556,0.000023823673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855524,0.00023942099,0.000558844,0.00023918088,0.00018993477,0.00021738175],"domain_scores_gemma":[0.9964035,0.0030269774,0.00008689476,0.0003427779,0.00007703315,0.00006280818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016370233,0.00012575579,0.00041113605,0.00008589532,0.000032826076,0.000014999384,0.000120292425,0.00010964428,0.000014181949],"category_scores_gemma":[0.00070229644,0.000085048836,0.00010692373,0.00032807013,0.0001958103,0.000021438726,0.000024753544,0.0001621988,0.000002325505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022476575,0.0028560113,0.8645623,0.0001814489,0.0018899104,0.000017213657,0.0010780463,0.00007031817,0.00031053316,0.0015918427,0.00039275194,0.12682489],"study_design_scores_gemma":[0.023298653,0.0019776337,0.57975787,0.0014345425,0.0025658673,0.0000028403238,0.0017060605,0.04900862,0.005485476,0.011661277,0.32246238,0.000638804],"about_ca_topic_score_codex":0.00009576013,"about_ca_topic_score_gemma":0.000045414552,"teacher_disagreement_score":0.32206962,"about_ca_system_score_codex":0.000031677835,"about_ca_system_score_gemma":0.000049182094,"threshold_uncertainty_score":0.3468191},"labels":[],"label_agreement":null},{"id":"W2143599673","doi":"10.1016/s0149-2918(03)80339-9","title":"The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: A post hoc analysis of data from CHAMPS","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Biogen","keywords":"Medicine; Post-hoc analysis; Multiple sclerosis; Interferon beta-1a; Magnetic resonance imaging; Placebo; Subgroup analysis; Population; Asymptomatic; Internal medicine; Nuclear medicine; Confidence interval; Radiology; Interferon beta; Pathology; Immunology","score_opus":0.20443163744878323,"score_gpt":0.41143816656857046,"score_spread":0.20700652911978723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143599673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609536,0.0014475886,0.0006452663,0.00006835114,0.00015363291,0.0011602658,0.00041755429,0.000007282901,0.0000047046055],"genre_scores_gemma":[0.98828065,0.004074238,0.0071564578,0.00007232776,0.000021192604,0.000049329836,0.00031476683,0.000023229035,0.000007810795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996581,0.000540238,0.0015908153,0.00044259054,0.0005337517,0.00031158095],"domain_scores_gemma":[0.9893863,0.008173835,0.000622939,0.0012258345,0.0004936313,0.00009742559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002089278,0.00019729305,0.0011485603,0.00015633753,0.000090179296,0.000006556629,0.0004947349,0.00016016349,0.00001366326],"category_scores_gemma":[0.0045750886,0.00012874392,0.00032576494,0.0004859174,0.0004317544,0.000045362285,0.0003931111,0.00026472574,0.0000015690737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038262468,0.0019204572,0.84801483,0.00022095366,0.010536981,2.648038e-7,0.00096899626,0.000010378806,0.0046123657,0.000011314825,0.00003398362,0.12984324],"study_design_scores_gemma":[0.007655691,0.0017377373,0.97383744,0.0003013096,0.0017521108,1.1460268e-8,0.00014767634,0.0017364698,0.011685146,0.000017918353,0.0010148047,0.00011369677],"about_ca_topic_score_codex":0.00009149753,"about_ca_topic_score_gemma":0.0008177454,"teacher_disagreement_score":0.12972954,"about_ca_system_score_codex":0.00008285359,"about_ca_system_score_gemma":0.000113533766,"threshold_uncertainty_score":0.5477139},"labels":[],"label_agreement":null},{"id":"W2146831409","doi":"10.1016/s0149-2918(02)85139-6","title":"A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Abbott Laboratories","keywords":"Medicine; Gemifloxacin; Chronic bronchitis; Clarithromycin; Exacerbation; Bronchitis; Regimen; Internal medicine; Respiratory tract infections; Randomized controlled trial; Sputum; Lower respiratory tract infection; Antibacterial agent; Antibiotics; Tuberculosis; Respiratory system","score_opus":0.18454128478575624,"score_gpt":0.4779295199573555,"score_spread":0.2933882351715993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146831409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956257,0.0019379208,0.00025518116,0.0014648625,0.00020339231,0.00030825156,0.000014188291,0.00002028234,0.0001702343],"genre_scores_gemma":[0.9929243,0.0059468187,0.00017807297,0.00069658,0.00008203969,0.0000061543233,0.000003715833,0.000016068385,0.0001462917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978306,0.0002035557,0.001386589,0.00025873914,0.00014400798,0.00017646949],"domain_scores_gemma":[0.99823177,0.0009778042,0.00026678768,0.00031897888,0.00006929125,0.00013539917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004391598,0.00014388085,0.00093941,0.00009723657,0.000043031734,0.000007170097,0.00006853126,0.00032809007,0.000070145856],"category_scores_gemma":[0.00010974082,0.00011539309,0.00018872165,0.00016901254,0.00073659734,0.000044721957,0.000056594425,0.00057468354,0.000004047274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027865706,0.0013369495,0.958622,0.00006465743,0.00032841126,0.000006461002,0.00012624732,0.000003200363,0.0011235676,0.000106678504,0.000024538225,0.038229465],"study_design_scores_gemma":[0.0031420419,0.0017640091,0.9920677,0.00013571815,0.00043298633,0.00002092562,0.00003557427,0.0014324147,0.00012378267,0.00006696443,0.0006728943,0.000104985425],"about_ca_topic_score_codex":0.0000049655173,"about_ca_topic_score_gemma":0.00007158763,"teacher_disagreement_score":0.03812448,"about_ca_system_score_codex":0.000023023023,"about_ca_system_score_gemma":0.000055546323,"threshold_uncertainty_score":0.4705594},"labels":[],"label_agreement":null},{"id":"W2149756516","doi":"10.1016/j.clinthera.2006.12.012","title":"A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease","year":2006,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Crohn's disease; Internal medicine; Meta-analysis; Placebo; Clinical trial; Randomized controlled trial; Antibiotics; Antimicrobial; Metronidazole; MEDLINE; Odds ratio; Disease; Pathology; Alternative medicine","score_opus":0.12201639231263539,"score_gpt":0.38989362991442017,"score_spread":0.2678772376017848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149756516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025281746,0.97224784,0.000035455196,0.000012112131,0.00008798373,0.0013364825,0.00089249696,0.000012714897,0.000093190785],"genre_scores_gemma":[0.012245082,0.98535246,0.000069200505,0.00028653076,0.000104579856,0.00004397765,0.001623952,0.000105071915,0.00016917245],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961315,0.00087381375,0.0014274853,0.0008594717,0.00034131136,0.00036644077],"domain_scores_gemma":[0.9971988,0.00015629435,0.0009895554,0.0013166043,0.00015785031,0.00018085829],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041828246,0.00060689653,0.0031937934,0.0002615789,0.000035718203,0.00002404075,0.0005245958,0.000531079,0.00005184344],"category_scores_gemma":[0.000039980863,0.0004068404,0.0040843585,0.00060700945,0.00034079122,0.0000050754597,0.00010471769,0.00037468164,0.0000061054266],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003479299,0.004900068,0.040431198,0.0018082352,0.5954733,0.0002188559,0.000016441354,0.00014267606,4.6583912e-7,0.000060512986,0.00006682797,0.3534021],"study_design_scores_gemma":[0.0015971864,0.0004865923,0.37626162,0.00016311811,0.43472445,2.0377745e-7,0.0000022612724,0.000014437228,0.0000029797186,0.000028235445,0.18589716,0.00082174107],"about_ca_topic_score_codex":0.000005734209,"about_ca_topic_score_gemma":0.000036955447,"teacher_disagreement_score":0.35258037,"about_ca_system_score_codex":0.00003260928,"about_ca_system_score_gemma":0.00045623785,"threshold_uncertainty_score":0.99983835},"labels":[],"label_agreement":null},{"id":"W2152372835","doi":"10.1016/j.clinthera.2009.01.006","title":"Cost-related prescription nonadherence in the united states and Canada: A system-level comparison using the 2007 international health policy survey in seven countries","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Medical prescription; Medicaid; Commonwealth; Prescription drug; Demography; Health insurance; Environmental health; Health care; Geography; Economic growth","score_opus":0.38715629219782005,"score_gpt":0.48971126807596205,"score_spread":0.102554975878142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152372835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950471,0.0008765661,0.0014860731,0.04554581,0.0003596244,0.0009900999,0.000061419974,0.000018819102,0.00019061427],"genre_scores_gemma":[0.97281873,0.0011543039,0.000109940825,0.025530094,0.00007672056,0.000009833997,0.000114318944,0.00000554345,0.00018053225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978285,0.0006722184,0.0007711472,0.00017681446,0.00034271038,0.00020864734],"domain_scores_gemma":[0.9985268,0.00075720897,0.0002585118,0.00023254067,0.00014858835,0.0000763294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022541445,0.000106807965,0.00028255483,0.0000708456,0.00007547688,0.00003105568,0.00022973477,0.00008142682,0.000020054218],"category_scores_gemma":[0.00022850915,0.000066008346,0.000020799858,0.00036925354,0.000147608,0.00003706175,0.000016957876,0.0004561004,0.000005917609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003323034,0.0002967606,0.9816836,0.000041475876,0.000064741835,0.000009689629,0.0017638893,0.00034019045,0.000004962497,0.0014668638,0.0040713213,0.009924161],"study_design_scores_gemma":[0.0011801911,0.0001451467,0.9031217,0.00028383685,0.000013381014,0.000018788285,0.0021530262,0.07928772,0.0000014481724,0.00012225416,0.013597778,0.00007468749],"about_ca_topic_score_codex":0.35857427,"about_ca_topic_score_gemma":0.14261156,"teacher_disagreement_score":0.2159627,"about_ca_system_score_codex":0.00027170323,"about_ca_system_score_gemma":0.0012186359,"threshold_uncertainty_score":0.8730335},"labels":[],"label_agreement":null},{"id":"W2156915678","doi":"10.1016/j.clinthera.2010.04.007","title":"Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: Results of a longitudinal, population-based study","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Mental Health; Agency for Healthcare Research and Quality","keywords":"Medicine; Medicaid; Prior authorization; Authorization; Population; Longitudinal study; Family medicine; Gerontology; Demography; Environmental health; Nursing; Health care; Economic growth","score_opus":0.10997978667253108,"score_gpt":0.4439780070284911,"score_spread":0.33399822035596005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156915678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975429,0.000105982326,0.000025558009,0.0013207821,0.00011969464,0.00082089606,0.000022813141,0.000015970165,0.000025404539],"genre_scores_gemma":[0.99846715,0.00047203235,0.00028288356,0.00060377596,0.00007793459,0.000010500321,0.000038460825,0.000017867449,0.000029379844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735683,0.00027710194,0.0011796881,0.0004103428,0.0005828453,0.0001931806],"domain_scores_gemma":[0.9964127,0.001959434,0.0005864977,0.00042403422,0.00030333505,0.00031402253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013878696,0.00019621961,0.0007393942,0.00023312017,0.000055543533,0.000019171846,0.00011508143,0.00022767473,0.000017928234],"category_scores_gemma":[0.0039519104,0.00014529098,0.00006456888,0.00032964928,0.000520834,0.00008914444,0.000048605747,0.00053428655,8.9200717e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009575181,0.0006570905,0.9919672,0.00003166064,0.00016665376,0.000016182736,0.00081381283,0.0000010488134,0.00059781683,0.00004125426,0.000030186582,0.004719547],"study_design_scores_gemma":[0.010806414,0.0021059054,0.9849751,0.00044667852,0.00017953935,0.0000067175956,0.00030848308,0.00089825876,0.000069560585,0.000081875354,0.0000066914404,0.00011478975],"about_ca_topic_score_codex":0.001334,"about_ca_topic_score_gemma":0.00094541005,"teacher_disagreement_score":0.0098488955,"about_ca_system_score_codex":0.000020858848,"about_ca_system_score_gemma":0.00026114171,"threshold_uncertainty_score":0.5924794},"labels":[],"label_agreement":null},{"id":"W2162575317","doi":"10.1016/s0149-2918(01)80100-4","title":"Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction","year":2001,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Pantoprazole; Medicine; Pharmacokinetics; Gastroenterology; Adverse effect; Internal medicine; Proton-pump inhibitor; Pharmacology; Omeprazole","score_opus":0.14867049779999697,"score_gpt":0.4505362289100531,"score_spread":0.30186573111005616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162575317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573934,0.0010778066,0.00025112048,0.00025957465,0.00074790453,0.00043768904,0.00003528851,0.00003137642,0.0014199286],"genre_scores_gemma":[0.9892456,0.007037435,0.00034518391,0.0029946966,0.00014855276,0.000013938326,0.000018254294,0.000034145603,0.00016222657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775743,0.0005069955,0.0007879646,0.00035183993,0.0002114452,0.00038433023],"domain_scores_gemma":[0.99865115,0.0004885116,0.00025764026,0.00021413073,0.0001799145,0.00020862672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084400835,0.00024950653,0.00048151865,0.00010439442,0.000079271114,0.000013523295,0.00018480573,0.00028872243,0.0002162623],"category_scores_gemma":[0.00003327462,0.00020715543,0.000075023,0.00028476652,0.00032074013,0.000088689136,0.00007727995,0.00074640306,0.000012118645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035822976,0.0012860523,0.8308301,0.000032331667,0.0002464356,0.000010419221,0.00019598995,0.0012566772,0.00068226946,0.00012087694,0.00005817244,0.16169839],"study_design_scores_gemma":[0.029929483,0.0011722406,0.78078264,0.000053424894,0.0010360525,0.000014527725,0.000073899864,0.05729382,0.00637532,0.0018942229,0.12055651,0.00081788615],"about_ca_topic_score_codex":0.0000059784425,"about_ca_topic_score_gemma":0.000007423084,"teacher_disagreement_score":0.1608805,"about_ca_system_score_codex":0.00001863717,"about_ca_system_score_gemma":0.000057760655,"threshold_uncertainty_score":0.8447553},"labels":[],"label_agreement":null},{"id":"W2162796691","doi":"10.1016/j.clinthera.2007.07.029","title":"Cost-Effectiveness of Irbesartan 300 mg Given Early Versus Late in Patients with Hypertension and a History of Type 2 Diabetes and Renal Disease: A Canadian Perspective","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; University of British Columbia; Université Laval; Dalhousie University; University of Ottawa","funders":"","keywords":"Irbesartan; Medicine; Microalbuminuria; Internal medicine; Diabetes mellitus; Type 2 diabetes; Nephropathy; Population; Disease; Endocrinology; Blood pressure","score_opus":0.07027654472147005,"score_gpt":0.3365074024345691,"score_spread":0.26623085771309907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162796691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948933,0.004229364,0.0000012750592,0.00007273062,0.00012285911,0.0004514508,0.000033045013,0.0000063468287,0.00018963302],"genre_scores_gemma":[0.9994834,0.00016340264,0.000042895732,0.00022989088,0.00002489446,0.0000032009211,0.000017671706,0.00001604862,0.000018594084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905366,0.00009750036,0.00026593296,0.00022369753,0.00014631345,0.00021292704],"domain_scores_gemma":[0.99833184,0.0007260498,0.00008470129,0.00017636953,0.00025749207,0.00042356347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040354455,0.00011486061,0.00038541018,0.000103812694,0.000015582988,0.0000025422553,0.00003753537,0.000092750175,0.000010110659],"category_scores_gemma":[0.0002442905,0.00009127254,0.00004831085,0.00011450064,0.00038812874,0.000039730723,0.000019676036,0.00015419703,5.903148e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008584004,0.00038216324,0.98676956,0.00009910502,0.00020647347,0.000013874582,0.00023369807,9.354499e-7,0.0001668215,0.000060454986,0.000019746047,0.0034631635],"study_design_scores_gemma":[0.008797244,0.002204511,0.9872447,0.00034598657,0.00033768322,1.0473588e-7,0.000072449424,0.00012927085,0.000040268587,0.000119640405,0.00060704455,0.000101093014],"about_ca_topic_score_codex":0.001117961,"about_ca_topic_score_gemma":0.00079129473,"teacher_disagreement_score":0.0045901053,"about_ca_system_score_codex":0.0003002564,"about_ca_system_score_gemma":0.0006647939,"threshold_uncertainty_score":0.3721986},"labels":[],"label_agreement":null},{"id":"W2164536330","doi":"10.1016/s0149-2918(04)90020-3","title":"Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Tolerability; Sumatriptan; Migraine; Dosing; Placebo; Anesthesia; Randomized controlled trial; Clinical endpoint; Clinical trial; Adverse effect; Internal medicine","score_opus":0.08507202168865079,"score_gpt":0.4190618196817311,"score_spread":0.3339897979930803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164536330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98750454,0.0024555868,0.00054850656,0.0010206098,0.000034070803,0.008330453,0.000051598392,0.000009646215,0.000044992838],"genre_scores_gemma":[0.9963444,0.0021267633,0.0010914656,0.00008481159,0.000048614533,0.00017739813,0.000011773022,0.0000134026195,0.00010137176],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99688995,0.00031966006,0.0021465714,0.00026423245,0.00019909034,0.00018046996],"domain_scores_gemma":[0.99133015,0.0072441967,0.0006942416,0.00039975095,0.00027545355,0.00005620794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023702132,0.00020704612,0.0020430677,0.00007448288,0.00005216887,0.0000046201876,0.000075170465,0.00010236446,0.0000032879877],"category_scores_gemma":[0.0021812234,0.00010799115,0.000582487,0.00014143375,0.0002788686,0.000026237536,0.000023166036,0.000127835,1.1930875e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94250125,0.012254879,0.013311395,0.00013845113,0.003261819,0.0000024980689,0.012743983,0.00006564775,0.0006139207,0.000114271206,0.000020277608,0.014971609],"study_design_scores_gemma":[0.953594,0.008318614,0.023532737,0.00019122713,0.0032228453,0.0000012684079,0.002860411,0.0072254413,0.0006310036,0.00017415964,0.00015164034,0.000096614815],"about_ca_topic_score_codex":0.00026498342,"about_ca_topic_score_gemma":0.0004521202,"teacher_disagreement_score":0.014874994,"about_ca_system_score_codex":0.00004168502,"about_ca_system_score_gemma":0.000110032655,"threshold_uncertainty_score":0.44037515},"labels":[],"label_agreement":null},{"id":"W2165778651","doi":"10.1016/j.clinthera.2008.06.003","title":"Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications","year":2008,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"National Institute on Aging; Canadian Institutes of Health Research; MedImmune; Pfizer; Amgen; Agency for Healthcare Research and Quality; U.S. Department of Health and Human Services","keywords":"Medicine; Medical prescription; Copayment; Population; Emergency department; Emergency medicine; Asthma; Poisson regression; Cost sharing; Cohort; Health care; Internal medicine; Environmental health; Psychiatry","score_opus":0.09781576141824182,"score_gpt":0.40349727840220095,"score_spread":0.3056815169839591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165778651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943047,0.0011003824,0.00064127427,0.0030152765,0.0002782708,0.0003976629,0.000004752148,0.000020867888,0.0002367888],"genre_scores_gemma":[0.99309134,0.003665336,0.0013923397,0.0010584182,0.00006431459,0.00006626045,0.000014224181,0.000011038259,0.0006367383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863535,0.00009139671,0.0006793678,0.00021793961,0.0002407344,0.00013518959],"domain_scores_gemma":[0.9990554,0.00011802798,0.00016774167,0.00031055766,0.00011482942,0.00023347892],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002454611,0.00009995228,0.0002635159,0.000080237296,0.000040223757,0.0000019172264,0.00009046877,0.00012588105,0.0009913028],"category_scores_gemma":[0.00022958632,0.00008269561,0.00006986884,0.00024077685,0.00024921438,0.000052053063,0.00002275511,0.00022706258,0.000028604434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010746055,0.0010267547,0.9949073,0.000054855453,0.000049754988,0.000012796744,0.00027963036,6.894749e-7,0.00019763103,0.000033007353,0.0006663657,0.0026637486],"study_design_scores_gemma":[0.0020038295,0.00033123614,0.9939367,0.0002475712,0.00007982347,0.000010067584,0.00013214951,0.00045161863,0.0002139203,0.00016018885,0.0023380972,0.00009479695],"about_ca_topic_score_codex":0.0000056371464,"about_ca_topic_score_gemma":0.0000021873752,"teacher_disagreement_score":0.0025689516,"about_ca_system_score_codex":0.00001650579,"about_ca_system_score_gemma":0.00026717235,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W2166470331","doi":"10.1016/j.clinthera.2013.07.195","title":"PP154—Personalising Health Care: Feasibility and Future Implications for All Stakeholder Groups Including Authorities, Physicians and Patients","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Stakeholder; Health care; Orphan drug; Personalized medicine; Genetic testing; Family medicine; Intensive care medicine; Public relations; Bioinformatics","score_opus":0.7040641131050797,"score_gpt":0.5257675236550097,"score_spread":0.17829658945007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166470331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84297276,0.015064753,0.0028614753,0.13446927,0.0008887867,0.002458592,0.0010001619,0.00006652476,0.00021769613],"genre_scores_gemma":[0.8893857,0.0034727615,0.009364594,0.09587157,0.0013765123,0.00021278161,0.00019799516,0.000062007704,0.00005609308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582297,0.00030895005,0.0027625675,0.0006417955,0.00005488594,0.00040884817],"domain_scores_gemma":[0.9963556,0.0015688486,0.0012825758,0.00041997933,0.00015244764,0.00022053454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050991233,0.0001930218,0.0008428081,0.00007102612,0.00043220833,0.00014302444,0.00015660193,0.00020392257,0.000018742205],"category_scores_gemma":[0.00044226358,0.00022789353,0.00011650065,0.000087063265,0.0001760672,0.00035303243,0.00006467433,0.00023632061,0.000020479269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025309333,0.00037952667,0.8373047,0.00072665507,0.00021765212,3.0067905e-8,0.0115409745,0.0000019917825,0.0000015491972,0.08863016,0.010538641,0.050632805],"study_design_scores_gemma":[0.001988078,0.00038780636,0.80528116,0.000058758025,0.000024367813,7.9717796e-7,0.0055778045,0.001032117,3.373436e-7,0.04200091,0.14323059,0.0004172656],"about_ca_topic_score_codex":0.00013962356,"about_ca_topic_score_gemma":0.000065989654,"teacher_disagreement_score":0.13269195,"about_ca_system_score_codex":0.0003649467,"about_ca_system_score_gemma":0.00009710495,"threshold_uncertainty_score":0.92932284},"labels":[],"label_agreement":null},{"id":"W2167573905","doi":"10.1016/j.clinthera.2005.09.007","title":"Incidence of infection during efalizumab therapy for psoriasis: Analysis of the clinical trial experience","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Dalhousie University","funders":"Genentech","keywords":"Efalizumab; Medicine; Psoriasis; Placebo; Incidence (geometry); Clinical trial; Adverse effect; Internal medicine; Randomized controlled trial; Immunology; Plaque psoriasis; Pathology","score_opus":0.27534577022948004,"score_gpt":0.4846407011721711,"score_spread":0.20929493094269108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167573905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11574934,0.8778932,0.000059545375,0.000012483215,0.0042013368,0.0018579508,0.00016936944,0.000031344673,0.000025433112],"genre_scores_gemma":[0.012646398,0.9859699,0.000091806956,0.000056478588,0.00050387345,0.00029499162,0.00010055796,0.000042169388,0.00029379816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99288255,0.002319195,0.0036602584,0.0006824627,0.000110105626,0.0003454313],"domain_scores_gemma":[0.99145633,0.0043938723,0.0026870843,0.0012250443,0.00020353016,0.00003412979],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018593185,0.00048174747,0.0038378548,0.000236994,0.00017003172,0.0000112153975,0.00074916525,0.0016306668,0.00011314418],"category_scores_gemma":[0.0005031048,0.00029279038,0.005903472,0.0009788304,0.00075476285,0.000055158234,0.00013639814,0.0005675515,0.000012506028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056960243,0.0010490438,0.00254804,0.0002730098,0.014731066,2.9636465e-7,0.00012069346,0.0000021096612,0.0000078913345,0.000045673787,0.000014649651,0.9755115],"study_design_scores_gemma":[0.02622962,0.0016335257,0.008196642,0.0010609571,0.03326081,0.000005750141,0.000021977221,0.0000048000784,0.0001860945,0.00003600958,0.9289055,0.00045829976],"about_ca_topic_score_codex":0.000015246968,"about_ca_topic_score_gemma":0.000026876662,"teacher_disagreement_score":0.9750532,"about_ca_system_score_codex":0.000055920187,"about_ca_system_score_gemma":0.0003675346,"threshold_uncertainty_score":0.99995244},"labels":[],"label_agreement":null},{"id":"W2167593269","doi":"10.1016/j.clinthera.2013.10.004","title":"Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science and Engineering Research Board","keywords":"Medicine; Everolimus; Renal cell carcinoma; Oncology; Second line; Internal medicine; Urology; First line","score_opus":0.2562351824834086,"score_gpt":0.42573841229528947,"score_spread":0.16950322981188087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167593269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993837,0.0014682906,0.00035214337,0.000092431714,0.0001379197,0.003674153,0.000056123787,0.000012067397,0.00036987627],"genre_scores_gemma":[0.9962452,0.00016033924,0.0026045246,0.00013022714,0.000061780505,0.00038188745,0.000056114746,0.00004072008,0.00031920182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976815,0.00036809396,0.0011038755,0.00034904262,0.0002000436,0.00029746763],"domain_scores_gemma":[0.99622595,0.0025124731,0.00031694345,0.00051423797,0.0002779061,0.0001524877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005899576,0.00025617424,0.0011698203,0.00010964155,0.000016938426,0.0000051625225,0.00010415956,0.00014381636,0.00014626903],"category_scores_gemma":[0.00004722644,0.00018450433,0.00047962097,0.00017511052,0.00017544893,0.000043984026,0.000022302647,0.00012480016,0.000013066383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013597802,0.023226643,0.668773,0.0036563207,0.0022665043,0.00012936171,0.0010786011,0.00042661457,0.17343657,0.00019567632,0.000078764795,0.11313413],"study_design_scores_gemma":[0.020569153,0.01870657,0.52673054,0.00013667783,0.0010139863,0.000014857552,0.000116041934,0.0020044076,0.4288399,0.0008165561,0.0008542601,0.00019707176],"about_ca_topic_score_codex":0.00008426157,"about_ca_topic_score_gemma":0.000019179344,"teacher_disagreement_score":0.25540334,"about_ca_system_score_codex":0.00018009447,"about_ca_system_score_gemma":0.00019567879,"threshold_uncertainty_score":0.7523868},"labels":[],"label_agreement":null},{"id":"W2172296024","doi":"10.1016/j.clinthera.2009.05.009","title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials","year":2009,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Bone health and treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Public Health","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Jadad scale; Zoledronic acid; Internal medicine; Meta-analysis; Placebo; Randomized controlled trial; Relative risk; Bone metastasis; Cancer; MEDLINE; Oncology; Surgery; Metastasis; Cochrane Library; Confidence interval; Pathology","score_opus":0.5296754584089889,"score_gpt":0.5751400170149549,"score_spread":0.04546455860596599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172296024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13498747,0.86018366,0.0000066632615,0.000076430886,0.000091206995,0.004342126,0.00027930288,0.000011183211,0.000021945623],"genre_scores_gemma":[0.06845579,0.93037695,0.000457592,0.00021584549,0.000026789634,0.00020086812,0.00019249464,0.00004425359,0.000029436216],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9779153,0.0100459,0.010059487,0.0009976628,0.00056978234,0.00041188096],"domain_scores_gemma":[0.9788555,0.015203958,0.004584962,0.00076956523,0.00024483947,0.00034119305],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.026779268,0.00067366136,0.031686526,0.0006458678,0.000025939926,0.000011422083,0.00013980998,0.0007991964,0.000037838578],"category_scores_gemma":[0.0023440188,0.00038122965,0.0045624436,0.0011796225,0.00075353746,0.00005994009,0.00007556363,0.0011693621,3.8158262e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02060302,0.0043301038,0.046538215,0.0030456947,0.24161845,0.000025724896,0.00004432274,0.0000055962623,1.8810912e-8,0.000015999676,0.0000015766686,0.68377125],"study_design_scores_gemma":[0.12466118,0.00076577585,0.11427946,0.0018957775,0.7549313,0.0000021628948,0.000004254289,0.00015454156,3.0814647e-7,0.000064786895,0.0029380133,0.00030247244],"about_ca_topic_score_codex":0.00073282747,"about_ca_topic_score_gemma":0.0003992652,"teacher_disagreement_score":0.6834688,"about_ca_system_score_codex":0.00008390988,"about_ca_system_score_gemma":0.00067055307,"threshold_uncertainty_score":0.999864},"labels":[],"label_agreement":null},{"id":"W2205630783","doi":"10.1016/j.clinthera.2015.10.002","title":"Lipid-modifying Therapy: The Clinician’s Perspective","year":2015,"lang":"en","type":"editorial","venue":"Clinical Therapeutics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Guideline; Task force; Position paper; Atherosclerotic cardiovascular disease; Canadian Cardiovascular Society; Scopus; Disease; Internal medicine; Cardiology; Family medicine; Intensive care medicine; MEDLINE; Myocardial infarction; Pathology","score_opus":0.17595069695128174,"score_gpt":0.46742499645707564,"score_spread":0.2914742995057939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205630783","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059351337,0.039662577,0.00014629148,0.0056658303,0.94258523,0.0021185,0.00009357966,0.0002356889,0.008898803],"genre_scores_gemma":[0.0011124733,0.0408418,0.0002666553,0.006910119,0.9476548,0.00009207741,0.00011789077,0.00022313168,0.0027810403],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928887,0.0012598466,0.0016001917,0.0010842752,0.002445192,0.00072177843],"domain_scores_gemma":[0.99032813,0.0033608237,0.0006704291,0.0028457588,0.0023039016,0.0004909745],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009542753,0.00065025035,0.0020821684,0.00008883333,0.00027302638,0.000112870905,0.0007407631,0.0027238026,0.00007776303],"category_scores_gemma":[0.003222202,0.0003824817,0.002240552,0.00033848378,0.00065467897,0.00005620567,0.00019506902,0.005680328,0.00022288543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009880601,0.0005143797,0.0001378493,0.000071219656,0.002814992,0.00004011847,0.00044463214,0.0000012052126,0.0000011192211,0.00014198152,0.8633383,0.13150613],"study_design_scores_gemma":[0.0048105223,0.0017638954,0.00019481349,0.0002192986,0.0011326275,0.000012895474,0.00070141186,0.00005358563,0.000004151736,0.0011246843,0.98955995,0.0004221839],"about_ca_topic_score_codex":0.00022513153,"about_ca_topic_score_gemma":0.000024028355,"teacher_disagreement_score":0.13108394,"about_ca_system_score_codex":0.0004991577,"about_ca_system_score_gemma":0.0042595644,"threshold_uncertainty_score":0.99986273},"labels":[],"label_agreement":null},{"id":"W2208246363","doi":"10.1016/j.clinthera.2015.11.017","title":"Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Exenatide; Medicine; Liraglutide; Discontinuation; Propensity score matching; Internal medicine; Glucagon-like peptide 1 receptor; Cohort; Retrospective cohort study; Persistence (discontinuity); Type 2 diabetes; Cohort study; Medical prescription; Observational study; Diabetes mellitus; Endocrinology; Pharmacology; Agonist","score_opus":0.4590459040180889,"score_gpt":0.4519623205870558,"score_spread":0.0070835834310331025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208246363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96961284,0.0012432253,0.0011254322,0.004017981,0.0008493215,0.00035387525,0.0000024157162,0.000086103806,0.022708813],"genre_scores_gemma":[0.9838139,0.00062552997,0.0029949036,0.0020965177,0.00036086323,0.000022735105,0.000007783869,0.000016766742,0.010061033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844134,0.000108482185,0.0005303486,0.00033291004,0.0003671767,0.00021974389],"domain_scores_gemma":[0.9984437,0.00037194722,0.00018695359,0.00038408075,0.00023700064,0.00037632074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070451153,0.00014152427,0.00033728906,0.000041306892,0.000056863206,0.000034970457,0.00014750227,0.00014288197,0.00008535136],"category_scores_gemma":[0.00050546014,0.00011545075,0.00009542471,0.00019764755,0.0003403187,0.000119064825,0.000046743906,0.00034346085,0.000369167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002977869,0.00088589656,0.56001055,0.000050572085,0.00039022614,0.000035783738,0.0011232118,0.0000022097443,0.00034174998,0.0037719696,0.008849785,0.42156014],"study_design_scores_gemma":[0.022289896,0.013850199,0.6530107,0.00070942444,0.0008634581,0.000039903,0.0047704885,0.0059312214,0.0004268372,0.004440554,0.2927735,0.00089379],"about_ca_topic_score_codex":0.0000100260295,"about_ca_topic_score_gemma":0.0000025870554,"teacher_disagreement_score":0.42066637,"about_ca_system_score_codex":0.00003419499,"about_ca_system_score_gemma":0.00024131406,"threshold_uncertainty_score":0.47450182},"labels":[],"label_agreement":null},{"id":"W2232323065","doi":"10.1016/j.clinthera.2015.05.012","title":"Pregnancy outcome following maternal exposure to pregabalin: a reason for concern? a collaborative entis and motherisk study","year":2015,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Pregabalin; Pregnancy; Obstetrics; Anesthesia; Outcome (game theory); Reproductive medicine","score_opus":0.23055452467364884,"score_gpt":0.48251641151236774,"score_spread":0.2519618868387189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232323065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996186,0.0036625748,0.0003731722,0.0009200599,0.001295522,0.0034435971,0.000055720488,0.00007681365,0.0002106731],"genre_scores_gemma":[0.9924886,0.00019233469,0.0026773002,0.0018299783,0.00023806331,0.00026421325,0.0000051207267,0.0000472463,0.0022571497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788237,0.00021951753,0.0008399421,0.0004224593,0.0002974527,0.0003382833],"domain_scores_gemma":[0.9985209,0.00028617628,0.00018156704,0.00034947257,0.0001613146,0.0005005807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007727157,0.00022540093,0.000633572,0.000040153158,0.00008849439,0.00004848428,0.00012621256,0.00014770546,0.000010998982],"category_scores_gemma":[0.00016970896,0.0001787616,0.0001341588,0.000121306104,0.00005655929,0.00007164055,0.000076471966,0.00021303994,0.000016797516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023699475,0.00067814684,0.9787233,0.00037825663,0.00031021505,0.000072567665,0.0030747885,0.0000014886206,0.000014208016,0.00006162406,0.000030982774,0.014284517],"study_design_scores_gemma":[0.035365142,0.046786122,0.87828255,0.009520109,0.0014396857,0.00008080993,0.0045927404,0.0003160658,0.001064496,0.0009808398,0.020683901,0.0008875248],"about_ca_topic_score_codex":0.000019602292,"about_ca_topic_score_gemma":0.000014542321,"teacher_disagreement_score":0.100440696,"about_ca_system_score_codex":0.00005676241,"about_ca_system_score_gemma":0.00011416471,"threshold_uncertainty_score":0.7289687},"labels":[],"label_agreement":null},{"id":"W2292084592","doi":"10.1016/j.clinthera.2016.02.011","title":"Opportunity Cost and Policy: A Utilization Review of Self-monitoring of Blood Glucose in Manitoba, Canada","year":2016,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Toronto","funders":"Microsoft","keywords":"Medicine; Test (biology); Medical prescription; Glucose test; Diabetes mellitus; Interrupted time series; Blood Glucose Self-Monitoring; Cost–benefit analysis; Blood test; Environmental health; Glycemic; Continuous glucose monitoring; Nursing; Psychological intervention; Internal medicine","score_opus":0.22584614396496902,"score_gpt":0.44703794167866223,"score_spread":0.2211917977136932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292084592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000691476,0.9971061,0.0000043179025,0.00023288,0.0003156998,0.0010885183,0.00011867695,0.00001151357,0.00043081606],"genre_scores_gemma":[0.00080858904,0.9979781,0.00011159262,0.00068025157,0.0002681595,0.000034563363,0.000044186923,0.000034041936,0.000040524457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667645,0.00030154164,0.0021192897,0.00030969668,0.00032901618,0.000264038],"domain_scores_gemma":[0.9972326,0.0011276819,0.000594175,0.00046378907,0.00029878863,0.0002829533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006629472,0.00029502762,0.002667435,0.00010535136,0.00002106867,0.0000035820105,0.0001668149,0.00038431582,0.000025463243],"category_scores_gemma":[0.001044405,0.00020249584,0.00033981662,0.0002677663,0.00015542579,0.000024905185,0.000075029406,0.0004384207,8.697785e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004117691,0.00040780002,0.0047957557,0.069795474,0.00046149103,0.000027639582,0.000008753018,1.8518198e-9,6.0103997e-7,0.00014193697,0.000023278562,0.9242961],"study_design_scores_gemma":[0.0016920448,0.00040018515,0.0003751071,0.18414004,0.003437505,0.00002830091,0.000012117144,0.000001827876,0.000003856986,0.00003868393,0.80968624,0.00018407096],"about_ca_topic_score_codex":0.0037731049,"about_ca_topic_score_gemma":0.0013341024,"teacher_disagreement_score":0.924112,"about_ca_system_score_codex":0.00010827744,"about_ca_system_score_gemma":0.0033841007,"threshold_uncertainty_score":0.8257541},"labels":[],"label_agreement":null},{"id":"W2295392739","doi":"10.1016/j.clinthera.2016.02.020","title":"Gap Between Official Guidelines and Clinical Practice for the Treatment of Rheumatoid Arthritis in São Paulo, Brazil","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Rheumatoid arthritis; Pharmacy; Adverse effect; Biological drugs; Clinical Practice; Alternative medicine; Family medicine; Intensive care medicine; Internal medicine; Pathology","score_opus":0.22568749630190257,"score_gpt":0.4925100112013367,"score_spread":0.2668225148994341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295392739","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094927,0.054412697,0.00391199,0.029781882,0.0004941798,0.0016247798,0.00011071163,0.00004808151,0.0001229952],"genre_scores_gemma":[0.387624,0.60863763,0.0021919252,0.0008119942,0.00053604145,0.000040324107,0.00000655402,0.000029732273,0.000121800105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964869,0.000395236,0.0019992557,0.0003930176,0.00033645536,0.00038913547],"domain_scores_gemma":[0.9844914,0.013989564,0.00033384794,0.0005104781,0.00046927304,0.00020544339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026430392,0.00021338084,0.0009284634,0.00006529469,0.00009753985,0.000024733203,0.00016134126,0.00025061492,0.000047637528],"category_scores_gemma":[0.003752611,0.00010964075,0.00037784604,0.00012878953,0.0007336099,0.000102698265,0.00004153306,0.00020482957,0.000013423116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017712862,0.0012386859,0.113875315,0.0000076113965,0.00060065766,0.00001015999,0.00014266139,1.723605e-7,0.000046272737,0.00027043177,0.0005532582,0.8814835],"study_design_scores_gemma":[0.021721534,0.011313481,0.07898721,0.0006005248,0.00006353393,0.000044778008,0.00055544666,0.0002945788,0.0002527249,0.0019919085,0.88393956,0.00023473156],"about_ca_topic_score_codex":0.000029454273,"about_ca_topic_score_gemma":0.0001903538,"teacher_disagreement_score":0.8833863,"about_ca_system_score_codex":0.000031534124,"about_ca_system_score_gemma":0.00025592235,"threshold_uncertainty_score":0.4492497},"labels":[],"label_agreement":null},{"id":"W2296997770","doi":"10.1016/j.clinthera.2016.02.023","title":"Biosimilars: A Multidisciplinary Perspective","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Amgen Canada; Teva Pharmaceutical Industries","keywords":"Biosimilar; Medicine; Pharmacovigilance; Multidisciplinary approach; Intensive care medicine; Pharmacology; Adverse effect; Internal medicine","score_opus":0.1402305023316203,"score_gpt":0.4411171042591477,"score_spread":0.30088660192752736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296997770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40917763,0.04290963,0.07833032,0.36887124,0.021047523,0.0027543707,0.0007183859,0.0019910794,0.0741998],"genre_scores_gemma":[0.97451866,0.00210899,0.0050951503,0.007757757,0.00029290305,0.0000133682415,0.000003054594,0.000042331332,0.010167782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798447,0.00061080896,0.00051663234,0.0004597559,0.00004045787,0.00038790514],"domain_scores_gemma":[0.99761504,0.0016236193,0.00011467765,0.0004455174,0.0001478897,0.00005324308],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009806433,0.00019227443,0.0003779862,0.000046120258,0.00011861142,0.0000100871475,0.00031129483,0.00053605984,0.0011004674],"category_scores_gemma":[0.0003220598,0.000100807425,0.0003276497,0.00013583609,0.0010286929,0.00005264817,0.00015421814,0.00033187546,0.0005511149],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015021126,0.0024460917,0.070010275,0.000013987109,0.00244259,0.000032306783,0.00040722694,1.3515303e-7,0.29933342,0.03607286,0.014460759,0.57327825],"study_design_scores_gemma":[0.008817505,0.0028956793,0.09073418,0.0001984774,0.00065611734,0.00007376583,0.000987303,0.00003098614,0.09082961,0.063180186,0.7403694,0.0012268091],"about_ca_topic_score_codex":0.0000016915241,"about_ca_topic_score_gemma":0.0000024496724,"teacher_disagreement_score":0.72590864,"about_ca_system_score_codex":0.000045516,"about_ca_system_score_gemma":0.00005438814,"threshold_uncertainty_score":0.99981266},"labels":[],"label_agreement":null},{"id":"W2320041514","doi":"10.1016/j.clinthera.2016.03.024","title":"Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Metformin; Medicine; Concomitant; Internal medicine; Retrospective cohort study; Hazard ratio; Proportional hazards model; Cohort study; Confounding; Cohort; Proton-pump inhibitor; Confidence interval; Insulin","score_opus":0.06983626572215627,"score_gpt":0.3746050386675284,"score_spread":0.30476877294537214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320041514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955931,0.00006318109,0.000098868135,0.00032142646,0.00014974592,0.0033506372,0.000010007939,0.000035715435,0.00037735217],"genre_scores_gemma":[0.99803996,0.0004671908,0.0003223943,0.00019195794,0.00008472211,0.00007245107,0.000007077844,0.00001682821,0.00079739594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986703,0.00009793324,0.000592002,0.00026616806,0.00023517323,0.00013843212],"domain_scores_gemma":[0.999001,0.00033063546,0.0001867454,0.00030285405,0.000105096326,0.0000736427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008125709,0.0001245538,0.0005073571,0.00004343022,0.000030651838,0.000009934652,0.000040753966,0.000083055216,0.000027386035],"category_scores_gemma":[0.00016553067,0.000070906004,0.00009117577,0.000085860236,0.00011488071,0.00009398377,0.00005516194,0.00008307441,0.000004738612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005526471,0.0009176709,0.955791,0.000017502374,0.0007507066,0.000005096805,0.000051880044,3.285583e-8,0.00012670761,0.0004297664,0.000013036371,0.041343972],"study_design_scores_gemma":[0.0050914166,0.0031009188,0.9871508,0.00008733138,0.0007278186,8.160022e-7,0.000052425374,0.00002478864,0.0004261255,0.00040708572,0.0028447828,0.00008570249],"about_ca_topic_score_codex":0.000012119203,"about_ca_topic_score_gemma":0.0000066083794,"teacher_disagreement_score":0.04125827,"about_ca_system_score_codex":0.00008844149,"about_ca_system_score_gemma":0.000017673943,"threshold_uncertainty_score":0.2891463},"labels":[],"label_agreement":null},{"id":"W2325862423","doi":"10.1016/j.clinthera.2016.03.008","title":"Patient-reported Symptoms of Tenosynovial Giant Cell Tumors","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; Plexxikon; Five Prime Therapeutics","keywords":"Medicine; Clinical significance; Ankle; Elbow; Physical therapy; Forearm; Internal medicine; Surgery; Oncology","score_opus":0.05029915522095849,"score_gpt":0.34106321151451385,"score_spread":0.29076405629355534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325862423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99255955,0.00020710843,0.00018755357,0.0005944323,0.0004231534,0.00035440634,0.000025018786,0.000053418342,0.0055953427],"genre_scores_gemma":[0.9967678,0.00018716708,0.0003717556,0.00086301356,0.00019087279,0.000008280997,0.000009305885,0.000030519026,0.0015712915],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979656,0.000082407394,0.0010644244,0.0002834401,0.00031116104,0.00029300037],"domain_scores_gemma":[0.99848443,0.0003264256,0.00035099292,0.00048158388,0.00015051526,0.00020604822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021691463,0.00018465113,0.0005361739,0.000042079937,0.000037287322,0.000005095715,0.00008640156,0.00016627491,0.00025389594],"category_scores_gemma":[0.00007820283,0.00009999345,0.00040243598,0.000113229034,0.00029102247,0.000044762488,0.000059750557,0.00013295416,0.000034806733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008759487,0.0025485952,0.36949083,0.000096837444,0.0008531808,0.00014164823,0.000091619004,2.6641837e-7,0.01124031,0.0006624814,0.00013091744,0.61386734],"study_design_scores_gemma":[0.03268437,0.028796975,0.72333425,0.0012455418,0.0026733216,0.00020423914,0.0002451482,0.00011817168,0.07655013,0.0024936146,0.13042314,0.0012311105],"about_ca_topic_score_codex":0.000019510351,"about_ca_topic_score_gemma":0.000001332433,"teacher_disagreement_score":0.61263627,"about_ca_system_score_codex":0.000035945603,"about_ca_system_score_gemma":0.00012134724,"threshold_uncertainty_score":0.40776145},"labels":[],"label_agreement":null},{"id":"W2410408783","doi":"10.1016/j.clinthera.2010.02.009","title":"","year":2010,"lang":"en","type":"letter","venue":"Clinical Therapeutics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bioequivalence; Medicine; Medical physics; Pharmacology; Pharmacokinetics","score_opus":0.876935786707712,"score_gpt":0.6757686286756017,"score_spread":0.20116715803211027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410408783","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012791753,0.00013653934,0.07220646,0.8971124,0.023321943,0.0031449303,0.0007191403,0.0013613594,0.00071803835],"genre_scores_gemma":[0.000019705452,0.0004941894,0.44790843,0.5025024,0.04732828,0.00017597295,0.00003823336,0.00058342033,0.0009494137],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.95587236,0.018411053,0.014794867,0.00425063,0.0034031377,0.0032679653],"domain_scores_gemma":[0.4574779,0.52900535,0.004880963,0.006742812,0.0011895129,0.0007034893],"candidate_categories":["metaresearch","metaepi_narrow","sts","open_science","research_integrity"],"consensus_categories":["metaresearch","metaepi_narrow","research_integrity"],"category_scores_codex":[0.037429236,0.002796024,0.009782285,0.0003541564,0.0005350096,0.0005372208,0.0061372467,0.0470534,0.00065551326],"category_scores_gemma":[0.35343856,0.0022996871,0.0051754806,0.00083508604,0.005394887,0.00019516078,0.0013445942,0.109906614,0.00014646584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004152901,0.0011647787,0.00077854434,0.00065735064,0.0026023872,0.0015875513,0.000059838145,1.1887262e-7,0.00003449313,0.008026936,0.909088,0.075584695],"study_design_scores_gemma":[0.0022472143,0.0007792296,0.00009599373,0.00020595593,0.0021653622,0.00003827127,0.0000078350295,0.000056326982,0.000054052765,0.5145257,0.47838274,0.001441311],"about_ca_topic_score_codex":0.000010736084,"about_ca_topic_score_gemma":0.000017347655,"teacher_disagreement_score":0.51059425,"about_ca_system_score_codex":0.00015485297,"about_ca_system_score_gemma":0.0008141387,"threshold_uncertainty_score":0.99924004},"labels":[],"label_agreement":null},{"id":"W2417060762","doi":"10.1016/j.clinthera.2009.07.025","title":"Foreword","year":2009,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Medicine","score_opus":0.1688052042258913,"score_gpt":0.4739794879269202,"score_spread":0.3051742837010289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417060762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6596065,0.0021069443,0.004729438,0.07062375,0.0019720152,0.0004375225,0.0000051325487,0.00043638918,0.26008233],"genre_scores_gemma":[0.97436774,0.0013925077,0.00065188855,0.01760446,0.0011365793,8.6254784e-7,8.078526e-7,0.000005247566,0.004839919],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990521,0.00014628157,0.00027067168,0.00013966589,0.00015975365,0.00023152528],"domain_scores_gemma":[0.9993214,0.00027906123,0.000055672896,0.00018269081,0.000058643807,0.00010250611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007514296,0.00006077635,0.00013988247,0.000016214195,0.00021689042,0.000029481369,0.0002224748,0.00013953193,0.0002293952],"category_scores_gemma":[0.00013626761,0.000053762622,0.00013232061,0.00013395169,0.00003153903,0.00008542796,0.000009156088,0.00017586199,0.00013745195],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037291873,0.00023704751,0.04604056,9.807313e-7,0.000026531496,0.000008442317,0.0013788104,7.952288e-7,0.000013234887,0.16818675,0.0071317526,0.7769378],"study_design_scores_gemma":[0.00032018955,0.00019769372,0.09920119,0.0000067861147,0.000023937917,2.6116825e-7,0.00022439398,0.000040703024,0.000010370643,0.06443922,0.8354157,0.00011952852],"about_ca_topic_score_codex":0.0000065289632,"about_ca_topic_score_gemma":0.000043604407,"teacher_disagreement_score":0.82828397,"about_ca_system_score_codex":0.000017286908,"about_ca_system_score_gemma":0.000087404755,"threshold_uncertainty_score":0.25117165},"labels":[],"label_agreement":null},{"id":"W2465354100","doi":"10.1016/s0149-2918(05)00164-5","title":"The authors' reply","year":2005,"lang":"en","type":"letter","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Vancouver General Hospital","funders":"","keywords":"Medicine","score_opus":0.11443495608230483,"score_gpt":0.42163994791307274,"score_spread":0.3072049918307679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465354100","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003768873,0.007838055,0.000035643217,0.98389995,0.0021309613,0.00042890702,0.000020854346,0.00014897807,0.005119738],"genre_scores_gemma":[0.00021721477,0.002628159,0.00013941932,0.9111706,0.032436345,0.000017921326,0.000056943496,0.00009080992,0.0532426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971857,0.0003817715,0.0009924526,0.00047250147,0.0005037316,0.00046384532],"domain_scores_gemma":[0.9964189,0.0016415281,0.00030960183,0.0012897495,0.00016056307,0.00017965179],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007442663,0.0003175339,0.00062010775,0.00003652681,0.00023703722,0.000062442974,0.00037304804,0.0012434025,0.00016718268],"category_scores_gemma":[0.0002997537,0.00017160347,0.000832977,0.00010528429,0.0006879701,0.000019436971,0.00007522804,0.0038845849,0.00045597492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008368872,0.00007404079,0.00085209234,0.000026295591,0.00020632781,0.00023015488,0.000007773013,1.195672e-7,8.885652e-7,0.000011019445,0.78122354,0.21728404],"study_design_scores_gemma":[0.00056300213,0.00039024325,0.0018903228,0.00008862561,0.0005700671,0.000028882569,0.000012404376,0.000037940234,0.000003859746,0.00015721387,0.9960452,0.000212251],"about_ca_topic_score_codex":6.673648e-7,"about_ca_topic_score_gemma":5.422842e-7,"teacher_disagreement_score":0.21707179,"about_ca_system_score_codex":0.000042357926,"about_ca_system_score_gemma":0.00041355798,"threshold_uncertainty_score":0.9984135},"labels":[],"label_agreement":null},{"id":"W2494843548","doi":"10.1016/j.clinthera.2016.07.002","title":"Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Rivaroxaban; Warfarin; Deep vein; Thrombosis; Heparin; Low molecular weight heparin; Anticoagulant; Intensive care medicine; Emergency medicine; Internal medicine; Atrial fibrillation","score_opus":0.043988631665709765,"score_gpt":0.3406257140647052,"score_spread":0.29663708239899544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494843548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959717,0.00028658673,0.00055925536,0.0013697295,0.000040632687,0.0012127334,0.000014017728,0.00003706305,0.0005083053],"genre_scores_gemma":[0.9960128,0.000358872,0.00028520738,0.0031562517,0.00003049169,0.00004320612,0.00005804334,0.00004530866,0.000009797397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998324,0.00026264196,0.000436907,0.00039716845,0.00029800573,0.00028128666],"domain_scores_gemma":[0.99892414,0.00027388314,0.00020327221,0.00036840362,0.00011407539,0.00011622037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002909508,0.00021014614,0.00040519418,0.00006689946,0.00013822508,0.00004010037,0.00009552362,0.00010577369,0.000008145885],"category_scores_gemma":[0.00005577826,0.00010761013,0.000041298736,0.00022093795,0.00027525786,0.00006277594,0.000056202563,0.00014729025,0.0000011601144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025014373,0.00092947995,0.97114056,0.000049971746,0.00018937506,0.0000020816062,0.002262074,0.0000065420304,8.0728137e-7,0.00037855652,0.000052411604,0.024737999],"study_design_scores_gemma":[0.00707597,0.003114922,0.98506653,0.00032225967,0.000270266,2.4350547e-7,0.00074449973,0.000105400606,0.000015505208,0.000014570254,0.0030998385,0.00016996467],"about_ca_topic_score_codex":0.000068604524,"about_ca_topic_score_gemma":0.00026509378,"teacher_disagreement_score":0.024568034,"about_ca_system_score_codex":0.00008259193,"about_ca_system_score_gemma":0.000038755836,"threshold_uncertainty_score":0.4388214},"labels":[],"label_agreement":null},{"id":"W2496344581","doi":"10.1016/j.clinthera.2016.07.001","title":"Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort Study","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Health Canada; START Clinic; Ontario Centre of Excellence for Child and Youth Mental Health","funders":"","keywords":"Methylphenidate; Medicine; Persistence (discontinuity); Attention deficit hyperactivity disorder; Confounding; Cohort; Population; Retrospective cohort study; Cohort study; Psychiatry; Pediatrics; Internal medicine; Environmental health","score_opus":0.07288785412241734,"score_gpt":0.3778513759225084,"score_spread":0.30496352180009106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2496344581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867418,0.000046630776,0.0085205175,0.0010191015,0.00023282618,0.003097406,0.00024647426,0.000059642574,0.000035622474],"genre_scores_gemma":[0.99824166,0.00026281737,0.00032807313,0.00008877071,0.000093543465,0.0003923872,0.00041720146,0.000055548448,0.00011998471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971322,0.00036490517,0.0010425455,0.000731084,0.00038808907,0.00034118278],"domain_scores_gemma":[0.99640614,0.0011812388,0.000990779,0.0005902876,0.00050932623,0.00032224477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064281205,0.0003343561,0.0007580374,0.0002606991,0.00037756993,0.000031927382,0.00010345308,0.00022435702,0.00008008109],"category_scores_gemma":[0.00067898975,0.00024042962,0.00031460205,0.00023404666,0.0001568209,0.00030811498,0.0000165715,0.00015581102,0.0000046018263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017017558,0.0025657713,0.9411148,0.000015624708,0.00091266574,0.0000010986894,0.00014025474,0.000005227662,0.00018038641,0.000029466268,4.9473783e-7,0.054864038],"study_design_scores_gemma":[0.007652355,0.002385606,0.9834996,0.00010685014,0.0020733702,0.0000013748723,0.0009358188,0.003026843,0.000007574878,0.000035787798,0.00004056096,0.00023426188],"about_ca_topic_score_codex":0.014877433,"about_ca_topic_score_gemma":0.044706274,"teacher_disagreement_score":0.054629777,"about_ca_system_score_codex":0.00096909737,"about_ca_system_score_gemma":0.00044151233,"threshold_uncertainty_score":0.9916826},"labels":[],"label_agreement":null},{"id":"W2515998798","doi":"10.1016/j.clinthera.2016.07.010","title":"Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study","year":2016,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Teva Pharmaceutical Industries; Genentech; GlaxoSmithKline","keywords":"Mepolizumab; Medicine; Asthma; Term (time); Open label; Adverse effect; Internal medicine; Eosinophil","score_opus":0.10297390262574992,"score_gpt":0.4248186128161392,"score_spread":0.3218447101903893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515998798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974188,0.00031090053,0.00007879456,0.00017363904,0.00009622967,0.001799928,0.00006027925,0.000022185939,0.000039245326],"genre_scores_gemma":[0.9988793,0.00017260452,0.00019117318,0.0005315755,0.000057531568,0.00001477139,0.000011794806,0.00003659766,0.000104666244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790776,0.00026369953,0.0008451356,0.00044165013,0.00027627757,0.00026549137],"domain_scores_gemma":[0.9984712,0.00036355655,0.00024364347,0.0005159473,0.00015143593,0.0002542439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003027233,0.00023053837,0.00068649085,0.00007008869,0.000055309985,0.000015989772,0.00022546922,0.00012754407,0.000033672855],"category_scores_gemma":[0.00010983188,0.00012652705,0.000053325715,0.00015313528,0.00035622943,0.00010361569,0.00018677345,0.00019856557,0.0000075157013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011159021,0.056928776,0.7010384,0.000028356568,0.00016687227,0.000038883678,0.000098564895,6.7019315e-8,0.000032288393,0.0000031668499,0.0000053959393,0.2305002],"study_design_scores_gemma":[0.21598022,0.011396425,0.77147657,0.0003668017,0.0001374442,0.000004505105,0.000035154964,0.0000071327627,0.000016346268,0.0000032414382,0.0004281591,0.00014799078],"about_ca_topic_score_codex":0.0000030774572,"about_ca_topic_score_gemma":0.000014434747,"teacher_disagreement_score":0.23035222,"about_ca_system_score_codex":0.00004080392,"about_ca_system_score_gemma":0.0001509678,"threshold_uncertainty_score":0.51596236},"labels":[],"label_agreement":null},{"id":"W2555880059","doi":"10.1016/j.clinthera.2016.09.020","title":"Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges","year":2016,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Diabetes Canada; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Hypoglycemia; Medicine; Glycemic; Intensive care medicine; Basal insulin; Basal (medicine); Diabetes mellitus; Type 2 diabetes; Insulin; Limiting; Type 1 diabetes; Internal medicine; Endocrinology","score_opus":0.38455393878351074,"score_gpt":0.4974917910868799,"score_spread":0.11293785230336917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555880059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006473439,0.98961055,0.000003071192,0.0010138139,0.00082259695,0.00083668577,0.000009972802,0.00008507516,0.0075534983],"genre_scores_gemma":[0.000014365274,0.9917833,0.00018973017,0.0009931966,0.0014803933,0.000021265314,0.000034001092,0.00011699808,0.005366703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970196,0.00036695055,0.0009985439,0.00066368055,0.00038147406,0.000569735],"domain_scores_gemma":[0.99652106,0.0020394956,0.00027324609,0.00075583375,0.00011442069,0.00029593872],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015184942,0.00043009626,0.0021988845,0.00018902779,0.00006077126,0.000048433438,0.00030971982,0.00077509345,0.00012052029],"category_scores_gemma":[0.00041732995,0.00025532368,0.0005145929,0.00021991205,0.0004122414,0.000050740513,0.00035105765,0.0010336713,0.00054433534],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026604792,0.0001795074,0.00015104943,0.009346172,0.001064143,0.000016857175,0.0000070809274,1.7269343e-9,1.6161208e-7,0.00016859562,0.00045480108,0.98858505],"study_design_scores_gemma":[0.00088368426,0.0008523979,0.00014606028,0.014486928,0.0013350629,0.0000012975972,0.000005631367,0.000011794901,2.1751558e-7,0.0003602594,0.9816152,0.00030147587],"about_ca_topic_score_codex":1.4623012e-7,"about_ca_topic_score_gemma":3.650047e-7,"teacher_disagreement_score":0.9882836,"about_ca_system_score_codex":0.000055292476,"about_ca_system_score_gemma":0.00024594238,"threshold_uncertainty_score":0.9999899},"labels":[],"label_agreement":null},{"id":"W2562743482","doi":"10.1016/j.clinthera.2016.11.002","title":"SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis","year":2016,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":344,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto; Winnipeg Regional Health Authority; Health Sciences Centre; University of Manitoba; LMC Diabetes & Endocrinology (Canada)","funders":"Yale University; AstraZeneca","keywords":"Medicine; Diabetic ketoacidosis; Diabetes mellitus; Glycemic; Intensive care medicine; Insulin; Ketoacidosis; Type 2 diabetes; Internal medicine; Type 1 diabetes; Endocrinology","score_opus":0.12819718465208363,"score_gpt":0.4582817856458242,"score_spread":0.3300846009937406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562743482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010482352,0.99577683,0.00007997915,0.0015341275,0.00052142434,0.0015120257,0.00039973165,0.000023071936,0.000047959766],"genre_scores_gemma":[0.000040325504,0.99462706,0.00021867768,0.0025975287,0.00042999256,0.00056843343,0.0008225704,0.000083444625,0.0006119604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609864,0.0009465695,0.0016983852,0.0007871485,0.00009722852,0.00037201878],"domain_scores_gemma":[0.99710196,0.001214743,0.00093355105,0.00041988346,0.00014706877,0.00018277856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019956385,0.00041983076,0.0017715778,0.000037942325,0.00012849263,0.00005122549,0.00022434734,0.0010717858,0.000020479012],"category_scores_gemma":[0.0013779497,0.0003194118,0.0009712131,0.00011448736,0.00025861908,0.0000070473197,0.00018926307,0.0003416646,0.000008267207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004874691,0.00030342594,0.00091055024,0.0026383218,0.001160348,1.17318756e-7,0.0000015049792,1.9071031e-9,3.2528467e-7,0.000018845056,0.010510227,0.9844515],"study_design_scores_gemma":[0.00084275706,0.0007382684,0.00007138775,0.01414525,0.004048549,7.3077746e-7,0.000004596061,0.0000011885478,0.0000012121714,0.0003288615,0.9794037,0.0004135066],"about_ca_topic_score_codex":4.3246834e-7,"about_ca_topic_score_gemma":0.000004387561,"teacher_disagreement_score":0.98403794,"about_ca_system_score_codex":0.00002038567,"about_ca_system_score_gemma":0.00014349582,"threshold_uncertainty_score":0.9999258},"labels":[],"label_agreement":null},{"id":"W2581166057","doi":"10.1016/j.clinthera.2017.01.006","title":"Factors Associated with the Use of Hyaluronic Acid and Corticosteroid Injections among Patients with Radiographically Confirmed Knee Osteoarthritis: A Retrospective Data Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; McMaster University","keywords":"Medicine; Osteoarthritis; Odds ratio; Corticosteroid; Confidence interval; Logistic regression; Internal medicine; Physical therapy; Hyaluronic acid; Radiography; Surgery; Pathology","score_opus":0.14598287254386777,"score_gpt":0.33804984858148135,"score_spread":0.19206697603761358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581166057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812263,0.0001622439,0.00015954782,0.00020009931,0.00009257325,0.00086442503,0.00032184407,0.00003979289,0.000036865637],"genre_scores_gemma":[0.9990248,0.00008900385,0.00016668797,0.00019361901,0.000027611766,0.000017066928,0.00035748899,0.00003259355,0.00009113341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817586,0.00017400402,0.0004744312,0.000506729,0.00039704415,0.0002719563],"domain_scores_gemma":[0.99668604,0.00048990664,0.0006535226,0.001655264,0.00034722296,0.00016801637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002902042,0.0002484565,0.00077115925,0.00010736052,0.00038411558,0.00013240572,0.00025847196,0.00019280505,0.000017327575],"category_scores_gemma":[0.00034082966,0.00013723693,0.00017556209,0.00032034054,0.0013213455,0.0002723308,0.00013803014,0.00040701497,4.4439153e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049616257,0.0004969141,0.9839163,0.0000035016342,0.0035548615,0.000007412717,0.00011110216,6.7008693e-7,0.000031532716,0.000026598023,0.0000057662064,0.011349218],"study_design_scores_gemma":[0.008068662,0.01215291,0.9720716,0.00011689825,0.0070165303,0.000001174657,0.00008595147,0.000120690886,0.00005627504,0.000025605654,0.00012371545,0.00016000455],"about_ca_topic_score_codex":0.000022238039,"about_ca_topic_score_gemma":0.0015740892,"teacher_disagreement_score":0.011844678,"about_ca_system_score_codex":0.000028921842,"about_ca_system_score_gemma":0.00007714407,"threshold_uncertainty_score":0.559636},"labels":[],"label_agreement":null},{"id":"W2587616376","doi":"10.1016/j.clinthera.2017.01.007","title":"A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"AstraZeneca","keywords":"Insulin degludec; Medicine; Insulin glargine; Glycemic; Hypoglycemia; Insulin; Diabetes mellitus; Type 1 diabetes; Type 2 Diabetes Mellitus; Internal medicine; Insulin analog; Insulin detemir; Endocrinology; Intensive care medicine; Human insulin","score_opus":0.3637011875830971,"score_gpt":0.5317562355104855,"score_spread":0.16805504792738835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587616376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018305205,0.9936341,8.705914e-7,0.00082513946,0.00016578882,0.0030756558,0.000038043494,0.000004557464,0.00042531735],"genre_scores_gemma":[0.00044464765,0.99858636,0.00008727853,0.00045562992,0.00016644516,0.00003061281,0.000024685984,0.000030358402,0.00017400605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99451035,0.0016063885,0.0027974935,0.00040647248,0.00040270414,0.00027657452],"domain_scores_gemma":[0.99089646,0.0059930724,0.0013745163,0.0015043563,0.00013516632,0.00009645233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055870786,0.00033644342,0.0039731534,0.0000835836,0.000050807215,0.000012804898,0.0006110573,0.00038810028,0.000016915323],"category_scores_gemma":[0.0011385173,0.00014472537,0.0010196047,0.00027945326,0.001598869,0.000021195641,0.00021889126,0.0006298658,0.0000019688625],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007265147,0.001641791,0.006546891,0.047047988,0.0009879963,0.0000019828092,0.000031349744,1.09293845e-8,7.504571e-8,0.00008199622,0.000056391036,0.94353086],"study_design_scores_gemma":[0.0026538419,0.0018687621,0.015600613,0.0733607,0.004078229,8.20827e-7,0.000006061132,0.000007991836,6.313107e-7,0.00006898178,0.9022401,0.00011326399],"about_ca_topic_score_codex":0.0000024978158,"about_ca_topic_score_gemma":0.0000027574458,"teacher_disagreement_score":0.9434176,"about_ca_system_score_codex":0.000021558193,"about_ca_system_score_gemma":0.00025141833,"threshold_uncertainty_score":0.59017295},"labels":[],"label_agreement":null},{"id":"W2602447991","doi":"10.1016/j.clinthera.2017.02.012","title":"Cost-effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary Prevention","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Food composition and properties","field":"Nursing","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Institute of Nutrition, Metabolism and Diabetes; PepsiCo","keywords":"Medicine; Myocardial infarction; Population; Coronary heart disease; Glucan; Internal medicine; Statin; Disease; Cholesterol; Environmental health","score_opus":0.25358479313547616,"score_gpt":0.45061023447045045,"score_spread":0.1970254413349743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602447991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931913,0.0005050639,0.0018017803,0.0013427233,0.0013382852,0.0012578635,0.000061269755,0.00003919762,0.00046250722],"genre_scores_gemma":[0.9975324,0.000033439843,0.0013296196,0.0008262282,0.000113665104,0.000048412792,0.0000393727,0.000026452635,0.00005039739],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984469,0.00046170666,0.00055187783,0.00022045297,0.00015187499,0.00016720778],"domain_scores_gemma":[0.9978388,0.0009782122,0.0003737285,0.000552317,0.00016701633,0.00008992282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012221079,0.00012350063,0.0004122125,0.000031515377,0.00019172872,0.000030712505,0.00028114076,0.00010356762,0.000012333025],"category_scores_gemma":[0.0001801894,0.00011031413,0.00027804455,0.000028167675,0.00041818185,0.00012515306,0.0000756092,0.00015724766,0.000002587682],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09511644,0.0024326958,0.23782277,0.0015168531,0.00047614836,0.0000033813155,0.00043991525,0.00012891668,0.020924961,0.0015601378,0.00015777539,0.63942003],"study_design_scores_gemma":[0.004326932,0.007268422,0.94791776,0.00093470956,0.00035622105,0.000002846148,0.00012495703,0.0011441115,0.011475403,0.015187833,0.01098565,0.00027512523],"about_ca_topic_score_codex":0.0000048521356,"about_ca_topic_score_gemma":0.0000016281901,"teacher_disagreement_score":0.71009505,"about_ca_system_score_codex":0.000038009628,"about_ca_system_score_gemma":0.000077188895,"threshold_uncertainty_score":0.44984797},"labels":[],"label_agreement":null},{"id":"W2606513711","doi":"10.1016/j.clinthera.2017.03.014","title":"Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Arthritis Society; Pfizer","keywords":"Biosimilar; Medicine; Tolerability; Interchangeability; Pharmacovigilance; Comparability; Harmonization; Intensive care medicine; Risk analysis (engineering); Pharmacology; Adverse effect; Internal medicine; Computer science","score_opus":0.5280349009826678,"score_gpt":0.5524155657184614,"score_spread":0.02438066473579359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606513711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025402458,0.99488246,0.000007963034,0.0023416206,0.0015350911,0.0007197348,0.000081670594,0.000026241165,0.000402702],"genre_scores_gemma":[0.000004685299,0.9952931,0.00050119165,0.003002611,0.00010746667,0.000013522552,0.000013984917,0.000029672938,0.001033767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953204,0.002003955,0.0017326808,0.00054237794,0.000060837636,0.00033979185],"domain_scores_gemma":[0.99524605,0.0017241889,0.001491615,0.0013736557,0.00012375665,0.00004075864],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028436582,0.0004584087,0.0037077614,0.000040555897,0.00020522616,0.000024416526,0.0012104533,0.0013417493,0.00008961535],"category_scores_gemma":[0.001223432,0.0002191183,0.0012333249,0.00014431759,0.0021302865,0.00002408518,0.00058320136,0.0014148275,0.000027328306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010029329,0.00011828992,0.00027870742,0.023200283,0.0010360294,0.0000014131369,0.0000035061587,8.7464863e-10,0.0000025340212,0.00058995275,0.0044426313,0.97031665],"study_design_scores_gemma":[0.0001932759,0.00015047174,0.000055850072,0.06241169,0.002812061,0.000028799011,0.0000021807705,7.1707916e-7,0.000014024798,0.0003208044,0.93374974,0.00026039124],"about_ca_topic_score_codex":0.0000017113398,"about_ca_topic_score_gemma":0.000001081794,"teacher_disagreement_score":0.97005624,"about_ca_system_score_codex":0.000020939337,"about_ca_system_score_gemma":0.0001776768,"threshold_uncertainty_score":0.9999547},"labels":[],"label_agreement":null},{"id":"W2617411803","doi":"10.1016/j.clinthera.2017.04.012","title":"Impact of a Multidisciplinary Heart Failure Postdischarge Management Clinic on Medication Adherence","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; University Health Network","funders":"VA Greater Los Angeles Healthcare System","keywords":"Medicine; Veterans Affairs; Retrospective cohort study; Confounding; Internal medicine; Heart failure; Logistic regression; Emergency medicine; Medication adherence; Multivariate analysis","score_opus":0.21203913768317195,"score_gpt":0.5122446090466707,"score_spread":0.30020547136349873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617411803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781958,0.00017051316,0.00047219818,0.0087402575,0.00055164756,0.0008048088,0.000016879905,0.00005807787,0.010989852],"genre_scores_gemma":[0.9913456,0.000725782,0.0029526653,0.0011962801,0.00021209235,0.00003348258,0.000022756834,0.0000196304,0.003491741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980522,0.000096943826,0.0008113389,0.00038822062,0.00041726755,0.00023403659],"domain_scores_gemma":[0.99714494,0.00025733182,0.0005961562,0.0016118034,0.00014750718,0.00024225726],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008170649,0.00017432364,0.0004828372,0.00005279704,0.0001749208,0.00002092132,0.00046708243,0.00018947551,0.0014516865],"category_scores_gemma":[0.00021687323,0.00012548725,0.000389066,0.00007132238,0.00044852603,0.000074483556,0.000112413974,0.00042511316,0.0015446285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010363325,0.0023396593,0.9189854,0.0001311952,0.00064780214,0.000014510155,0.00009426333,9.2809915e-7,0.00067841844,0.0007090308,0.013392694,0.061969712],"study_design_scores_gemma":[0.0024373375,0.002655132,0.9868631,0.00044792186,0.00015475054,0.000006717242,0.00007726387,0.00043317085,0.00011682741,0.00067953154,0.005996052,0.00013219635],"about_ca_topic_score_codex":0.000006597984,"about_ca_topic_score_gemma":9.910278e-7,"teacher_disagreement_score":0.06787764,"about_ca_system_score_codex":0.000033699234,"about_ca_system_score_gemma":0.00016503643,"threshold_uncertainty_score":0.9994611},"labels":[],"label_agreement":null},{"id":"W2620812925","doi":"10.1016/j.clinthera.2017.05.343","title":"Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks’ Gestation and >7 Days of age","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Gentamicin; Dosing; Gestation; Gestational age; Pediatrics; Pregnancy; Antibiotics; Internal medicine","score_opus":0.08690911255659305,"score_gpt":0.4143771514170336,"score_spread":0.3274680388604405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620812925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664414,0.0009495472,0.00019132544,0.00075100607,0.00023085372,0.00024955077,0.000014044826,0.000010860345,0.0009586776],"genre_scores_gemma":[0.9948606,0.0028003596,0.0016290477,0.00034229897,0.00009898859,4.5264466e-7,0.000014518322,0.000022657861,0.00023106048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866116,0.0000699631,0.0006920804,0.00022708085,0.00017903587,0.0001706633],"domain_scores_gemma":[0.9987042,0.0002957022,0.0004078434,0.00041541512,0.000093452756,0.00008339397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005454139,0.00013212074,0.00048385718,0.00005401777,0.00005698352,0.000017167871,0.00015659697,0.00018072226,0.000020174068],"category_scores_gemma":[0.0001586337,0.000108923916,0.00012001146,0.000042833686,0.00042240648,0.00004134565,0.0001339842,0.0002822271,0.0000021012875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027503,0.0020078882,0.49583215,0.0008424567,0.00054803514,0.00014095135,0.0016907521,0.000037715796,0.26519474,0.0017084279,0.00027865762,0.22896792],"study_design_scores_gemma":[0.003867709,0.00068214076,0.96308607,0.00050182815,0.00030161807,0.000013656451,0.00006375058,0.00945443,0.018576387,0.00060680456,0.002707886,0.00013769687],"about_ca_topic_score_codex":0.000009099695,"about_ca_topic_score_gemma":0.000012185952,"teacher_disagreement_score":0.46725395,"about_ca_system_score_codex":0.000018976873,"about_ca_system_score_gemma":0.000030389969,"threshold_uncertainty_score":0.44417885},"labels":[],"label_agreement":null},{"id":"W2629949851","doi":"10.1016/j.clinthera.2017.05.014","title":"The Pharmacodynamic Effects of Rituximab at Very Low Doses","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Medicine; Rituximab; Pharmacokinetics; Biosimilar; Pharmacodynamics; Dosing; Pharmacology; Randomized controlled trial; Internal medicine; Immunogenicity; Gastroenterology; Immunology; Antibody; Lymphoma","score_opus":0.06536303396905699,"score_gpt":0.4256538472883188,"score_spread":0.3602908133192618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2629949851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96501815,0.016482757,0.00040824982,0.0053049866,0.008843136,0.0004915791,0.000034432578,0.00006517239,0.003351543],"genre_scores_gemma":[0.9884592,0.005894283,0.00021730603,0.0013081392,0.000101434714,0.0000054305174,0.0000026726866,0.00001465312,0.0039968323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998459,0.00048482168,0.00048732193,0.00023067952,0.000042000833,0.00029619844],"domain_scores_gemma":[0.9950348,0.003759208,0.00032739036,0.0007831208,0.00006580972,0.000029666578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095872313,0.00014621965,0.0003999066,0.000013077643,0.0006698206,0.000029117338,0.00072242523,0.00035267428,0.00008564527],"category_scores_gemma":[0.00055290095,0.000083213905,0.00031059905,0.000028989954,0.001989577,0.00003348847,0.00028449408,0.00042854217,0.00010916512],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014798162,0.0014022146,0.025248805,0.00011761992,0.0020636336,0.000014184415,0.00004783778,3.055573e-7,0.20016831,0.002013023,0.0026005064,0.76484376],"study_design_scores_gemma":[0.008905085,0.0010092395,0.100684114,0.0001376534,0.0008649499,0.000016785953,0.000023234019,0.00024550164,0.3573823,0.0040864516,0.5262074,0.00043732263],"about_ca_topic_score_codex":0.0000033588922,"about_ca_topic_score_gemma":0.000006117741,"teacher_disagreement_score":0.76440644,"about_ca_system_score_codex":0.000015309093,"about_ca_system_score_gemma":0.000031253345,"threshold_uncertainty_score":0.7330679},"labels":[],"label_agreement":null},{"id":"W2638761751","doi":"10.1016/j.clinthera.2017.05.357","title":"Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Ottawa Hospital","funders":"Janssen Scientific Affairs; Sanofi; Amgen","keywords":"Medicine; Rivaroxaban; Cohort; Internal medicine; Retrospective cohort study; Cohort study; Venous thromboembolism; Confounding; Surgery; Warfarin; Atrial fibrillation; Thrombosis","score_opus":0.12558003576822044,"score_gpt":0.4136689628979558,"score_spread":0.28808892712973533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2638761751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339014,0.0001998129,0.0001853158,0.000160288,0.0012903442,0.0032157942,0.00018881945,0.00011413557,0.0012553284],"genre_scores_gemma":[0.9958309,0.0020955,0.0003982091,0.00045186194,0.0004021624,0.00019102315,0.00026260433,0.00012035119,0.0002474083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963955,0.000240127,0.001065598,0.0009339715,0.0006022326,0.00076256384],"domain_scores_gemma":[0.9948855,0.00072345336,0.0015083378,0.0017889735,0.0007468691,0.00034687502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006319775,0.0005693689,0.0018635854,0.00010812129,0.0008471504,0.00028109548,0.0006932762,0.0003423782,0.00004999548],"category_scores_gemma":[0.0006941908,0.0004069018,0.0005623924,0.00014940945,0.0010448787,0.00034865408,0.00017606998,0.00055201474,0.0000165922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022896412,0.0046042646,0.92025024,0.000032620115,0.002855532,0.0000056090353,0.00028926722,0.000004513137,0.0000046267746,0.00004569078,0.000675797,0.06894219],"study_design_scores_gemma":[0.022713283,0.005691614,0.9627698,0.0002963176,0.0023750237,8.62173e-8,0.000054324868,0.00023248202,0.00017320778,0.00012611326,0.005064358,0.0005033886],"about_ca_topic_score_codex":0.0002858057,"about_ca_topic_score_gemma":0.0001657071,"teacher_disagreement_score":0.068438806,"about_ca_system_score_codex":0.00007536501,"about_ca_system_score_gemma":0.000072701805,"threshold_uncertainty_score":0.9998383},"labels":[],"label_agreement":null},{"id":"W2643899025","doi":"10.1016/j.clinthera.2017.06.002","title":"Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Rivaroxaban; Pulmonary embolism; Propensity score matching; Warfarin; Medical prescription; Internal medicine; Anticoagulant; Pharmacy; Emergency medicine; Heparin; Intensive care medicine; Pharmacology","score_opus":0.0485833189251447,"score_gpt":0.36859760766046107,"score_spread":0.32001428873531634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2643899025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372673,0.000073286996,0.000047973663,0.0002566411,0.00027062974,0.00068563357,0.000005236427,0.000016544785,0.00491735],"genre_scores_gemma":[0.9987296,0.0002996055,0.00022971565,0.00054989057,0.00007976037,0.000015991463,0.000012220347,0.000026688997,0.00005653798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869287,0.00013710385,0.00043174802,0.0002747874,0.00024931107,0.00021417078],"domain_scores_gemma":[0.99845034,0.00027252396,0.00025049577,0.0008319313,0.00010932167,0.00008540151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070819433,0.00014545427,0.0007162291,0.000052670657,0.0000712487,0.000019245572,0.00023372225,0.0001250889,0.000022981127],"category_scores_gemma":[0.00009181713,0.000105911764,0.00012750248,0.000041621573,0.00025264447,0.00008045577,0.00011500374,0.00022603254,0.000009200265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009555163,0.003604861,0.9686798,0.00015934408,0.00024020996,0.000018885748,0.00003459845,0.0000056752506,0.000030248342,0.0015527591,0.00001544937,0.02470268],"study_design_scores_gemma":[0.004535896,0.0010892628,0.9911371,0.00041408953,0.00019381473,5.05783e-7,0.000007128614,0.000058995225,0.000109899476,0.0008097313,0.0015221547,0.000121443954],"about_ca_topic_score_codex":0.000041526302,"about_ca_topic_score_gemma":0.000004360561,"teacher_disagreement_score":0.024581237,"about_ca_system_score_codex":0.000029457655,"about_ca_system_score_gemma":0.00004477005,"threshold_uncertainty_score":0.43189564},"labels":[],"label_agreement":null},{"id":"W2657350677","doi":"10.1016/j.clinthera.2017.05.015","title":"On Demand Sildenafil as a Treatment of Raynaud’s Phenomenon: A Series of N-of-1 Trials","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sildenafil; Series (stratigraphy); Dermatology; Internal medicine","score_opus":0.3710701584356086,"score_gpt":0.4936264378309607,"score_spread":0.12255627939535213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2657350677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874195,0.0075213904,0.00001537903,0.0005284114,0.0004426633,0.0005420775,0.00003753246,0.0000117092595,0.0034813606],"genre_scores_gemma":[0.98482066,0.013843453,0.00013743443,0.00014826443,0.00020081634,0.000010765228,0.0000045710667,0.000016895268,0.000817137],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977379,0.00024932425,0.0014527406,0.00019423288,0.00024039877,0.00012544762],"domain_scores_gemma":[0.9962397,0.0013703476,0.0012953687,0.0008315923,0.00014675838,0.000116236355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093326205,0.00014831137,0.0014218199,0.000042525895,0.000056114444,0.000008347944,0.00014643357,0.00021685936,0.00012017028],"category_scores_gemma":[0.0009979722,0.00008802382,0.0006068565,0.000039833078,0.00045340747,0.000026866255,0.000022900007,0.000072101684,0.000009539868],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048032906,0.02643163,0.32442972,0.0013111894,0.019578867,0.00007612047,0.003934038,0.00005768418,0.066286,0.012429729,0.0008943171,0.4965378],"study_design_scores_gemma":[0.107204795,0.107672505,0.48919472,0.013174047,0.019180749,0.000076694225,0.0025047546,0.0003939121,0.22351715,0.016278718,0.019675711,0.0011262328],"about_ca_topic_score_codex":0.00001971609,"about_ca_topic_score_gemma":9.60039e-7,"teacher_disagreement_score":0.49541157,"about_ca_system_score_codex":0.000019654022,"about_ca_system_score_gemma":0.00016406058,"threshold_uncertainty_score":0.35895073},"labels":[],"label_agreement":null},{"id":"W2695054962","doi":"10.1016/s0149-2918(04)00095-5","title":"Corrections","year":2004,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"","keywords":"Medicine; Medical physics","score_opus":0.2675607368681606,"score_gpt":0.47940325895963154,"score_spread":0.21184252209147092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2695054962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9237422,0.0005403427,0.01733383,0.0031184212,0.0062926896,0.00048143463,0.000045752156,0.0015372023,0.04690813],"genre_scores_gemma":[0.99095833,0.00013421736,0.0033558784,0.0042162966,0.0005110137,0.00000810906,0.0000061659593,0.00007266251,0.0007372944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987367,0.000107155145,0.00048419138,0.00024605627,0.00017198575,0.0002539359],"domain_scores_gemma":[0.99889475,0.00033623588,0.00009903891,0.00045041117,0.0000903811,0.00012919585],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005906203,0.00011772498,0.00019914462,0.00003948648,0.00011238815,0.000029054958,0.00021466603,0.00015737655,0.0001506553],"category_scores_gemma":[0.00014636862,0.00010462147,0.00020676557,0.00031321927,0.0002926118,0.0000625066,0.000038128666,0.00041642642,0.0108065335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009255914,0.0124136275,0.33013502,0.000023039222,0.0020787432,0.00010241846,0.001641969,0.0059459773,0.0085339,0.17291115,0.00947273,0.45581585],"study_design_scores_gemma":[0.0042673014,0.00070247403,0.06771048,0.000032689055,0.00023710271,0.000021294829,0.00017488199,0.00046449827,0.0012655029,0.06468914,0.8598962,0.0005384283],"about_ca_topic_score_codex":0.000006961685,"about_ca_topic_score_gemma":0.000018848155,"teacher_disagreement_score":0.85042346,"about_ca_system_score_codex":0.000070666036,"about_ca_system_score_gemma":0.00011250548,"threshold_uncertainty_score":0.98996365},"labels":[],"label_agreement":null},{"id":"W2697100744","doi":"10.1016/j.clinthera.2017.05.346","title":"Uterine Artery Embolization and Surgical Methods for the Treatment of Symptomatic Uterine Leiomyomas: A Systemic Review and Meta-analysis Followed by Indirect Treatment Comparison","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Uterine Myomas and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Uterine artery embolization; Relative risk; Hysterectomy; Meta-analysis; Embolization; Uterine leiomyoma; Randomized controlled trial; Gynecology; Uterine artery; Leiomyoma; Surgery; Obstetrics; Internal medicine; Confidence interval; Pregnancy; Gestation","score_opus":0.500894990419897,"score_gpt":0.5947416131452079,"score_spread":0.09384662272531086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2697100744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010101866,0.991457,0.0018618036,0.00040879878,0.00012338291,0.005520616,0.00046861335,0.000036825757,0.000021935855],"genre_scores_gemma":[0.00021130282,0.9926243,0.0032526574,0.000108194625,0.00009472787,0.0014878195,0.00049800606,0.00007609952,0.0016468947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952475,0.0009931911,0.0024933435,0.00076735776,0.0001914862,0.00030713953],"domain_scores_gemma":[0.99347603,0.003019207,0.0017573647,0.0014288565,0.000111590394,0.00020697276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010003926,0.00085904216,0.013154913,0.00015111515,0.0001602672,0.000069831745,0.00020022171,0.0003642907,0.000055807403],"category_scores_gemma":[0.000048797046,0.00039938424,0.004251697,0.00024929433,0.00024931988,0.000040439198,0.00006595606,0.00013147804,0.0000020289554],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055610883,0.0010306934,0.00019585023,0.013316214,0.29772314,0.000015114808,0.00003971022,8.8794934e-8,1.8951783e-7,0.000008541046,0.000024197509,0.68759066],"study_design_scores_gemma":[0.0013894616,0.0020703594,0.000025996378,0.000620308,0.47696975,0.00013334694,0.0000026942325,0.00022245625,0.0000012161215,0.0000037108307,0.5184009,0.00015980184],"about_ca_topic_score_codex":0.000013957568,"about_ca_topic_score_gemma":0.0000047790227,"teacher_disagreement_score":0.68743086,"about_ca_system_score_codex":0.00012929703,"about_ca_system_score_gemma":0.00010573054,"threshold_uncertainty_score":0.9998458},"labels":[],"label_agreement":null},{"id":"W2748536545","doi":"10.1016/j.clinthera.2017.07.036","title":"Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Natural Science Foundation of China","keywords":"Saxagliptin; Vildagliptin; Alogliptin; Medicine; Sitagliptin; Linagliptin; Internal medicine; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes; Adverse effect; Sitagliptin Phosphate; Placebo; Dipeptidyl peptidase-4; Gastroenterology; Pharmacology; Diabetes mellitus; Randomized controlled trial; Endocrinology; Pathology","score_opus":0.3313066883383314,"score_gpt":0.46532881768452417,"score_spread":0.1340221293461928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748536545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016476713,0.9957038,0.000005559825,0.000075657816,0.000100405494,0.0038535462,0.000023540448,0.000022084474,0.00019892062],"genre_scores_gemma":[0.00008774848,0.99686533,0.0007347708,0.00060097117,0.000090447626,0.00023258077,0.00013032439,0.000053985186,0.0012038365],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99482155,0.0008370346,0.002974329,0.0006028051,0.00034751958,0.0004167577],"domain_scores_gemma":[0.9948285,0.0011042561,0.0022346247,0.001485443,0.00014828173,0.0001988956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028134456,0.00061141275,0.014145874,0.00024112387,0.000044660293,0.000012222839,0.00033935628,0.00018261815,0.00008143632],"category_scores_gemma":[0.0006136833,0.00037539005,0.004510362,0.0006508168,0.00019010558,0.00005221457,0.00021303417,0.0005061666,0.000037607446],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011284958,0.00050828315,0.002254699,0.7585156,0.21933296,0.000040202318,0.0000051990473,0.0000010484858,4.9797095e-9,0.00001580295,0.00011846259,0.01919648],"study_design_scores_gemma":[0.00033280978,0.00045458451,0.00007714605,0.2079492,0.75486565,0.0000042117176,0.000003191237,0.0000147595465,8.98917e-9,0.000017561275,0.036074966,0.00020591696],"about_ca_topic_score_codex":0.0000020133612,"about_ca_topic_score_gemma":0.000005703983,"teacher_disagreement_score":0.5505664,"about_ca_system_score_codex":0.00006404764,"about_ca_system_score_gemma":0.0001297673,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2760923115","doi":"10.1016/j.clinthera.2017.09.006","title":"Enrollment of Neonates in More Than One Clinical Trial","year":2017,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Health Canada; National Institutes of Health","keywords":"Medicine; Observational study; Clinical trial; Population; Intensive care medicine; Pediatrics; Legislature; Family medicine; Environmental health; Internal medicine; Law","score_opus":0.8577238101874483,"score_gpt":0.6899087037792202,"score_spread":0.16781510640822805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760923115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002757361,0.9915141,0.0000050752274,0.0015126307,0.0019553688,0.0021647306,0.000035466364,0.000026744756,0.002510153],"genre_scores_gemma":[0.00025363604,0.9954699,0.00035136731,0.0012024624,0.0020842836,0.00006525504,0.00003611483,0.00006357378,0.00047337316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929819,0.0011496055,0.004213357,0.0006882949,0.0005130542,0.00045378925],"domain_scores_gemma":[0.9875071,0.008782,0.0021216806,0.0011488646,0.00012976403,0.0003105962],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00551115,0.0005004832,0.00615098,0.00009177818,0.00008413028,0.000032257347,0.00062498124,0.0011431779,0.00013119352],"category_scores_gemma":[0.0025615739,0.00032967707,0.0023524777,0.00016405896,0.0008689794,0.000057847516,0.0003457447,0.002618973,0.000067100504],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009030008,0.0027120959,0.00097389176,0.0032346698,0.0022926587,0.000044610195,0.000018957766,2.5340555e-8,2.909863e-8,0.000060832404,0.00009494857,0.9815373],"study_design_scores_gemma":[0.02583913,0.0022636896,0.0005403908,0.006468027,0.005714169,0.000007640854,0.000014809684,0.000014796158,2.689585e-7,0.00013255207,0.9587192,0.00028532557],"about_ca_topic_score_codex":0.000013280586,"about_ca_topic_score_gemma":0.0000067995006,"teacher_disagreement_score":0.98125196,"about_ca_system_score_codex":0.00006165288,"about_ca_system_score_gemma":0.0005472521,"threshold_uncertainty_score":0.99991554},"labels":[],"label_agreement":null},{"id":"W2762654722","doi":"10.1016/j.clinthera.2017.08.018","title":"Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"START Clinic; Université de Montréal; Ontario Centre of Excellence for Child and Youth Mental Health","funders":"Janssen Canada; Health Canada","keywords":"Methylphenidate; Medicine; Adverse effect; Pharmacovigilance; Immediate release; Population; Adverse Event Reporting System; Bioequivalence; Pharmacology; Attention deficit hyperactivity disorder; Psychiatry; Pharmacokinetics; Environmental health","score_opus":0.3360918816147973,"score_gpt":0.5414426882056637,"score_spread":0.20535080659086635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762654722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966742,0.0004535183,0.00022467997,0.00097019266,0.00061628025,0.00047824584,0.00035196746,0.00002374913,0.00020717397],"genre_scores_gemma":[0.99717087,0.0015098733,0.00023044618,0.0006451447,0.00014522774,0.000043442287,0.00014343753,0.000026955944,0.00008457702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99089646,0.0009875972,0.006345204,0.0006771988,0.0004809195,0.0006125984],"domain_scores_gemma":[0.9839938,0.0032295475,0.011181949,0.0010490896,0.0002380728,0.0003075252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00526919,0.00037534084,0.001731569,0.00035801582,0.00029466616,0.000009973449,0.0007880064,0.00022850247,0.00030643947],"category_scores_gemma":[0.0025524464,0.00034055108,0.0005745005,0.0006787251,0.0005823005,0.00024983042,0.00020787734,0.0014551263,0.000003901288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024291803,0.0006772459,0.9696893,0.000053218893,0.0030097999,0.0005901533,0.00034189783,0.0038086697,0.0034893497,0.00009252467,0.000020325228,0.017984606],"study_design_scores_gemma":[0.0021896027,0.0000686278,0.9660333,0.00014945256,0.0043412303,0.000020980233,0.0017064313,0.017894508,0.004625994,0.0001761968,0.0024063108,0.00038738034],"about_ca_topic_score_codex":0.06870232,"about_ca_topic_score_gemma":0.33433586,"teacher_disagreement_score":0.26563355,"about_ca_system_score_codex":0.00030533862,"about_ca_system_score_gemma":0.0019898089,"threshold_uncertainty_score":0.99990463},"labels":[],"label_agreement":null},{"id":"W2765477536","doi":"10.1016/j.clinthera.2017.10.003","title":"Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec; McGill University","funders":"","keywords":"Medicine; Canagliflozin; Sulfonylurea; Glycemic; Type 2 Diabetes Mellitus; Randomized controlled trial; Diabetes mellitus; Weight loss; Internal medicine; Endocrinology; Obesity","score_opus":0.016708703572632867,"score_gpt":0.2982125618759192,"score_spread":0.28150385830328634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765477536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909016,0.00055492995,0.000029324756,0.00082814734,0.0004338884,0.006327387,0.000005863671,0.000025453714,0.00089340424],"genre_scores_gemma":[0.99688697,0.000907353,0.00008646886,0.0013813515,0.00015122686,0.0002508594,0.000028729473,0.000034132845,0.0002728932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977697,0.000305514,0.0008206964,0.0004047464,0.00030094243,0.00039839116],"domain_scores_gemma":[0.9977955,0.0009797647,0.0004420423,0.0005208274,0.00012137773,0.0001404636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011667091,0.0003021422,0.0019646122,0.0001312304,0.00007783267,0.00007176481,0.0001244856,0.00018224402,0.000032080876],"category_scores_gemma":[0.00028881725,0.00017323559,0.00016033358,0.000092108596,0.0005423353,0.00012144908,0.00003668817,0.00031510566,0.0000055564146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58355314,0.00078491075,0.41075435,0.00001612925,0.0011370019,0.00001843259,0.00002460965,0.0000024639232,6.276215e-7,0.00018889901,0.000012059993,0.0035073732],"study_design_scores_gemma":[0.8337185,0.004641116,0.15788887,0.0001594363,0.0014928257,1.9518791e-7,0.000013156114,0.00070454564,0.0000017779721,0.0002251721,0.0009737079,0.00018070833],"about_ca_topic_score_codex":0.00008576165,"about_ca_topic_score_gemma":0.0003655337,"teacher_disagreement_score":0.2528655,"about_ca_system_score_codex":0.00009822058,"about_ca_system_score_gemma":0.00011404809,"threshold_uncertainty_score":0.70643425},"labels":[],"label_agreement":null},{"id":"W2765923679","doi":"10.1016/j.clinthera.2017.10.002","title":"Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Dulaglutide; Insulin glargine; Placebo; Diabetes mellitus; Type 2 diabetes; Internal medicine; Repeated measures design; Urology; Exenatide; Endocrinology","score_opus":0.04830368495985739,"score_gpt":0.3371819936526016,"score_spread":0.2888783086927442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765923679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961338,0.00005518626,0.000005135748,0.0011448644,0.00017224766,0.00127445,0.000011269736,0.0000993496,0.0011036688],"genre_scores_gemma":[0.99579597,0.000039700215,0.001154048,0.0019426274,0.00003458011,0.000039947943,0.00012310654,0.000057208057,0.0008128436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803674,0.000056914057,0.00064010476,0.00046402862,0.0003644127,0.00043779906],"domain_scores_gemma":[0.9979885,0.00010066992,0.00032504482,0.0010249582,0.0003245147,0.00023631133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001932363,0.00031696862,0.00075802277,0.0001574837,0.00011149088,0.00006852559,0.00017712075,0.00013368212,0.000043630193],"category_scores_gemma":[0.00017349143,0.00019371657,0.00008588277,0.00030794888,0.0001588057,0.00010874469,0.0000846353,0.00022480161,0.00005863742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015839991,0.0022025418,0.9620193,0.000015003303,0.0013470587,0.000056096014,0.0000374641,0.000006616181,0.000016958475,0.000013487845,0.000080481506,0.03262096],"study_design_scores_gemma":[0.012561535,0.006531598,0.97453344,0.0001938464,0.00064119237,2.0982516e-7,0.00001967318,0.00006749608,0.000337156,0.000021321615,0.0048333476,0.0002591594],"about_ca_topic_score_codex":0.0000144959695,"about_ca_topic_score_gemma":0.000032385484,"teacher_disagreement_score":0.032361798,"about_ca_system_score_codex":0.00006745768,"about_ca_system_score_gemma":0.00007334518,"threshold_uncertainty_score":0.78995323},"labels":[],"label_agreement":null},{"id":"W2769176372","doi":"10.1016/j.clinthera.2017.10.016","title":"Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Metformin; Dipeptidyl peptidase-4; Pharmacology; Cotransporter; Internal medicine; Sodium; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.08102948794696149,"score_gpt":0.373015477501862,"score_spread":0.2919859895549005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769176372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987589,0.0003284146,0.00028772143,0.004332797,0.0029575373,0.0019643898,0.00020990461,0.00023215113,0.002098097],"genre_scores_gemma":[0.97889555,0.0009872782,0.0024452487,0.010596919,0.0029587673,0.00009935607,0.00026490085,0.00013438793,0.0036176231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959019,0.00012561165,0.0016510062,0.00083999144,0.0006855167,0.0007959835],"domain_scores_gemma":[0.9961091,0.00035462462,0.00085506943,0.0016184876,0.00027974535,0.0007829297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087349373,0.0005986625,0.0012222828,0.00016113899,0.0005737274,0.00028404497,0.0004481764,0.00037919258,0.0004342766],"category_scores_gemma":[0.00062315626,0.00045885766,0.0005767283,0.0001576951,0.00034585586,0.00027008553,0.00027405223,0.0005925907,0.00040692938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004034665,0.0055566956,0.14712341,0.00025770487,0.0015563887,0.0011112012,0.00078869594,0.0000016680428,0.0018278188,0.00013826492,0.013118563,0.82448494],"study_design_scores_gemma":[0.0090541355,0.006605882,0.097039916,0.001902827,0.00276502,0.000025406789,0.0004674697,0.00023456532,0.012805956,0.00014498866,0.8677527,0.0012011741],"about_ca_topic_score_codex":0.000019428677,"about_ca_topic_score_gemma":0.000051475905,"teacher_disagreement_score":0.8546341,"about_ca_system_score_codex":0.00015422206,"about_ca_system_score_gemma":0.00021553821,"threshold_uncertainty_score":0.9997863},"labels":[],"label_agreement":null},{"id":"W2770623194","doi":"10.1016/j.clinthera.2017.11.001","title":"Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Basal (medicine); Diabetes mellitus; Logistic regression; Type 2 diabetes; Insulin; Exenatide; Type 2 Diabetes Mellitus; Endocrinology","score_opus":0.06292542923687601,"score_gpt":0.3321202038179004,"score_spread":0.2691947745810244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770623194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971031,0.000100911086,0.000003570484,0.00055505487,0.0001812181,0.000614014,0.000011606962,0.000032637792,0.0013978824],"genre_scores_gemma":[0.9973909,0.00038647445,0.00005442513,0.001065768,0.00009425804,0.000016927299,0.00005652379,0.00003626714,0.00089840835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988704,0.000056688426,0.0003099697,0.00021498659,0.0002833011,0.0002646933],"domain_scores_gemma":[0.9977915,0.0004932743,0.0005358075,0.0007937053,0.0003114372,0.000074239004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030517834,0.00018531729,0.00046177633,0.000023331957,0.00023959739,0.000063572836,0.00027214395,0.00010402516,0.000035966423],"category_scores_gemma":[0.00019264055,0.00009165371,0.000084125,0.000089947614,0.00052338716,0.000087432716,0.00006114436,0.00020498053,0.0000058893966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028069926,0.0010643022,0.98597175,0.000015403097,0.0014174818,0.0000016841901,0.000045799618,6.4817107e-7,0.0000034262762,0.000010957486,0.00017036899,0.011017468],"study_design_scores_gemma":[0.00411362,0.0032707413,0.97607654,0.0001491004,0.0005838023,2.3158426e-8,0.000008939468,0.00010696393,0.000072307776,0.000010362523,0.01548651,0.000121076584],"about_ca_topic_score_codex":0.0000112258285,"about_ca_topic_score_gemma":0.000048562328,"teacher_disagreement_score":0.01531614,"about_ca_system_score_codex":0.000025492653,"about_ca_system_score_gemma":0.000035123423,"threshold_uncertainty_score":0.37375298},"labels":[],"label_agreement":null},{"id":"W2792610153","doi":"10.1016/j.clinthera.2018.02.001","title":"Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); St. Michael's Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Population Health Research Institute; Université Laval; Southlake Regional Health Center; McMaster University","funders":"University of Toronto; AbbVie","keywords":"Medicine; Adalimumab; Retrospective cohort study; Observational study; Persistence (discontinuity); Cohort; Cohort study; Family medicine; Emergency medicine; Internal medicine; Tumor necrosis factor alpha","score_opus":0.17377316753158478,"score_gpt":0.4329392501373779,"score_spread":0.2591660826057931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792610153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977741,0.00020991842,6.699926e-7,0.0001223315,0.00011127334,0.0014503164,0.000058294674,0.000010284712,0.00026276437],"genre_scores_gemma":[0.99916345,0.00034765407,0.00007276795,0.00029530225,0.00004228037,0.00004171795,0.000011069983,0.000013235688,0.0000125056185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980638,0.0002628859,0.00048632617,0.00031086567,0.00062528515,0.0002508218],"domain_scores_gemma":[0.99860847,0.00018731074,0.00012823736,0.00041692145,0.0005052703,0.00015379579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000376941,0.00013497732,0.00038852202,0.00002577936,0.000088006454,0.000015888227,0.00016034393,0.00006163282,0.00008835941],"category_scores_gemma":[0.00017883755,0.00008372221,0.00009586264,0.00017526287,0.00045952335,0.000047820908,0.000055611836,0.0003497827,0.0000012900745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000520519,0.00093083933,0.95593894,0.000005682286,0.00017768229,0.000008759937,0.0015825694,0.0000016999646,0.000013838699,0.000024635643,0.000025131689,0.04076968],"study_design_scores_gemma":[0.0016371857,0.019875921,0.9749347,0.00006866695,0.000013842567,0.0000055733763,0.0029031804,0.00026986815,0.000026153348,0.00003809117,0.00014267045,0.000084166095],"about_ca_topic_score_codex":0.075530685,"about_ca_topic_score_gemma":0.29836005,"teacher_disagreement_score":0.22282936,"about_ca_system_score_codex":0.00040829004,"about_ca_system_score_gemma":0.0020400155,"threshold_uncertainty_score":0.93062544},"labels":[],"label_agreement":null},{"id":"W2793037442","doi":"10.1016/j.clinthera.2018.02.014","title":"The Use of Multivitamin/Multimineral Supplements: A Modified Delphi Consensus Panel Report","year":2018,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Antioxidant Activity and Oxidative Stress","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Rural Development Administration; Pfizer","keywords":"Medicine; Delphi method; Multivitamin; Population; Micronutrient; Environmental health; Vitamin; Computer science","score_opus":0.6904788816032111,"score_gpt":0.5231642456550175,"score_spread":0.16731463594819362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793037442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015511248,0.99295723,0.0008695608,0.00032942783,0.0012126641,0.0023296648,0.00048249456,0.00007441064,0.00019342989],"genre_scores_gemma":[0.00047003428,0.99268657,0.0024957135,0.0002756371,0.0006758474,0.000047854344,0.00030111405,0.000091392954,0.0029558465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99452966,0.00093643565,0.002841706,0.0006989135,0.0005012033,0.00049209275],"domain_scores_gemma":[0.98706776,0.008755256,0.0019633695,0.0014707458,0.00055172073,0.00019114043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015920276,0.0005719559,0.0028120226,0.00009405019,0.00018786127,0.000047186393,0.00035267542,0.0007589786,0.000031461856],"category_scores_gemma":[0.0022214723,0.00033215707,0.0015300787,0.00027297813,0.0018639958,0.000053620613,0.00020462516,0.001114235,0.00002718256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037731818,0.00095113064,0.00038524426,0.0025488643,0.0030212596,0.00029092297,0.000052714713,5.542663e-7,0.000003959657,0.000108417924,0.003079268,0.9891803],"study_design_scores_gemma":[0.0012365482,0.00055360905,0.00023022588,0.004517531,0.0035298076,0.0002926286,0.000032893728,0.00039280893,0.000007602991,0.000022937678,0.9888539,0.0003295558],"about_ca_topic_score_codex":0.000029081568,"about_ca_topic_score_gemma":0.000020186355,"teacher_disagreement_score":0.9888508,"about_ca_system_score_codex":0.000060704562,"about_ca_system_score_gemma":0.0005684155,"threshold_uncertainty_score":0.99991304},"labels":[],"label_agreement":null},{"id":"W2793122709","doi":"10.1016/j.clinthera.2017.12.015","title":"An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Amgen","keywords":"Medicine; Enzalutamide; Denosumab; Cabazitaxel; Prostate cancer; Zoledronic acid; Concomitant; Abiraterone acetate; Internal medicine; Oncology; Docetaxel; Cohort; Population; Cancer; Androgen deprivation therapy; Osteoporosis","score_opus":0.5229752836077713,"score_gpt":0.5422627704409436,"score_spread":0.019287486833172274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793122709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967572,0.0018377154,0.0000067728083,0.00056586496,0.000091990114,0.00070064486,0.00001890137,0.000010742638,0.000010133678],"genre_scores_gemma":[0.99435335,0.004697807,0.00037430663,0.00027480838,0.00008129708,0.00003087735,0.0000064690753,0.000017677283,0.00016339947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985822,0.0001692296,0.0006100791,0.00021928865,0.00023640034,0.000182845],"domain_scores_gemma":[0.99891615,0.000334483,0.00015062769,0.00025578504,0.00027243796,0.00007053064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004608291,0.00010980796,0.0004093985,0.000067786794,0.000038203532,0.0000105890385,0.00007984561,0.00006385771,0.00006646112],"category_scores_gemma":[0.000052891748,0.00006905657,0.000040400904,0.00021062835,0.00044538704,0.00010512159,0.000036185636,0.00017857268,5.8453276e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043936176,0.0016261608,0.95285195,0.000045223816,0.0003773166,0.000011907694,0.004300743,0.0000031971178,0.003518934,0.00002954683,0.000009085303,0.03283233],"study_design_scores_gemma":[0.009481184,0.009269141,0.97312945,0.00015944238,0.00015080253,0.0000024029487,0.0023385554,0.0013828148,0.0028080977,0.00014132155,0.0010327739,0.00010401407],"about_ca_topic_score_codex":0.00010308402,"about_ca_topic_score_gemma":0.00042563677,"teacher_disagreement_score":0.032728314,"about_ca_system_score_codex":0.00004131283,"about_ca_system_score_gemma":0.00030419338,"threshold_uncertainty_score":0.28160453},"labels":[],"label_agreement":null},{"id":"W2804830120","doi":"10.1016/j.clinthera.2018.04.017","title":"Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); St. Michael's Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; Population Health Research Institute; Université Laval; University of Toronto; McMaster University","funders":"AbbVie","keywords":"Medicine; Discontinuation; Hazard ratio; Adalimumab; Odds ratio; Retrospective cohort study; Internal medicine; Proportional hazards model; Logistic regression; Medical prescription; Cohort study; Pharmacy; Emergency medicine; Confidence interval; Family medicine; Rheumatoid arthritis; Pharmacology","score_opus":0.18125621461014604,"score_gpt":0.42030246243275043,"score_spread":0.2390462478226044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804830120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996938,0.000018566416,0.000008055846,0.0008563236,0.0005343201,0.0010400881,0.00002218671,0.000014283187,0.00056817743],"genre_scores_gemma":[0.997096,0.000018328763,0.00007380086,0.002351815,0.0001363219,0.000013985507,0.000011244776,0.000011542641,0.00028697314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973715,0.00041429058,0.001123383,0.00033505497,0.0005819162,0.00017385356],"domain_scores_gemma":[0.9970888,0.0013487841,0.000355695,0.00082910375,0.0002899469,0.000087710076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008426684,0.0001323833,0.00047590534,0.000020552656,0.00006398248,0.000009123979,0.00036064527,0.00006464659,0.00009891151],"category_scores_gemma":[0.0007427627,0.00008367323,0.000045897963,0.0002333312,0.00014442531,0.000025594472,0.000078914796,0.00035239378,0.00004192409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005672742,0.0035166799,0.98347104,0.000001993333,0.00012486034,0.000001923398,0.0011190383,4.173967e-7,0.0000023661767,0.0000034160942,0.0010114479,0.010179548],"study_design_scores_gemma":[0.009347116,0.0036005324,0.98026437,0.00008257211,0.00008263242,7.034323e-8,0.0049857195,0.000119752134,0.000006592646,0.000032656713,0.0013950913,0.000082924314],"about_ca_topic_score_codex":0.085788585,"about_ca_topic_score_gemma":0.18270329,"teacher_disagreement_score":0.0969147,"about_ca_system_score_codex":0.000048366197,"about_ca_system_score_gemma":0.00036846794,"threshold_uncertainty_score":0.92029923},"labels":[],"label_agreement":null},{"id":"W2892219070","doi":"10.1136/jnnp-2018-ehdn.263","title":"J03 Partial lowering of total huntingtin levels to treat adults with huntington’s disease (hd): potential benefits and theoretical risks from human studies and animal models","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Huntingtin; Huntington's disease; Disease; Huntingtin Protein; Medicine; Internal medicine","score_opus":0.18597729657309145,"score_gpt":0.4002795123386173,"score_spread":0.21430221576552586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892219070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802405,0.00035916528,0.0004497716,0.0003109355,0.0001682371,0.00041192299,0.0001771835,0.000053024363,0.000045702447],"genre_scores_gemma":[0.9978267,0.00019046899,0.00059882394,0.0008465702,0.0004544127,0.000018221552,0.0000022088905,0.000050116585,0.000012488206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972422,0.00026235828,0.0006902809,0.0009901841,0.00039923788,0.00041575445],"domain_scores_gemma":[0.9980333,0.00074236264,0.00020634643,0.00041937546,0.00019748053,0.0004011219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025830313,0.00033352352,0.00052733294,0.00005514493,0.0002900952,0.00008762994,0.00020946188,0.00009114846,0.000033236443],"category_scores_gemma":[0.0005423331,0.00026257447,0.00010138004,0.00013818005,0.0022014533,0.00011945716,0.00039314682,0.00019986783,0.000004498174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015701268,0.0023062183,0.10357106,0.00027248042,0.0004064861,0.00007895687,0.0054107616,0.0018232041,0.77811354,0.029342802,0.00003214015,0.06294105],"study_design_scores_gemma":[0.00360875,0.004344122,0.22490075,0.00037843463,0.0006210817,0.0000047219887,0.00040037345,0.0074275215,0.7514052,0.006163179,0.000009122424,0.0007367683],"about_ca_topic_score_codex":0.000012059491,"about_ca_topic_score_gemma":0.000009396299,"teacher_disagreement_score":0.121329695,"about_ca_system_score_codex":0.000009847181,"about_ca_system_score_gemma":0.00004509124,"threshold_uncertainty_score":0.99998266},"labels":[],"label_agreement":null},{"id":"W2901822462","doi":"10.1016/j.clinthera.2018.10.014","title":"Effects of a Self–micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca Schweiz; Diagnostic Services Manitoba; Regeneron Pharmaceuticals; Amgen Foundation; Alere; Amarin Corporation; Pharmavite; Amgen","keywords":"Bioavailability; Eicosapentaenoic acid; Docosahexaenoic acid; Medicine; Crossover study; Ingestion; Capsule; Dosing; Bioequivalence; Fatty acid; Pharmacology; Internal medicine; Chemistry; Biochemistry; Polyunsaturated fatty acid; Placebo; Biology","score_opus":0.07939323623796085,"score_gpt":0.3966575434453349,"score_spread":0.31726430720737403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901822462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442595,0.0008824967,0.00001721357,0.0005900326,0.00024226287,0.0037608985,0.00002164126,0.000036122477,0.00002335315],"genre_scores_gemma":[0.9989873,0.00030092223,0.00029295246,0.00023560185,0.00006140374,0.00008781228,0.0000023688324,0.000030338373,0.0000012974908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99482936,0.0021752438,0.0012468682,0.000591754,0.00046832734,0.0006884224],"domain_scores_gemma":[0.9965091,0.0021887491,0.00038352655,0.00051976054,0.00020461794,0.00019426104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00584204,0.00025696997,0.0008071653,0.0002337373,0.00014932653,0.000044025204,0.00022487801,0.00015021372,0.0000035345445],"category_scores_gemma":[0.0004686403,0.00018440947,0.000061662664,0.00053450145,0.00040743576,0.00014735236,0.00015116074,0.00068352383,0.000002787072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19906989,0.0051328028,0.49546587,0.0055196974,0.0005740593,0.000023641527,0.08048402,0.0000058684404,0.07611623,0.000045999554,0.000014410853,0.13754751],"study_design_scores_gemma":[0.036686014,0.06987796,0.7567661,0.001142935,0.00014245082,0.0000051875327,0.0124572925,0.0027025705,0.11925851,0.000329467,0.00012514592,0.00050636416],"about_ca_topic_score_codex":0.000098896984,"about_ca_topic_score_gemma":0.00040187733,"teacher_disagreement_score":0.2613002,"about_ca_system_score_codex":0.0005230153,"about_ca_system_score_gemma":0.0001922529,"threshold_uncertainty_score":0.752},"labels":[],"label_agreement":null},{"id":"W2906080560","doi":"10.1016/j.clinthera.2018.11.007","title":"Prevalence of Medication Nonadherence to Co-medication Compared to Immunosuppressants in Heart Transplant Recipients: Findings From the International Cross-sectional BRIGHT Study","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; St. Paul's Hospital; University of Ottawa; Toronto General Hospital","funders":"Universidade da Coruña; International Society for Heart and Lung Transplantation; Schweizerische Akademie der Medizinischen Wissenschaften; Medizinischen Hochschule Hannover; Astellas Pharma US; Agence Nationale de la Recherche; International Transplant Nurses Society; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares; Astellas Pharma Europe; Astellas Pharma; George Washington University; U.S. Department of Veterans Affairs","keywords":"Medicine; Discontinuation; Internal medicine; Logistic regression; Heart transplantation; Odds ratio; Medication adherence; Regimen; Polypharmacy; Cross-sectional study; Psychological intervention; Heart failure","score_opus":0.1459644333441166,"score_gpt":0.47004556346002474,"score_spread":0.3240811301159081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906080560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554473,0.000035133202,0.000757069,0.0014925069,0.00087451417,0.0009085268,0.00023816874,0.000023672566,0.0001256491],"genre_scores_gemma":[0.99610394,0.00014980584,0.0007313301,0.0024739017,0.00019189481,0.00005485088,0.000109815446,0.000014299702,0.0001701795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771714,0.00013683486,0.0009390115,0.00037899954,0.00066873454,0.00015925006],"domain_scores_gemma":[0.99834836,0.0008144791,0.00012970077,0.00036358638,0.00021450702,0.00012935846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078313774,0.00013341432,0.00027632786,0.00007337019,0.00007510004,0.000025319374,0.00038179214,0.00009554599,0.000404589],"category_scores_gemma":[0.000108047534,0.00009119577,0.00009129849,0.00017925595,0.00019735609,0.00006797421,0.00002496587,0.0002045482,0.0001726639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014066303,0.0010273425,0.99432725,0.000012292167,0.0002225199,0.0000031699956,0.0013426874,0.0000068051327,0.00084549276,0.000011279022,0.00008087554,0.00071364583],"study_design_scores_gemma":[0.0031602026,0.00070241943,0.9932466,0.00033526757,0.00009153126,0.000005577568,0.000057410918,0.00016060528,0.0012697038,0.000058711274,0.00082898396,0.00008296453],"about_ca_topic_score_codex":0.00010588265,"about_ca_topic_score_gemma":0.000039553604,"teacher_disagreement_score":0.0017535725,"about_ca_system_score_codex":0.00006630199,"about_ca_system_score_gemma":0.00008956535,"threshold_uncertainty_score":0.44299656},"labels":[],"label_agreement":null},{"id":"W2915698847","doi":"10.1016/j.clinthera.2019.01.017","title":"A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University; Supratek Pharma (Canada); Pharma Medica Research (Canada); BioPhage Pharma (Canada)","funders":"Regeneron Pharmaceuticals; Sanofi; Aegerion Pharmaceuticals; Amgen","keywords":"Bioavailability; Medicine; Cmax; Docosahexaenoic acid; Meal; Pharmacokinetics; Crossover study; Eicosapentaenoic acid; Fatty acid; Pharmacology; Food science; Internal medicine; Chemistry; Biochemistry; Polyunsaturated fatty acid","score_opus":0.22731954813182578,"score_gpt":0.4593779968017172,"score_spread":0.23205844866989142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915698847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655044,0.000100551224,0.00023775376,0.0009987553,0.00011780061,0.0018874463,0.000009489465,0.000020765492,0.0000770065],"genre_scores_gemma":[0.99735993,0.0000137574325,0.0013616509,0.0011742413,0.000046697634,0.000015468218,0.000012041026,0.00001412811,0.0000020579153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738497,0.00082671404,0.00077758107,0.00037298424,0.00031937496,0.0003184035],"domain_scores_gemma":[0.99691087,0.0021686521,0.00021405537,0.00042078804,0.00016054856,0.00012509178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027040758,0.0001581739,0.00043282713,0.000079457604,0.0001469249,0.00009324184,0.00018947358,0.0001230429,0.0000072195485],"category_scores_gemma":[0.00031948634,0.000113637274,0.000037430837,0.00022920081,0.00010464944,0.00027205225,0.0000974861,0.0004416732,0.000003592058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005067357,0.001268381,0.8953782,0.00006990065,0.00003863275,7.657715e-7,0.05137013,0.00007799281,0.0059181224,0.00009070465,0.0000029398034,0.0407169],"study_design_scores_gemma":[0.005346925,0.018274726,0.92185926,0.00008655975,0.000033307966,0.0000019388483,0.023342652,0.025624871,0.0030381135,0.0021228837,0.00008890806,0.00017986285],"about_ca_topic_score_codex":0.00025223807,"about_ca_topic_score_gemma":0.0011464348,"teacher_disagreement_score":0.04053704,"about_ca_system_score_codex":0.00005359748,"about_ca_system_score_gemma":0.00003401599,"threshold_uncertainty_score":0.46339935},"labels":[],"label_agreement":null},{"id":"W2921916991","doi":"10.1016/j.clinthera.2019.01.011","title":"Treatment Avenues in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Split-gender Pharmacogenomic Study of Gene-expression Modules","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Fibromyalgia and Chronic Fatigue Syndrome Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Neurological Disorders and Stroke; National Institutes of Health; U.S. Department of Defense","keywords":"Medicine; Pharmacogenomics; Chronic fatigue syndrome; Immune system; Etiology; Bioinformatics; Immunology; Internal medicine; Pharmacology; Biology","score_opus":0.14413865389393046,"score_gpt":0.4235822949773055,"score_spread":0.27944364108337505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921916991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929023,0.00456312,0.00003436467,0.00007641832,0.00032658325,0.0017969718,0.000018940947,0.00003799839,0.00024333855],"genre_scores_gemma":[0.99677414,0.001966143,0.00057201204,0.00001510829,0.0000593779,0.00006959059,0.000031446285,0.000056280896,0.0004559098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674547,0.00043870936,0.0010956601,0.0006482757,0.0005317483,0.00054016383],"domain_scores_gemma":[0.99822575,0.0004151372,0.00020906089,0.0008550576,0.00009493533,0.00020003752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005137908,0.00031106244,0.0009553329,0.0001856995,0.000045953002,0.00001572799,0.00028258903,0.00024302497,0.00048730118],"category_scores_gemma":[0.000026416918,0.000244569,0.00028550703,0.0002909422,0.00018727678,0.000070655784,0.0000826346,0.0004854186,0.00013259822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010733391,0.010292025,0.85620254,0.0019003367,0.0013920298,0.0007389017,0.0028736868,0.00039883348,0.09049214,0.00007653834,0.000024065703,0.034535542],"study_design_scores_gemma":[0.03270113,0.025625098,0.91944754,0.0011414203,0.0005264369,0.00029016615,0.0020470754,0.0070049297,0.0096088415,0.0003160643,0.0006495104,0.00064176327],"about_ca_topic_score_codex":0.00004299416,"about_ca_topic_score_gemma":0.0000021353928,"teacher_disagreement_score":0.080883294,"about_ca_system_score_codex":0.00045307027,"about_ca_system_score_gemma":0.00046394326,"threshold_uncertainty_score":0.9973234},"labels":[],"label_agreement":null},{"id":"W2936015911","doi":"10.1016/j.clinthera.2019.03.014","title":"Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Tolerability; Placebo; Cmax; Pharmacokinetics; Adverse effect; Internal medicine; Somnolence; Clinical endpoint; Gastroenterology; Pharmacology; Randomized controlled trial","score_opus":0.15517916441964608,"score_gpt":0.4714962081079359,"score_spread":0.31631704368828983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936015911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970715,0.00018391125,0.0000017268636,0.00036162135,0.0005889857,0.0015693874,0.0000076267816,0.000019942378,0.00019530593],"genre_scores_gemma":[0.99567324,0.0019921982,0.000012186079,0.0021548567,0.00003804652,0.000017265938,1.3366183e-7,0.000021510878,0.000090558526],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99521226,0.0022802167,0.0011490326,0.00057064666,0.0004352235,0.00035262876],"domain_scores_gemma":[0.99075115,0.008355334,0.000338245,0.00036415216,0.00007308032,0.000118041804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021590889,0.00018744984,0.0009811008,0.00021611333,0.00003922884,0.00001669306,0.00047671644,0.00008796108,0.000042385116],"category_scores_gemma":[0.0014589925,0.0001354552,0.00014527667,0.00086101005,0.0011979727,0.00010364691,0.00021371845,0.00048670068,0.000009153108],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040549874,0.0035768868,0.115643226,0.000065248794,0.00001675786,0.000027470101,0.0007993007,0.000015412003,0.8382458,0.000019951802,0.0000025021868,0.0010375454],"study_design_scores_gemma":[0.46189237,0.020488907,0.044158824,0.000086474894,0.00020736673,0.00004355268,0.00078559044,0.009611647,0.46099305,0.00069813756,0.0003390503,0.0006950297],"about_ca_topic_score_codex":0.000010895795,"about_ca_topic_score_gemma":0.0000031992538,"teacher_disagreement_score":0.4213425,"about_ca_system_score_codex":0.000009042164,"about_ca_system_score_gemma":0.00008377149,"threshold_uncertainty_score":0.55237025},"labels":[],"label_agreement":null},{"id":"W2937927179","doi":"10.1016/j.clinthera.2019.03.008","title":"An Analysis of Time to Improvement in Oxygenation in Japanese Preterm and Late Preterm or Term Neonates With Hypoxic Respiratory Failure and Pulmonary Hypertension","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Oxygenation; Discontinuation; Gestational age; Pulmonary hypertension; Oxygenation index; Anesthesia; Respiratory failure; Respiratory system; Internal medicine; Pregnancy","score_opus":0.06896053813673853,"score_gpt":0.39254943312946716,"score_spread":0.32358889499272864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937927179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997633,0.0005710928,0.0000020178506,0.00044052445,0.000017051321,0.00126837,0.000011566015,0.000014957278,0.000041457417],"genre_scores_gemma":[0.9963111,0.0002514767,0.00024571424,0.0029429325,0.000022736387,0.00002782322,0.000012847069,0.000028435259,0.00015693375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776477,0.00023949775,0.00076435,0.0005426512,0.000386561,0.0003022004],"domain_scores_gemma":[0.9983136,0.00061371183,0.00014290329,0.00050462113,0.00014614678,0.0002790165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012817347,0.0001789578,0.00069858227,0.0005341474,0.000022340884,0.00001703408,0.00012086698,0.00021628765,0.00006347544],"category_scores_gemma":[0.0001229316,0.00012351766,0.00005124734,0.0006958583,0.00014254305,0.00012755509,0.000083592065,0.00037079022,0.000007687469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071394285,0.00050108926,0.6618579,0.0004242021,0.00025380854,0.00014659652,0.00037648925,0.000050761086,0.1319031,0.0000017985175,9.3720587e-7,0.19734392],"study_design_scores_gemma":[0.0026713698,0.0063319616,0.96557903,0.00024735107,0.00021739921,0.000007055238,0.00011204799,0.0231745,0.00079119497,0.000010773098,0.0006843678,0.00017295576],"about_ca_topic_score_codex":0.00003054109,"about_ca_topic_score_gemma":0.00016589818,"teacher_disagreement_score":0.30372116,"about_ca_system_score_codex":0.000072707946,"about_ca_system_score_gemma":0.00016925881,"threshold_uncertainty_score":0.5036904},"labels":[],"label_agreement":null},{"id":"W2953227034","doi":"10.1016/j.clinthera.2019.04.015","title":"Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; St. Paul's Hospital; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Birmingham Biomedical Research Centre; Michael Smith Health Research BC; Arthritis Society; Medical Research Council; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Rheumatoid arthritis; Population; Intensive care medicine; Psychological intervention; Adverse effect; Physical therapy; Internal medicine; Environmental health; Psychiatry","score_opus":0.1473631516388597,"score_gpt":0.35547830035868144,"score_spread":0.20811514871982173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953227034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924931,0.0045247274,0.00015182323,0.00032685246,0.00012948373,0.0018323355,0.00018976587,0.000021180735,0.0003307668],"genre_scores_gemma":[0.9518273,0.04470656,0.0028693387,0.00022298211,0.000026388338,0.00007232802,0.00004467129,0.000023560517,0.0002068918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827826,0.00018478582,0.0006301834,0.00033622616,0.00029465702,0.0002759144],"domain_scores_gemma":[0.99814266,0.0010489121,0.0002006973,0.00026918933,0.00013637856,0.00020214591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008473993,0.00014603633,0.00056868064,0.000068294015,0.000067382956,0.000020177948,0.00012041278,0.00013445581,0.000079148514],"category_scores_gemma":[0.00033473337,0.00011499456,0.0001601966,0.00009527217,0.00021720893,0.000061019993,0.0001173131,0.0001823093,0.000031326956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006939147,0.00043874804,0.7423723,0.000045605455,0.00032679402,1.1162974e-7,0.0005584904,7.755675e-7,0.000034519428,0.0003822256,0.00013976046,0.25500676],"study_design_scores_gemma":[0.013047862,0.008283915,0.9036843,0.0005804841,0.000025960942,0.0000036423532,0.0004036748,0.00022473342,0.002257486,0.00813795,0.06303489,0.00031506052],"about_ca_topic_score_codex":0.000004256989,"about_ca_topic_score_gemma":0.000009650502,"teacher_disagreement_score":0.25469172,"about_ca_system_score_codex":0.000012874376,"about_ca_system_score_gemma":0.00006149981,"threshold_uncertainty_score":0.4689342},"labels":[],"label_agreement":null},{"id":"W2953263983","doi":"10.1016/j.clinthera.2019.04.019","title":"Preventing Rheumatoid Arthritis: A Global Challenge","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Rheumatoid arthritis; Intensive care medicine; Arthritis; Immunology","score_opus":0.06762267121845453,"score_gpt":0.3896698648654858,"score_spread":0.32204719364703127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953263983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341472,0.039327007,0.00015613325,0.002346403,0.00064945064,0.0007206541,0.000012378821,0.00020184126,0.022438979],"genre_scores_gemma":[0.8167728,0.18061034,0.00083142397,0.0011512667,0.00015183649,0.000015502652,0.000011012844,0.00003016488,0.00042563755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760634,0.00019533736,0.00076458877,0.00042962978,0.0004572058,0.0005468775],"domain_scores_gemma":[0.9985534,0.00027878908,0.0001302442,0.0005968691,0.00014318732,0.00029748827],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087704364,0.00020508489,0.0006143639,0.000037561087,0.00008205347,0.00005622551,0.00020041781,0.00021724754,0.00077340036],"category_scores_gemma":[0.00013920089,0.00017631265,0.00037461345,0.00018549703,0.00021243189,0.00011166623,0.000100729645,0.0004966585,0.0013028205],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004951947,0.0009875997,0.28340286,0.00005102802,0.00055735215,0.000055441327,0.00013918761,0.000001070982,0.00016844254,0.0074587804,0.0003621802,0.7063209],"study_design_scores_gemma":[0.021218153,0.005423434,0.112792164,0.0023781965,0.000020326404,0.00049472024,0.00074654084,0.0019581325,0.00026502856,0.021920811,0.83189535,0.00088713446],"about_ca_topic_score_codex":0.0000061638957,"about_ca_topic_score_gemma":0.00001015341,"teacher_disagreement_score":0.8315332,"about_ca_system_score_codex":0.00004115026,"about_ca_system_score_gemma":0.00018245525,"threshold_uncertainty_score":0.99947476},"labels":[],"label_agreement":null},{"id":"W2963448461","doi":"10.1016/j.clinthera.2019.07.004","title":"Should Clinical Trials Be Terminated Early?","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Interim; Medicine; Clinical trial; Sample size determination; Adverse effect; Early stopping; Intensive care medicine; Internal medicine; Law; Statistics","score_opus":0.9506823842536484,"score_gpt":0.7409873142813458,"score_spread":0.20969506997230258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963448461","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84267116,0.0003619806,0.07936868,0.009901908,0.030800104,0.0069070496,0.00043206388,0.0015056494,0.028051393],"genre_scores_gemma":[0.24180593,0.001341014,0.7195566,0.023020424,0.0053817215,0.00009701111,0.000012380942,0.00038774317,0.008397133],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96615845,0.020564515,0.010011037,0.0013646063,0.0010117276,0.00088964764],"domain_scores_gemma":[0.58504224,0.4097453,0.0020622844,0.0021544455,0.00038806302,0.00060765643],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.097772725,0.00061377883,0.0046441825,0.000106662796,0.00010824575,0.0001427288,0.0012756083,0.001869364,0.0028813411],"category_scores_gemma":[0.2801905,0.00045837718,0.0023066725,0.00045915268,0.0009239437,0.00012717223,0.0003813094,0.0026541771,0.0010997886],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028589962,0.0045223106,0.12955922,0.0002255195,0.0027813157,0.000078788624,0.00015274227,0.0000015221248,0.00025313522,0.17745571,0.015666753,0.666444],"study_design_scores_gemma":[0.007517703,0.0022584621,0.015243738,0.00016719064,0.0011782529,0.000007080418,0.000060030285,0.0010850719,0.0002454813,0.89726263,0.07410011,0.0008742362],"about_ca_topic_score_codex":0.0000036670342,"about_ca_topic_score_gemma":0.0000015767736,"teacher_disagreement_score":0.7198069,"about_ca_system_score_codex":0.000050215724,"about_ca_system_score_gemma":0.00022528546,"threshold_uncertainty_score":0.9997868},"labels":[],"label_agreement":null},{"id":"W2964113647","doi":"10.1016/j.clinthera.2019.07.005","title":"Coadministration of Sublingual Immunotherapy Tablets and Management of Potential Adverse Effects: Austrian, German, and Swiss Expert Recommendations","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"ALK-Abelló; AstraZeneca Schweiz; Allergopharma; Dr. Willmar Schwabe; AllerGen; HAL Allergy; De Blindas Vänner; Boehringer Ingelheim Stiftung; Allergy Therapeutics; Mylan; AstraZeneca; Thermo Fisher Scientific; Novartis Pharma; Auris Health; Sanofi","keywords":"Medicine; Sublingual immunotherapy; Slit; Tolerability; Adverse effect; Allergy; Route of administration; Intensive care medicine; Sublingual administration; Dermatology; Pharmacology; Allergen; Immunology","score_opus":0.051814049974037206,"score_gpt":0.39427367263491137,"score_spread":0.34245962266087415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964113647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950336,0.0006584655,0.0015693351,0.0014041665,0.00033765013,0.0005245244,0.000006468076,0.000014032018,0.0004517636],"genre_scores_gemma":[0.9850395,0.011465489,0.0024265405,0.0005818263,0.00007554027,0.0000031692794,0.00005118082,0.000013675596,0.00034311743],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99894977,0.00008484241,0.00055720215,0.00017431285,0.00013894623,0.00009493636],"domain_scores_gemma":[0.99926126,0.0001725836,0.00021518409,0.00019518344,0.000106120366,0.00004969625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003114349,0.000096649754,0.0003191523,0.000041527328,0.000029004832,0.0000072200223,0.000035401954,0.00012095156,0.000051888775],"category_scores_gemma":[0.000011795406,0.00008476111,0.00006386078,0.000074851916,0.00011364462,0.000052500123,0.000023698989,0.00010386401,0.0000019350337],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007485523,0.0038835935,0.063164555,0.0021081152,0.0051637962,0.00013254938,0.0048261606,0.00004350837,0.09937488,0.016958695,0.0012474757,0.79561114],"study_design_scores_gemma":[0.06318639,0.013484424,0.77344817,0.0029103295,0.0017642634,0.0002392651,0.0059372704,0.021734314,0.023244241,0.0028211547,0.08992729,0.0013028836],"about_ca_topic_score_codex":0.0000056007298,"about_ca_topic_score_gemma":7.537007e-7,"teacher_disagreement_score":0.79430825,"about_ca_system_score_codex":0.000008766083,"about_ca_system_score_gemma":0.000028863205,"threshold_uncertainty_score":0.34564576},"labels":[],"label_agreement":null},{"id":"W2969485794","doi":"10.1016/j.clinthera.2019.07.007","title":"Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"Johnson and Johnson; Roche; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Novartis; Sanofi; GlaxoSmithKline; Merck; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca","keywords":"Medicine; Mepolizumab; Asthma; Eosinophilic; Term (time); Intensive care medicine; Pediatrics; Dermatology; Internal medicine; Eosinophil; Pathology","score_opus":0.03179643496942163,"score_gpt":0.3498150675439138,"score_spread":0.31801863257449214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969485794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966451,0.00049061835,0.000005642051,0.0008214859,0.00018727031,0.0016038733,0.000020737923,0.00001598686,0.00020930683],"genre_scores_gemma":[0.9969422,0.00021452433,0.000013690135,0.0024509993,0.0001364201,0.000006245721,0.000009963263,0.000030128027,0.00019578406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975724,0.00039996835,0.0009947496,0.0003720969,0.00041834312,0.00024243715],"domain_scores_gemma":[0.9972447,0.0013356492,0.00030324684,0.00079849566,0.00017999526,0.00013788807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886696,0.00020809365,0.000651037,0.00003259629,0.000085697706,0.000016933516,0.00025561935,0.00016705359,0.000052470623],"category_scores_gemma":[0.00007033478,0.000093255985,0.00015980542,0.00022248142,0.0006046274,0.00004348839,0.00013661094,0.0006003982,0.000015080776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029485158,0.002547672,0.9147559,0.00002264281,0.00023742426,0.000008148665,0.000151552,0.0000056351064,7.093929e-7,0.00003072477,0.000013466064,0.079277605],"study_design_scores_gemma":[0.009642623,0.0056737815,0.9823314,0.000084010455,0.00028213003,0.0000037467141,0.00035054516,0.000045405497,0.000001086703,0.000022215161,0.0014367294,0.00012631917],"about_ca_topic_score_codex":0.000007079092,"about_ca_topic_score_gemma":0.000053608,"teacher_disagreement_score":0.07915128,"about_ca_system_score_codex":0.000024064713,"about_ca_system_score_gemma":0.0001548686,"threshold_uncertainty_score":0.38028687},"labels":[],"label_agreement":null},{"id":"W2974734960","doi":"10.1016/j.clinthera.2019.08.009","title":"Culinary Medicine: Advancing a Framework for Healthier Eating to Improve Chronic Disease Management and Prevention","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Obesity and Health Practices","field":"Health Professions","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Acadia University","keywords":"Psychological intervention; Medicine; Intervention (counseling); Alternative medicine; Public health; Chronic disease; Lexicon; Disease; Resource (disambiguation); Health care; Disease management; Gerontology; Family medicine; Nursing; Health management system; Pathology","score_opus":0.1650821036915759,"score_gpt":0.5821195409350568,"score_spread":0.4170374372434809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974734960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61935717,0.011184705,0.19897501,0.12815651,0.013340241,0.022462478,0.000048475096,0.00040056423,0.0060748416],"genre_scores_gemma":[0.38609704,0.02894687,0.32019123,0.22006439,0.011158672,0.0020020902,0.00007166846,0.000247255,0.031220768],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969386,0.0006767804,0.0010605644,0.0004904797,0.00020668993,0.0006269068],"domain_scores_gemma":[0.99292564,0.0055662505,0.00047650022,0.0004536289,0.000109276596,0.0004687122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035572783,0.00016566008,0.00042494427,0.00006357945,0.0006809038,0.000009079515,0.00015973291,0.00028612153,0.00030418148],"category_scores_gemma":[0.0006142255,0.00013953273,0.000085228254,0.00014205421,0.00006568854,0.00014898753,0.00017338115,0.0009976289,0.00027400206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00390726,0.00062616746,0.29498705,0.023844674,0.00039003004,0.000008917928,0.0047038877,0.000047607933,0.00005682191,0.09507647,0.004283702,0.5720674],"study_design_scores_gemma":[0.0046089385,0.0048336037,0.1678518,0.0066569624,0.00040012924,4.2772197e-7,0.0036653683,0.0041847993,0.0000010800619,0.11729759,0.6900798,0.000419507],"about_ca_topic_score_codex":0.000009273195,"about_ca_topic_score_gemma":0.00003673977,"teacher_disagreement_score":0.6857961,"about_ca_system_score_codex":0.00016095079,"about_ca_system_score_gemma":0.00029393687,"threshold_uncertainty_score":0.568998},"labels":[],"label_agreement":null},{"id":"W2977065657","doi":"10.1016/j.clinthera.2019.07.021","title":"Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Exhaled nitric oxide; Omalizumab; Asthma; Bronchiectasis; Internal medicine; Cystic fibrosis; Allergy; Biomarker; Gastroenterology; Immunoglobulin E; Lung; Immunology; Spirometry","score_opus":0.03470584024107407,"score_gpt":0.3423681528676716,"score_spread":0.3076623126265975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977065657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559474,0.000012016455,0.0000020804307,0.00027343776,0.00007206669,0.0011348659,0.000022261345,0.000023969138,0.002864536],"genre_scores_gemma":[0.99873525,0.000012956735,0.000024697587,0.00045755776,0.000024183586,0.000009395708,0.000009596251,0.000026857455,0.0006995144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816763,0.00028061413,0.0005281149,0.00025056986,0.00061679207,0.00015630451],"domain_scores_gemma":[0.99789345,0.0005535795,0.0005916487,0.00048180792,0.00041083922,0.000068659625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043321526,0.00016899101,0.0006044632,0.000068034766,0.00003577719,0.000005564467,0.00011108294,0.00008803726,0.00006050155],"category_scores_gemma":[0.00009179537,0.00007755297,0.00015173029,0.00032552387,0.00014997229,0.000026695647,0.00002234129,0.00019959145,0.000010280817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030231078,0.0028952465,0.9910507,0.000012281063,0.0017325617,0.0000031976735,0.00012404288,0.0000034626016,0.000009876328,0.00009620926,0.000029768265,0.0010195323],"study_design_scores_gemma":[0.005965299,0.0095015755,0.9830754,0.00008201021,0.0003389289,8.8132865e-8,0.00042520234,0.000015795295,0.00005968859,0.0000115301755,0.00043040863,0.00009406818],"about_ca_topic_score_codex":0.00001906827,"about_ca_topic_score_gemma":0.000045983117,"teacher_disagreement_score":0.007975309,"about_ca_system_score_codex":0.000089220135,"about_ca_system_score_gemma":0.00008934735,"threshold_uncertainty_score":0.3162518},"labels":[],"label_agreement":null},{"id":"W2979480540","doi":"10.1016/j.clinthera.2019.09.008","title":"Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"China Medical Board","keywords":"Medicine; Osimertinib; Docetaxel; T790M; Oncology; Pemetrexed; Lung cancer; Internal medicine; Epidermal growth factor receptor; Cost effectiveness; Gemcitabine; Cancer; Chemotherapy; Erlotinib; Gefitinib; Cisplatin","score_opus":0.03739784824940182,"score_gpt":0.4140337343373992,"score_spread":0.37663588608799736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979480540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442744,0.00045896543,0.000033133656,0.00007925722,0.00021388243,0.003763388,0.00006414419,0.000016886268,0.0009428902],"genre_scores_gemma":[0.99827147,0.00026719412,0.00021853481,0.0002681043,0.000020402087,0.00027353037,0.00009725339,0.00003973383,0.00054375327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984812,0.00015003941,0.00058268395,0.00037257484,0.00015120495,0.00026230898],"domain_scores_gemma":[0.9988884,0.00036776494,0.0002032072,0.00032526755,0.00011799372,0.00009738986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019789638,0.00022409766,0.0006839286,0.00009494471,0.000016821623,0.000005572321,0.00007246608,0.00013206905,0.00018048527],"category_scores_gemma":[0.000012483007,0.0001529944,0.00010928351,0.00030231828,0.000059129507,0.000053278156,0.000017828204,0.00021212592,0.000010374416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004437836,0.0036116235,0.9649978,0.00018132036,0.00039832163,0.000012047164,0.0005806823,0.0012242154,0.00036981687,0.000005430781,8.42132e-7,0.02418004],"study_design_scores_gemma":[0.03767772,0.0050822934,0.95104045,0.0005489073,0.00041974016,5.1305346e-7,0.00006871814,0.0011091976,0.0035497076,0.000021778254,0.00031822769,0.00016276605],"about_ca_topic_score_codex":0.00022546679,"about_ca_topic_score_gemma":0.00022941545,"teacher_disagreement_score":0.033239882,"about_ca_system_score_codex":0.00040931033,"about_ca_system_score_gemma":0.0004509883,"threshold_uncertainty_score":0.623893},"labels":[],"label_agreement":null},{"id":"W2979631455","doi":"10.1016/j.clinthera.2019.09.011","title":"Predictors of High-cost Patients With Noninfectious Inflammatory Eye Diseases","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Ocular Diseases and Behçet’s Syndrome","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Dermatology; Intensive care medicine","score_opus":0.015693435033223433,"score_gpt":0.3044360281053684,"score_spread":0.28874259307214495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979631455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978036,0.00018366988,0.000031405423,0.00009430145,0.00070953503,0.00077126914,0.00007499359,0.000070138056,0.0002610876],"genre_scores_gemma":[0.99837893,0.000114467715,0.00007798414,0.00068831886,0.00016892189,0.00000999489,0.00008861747,0.000040670122,0.00043209567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998506,0.00006877504,0.0005241792,0.00028998023,0.00038744134,0.00022360009],"domain_scores_gemma":[0.9986107,0.00016514727,0.00021052518,0.00055702653,0.0002071189,0.000249486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116489726,0.00017553377,0.0005089266,0.00005255684,0.00002876028,0.000010349159,0.000108833476,0.00014582775,0.00029094287],"category_scores_gemma":[0.000046892066,0.00012055784,0.0002461541,0.00013754702,0.00020505764,0.00006333057,0.00004595929,0.00021685436,0.00008809014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005990239,0.00142709,0.9930808,0.000098669916,0.0005061608,0.0000092409055,0.000014713485,0.000013042729,0.00001530249,0.00003836833,0.00005950271,0.0041381074],"study_design_scores_gemma":[0.0048908694,0.0021054284,0.98311704,0.0001273558,0.00075704535,0.0000015110771,0.000010159473,0.000048431713,0.00003586191,0.0000407559,0.008716977,0.0001485695],"about_ca_topic_score_codex":0.0000034122336,"about_ca_topic_score_gemma":0.0000010710785,"teacher_disagreement_score":0.009963742,"about_ca_system_score_codex":0.000029177996,"about_ca_system_score_gemma":0.00015461571,"threshold_uncertainty_score":0.49162057},"labels":[],"label_agreement":null},{"id":"W2983218063","doi":"10.1016/j.clinthera.2019.10.003","title":"Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Bioavailability; Dosing; Pharmacology; Meal; Oral administration; Eicosapentaenoic acid; Docosahexaenoic acid; Fatty acid; Internal medicine; Polyunsaturated fatty acid; Biochemistry","score_opus":0.2166503100019288,"score_gpt":0.4790196761743404,"score_spread":0.2623693661724116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983218063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330163,0.0024114104,0.000041242147,0.0023964818,0.00086587685,0.0007486479,0.000014935066,0.00002038612,0.00019936218],"genre_scores_gemma":[0.9954458,0.00057978235,0.0010803477,0.0027156454,0.000117659874,0.000008832074,0.0000075354906,0.000025483461,0.000018916697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699104,0.00093903334,0.0007137767,0.00030580748,0.00065184676,0.000398487],"domain_scores_gemma":[0.998238,0.00090155104,0.000127329,0.0002778331,0.00029674784,0.00015851796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003927207,0.0001321124,0.00035692728,0.00010639353,0.00003395901,0.000021313226,0.00013243416,0.00017598183,0.00014225273],"category_scores_gemma":[0.0003947732,0.00011797155,0.00007865691,0.00020158412,0.00021941483,0.000088891844,0.00005058232,0.00047510187,0.000037263395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065632523,0.0012692916,0.70217174,0.00023480493,0.00007274957,0.0000018214222,0.00077373564,0.0002610136,0.008420597,0.00001269687,0.00016086442,0.28005743],"study_design_scores_gemma":[0.022578731,0.008219491,0.6572372,0.0002924312,0.00029439543,0.0000042490283,0.00063516316,0.28480715,0.009685529,0.0015267603,0.014229523,0.0004894466],"about_ca_topic_score_codex":0.00007208998,"about_ca_topic_score_gemma":0.00023164826,"teacher_disagreement_score":0.28454614,"about_ca_system_score_codex":0.000118426826,"about_ca_system_score_gemma":0.00013489867,"threshold_uncertainty_score":0.481074},"labels":[],"label_agreement":null},{"id":"W2988078111","doi":"10.1016/j.clinthera.2019.10.002","title":"Perioperative Opioid-sparing Strategies: Utility of Conventional NSAIDs in Adults","year":2019,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Allergan; Pfizer; Servier; GlaxoSmithKline; AstraZeneca; Johnson and Johnson","keywords":"Medicine; Perioperative; Opioid; Anesthesia; Intensive care medicine; Internal medicine","score_opus":0.27472105368532884,"score_gpt":0.478285728862116,"score_spread":0.20356467517678717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988078111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003283682,0.9918038,0.0002701904,0.0000482093,0.00020661723,0.0015893071,0.000007594954,0.000021628288,0.0057242336],"genre_scores_gemma":[0.0015827555,0.9958241,0.0004274116,0.00068430166,0.00017034913,0.000038167887,0.00010725306,0.000037613925,0.0011280521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673724,0.00057307136,0.0016844266,0.00047720186,0.00029051024,0.00023755491],"domain_scores_gemma":[0.9977882,0.0009866315,0.00045253677,0.00057756406,0.0001125796,0.00008251311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014984406,0.00033154208,0.0024858417,0.00011251786,0.000022002618,0.000017831491,0.00024381641,0.00051266595,0.00034417858],"category_scores_gemma":[0.00006752353,0.00024638075,0.0008864339,0.00023510652,0.00027882634,0.000045415523,0.000059939575,0.0008035019,0.00007814373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024723943,0.0008356756,0.011753244,0.041575484,0.0008680823,0.00003505115,0.00019696637,0.0000011715283,4.0199073e-8,0.005802781,0.00009409316,0.93859017],"study_design_scores_gemma":[0.0011938679,0.00046793447,0.0042096693,0.017532256,0.0010566878,0.000008013834,0.00027128425,0.00028308513,9.200898e-8,0.00010585767,0.97466224,0.00020900724],"about_ca_topic_score_codex":0.000013010891,"about_ca_topic_score_gemma":0.0000054867673,"teacher_disagreement_score":0.9745681,"about_ca_system_score_codex":0.000045818597,"about_ca_system_score_gemma":0.0007476487,"threshold_uncertainty_score":0.99999887},"labels":[],"label_agreement":null},{"id":"W2991821408","doi":"10.1016/j.clinthera.2019.11.007","title":"Hypnosis Program Effectiveness in a 12-week Home Care Intervention To Manage Chronic Pain in Elderly Women: A Pilot Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pain Management and Placebo Effect","field":"Neuroscience","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Hypnosis; Medicine; Physical therapy; Population; Psychological intervention; Chronic pain; Intervention (counseling); Randomized controlled trial; Alternative medicine; Psychiatry; Internal medicine","score_opus":0.10445117963230222,"score_gpt":0.39467741312730487,"score_spread":0.29022623349500265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991821408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915776,0.000120870805,0.0009197755,0.00012495916,0.0009882665,0.005627397,0.000004198715,0.00012956567,0.0005073537],"genre_scores_gemma":[0.997603,0.00009659831,0.000055541586,0.000880019,0.00013641681,0.0009980295,0.000005339171,0.00003704463,0.00018803854],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.98913753,0.008476863,0.0007212558,0.0007615783,0.00029279737,0.00060997467],"domain_scores_gemma":[0.99255794,0.0066949814,0.00014112952,0.00048107983,0.000018734232,0.0001061394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011940246,0.0002669817,0.0005661637,0.0002942544,0.00003948899,0.00011303531,0.0005224939,0.00015626615,0.000055775716],"category_scores_gemma":[0.0010082639,0.0002432566,0.00022434404,0.0007502193,0.0000770961,0.0001393989,0.0001587692,0.00052193325,0.0001926363],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023482794,0.0027903183,0.031304866,0.0005244119,0.000037007307,0.000040196282,0.0005947925,0.00019355204,0.0017207315,0.00013732864,0.00001164767,0.9391624],"study_design_scores_gemma":[0.27864924,0.29110515,0.27593157,0.0031580778,0.00016093208,0.0000025587221,0.0014106813,0.04711251,0.0024632495,0.0039509614,0.09307175,0.0029833205],"about_ca_topic_score_codex":0.000022105793,"about_ca_topic_score_gemma":0.00013497572,"teacher_disagreement_score":0.93617904,"about_ca_system_score_codex":0.0003946641,"about_ca_system_score_gemma":0.000034923945,"threshold_uncertainty_score":0.9919716},"labels":[],"label_agreement":null},{"id":"W3002318915","doi":"10.1016/j.clinthera.2019.11.010","title":"Population Pharmacokinetics and Exposure–Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck Sharp and Dohme; Genentech; Sanofi; Kyowa Hakko Kirin; Bristol-Myers Squibb; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Celltrion; Janssen Scientific Affairs; Janssen Research and Development; UCB; AbbVie; Danone; Therakos; Pfizer; Biogen; Celgene; Novo Nordisk; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline; Tillotts Pharma; Allergan; Seres Therapeutics; Amgen; Eli Lilly and Company; Dr. Falk Pharma; Abbott Laboratories","keywords":"Golimumab; Medicine; Pharmacokinetics; Population; Ulcerative colitis; Internal medicine; Adverse effect; Pharmacology; Gastroenterology; Etanercept; Tumor necrosis factor alpha","score_opus":0.047074113137548015,"score_gpt":0.33687811980345117,"score_spread":0.28980400666590317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002318915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962412,0.00005503444,0.0027845807,0.00033853357,0.000034681674,0.00041651883,0.00006192967,0.000009588329,0.00005790999],"genre_scores_gemma":[0.9966331,0.00013611722,0.0009987305,0.0020538685,0.00009474904,0.000017032375,0.000030651012,0.000027151154,0.000008560882],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985901,0.00033892985,0.00042876552,0.0003490978,0.00012414074,0.00016897927],"domain_scores_gemma":[0.999345,0.000067312045,0.000099702076,0.00016066874,0.00015350438,0.00017380495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023387696,0.00015484644,0.0002248595,0.000026673635,0.000029412573,0.000012574702,0.00010229306,0.0001391677,0.0000044958533],"category_scores_gemma":[0.00012619355,0.00014471356,0.000050784223,0.000087832836,0.000067555615,0.0000075604817,0.00006759711,0.00014627104,0.0000014979629],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8246756,0.000509018,0.03194449,0.00017199958,0.00044362328,0.0001056022,0.0047358577,0.10983808,0.006172831,0.00014222029,0.000028755441,0.021231882],"study_design_scores_gemma":[0.005173378,0.0020623445,0.7810847,0.000079299956,0.0000672801,0.0000033124225,0.0004205198,0.20652175,0.0039658425,0.00010441553,0.00016375248,0.00035341483],"about_ca_topic_score_codex":0.0000062852982,"about_ca_topic_score_gemma":0.000040411694,"teacher_disagreement_score":0.81950223,"about_ca_system_score_codex":0.000013613497,"about_ca_system_score_gemma":0.000091382324,"threshold_uncertainty_score":0.5901248},"labels":[],"label_agreement":null},{"id":"W3016116922","doi":"10.1016/j.clinthera.2020.03.001","title":"Use of Direct Oral Anticoagulants Versus Traditional Therapies for Acute Venous Thromboembolism After Direct Discharge From the Emergency Department or After Hospitalization: An Audit of 16 Canadian Hospitals","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Regina Qu'Appelle Health Region; University of Alberta","funders":"Pfizer Canada; Bristol-Myers Squibb Canada; Novo Nordisk; LEO Pharma; Baxter International","keywords":"Medicine; Pulmonary embolism; Emergency department; Warfarin; Retrospective cohort study; Deep vein; Cohort; Emergency medicine; Thrombosis; Medical record; Venous thromboembolism; Cohort study; Internal medicine; Pediatrics; Atrial fibrillation","score_opus":0.1897007310661655,"score_gpt":0.38236240271188204,"score_spread":0.19266167164571654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016116922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98652667,0.0017823596,0.00020754183,0.005116932,0.0013329186,0.001613366,0.003226805,0.00004221471,0.00015121575],"genre_scores_gemma":[0.98731184,0.0059761973,0.00081921817,0.004443081,0.0006409854,0.00022227287,0.0004789804,0.00006619715,0.000041198706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760884,0.0001810728,0.00094514614,0.0004816531,0.00038852112,0.00039477544],"domain_scores_gemma":[0.9980516,0.0005482735,0.00029616038,0.00054817466,0.00021596927,0.00033980943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002818253,0.00030812592,0.0012921742,0.000045030527,0.00010418941,0.000033429573,0.0002631073,0.0001797158,0.00082056934],"category_scores_gemma":[0.0001376445,0.00019987505,0.00043546758,0.00021038472,0.0002466469,0.00017454072,0.000052290645,0.00015194864,0.000008453399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03040465,0.021250956,0.7431577,0.0006820399,0.06560262,0.00027250257,0.02048162,0.00009629588,0.00064644695,0.0050137113,0.04306115,0.0693303],"study_design_scores_gemma":[0.0025532534,0.0063377307,0.95290697,0.00013069478,0.004386457,8.256345e-7,0.00022835808,0.00031785763,0.0004526954,0.00042580417,0.031889353,0.00037001897],"about_ca_topic_score_codex":0.0011257713,"about_ca_topic_score_gemma":0.0042312546,"teacher_disagreement_score":0.20974924,"about_ca_system_score_codex":0.00005990491,"about_ca_system_score_gemma":0.0002438136,"threshold_uncertainty_score":0.8984659},"labels":[],"label_agreement":null},{"id":"W3018455288","doi":"10.1016/j.clinthera.2020.03.006","title":"Use of Real-world Data for New Drug Applications and Line Extensions","year":2020,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Sanofi","keywords":"Medicine; Orphan drug; Timeline; Drug; Agency (philosophy); Regulatory science; Food and drug administration; Drug approval; Tolerability; Regulatory agency; MEDLINE; Pharmacology; Family medicine; Data science; Adverse effect; Bioinformatics; Computer science; Pathology","score_opus":0.7882468021714223,"score_gpt":0.643252198100617,"score_spread":0.14499460407080533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018455288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007530057,0.9879832,0.001211887,0.0014845926,0.000987835,0.0026180376,0.005360155,0.0001246973,0.00022202604],"genre_scores_gemma":[0.000012266589,0.98808026,0.0027617519,0.003054762,0.0018223173,0.00015437017,0.0014616485,0.00008760822,0.002565017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965003,0.000544426,0.0016103343,0.00085204147,0.00012536434,0.00036751406],"domain_scores_gemma":[0.98810375,0.009181015,0.0009836343,0.0010817479,0.00013042205,0.0005194418],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008755557,0.0004559788,0.0020805444,0.00013378898,0.0002029792,0.000029449637,0.00087217824,0.00044480266,0.00006455365],"category_scores_gemma":[0.00022215514,0.00039101217,0.00054103945,0.0005368155,0.00054570416,0.00015925433,0.0004555767,0.0017322358,0.00005686081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007962861,0.00034675814,0.000044513257,0.0013658885,0.0011969248,0.0000041900357,0.000018295885,0.000005871252,0.0000063571283,0.000983712,0.021606218,0.97434163],"study_design_scores_gemma":[0.0006350165,0.000062445346,0.0000071047916,0.0004107394,0.00720804,0.000007067938,0.000009765002,0.0013483843,0.0000069974326,0.00028068738,0.989674,0.00034976643],"about_ca_topic_score_codex":0.000018617202,"about_ca_topic_score_gemma":0.000039748287,"teacher_disagreement_score":0.9739919,"about_ca_system_score_codex":0.000033950102,"about_ca_system_score_gemma":0.00075273553,"threshold_uncertainty_score":0.9998542},"labels":[],"label_agreement":null},{"id":"W3022820044","doi":"10.1016/j.clinthera.2020.03.010","title":"Psychological Stress and Chronic Urticaria: A Neuro-immuno-cutaneous Crosstalk. A Systematic Review of the Existing Evidence","year":2020,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto","funders":"","keywords":"Medicine; Crosstalk; Chronic urticaria; Dermatology","score_opus":0.2640779230129689,"score_gpt":0.48851438396462327,"score_spread":0.22443646095165437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022820044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014218453,0.9943872,0.000030941406,0.0012657676,0.0004988679,0.0034604701,0.000050105,0.00006232079,0.00023011866],"genre_scores_gemma":[0.00015659328,0.9968932,0.0000842267,0.0022879264,0.0002491097,0.00011379529,0.000014216465,0.00006098037,0.0001399112],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9943457,0.0013639696,0.0029120513,0.0006345063,0.0004225552,0.00032120073],"domain_scores_gemma":[0.99155885,0.0055089877,0.001227525,0.0013188804,0.00017971698,0.00020601174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006240739,0.00046815208,0.0042416397,0.000037690676,0.00014075123,0.0000415006,0.000573734,0.000712108,0.00005341979],"category_scores_gemma":[0.004678449,0.00023881903,0.001471512,0.00054276775,0.00090208184,0.000028637418,0.0002695311,0.0021560728,0.00003475156],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001962635,0.00026540173,0.000013340426,0.9339141,0.0038584506,0.00019981618,0.00002979216,6.957492e-8,0.000002265585,0.00036196597,0.000043036114,0.061292097],"study_design_scores_gemma":[0.00027608086,0.00077543996,0.0000100415655,0.87192005,0.07863281,0.0015530757,0.0000075961893,0.000047689333,3.3499555e-7,0.00006044229,0.04650075,0.00021568067],"about_ca_topic_score_codex":6.9403796e-7,"about_ca_topic_score_gemma":2.9658747e-7,"teacher_disagreement_score":0.074774355,"about_ca_system_score_codex":0.00008596083,"about_ca_system_score_gemma":0.0005077646,"threshold_uncertainty_score":0.97387576},"labels":[],"label_agreement":null},{"id":"W3029612300","doi":"10.1016/j.clinthera.2020.05.001","title":"Elevated Circulating Th2 Cells in Women With Asthma and Psychological Morbidity: A New Asthma Endotype?","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Western University","funders":"Faculty of Medicine and Dentistry, University of Alberta; Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia; Canadian Institutes of Health Research; Western University; Canada Foundation for Innovation","keywords":"Endotype; Medicine; Asthma; Allergic asthma; Immunology","score_opus":0.14290695703623252,"score_gpt":0.3860366618271929,"score_spread":0.24312970479096035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029612300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960049,0.00050000276,0.0003676524,0.0021861966,0.000077183446,0.00032081036,0.000005464805,0.000089607485,0.0004481754],"genre_scores_gemma":[0.979629,0.00020596408,0.0010569273,0.018519292,0.0004488005,0.00000796148,0.0000035107307,0.00003312407,0.00009543939],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982413,0.00015941204,0.00053632044,0.0004786677,0.00023041853,0.00035390083],"domain_scores_gemma":[0.9987244,0.0002458284,0.000120424025,0.0002431599,0.000046619298,0.00061955483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026612577,0.00020489353,0.0005232097,0.0000352137,0.000042766456,0.000025878951,0.00010325291,0.00021468094,0.0001733126],"category_scores_gemma":[0.0001232617,0.00014051041,0.0000784664,0.00028702215,0.00021017905,0.000044056673,0.000051309216,0.0005584423,0.0000375555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008474393,0.0019411257,0.2863409,0.00014782882,0.0003123949,0.0012583319,0.0018840801,0.000070423106,0.015483578,0.00010382119,0.0005929101,0.6833902],"study_design_scores_gemma":[0.012972078,0.0115906,0.7908011,0.00021728073,0.000109096356,0.00008930778,0.0007538387,0.0027681526,0.0006277004,0.00036587147,0.17911528,0.0005896824],"about_ca_topic_score_codex":0.0000039202514,"about_ca_topic_score_gemma":0.0000018699069,"teacher_disagreement_score":0.68280053,"about_ca_system_score_codex":0.000035382935,"about_ca_system_score_gemma":0.00020614504,"threshold_uncertainty_score":0.5729849},"labels":[],"label_agreement":null},{"id":"W3045055014","doi":"10.1016/j.clinthera.2020.06.007","title":"Effect of a Peer-led Lifestyle Intervention on Individuals With Normal Weight Obesity: Insights From the Kerala Diabetes Prevention Program","year":2020,"lang":"en","type":"letter","venue":"Clinical Therapeutics","topic":"Diabetes Management and Education","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"National Health and Medical Research Council; Fogarty International Center; National Institutes of Health; University of Melbourne; Ascend Therapeutics","keywords":"Medicine; Blood pressure; Diabetes mellitus; Glycemic; Obesity; Randomized controlled trial; Intervention (counseling); Physical therapy; Cohort; Psychological intervention; Type 2 diabetes; Blood lipids; Internal medicine; Endocrinology; Cholesterol","score_opus":0.03741535752521155,"score_gpt":0.3621695605767674,"score_spread":0.3247542030515559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045055014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521966,0.0004138481,0.000027473247,0.24273075,0.0010971774,0.0027457294,0.000025771858,0.00014757493,0.0006150546],"genre_scores_gemma":[0.50961787,0.0002970187,0.00078611204,0.4654136,0.011833296,0.0005738187,0.006684595,0.00020298046,0.0045907022],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960734,0.0012450435,0.00094815163,0.00055150024,0.00085666456,0.00032521007],"domain_scores_gemma":[0.9960766,0.0021692235,0.0007926425,0.0006909334,0.00018284844,0.00008778671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094796374,0.0004304689,0.0009881662,0.00009720396,0.00008315208,0.00009708329,0.0003824558,0.00060573523,0.000089331224],"category_scores_gemma":[0.00028111282,0.00024790788,0.00063679076,0.00029552454,0.00025714654,0.00009230895,0.000107258165,0.0019364,0.0000768206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079994136,0.0025525582,0.40282786,0.0013644156,0.005322857,0.000023661429,0.00037562483,9.088646e-7,0.000012593912,0.000027243232,0.31747127,0.26922107],"study_design_scores_gemma":[0.005289088,0.024378702,0.07190331,0.0027968355,0.006578786,5.165476e-7,0.000027316555,0.0002731863,0.00075178925,0.00066582445,0.88691205,0.00042260936],"about_ca_topic_score_codex":0.0000049035903,"about_ca_topic_score_gemma":0.000002551306,"teacher_disagreement_score":0.5694408,"about_ca_system_score_codex":0.00004398446,"about_ca_system_score_gemma":0.0000777248,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W3088988710","doi":"10.1016/j.clinthera.2020.08.013","title":"Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit–Risk Models: The Example of Rotavirus Vaccination in France","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"GlaxoSmithKline Biologicals; GlaxoSmithKline","keywords":"Medicine; Construct (python library); Vaccination; Rotavirus; Event (particle physics); Rotavirus vaccine; Virology; Virus","score_opus":0.41461355199072586,"score_gpt":0.5132463992458197,"score_spread":0.09863284725509386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088988710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7764498,0.00018510285,0.22115791,0.001559299,0.000056787685,0.00049920287,0.000057125162,0.000012149056,0.000022594708],"genre_scores_gemma":[0.98998266,0.0003523867,0.0072704456,0.0022715505,0.00005703669,0.000009412247,0.000039320097,0.000012969022,0.000004219609],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99807334,0.0005281747,0.00078119774,0.00024274005,0.00017324895,0.00020128996],"domain_scores_gemma":[0.998696,0.0005975245,0.00021410211,0.00016309379,0.00020801839,0.0001212325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008074426,0.00010668218,0.00041254313,0.000048288854,0.000042419066,0.0000075635894,0.000101104604,0.00010158105,0.0000347595],"category_scores_gemma":[0.0010432354,0.000074285104,0.00011533773,0.00028073697,0.00011848398,0.00008167398,0.000036762303,0.00041182668,0.000004876572],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004009084,0.0003155912,0.29819584,0.000073750154,0.00028619973,0.000010782739,0.0013885649,0.55905676,0.004355942,0.003929298,0.000027856562,0.12835036],"study_design_scores_gemma":[0.0014056925,0.0016597192,0.10983187,0.000080836675,0.00004617349,0.0000016228737,0.00024407251,0.8828717,0.00012328473,0.0032622414,0.0004134534,0.0000593308],"about_ca_topic_score_codex":0.00024270872,"about_ca_topic_score_gemma":0.000038597223,"teacher_disagreement_score":0.32381496,"about_ca_system_score_codex":0.00004146793,"about_ca_system_score_gemma":0.00005439277,"threshold_uncertainty_score":0.30292588},"labels":[],"label_agreement":null},{"id":"W3089860191","doi":"10.1016/j.clinthera.2020.09.012","title":"Caregivers' Willingness to Accept Expedited Vaccine Research During the COVID-19 Pandemic: A Cross-sectional Survey","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women and Children’s Health Research Institute; Alberta Children's Hospital; University of Calgary; University of Alberta; University of Saskatchewan; BC Children's Hospital; University of Toronto; SickKids Foundation; Hospital for Sick Children; University of British Columbia","funders":"","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cross-sectional study; Virology; Family medicine; Internal medicine; Infectious disease (medical specialty); Outbreak; Pathology","score_opus":0.5822064516313651,"score_gpt":0.5673103875499281,"score_spread":0.014896064081436955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089860191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98112446,0.0003205547,0.0007117739,0.015758337,0.00079181907,0.0005310188,0.00003910095,0.00015281556,0.000570147],"genre_scores_gemma":[0.98124784,0.00086934236,0.000035420362,0.013440112,0.00323976,0.000022797984,0.000010465658,0.000024883355,0.001109375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950952,0.0022623015,0.0006333796,0.00056994293,0.00084323407,0.0005959465],"domain_scores_gemma":[0.99187756,0.006256289,0.00011795622,0.0003796391,0.00064487703,0.0007236966],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0070582484,0.00015347484,0.0002919366,0.000050186554,0.0018112973,0.00030798273,0.0010562264,0.0002992003,0.0007757699],"category_scores_gemma":[0.0074276994,0.000118511474,0.00018255919,0.0011357787,0.00015007888,0.00016486498,0.00026450815,0.00091281126,0.00015473191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000501632,0.000055381926,0.98707134,0.000010519657,0.000054206364,0.000009883574,0.008946061,0.0000798142,0.000028181059,0.00020505794,0.0023847965,0.00065311743],"study_design_scores_gemma":[0.0008073316,0.00012214787,0.77370906,0.0000030007989,0.000007419908,0.000001162321,0.0014682843,0.00003644024,0.000004365304,0.0002826325,0.2234161,0.00014203473],"about_ca_topic_score_codex":0.000661327,"about_ca_topic_score_gemma":0.0022287522,"teacher_disagreement_score":0.22103131,"about_ca_system_score_codex":0.00022602137,"about_ca_system_score_gemma":0.00067883235,"threshold_uncertainty_score":0.99948823},"labels":[],"label_agreement":null},{"id":"W3096218012","doi":"10.1016/j.clinthera.2020.09.014","title":"Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Multiple sclerosis; Retrospective cohort study; Pediatrics; Internal medicine; Psychiatry","score_opus":0.21483444580870006,"score_gpt":0.37692185075691126,"score_spread":0.1620874049482112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096218012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641067,0.00022127808,0.00024607047,0.0016199425,0.00006886247,0.00077024754,0.00043402993,0.00012592225,0.000102960024],"genre_scores_gemma":[0.99137324,0.0063420185,0.0006023351,0.0010286681,0.00026914195,0.000050869065,0.00022291241,0.00004338639,0.00006740206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972602,0.00028218416,0.00077181455,0.0008220474,0.00047170068,0.00039204158],"domain_scores_gemma":[0.9973571,0.001151222,0.00020662893,0.0004762513,0.00026972647,0.0005390771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014382876,0.00033761954,0.0011662188,0.00009736848,0.00016083245,0.00005702391,0.00013132904,0.00023253297,0.0001197893],"category_scores_gemma":[0.0006245622,0.00024405017,0.0005383855,0.00059779384,0.0003849047,0.00008016008,0.00014465215,0.0003914781,0.000023524077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075703167,0.0008086213,0.96176565,0.000009872721,0.0061447173,0.000011189359,0.000845776,0.000004606603,0.00019031137,0.0000012501621,0.000057663197,0.0294033],"study_design_scores_gemma":[0.008287708,0.0026136294,0.9752365,0.000045849974,0.002777944,1.111987e-7,0.00023222962,0.009833838,0.0003491895,0.000012002089,0.00039977639,0.00021122347],"about_ca_topic_score_codex":0.00084706384,"about_ca_topic_score_gemma":0.00034485437,"teacher_disagreement_score":0.029192075,"about_ca_system_score_codex":0.00016643055,"about_ca_system_score_gemma":0.00003547482,"threshold_uncertainty_score":0.9952077},"labels":[],"label_agreement":null},{"id":"W3114739779","doi":"10.1016/j.clinthera.2020.12.006","title":"Low Serum Zinc Levels and Associated Risk Factors in Hospitalized Patients Receiving Oral or Enteral Nutrition: A Case-control Study","year":2020,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Clinical Nutrition and Gastroenterology","field":"Nursing","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brandon University","funders":"","keywords":"Medicine; Parenteral nutrition; Enteral administration; Case-control study; Internal medicine; Intensive care medicine","score_opus":0.11032165875417899,"score_gpt":0.38350630919500384,"score_spread":0.27318465044082485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114739779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875082,0.00002758649,0.00006075128,0.0097564105,0.0008858787,0.0012172945,0.00043110945,0.00011008884,0.0000026878718],"genre_scores_gemma":[0.978026,0.000054326643,0.00012236882,0.021532582,0.00017792732,0.000022374346,0.000018748133,0.000041240874,0.000004470333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504256,0.0021764152,0.0014633866,0.00061328325,0.00023428201,0.0004700769],"domain_scores_gemma":[0.99658775,0.0023514368,0.00040443699,0.00022492002,0.00013041412,0.00030101385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085321907,0.00029807532,0.0009194789,0.00006282751,0.00013981559,0.00008080005,0.00018713361,0.0003334295,0.000094101735],"category_scores_gemma":[0.0020404467,0.00024793984,0.00024240348,0.00026126733,0.00019393938,0.0001356626,0.000084404295,0.0009404421,0.00000637973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035797409,0.0060476954,0.98090094,0.000019579114,0.00023103273,0.00014745836,0.0008536066,0.0000026542698,0.000004587655,2.6202295e-7,0.00023283067,0.007979598],"study_design_scores_gemma":[0.035118267,0.009783755,0.9517124,0.000074655625,0.00024106148,0.0000063772654,0.0005054075,0.0018312249,0.0000071409504,0.0001068964,0.0003911532,0.0002216381],"about_ca_topic_score_codex":0.000024603054,"about_ca_topic_score_gemma":0.00038774774,"teacher_disagreement_score":0.031538524,"about_ca_system_score_codex":0.00006360419,"about_ca_system_score_gemma":0.000008145745,"threshold_uncertainty_score":0.99999726},"labels":[],"label_agreement":null},{"id":"W3115860485","doi":"10.1016/j.clinthera.2020.12.009","title":"The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease","year":2020,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; National Institutes of Health; Valeant Pharmaceuticals International; Novo Nordisk; National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences","keywords":"Medicine; Nonalcoholic fatty liver disease; Subspecialty; Hepatology; Workforce; Liver disease; Intensive care medicine; Scope of practice; Health care; Internal medicine; Disease; Family medicine; Fatty liver","score_opus":0.12367906916742565,"score_gpt":0.46151937740627763,"score_spread":0.33784030823885197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115860485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000100267025,0.9956637,7.816312e-7,0.0011989028,0.00009705127,0.002331571,0.00012081219,0.000009237369,0.00047769252],"genre_scores_gemma":[0.006171114,0.9920046,0.00010759215,0.0012258327,0.00014664799,0.00022673921,0.00007324429,0.00003581594,0.00000843681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970759,0.0008334769,0.0011174814,0.00034162166,0.0004388518,0.0001926283],"domain_scores_gemma":[0.99181724,0.006283515,0.00074754254,0.0007818338,0.000207909,0.00016197095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004244065,0.00028520057,0.0013249237,0.000030456353,0.000049938808,0.000017274557,0.00039263236,0.00016347267,0.000007989025],"category_scores_gemma":[0.0007375297,0.00013274938,0.0010899142,0.0002614701,0.00031317674,0.000047758418,0.000082943465,0.00054191734,0.00001440733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003361039,0.001155735,0.0016940673,0.003220333,0.0010050819,0.000075627526,0.00043947325,5.0785826e-7,3.7694395e-8,0.00040403678,0.000022080221,0.9916469],"study_design_scores_gemma":[0.0008267733,0.00045712193,0.0030399074,0.0034898852,0.009621223,0.0000037480338,0.0009971696,0.000010503692,9.2320965e-7,0.00006835102,0.9813682,0.0001162206],"about_ca_topic_score_codex":0.000012442249,"about_ca_topic_score_gemma":0.000004507861,"teacher_disagreement_score":0.9915307,"about_ca_system_score_codex":0.00006532209,"about_ca_system_score_gemma":0.0008886933,"threshold_uncertainty_score":0.5413363},"labels":[],"label_agreement":null},{"id":"W3130274706","doi":"10.1016/j.clinthera.2021.01.011","title":"Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Paliperidone Palmitate; Medicine; Medicaid; Schizophrenia (object-oriented programming); Risperidone; Paliperidone; Antipsychotic; Psychiatry; Emergency medicine; Health care","score_opus":0.06597402264075836,"score_gpt":0.34481048679988197,"score_spread":0.2788364641591236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130274706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141395,0.0049520866,0.00001706164,0.0027957954,0.00006947903,0.00060405955,0.000034292254,0.000029297364,0.000083991705],"genre_scores_gemma":[0.98930126,0.007645245,0.0018466959,0.00086825347,0.00012395668,0.000051061605,0.000039100607,0.000035339428,0.00008908669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978711,0.00034554044,0.0005800678,0.00042936756,0.00048049193,0.00029340238],"domain_scores_gemma":[0.9974864,0.0012288549,0.0001941795,0.00054812874,0.0002949464,0.000247488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055236573,0.00023558631,0.00051233085,0.00005595504,0.00014170435,0.00008826517,0.000094936695,0.00019346706,0.000031758696],"category_scores_gemma":[0.0002707421,0.0001312679,0.00010243893,0.00029040143,0.0010068086,0.0001231927,0.00006446002,0.00052279735,0.0000020927926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030896492,0.00050048914,0.7608929,0.000035168814,0.00072329416,0.0001887832,0.00058218,0.0000011071908,0.000055289944,0.00042054374,0.000019429428,0.20568429],"study_design_scores_gemma":[0.010232351,0.002885936,0.9833365,0.00043592317,0.000280016,0.00005904216,0.0003289756,0.000324102,0.00032586727,0.00062723074,0.001024867,0.00013915183],"about_ca_topic_score_codex":0.000021064403,"about_ca_topic_score_gemma":0.0010719851,"teacher_disagreement_score":0.22244361,"about_ca_system_score_codex":0.000023125009,"about_ca_system_score_gemma":0.00027037162,"threshold_uncertainty_score":0.53529495},"labels":[],"label_agreement":null},{"id":"W3142925431","doi":"10.1016/j.clinthera.2013.03.003","title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement","year":2013,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Institute of Health Economics","funders":"","keywords":"Checklist; Medicine; Government (linguistics); Statement (logic); Delphi method; Consolidated Standards of Reporting Trials; Psychological intervention; Systematic review; Economic evaluation; Delphi; MEDLINE; Public relations; Medical education; Political science; Psychology; Nursing; Law; Computer science","score_opus":0.7706788646709188,"score_gpt":0.6240418205093039,"score_spread":0.14663704416161494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142925431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80747,0.006355439,0.012589005,0.15134838,0.0048147757,0.0054305787,0.000912241,0.00031326019,0.010766311],"genre_scores_gemma":[0.9132742,0.0014936682,0.0060557146,0.07693618,0.0008925586,0.00035756952,0.00020926214,0.00009930509,0.00068148854],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97924507,0.0013255688,0.017659122,0.0008503775,0.00026310902,0.00065676763],"domain_scores_gemma":[0.9818397,0.0015108511,0.014903641,0.0009645515,0.0003764186,0.0004048034],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.109637626,0.00027606453,0.0016144634,0.00017939914,0.00027605583,0.00020736738,0.00032585338,0.0002428933,0.0038851246],"category_scores_gemma":[0.006454372,0.00032746032,0.00028012876,0.00012566257,0.00017414476,0.00050586177,0.00007578347,0.00038953277,0.0037447785],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011269358,0.001098374,0.37476006,0.00065837096,0.002030956,0.0000027736944,0.0054770187,0.0024079157,0.000014607619,0.064307846,0.47113347,0.077995904],"study_design_scores_gemma":[0.004588061,0.0007758669,0.08784374,0.00017747248,0.000059995386,0.000009583388,0.0029122373,0.16642337,0.000017283048,0.065292805,0.6707569,0.0011427235],"about_ca_topic_score_codex":0.00081855315,"about_ca_topic_score_gemma":0.00009675529,"teacher_disagreement_score":0.28691635,"about_ca_system_score_codex":0.0023515562,"about_ca_system_score_gemma":0.0015908945,"threshold_uncertainty_score":0.99991775},"labels":[],"label_agreement":null},{"id":"W3147478982","doi":"","title":"How much are atypical antipsychotic agents being used, and do they reach the populations who need them ? A Canadian experience.","year":2002,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antipsychotic; Atypical antipsychotic; Psychiatry; Schizophrenia (object-oriented programming)","score_opus":0.350396705278486,"score_gpt":0.4237792688326109,"score_spread":0.07338256355412492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147478982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602484,0.0006504264,0.000020370444,0.037526872,0.0001854394,0.00052782276,0.000009984436,0.000034285917,0.0007964047],"genre_scores_gemma":[0.9951242,0.0010477075,0.0005713054,0.0020876208,0.00025532217,0.000030582294,0.0000076732795,0.00002750804,0.00084806315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998334,0.00020382882,0.00031364872,0.0003422687,0.00033576816,0.00047051592],"domain_scores_gemma":[0.99831265,0.00037892748,0.00007479321,0.00058719,0.00008087642,0.00056554173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031101098,0.00017992691,0.0003238492,0.000061543746,0.00033458348,0.00015496602,0.00018380745,0.00017088084,0.00013712262],"category_scores_gemma":[0.00021323444,0.00010707541,0.00015443383,0.00018928079,0.00027417176,0.000063352236,0.00003671974,0.0004865055,0.000041756186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065378466,0.00038147793,0.93627214,0.000009532172,0.00027624294,0.00011959176,0.0020380428,3.5703417e-7,0.0000118603275,0.005998694,0.0007846395,0.053453624],"study_design_scores_gemma":[0.004200427,0.00039065527,0.96599966,0.000108962806,0.00022098799,0.000097972996,0.0023865239,0.0026923588,0.000018299106,0.01125678,0.012417171,0.00021020604],"about_ca_topic_score_codex":0.0005215038,"about_ca_topic_score_gemma":0.005985671,"teacher_disagreement_score":0.05324342,"about_ca_system_score_codex":0.00006946902,"about_ca_system_score_gemma":0.00006986965,"threshold_uncertainty_score":0.43664083},"labels":[],"label_agreement":null},{"id":"W3164708089","doi":"10.1016/j.clinthera.2021.04.018","title":"Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Quality of life (healthcare); Internal medicine; Oncology; Surgery","score_opus":0.1398493622231116,"score_gpt":0.33563401998709,"score_spread":0.19578465776397844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164708089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228346,0.0023970506,0.0040167808,0.00027539177,0.0000422186,0.0007998452,0.000037482994,0.00002597146,0.0001217883],"genre_scores_gemma":[0.99468076,0.0005192845,0.004067989,0.0003074984,0.000032551998,0.000028740342,0.00026070824,0.000031053587,0.00007139759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773216,0.00036568777,0.0008064655,0.00053523935,0.00027249492,0.00028792853],"domain_scores_gemma":[0.9985778,0.00027039775,0.00016764348,0.0004846432,0.0003315739,0.00016794188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041153282,0.00025555643,0.0011899335,0.00010933962,0.000056915236,0.000030425668,0.000081633356,0.00020401686,0.00011126379],"category_scores_gemma":[0.000027279453,0.00019307838,0.00018621716,0.0011184314,0.0003477971,0.000076140124,0.000019003463,0.0002555358,0.0000010196617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005337479,0.00092166173,0.97988087,0.00009121523,0.0014143456,0.0002600189,0.0004231724,0.000065595625,0.004148572,0.00001835303,0.000003113002,0.0074355965],"study_design_scores_gemma":[0.017791625,0.0018401734,0.8501643,0.00018594769,0.0057543386,0.000028863225,0.00047217545,0.087633654,0.034606967,0.000026190279,0.0011357104,0.00036006342],"about_ca_topic_score_codex":0.00006861362,"about_ca_topic_score_gemma":0.00038409742,"teacher_disagreement_score":0.12971659,"about_ca_system_score_codex":0.000042278967,"about_ca_system_score_gemma":0.0003527104,"threshold_uncertainty_score":0.7873508},"labels":[],"label_agreement":null},{"id":"W3196015703","doi":"10.1016/j.clinthera.2021.07.015","title":"Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bayer (Canada); LMC Diabetes & Endocrinology (Canada)","funders":"Bayer Canada","keywords":"Medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Disease; Internal medicine; Disease registry; Endocrinology","score_opus":0.05534864959786159,"score_gpt":0.35797554397610654,"score_spread":0.30262689437824497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196015703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829152,0.008756425,6.937377e-7,0.006104915,0.00049707736,0.0012974621,0.000145592,0.000021297417,0.00026132978],"genre_scores_gemma":[0.99283135,0.0020768119,0.000024130943,0.0034505357,0.00012324273,0.00007864896,0.00008798977,0.000037814105,0.0012894489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971027,0.00037777037,0.0010251803,0.00051164225,0.00041073727,0.00057201774],"domain_scores_gemma":[0.9968127,0.0005055237,0.0002465048,0.0013743042,0.00015318429,0.00090778194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007864252,0.00028352832,0.0007564335,0.00014353757,0.000052961863,0.00002400094,0.0004047319,0.00011423605,0.00024025228],"category_scores_gemma":[0.0014397115,0.00020654169,0.0002760662,0.0005577677,0.0004004929,0.000068015914,0.00015951488,0.00038327454,0.000013822423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098680466,0.003349014,0.98883426,0.001028599,0.00058284536,0.00008540354,0.00011042144,0.000038900896,0.000025467907,0.00010386187,0.0003673837,0.0053751874],"study_design_scores_gemma":[0.0039343787,0.0009734774,0.9841308,0.0008837475,0.0012565337,3.9926938e-8,0.00006560287,0.0017906979,0.00007360287,0.0002448849,0.0064484547,0.0001977774],"about_ca_topic_score_codex":0.0006458544,"about_ca_topic_score_gemma":0.0057755862,"teacher_disagreement_score":0.009916169,"about_ca_system_score_codex":0.00045305007,"about_ca_system_score_gemma":0.0039416812,"threshold_uncertainty_score":0.84225255},"labels":[],"label_agreement":null},{"id":"W3203749571","doi":"10.1016/j.clinthera.2021.09.003","title":"The Health Care Resource Utilization and Costs Among Patients With Type 2 Diabetes and Either Cardiovascular Disease or Cardiovascular Risk Factors An Analysis of a US Health Insurance Database","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Cohort; Cohort study; Type 2 diabetes; Internal medicine; Risk factor; Disease; Retrospective cohort study; Diabetes mellitus; Endocrinology","score_opus":0.0849999560398354,"score_gpt":0.37183082710739734,"score_spread":0.28683087106756194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203749571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9327624,0.06598844,0.00014559185,0.000105573716,0.00005465444,0.0005926765,0.0003060194,0.000028815237,0.000015845255],"genre_scores_gemma":[0.9731092,0.025499202,0.00007400326,0.00045856417,0.000035367444,0.00000833197,0.00076998945,0.00003198064,0.000013395133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972223,0.00090062426,0.0005097368,0.0005355949,0.000556322,0.0002754414],"domain_scores_gemma":[0.9975554,0.00027775508,0.00023646752,0.0012813248,0.00027299952,0.00037607126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081892463,0.00020295208,0.0008618127,0.00006953123,0.00022546,0.000054233584,0.000095787815,0.0000537298,0.000006688282],"category_scores_gemma":[0.00022045623,0.00012395423,0.00033823424,0.00065717654,0.00036950238,0.00009231997,0.00008878717,0.00018979472,1.7299509e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003905136,0.00020621037,0.8853842,0.0002167793,0.012247972,0.0000063422426,0.0003013501,0.0004018516,4.3320856e-8,0.000010771977,0.000009695444,0.10082427],"study_design_scores_gemma":[0.0019007415,0.0006271974,0.9778707,0.00013866276,0.006140852,1.1201851e-7,0.0014531037,0.0022275804,0.0000011016698,0.0000027016065,0.009505706,0.0001315171],"about_ca_topic_score_codex":0.0002444617,"about_ca_topic_score_gemma":0.00029773245,"teacher_disagreement_score":0.10069275,"about_ca_system_score_codex":0.00010298126,"about_ca_system_score_gemma":0.00039877027,"threshold_uncertainty_score":0.5054707},"labels":[],"label_agreement":null},{"id":"W3213747091","doi":"10.1016/j.clinthera.2021.11.003","title":"Willingness to Accept Expedited COVID-19 Vaccine Research for Children Aged <12 Years After Adult Vaccine Approval","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; BC Children's Hospital; University of British Columbia","funders":"Emory University; University of Toronto; BC Children's Hospital; Children's Health Research Institute; Children's Healthcare of Atlanta; Seattle Children's Research Institute; Women and Children's Health Research Institute; Hospital for Sick Children; Université de Montréal; University of Alberta; University of Washington; Children's Hospital Los Angeles","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Virology; Family medicine; Internal medicine; Infectious disease (medical specialty); Outbreak","score_opus":0.2020352405180424,"score_gpt":0.4946864948235985,"score_spread":0.2926512543055561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213747091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96036255,0.0011853839,0.004582351,0.030166076,0.0013239334,0.0016435119,0.00007011686,0.00018884394,0.00047725678],"genre_scores_gemma":[0.96086323,0.0019244524,0.002882851,0.024915945,0.005332957,0.00023566915,0.00007974395,0.00007930155,0.0036858649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954036,0.0011760753,0.0008894958,0.0008401073,0.0007619547,0.0009287834],"domain_scores_gemma":[0.99461305,0.0028476045,0.00013651926,0.0007395705,0.00088860985,0.00077462837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003946837,0.00023690035,0.0005662482,0.00012493775,0.0006719095,0.00023151675,0.0006898912,0.00046240413,0.00087809865],"category_scores_gemma":[0.004823836,0.00023253229,0.0003618695,0.000975082,0.000051955245,0.00019107423,0.000244282,0.0006818018,0.0001041955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033931297,0.001681137,0.7698749,0.00009316077,0.00060880085,0.00017549965,0.019496113,0.00003868217,0.00029302854,0.00464116,0.11550484,0.084199555],"study_design_scores_gemma":[0.0052200574,0.00060887216,0.555235,0.000055241886,0.00014930143,0.0000047136878,0.002229417,0.000048445792,0.00013131561,0.0063874368,0.4293246,0.0006055667],"about_ca_topic_score_codex":0.00010519024,"about_ca_topic_score_gemma":0.0022079393,"teacher_disagreement_score":0.31381977,"about_ca_system_score_codex":0.00016799851,"about_ca_system_score_gemma":0.00093242724,"threshold_uncertainty_score":0.9614565},"labels":[],"label_agreement":null},{"id":"W4200033621","doi":"10.1016/j.clinthera.2021.11.019","title":"Industry Sponsor Influence in Clinical Trial Reporting in Canada: A Qualitative Interview Study","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Victoria; University of British Columbia; University of British Columbia Hospital","funders":"University of British Columbia; Ministry of Health, British Columbia","keywords":"Clinical trial; Medicine; Institutional review board; Family medicine; Qualitative research; Research ethics; Clinical research; Alternative medicine; Drug trial; Medical education; Psychiatry; Internal medicine; Pathology","score_opus":0.9111908205063685,"score_gpt":0.7403563081261063,"score_spread":0.17083451238026215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200033621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868008,0.0009686835,0.000005317715,0.0071505443,0.0030913833,0.0012988402,0.000037434053,0.000039221697,0.0006078108],"genre_scores_gemma":[0.9678626,0.0006930961,0.000076349264,0.030336827,0.00055928004,0.00011156265,0.000012182158,0.000033451528,0.00031461805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9670884,0.022455243,0.0081275115,0.0009849115,0.00039117047,0.00095277076],"domain_scores_gemma":[0.984224,0.012146388,0.0018268783,0.00063672604,0.00039578133,0.0007701879],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.031843394,0.00038267463,0.0014785661,0.00009611962,0.00013725212,0.000032154818,0.00054932997,0.0025730794,0.0007405558],"category_scores_gemma":[0.01317476,0.00037468175,0.00029040492,0.0009573168,0.00038005065,0.00015423831,0.0003116999,0.019405214,0.000034001652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010314238,0.005081109,0.91365695,0.0000693786,0.00031772754,0.003221213,0.0025838378,0.00014680499,0.00002271425,0.00016126932,0.00023196895,0.06419281],"study_design_scores_gemma":[0.084633484,0.0018454607,0.80237895,0.00032934963,0.0003753201,0.000060470735,0.036356717,0.0019661044,0.00026245785,0.0012165433,0.069571204,0.001003936],"about_ca_topic_score_codex":0.02805846,"about_ca_topic_score_gemma":0.40844715,"teacher_disagreement_score":0.38038868,"about_ca_system_score_codex":0.0005893323,"about_ca_system_score_gemma":0.006992194,"threshold_uncertainty_score":0.99987054},"labels":[{"model":"gemma","categories":["metaresearch","research_integrity"],"domain":"reporting","study_design":"qualitative","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"high"},{"model":"gpt","categories":["metaresearch","research_integrity"],"domain":"reporting","study_design":"qualitative","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4200332531","doi":"10.1016/j.clinthera.2021.09.021","title":"Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children","year":2021,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Warfarin; Anticoagulant; Incidence (geometry); Population; Major bleeding; Pediatrics; Venous thromboembolism; Dabigatran; Intensive care medicine; Surgery; Internal medicine; Thrombosis; Atrial fibrillation; Environmental health","score_opus":0.10850191429847511,"score_gpt":0.38563337894563177,"score_spread":0.27713146464715666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200332531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831975,0.0006010432,0.00007343561,0.00051320775,0.000118279575,0.00019897733,0.000004917448,0.000023183655,0.0001471838],"genre_scores_gemma":[0.99080396,0.004816106,0.0029607678,0.0012411253,0.00008273971,0.0000018571128,0.000007897034,0.000018973307,0.00006655271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987054,0.000108169086,0.0005614216,0.0002881842,0.00016761635,0.00016925033],"domain_scores_gemma":[0.9990286,0.00036917135,0.0001252793,0.00025901367,0.00010569751,0.000112206566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044298303,0.00011997171,0.0006301556,0.0000785013,0.000036369307,0.00002642249,0.00004860278,0.00013605751,0.000021786449],"category_scores_gemma":[0.00012893252,0.00010748877,0.00006128524,0.00023840478,0.00016997132,0.000077638906,0.000091677706,0.00026202004,0.0000015452569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004294178,0.00049707684,0.97247714,0.000037942384,0.00020495524,0.000020106136,0.00018257914,7.786543e-7,0.012609054,0.005879623,0.0000044755634,0.008043313],"study_design_scores_gemma":[0.0016802239,0.00023661749,0.9888607,0.00020537146,0.00029034895,0.000060114537,0.000058602156,0.0005743171,0.0058404556,0.0020238191,0.00006167412,0.000107734915],"about_ca_topic_score_codex":0.00007471368,"about_ca_topic_score_gemma":0.000058747515,"teacher_disagreement_score":0.016383568,"about_ca_system_score_codex":0.000011063542,"about_ca_system_score_gemma":0.00008126599,"threshold_uncertainty_score":0.43832648},"labels":[],"label_agreement":null},{"id":"W4220781979","doi":"10.1016/j.clinthera.2022.01.011","title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Checklist; Economic evaluation; Medicine; Context (archaeology); Public health; Health care; Stakeholder; Guideline; Statement (logic); Population; Public relations; Political science; Psychology; Nursing; Environmental health; Law","score_opus":0.6363331745438332,"score_gpt":0.619695330231166,"score_spread":0.016637844312667238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220781979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46693772,0.029090673,0.046926104,0.38315502,0.020482687,0.020874986,0.028580552,0.00083408813,0.0031181811],"genre_scores_gemma":[0.8013367,0.0037709416,0.019527163,0.15600407,0.002626632,0.0053111776,0.008547206,0.0005598432,0.002316255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9492978,0.004077766,0.04265014,0.0020231768,0.00059372344,0.0013574177],"domain_scores_gemma":[0.9218184,0.0024286672,0.07306914,0.0016596591,0.00048018954,0.0005439898],"candidate_categories":["metaresearch","metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.32084998,0.000501705,0.0029734208,0.0004809807,0.0020274625,0.00021378096,0.000684297,0.0002186742,0.0035549223],"category_scores_gemma":[0.01549245,0.0007006325,0.000672613,0.0003283152,0.00020494207,0.00051497604,0.00026496904,0.00085555355,0.0002226015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00070679485,0.0012155448,0.08791472,0.00092849944,0.0028117325,0.000005069936,0.008111064,0.095172085,0.000018855875,0.041183036,0.72680944,0.035123125],"study_design_scores_gemma":[0.004692751,0.0012170754,0.0066643194,0.00009101746,0.00008362358,0.00002369419,0.0035196047,0.34068233,0.000009936935,0.015849823,0.6262305,0.0009353677],"about_ca_topic_score_codex":0.0007716853,"about_ca_topic_score_gemma":0.00051298534,"teacher_disagreement_score":0.334399,"about_ca_system_score_codex":0.013162019,"about_ca_system_score_gemma":0.010286232,"threshold_uncertainty_score":0.9995445},"labels":[],"label_agreement":null},{"id":"W4220791188","doi":"10.1016/j.clinthera.2022.03.002","title":"Insomnia Treatment Preferences Among Primary Care Patients","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Sleep and related disorders","field":"Psychology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Aging; National Institutes of Health; Canadian Psychological Association","keywords":"Insomnia; Medicine; Anxiety; Depression (economics); Preference; Psychiatry; Clinical psychology; Primary care; Family medicine","score_opus":0.08627252682757995,"score_gpt":0.37878177241428546,"score_spread":0.2925092455867055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220791188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94795686,0.0025314288,0.000006754708,0.000076840195,0.0028321773,0.00036925112,0.000040022114,0.0000874148,0.046099264],"genre_scores_gemma":[0.99580145,0.00046385403,0.00003850995,0.0017103025,0.00009300384,0.00011349908,0.0001710129,0.000027968199,0.0015804281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828005,0.00045964995,0.00044489425,0.00035779932,0.00019993431,0.00025768965],"domain_scores_gemma":[0.999071,0.0002735034,0.00014026498,0.00038982887,0.000043469976,0.00008192617],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013071121,0.00015600394,0.00024267127,0.00004565488,0.00022826534,0.000013017173,0.00026114323,0.0001734096,0.0012658146],"category_scores_gemma":[0.000006116666,0.00012237467,0.00019730581,0.00015184977,0.00017506558,0.000024824916,0.0000898864,0.0003976758,0.00012380414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014981431,0.0019470601,0.6823191,0.0000028096372,0.0006692042,0.0000050334766,0.0033420138,0.000017728524,4.3195936e-7,0.000124951,0.00040245432,0.31101936],"study_design_scores_gemma":[0.005987302,0.0033808534,0.7587768,0.0000057787215,0.0003855257,8.058515e-7,0.0046510343,0.000012575104,0.0000023777366,0.00042766615,0.22609432,0.00027499223],"about_ca_topic_score_codex":0.00003522772,"about_ca_topic_score_gemma":0.0000086525615,"teacher_disagreement_score":0.31074437,"about_ca_system_score_codex":0.00010981568,"about_ca_system_score_gemma":0.000052464547,"threshold_uncertainty_score":0.99964714},"labels":[],"label_agreement":null},{"id":"W4220830401","doi":"10.1016/j.clinthera.2021.12.012","title":"Effects of Vitamin D Supplementation on Bone Health and Bone-related Parameters in HIV-infected Patients: A Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Coastal Health","funders":"","keywords":"Medicine; Vitamin D and neurology; Meta-analysis; Bone mineral; Internal medicine; Parathyroid hormone; vitamin D deficiency; Randomized controlled trial; Vitamin; Bone health; Bone density; Gastroenterology; Clinical trial; Osteoporosis; Calcium","score_opus":0.1643892349202919,"score_gpt":0.468002889916494,"score_spread":0.30361365499620213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220830401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018433282,0.9899062,0.000011620502,0.00057106465,0.000032829244,0.009078005,0.00017750073,0.000023349634,0.000015127451],"genre_scores_gemma":[0.00022549077,0.99425715,0.00030279817,0.0024097126,0.0000029090281,0.0011133541,0.0015399305,0.00004543763,0.00010319858],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99244857,0.0025366514,0.003814662,0.00060232444,0.0003337011,0.0002640825],"domain_scores_gemma":[0.9928596,0.0040275576,0.0021387136,0.00065092964,0.00007578215,0.00024741096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014734721,0.00043377478,0.009217429,0.0005017277,0.00008498574,0.000010349422,0.0000856033,0.00024891575,0.00006606168],"category_scores_gemma":[0.00043387213,0.00029308788,0.0013083433,0.0013166603,0.00009129607,0.000026951693,0.000057184032,0.0007079433,0.000009578272],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030976465,0.0019336038,0.0002944957,0.8679093,0.101180054,0.000012228796,0.00012461292,4.5611822e-7,5.0888067e-9,0.0000735914,0.000058720863,0.02838195],"study_design_scores_gemma":[0.0024609643,0.002264319,0.00022689215,0.04313101,0.9383893,0.000012376033,0.000015120463,0.000032720534,3.708571e-8,0.000019535102,0.013198711,0.00024903394],"about_ca_topic_score_codex":0.000018509787,"about_ca_topic_score_gemma":0.000004406795,"teacher_disagreement_score":0.8372092,"about_ca_system_score_codex":0.00021499228,"about_ca_system_score_gemma":0.00020728564,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W4223641903","doi":"10.1016/j.clinthera.2022.02.006","title":"Sex Differences in Physical Activity and Incident Stroke: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Physical Activity and Health","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network","funders":"National Institute on Minority Health and Health Disparities; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke; Agency for Healthcare Research and Quality","keywords":"Medicine; Stroke (engine); Observational study; Meta-analysis; Physical therapy; MEDLINE; Physical activity; Epidemiology; Gerontology; Internal medicine","score_opus":0.4479583517260031,"score_gpt":0.5292470480853367,"score_spread":0.08128869635933361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223641903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018227544,0.99436694,0.0000064199994,0.0002478941,0.00012520149,0.0031599207,0.000037409092,0.000040179326,0.00019326476],"genre_scores_gemma":[0.001726893,0.996187,0.000012372802,0.0011075279,0.00025734917,0.0003633579,0.000015729058,0.000042972682,0.00028684223],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.995364,0.0020240129,0.0011507447,0.0006067794,0.0005133649,0.00034106686],"domain_scores_gemma":[0.9931836,0.005152321,0.00073598145,0.00066215603,0.000021694623,0.00024420518],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014524859,0.00044615084,0.0085305525,0.0000823006,0.000077189994,0.00002101978,0.0002510379,0.00027088428,0.000036366317],"category_scores_gemma":[0.00050640973,0.00029148496,0.00092895434,0.00032105486,0.00019354807,0.000054107513,0.00023906695,0.0025050465,0.000020702073],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013730276,0.0019813231,0.000057312252,0.64964193,0.00030291427,0.00002115604,0.000031198844,1.7840976e-9,6.197029e-8,0.00006267565,0.000006667034,0.34788105],"study_design_scores_gemma":[0.0008402239,0.002090757,0.00050286454,0.7522676,0.014597797,0.0000966711,0.000032747237,0.00016181615,1.8250245e-7,0.00027993898,0.2284584,0.00067099294],"about_ca_topic_score_codex":0.000012657487,"about_ca_topic_score_gemma":0.000005260994,"teacher_disagreement_score":0.34721005,"about_ca_system_score_codex":0.00019717502,"about_ca_system_score_gemma":0.0004996876,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W4252306380","doi":"10.1016/s0149-2918(10)00041-x","title":"","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Traditional medicine","score_opus":0.21719887360812087,"score_gpt":0.49184641153015707,"score_spread":0.2746475379220362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252306380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894974,0.00006189457,0.00068055524,0.0029725132,0.0040718243,0.00049867725,0.000030385334,0.0011593289,0.0010273922],"genre_scores_gemma":[0.96859306,0.0000702927,0.014357014,0.014579209,0.0019972976,0.000031289663,0.000012096394,0.00024476444,0.00011496692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941063,0.0007471984,0.0022598885,0.0010272098,0.00073207327,0.0011273212],"domain_scores_gemma":[0.99121016,0.0044582402,0.00055688503,0.0025432445,0.0004663232,0.00076515286],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007323691,0.0004869133,0.0008377834,0.00011292286,0.00033448014,0.0001755452,0.0015642527,0.0008741389,0.00015402051],"category_scores_gemma":[0.0016519022,0.00041340312,0.0007652708,0.0007270865,0.0020828042,0.00037285156,0.00027281532,0.0041481783,0.0018866112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006049383,0.0019857292,0.69185966,0.000004064555,0.00033259025,0.00002504805,0.00022369469,0.000008760918,0.19134103,0.012757939,0.00016857433,0.10068799],"study_design_scores_gemma":[0.0059075267,0.0008646861,0.67953,0.000009901021,0.00030994668,0.000060430695,0.000136056,0.003882354,0.0074408823,0.025537675,0.27534002,0.0009805094],"about_ca_topic_score_codex":0.0000091389975,"about_ca_topic_score_gemma":0.00023884744,"teacher_disagreement_score":0.27517143,"about_ca_system_score_codex":0.000021659449,"about_ca_system_score_gemma":0.00018627895,"threshold_uncertainty_score":0.9998318},"labels":[],"label_agreement":null},{"id":"W4280604484","doi":"10.1016/j.clinthera.2022.04.002","title":"Clinical Profile and Sex-Specific Recovery With Cardiac Rehabilitation After Coronary Artery Bypass Grafting Surgery","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myocardial infarction; Hematocrit; Rehabilitation; Retrospective cohort study; Internal medicine; Revascularization; Adverse effect; Artery; Cohort; Surgery; Canadian Cardiovascular Society; Cardiology; Physical therapy; Angina","score_opus":0.07709193549242335,"score_gpt":0.3887840700482808,"score_spread":0.3116921345558574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280604484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038506,0.0029285972,0.000045327044,0.0025248954,0.0021422787,0.0012292848,0.00009868344,0.000090328445,0.00055553904],"genre_scores_gemma":[0.9805831,0.0042569083,0.002332902,0.010916888,0.000953275,0.00029650496,0.00013298,0.00006500756,0.00046246758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564445,0.0013166906,0.0014287507,0.0006500515,0.00046909484,0.00049093575],"domain_scores_gemma":[0.992926,0.005722268,0.00024825294,0.0005313592,0.00008115808,0.0004909752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052819573,0.00021597944,0.0009630262,0.000089590096,0.0002523603,0.000018120187,0.00005810269,0.00018007611,0.00012477193],"category_scores_gemma":[0.00011780337,0.00018517199,0.0004570516,0.00023661535,0.0003281471,0.00007797173,0.00010777075,0.0010952892,0.000017118831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038532668,0.00046268146,0.7242688,0.00012332559,0.00012282959,0.00006472731,0.0001606334,7.1194364e-7,0.0000058070514,0.00000912821,0.0018741004,0.269054],"study_design_scores_gemma":[0.0018499007,0.004508875,0.7724237,0.000087039865,0.00016551916,0.00015732096,0.0010053187,0.00005662831,0.0000032296034,0.00010074917,0.21941118,0.00023057064],"about_ca_topic_score_codex":0.0000062281715,"about_ca_topic_score_gemma":0.0000020040081,"teacher_disagreement_score":0.26882342,"about_ca_system_score_codex":0.00017433337,"about_ca_system_score_gemma":0.0005655721,"threshold_uncertainty_score":0.7551094},"labels":[],"label_agreement":null},{"id":"W4281779504","doi":"10.1016/j.clinthera.2022.05.003","title":"The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Medicine; Insulin glargine; Biosimilar; Cohort; Insulin; Internal medicine; Demography; Emergency medicine; Hypoglycemia","score_opus":0.11285164216540466,"score_gpt":0.46329973149812775,"score_spread":0.3504480893327231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281779504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863855,0.0014659241,0.0019118023,0.008581936,0.0006193983,0.00038924877,0.000044677523,0.000041646275,0.0005598591],"genre_scores_gemma":[0.9892429,0.0006672333,0.00068887294,0.008504657,0.00035600402,0.000041528143,0.000021115438,0.00002041205,0.00045727807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980979,0.00020655645,0.0006862384,0.00026176867,0.0005210899,0.0002264784],"domain_scores_gemma":[0.9979331,0.0008594185,0.0001953884,0.00064201595,0.00008315229,0.00028694593],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011732467,0.00012620536,0.00036039535,0.00003546239,0.00019907876,0.000010653627,0.00040423177,0.000076687276,0.0017632842],"category_scores_gemma":[0.00028918494,0.00007927451,0.00024510996,0.00027740962,0.00014514553,0.000020710462,0.00015363234,0.0007075648,0.00016036646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045789005,0.003484289,0.39395317,0.00003822195,0.0019957335,0.00008539035,0.0009628962,0.00007084543,0.0074713123,0.0014861788,0.059241764,0.5266313],"study_design_scores_gemma":[0.0038635284,0.0029585818,0.24882744,0.00008568448,0.00019175335,0.000016538579,0.00049438124,0.0059345844,0.0004036513,0.0021519007,0.73482126,0.0002507003],"about_ca_topic_score_codex":0.000026148706,"about_ca_topic_score_gemma":7.642752e-7,"teacher_disagreement_score":0.6755795,"about_ca_system_score_codex":0.00008051152,"about_ca_system_score_gemma":0.00043203076,"threshold_uncertainty_score":0.99914926},"labels":[],"label_agreement":null},{"id":"W4281782658","doi":"10.1016/j.clinthera.2022.05.002","title":"Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Discontinuation; Janus kinase inhibitor; Rheumatoid arthritis; Cohort; Methotrexate; Internal medicine; Retrospective cohort study; Medical prescription; Cohort study; Surgery; Pharmacology","score_opus":0.13732427891017976,"score_gpt":0.41875820410717013,"score_spread":0.2814339251969904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281782658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971843,0.00079475576,0.00055794156,0.00024608054,0.00012422359,0.0007147312,0.000113675495,0.000041968106,0.00022231959],"genre_scores_gemma":[0.99149406,0.0055931075,0.0022772125,0.00024441027,0.000014917601,0.00007778114,0.00020165258,0.000042025596,0.000054824053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962013,0.0011530771,0.0011829782,0.00038793226,0.00067598384,0.00039876375],"domain_scores_gemma":[0.9977146,0.0008191675,0.00048131618,0.00036136876,0.00046653685,0.0001570593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019472266,0.00022986779,0.00075398677,0.0002449212,0.0001783717,0.00003919086,0.00020967537,0.00008030744,0.0007673225],"category_scores_gemma":[0.0006699299,0.00016950317,0.00027628508,0.00064982625,0.00033736756,0.000239681,0.00012405339,0.0006605964,0.0000051361685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002789975,0.0018088561,0.8463413,0.000013527043,0.00035687324,0.000018798177,0.0011607133,0.00006475111,0.000083006315,0.000112590904,0.000019963112,0.14722963],"study_design_scores_gemma":[0.014878031,0.008955775,0.9706107,0.00039731828,0.000016075839,0.00003495061,0.0010007647,0.0022256703,0.00010086995,0.00040333834,0.0011092755,0.00026724892],"about_ca_topic_score_codex":0.00008800397,"about_ca_topic_score_gemma":0.000090409805,"teacher_disagreement_score":0.14696237,"about_ca_system_score_codex":0.00014304169,"about_ca_system_score_gemma":0.00032742292,"threshold_uncertainty_score":0.8401643},"labels":[],"label_agreement":null},{"id":"W4284878686","doi":"10.1016/j.clinthera.2022.06.006","title":"Nonpharmacological Interventions for the Management of Testosterone and Sperm Parameters: A Scoping Review","year":2022,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brandon University","funders":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Testosterone (patch); Nutraceutical; Male infertility; Vitamin D and neurology; Infertility; Nutritional Supplementation; Psychological intervention; Endocrinology; Internal medicine; Pregnancy; Biology","score_opus":0.7100978350239662,"score_gpt":0.6047593908499179,"score_spread":0.10533844417404825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284878686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000052596793,0.99333525,0.00011718016,0.00074048666,0.00035871725,0.005244796,0.00003148103,0.0000137458255,0.00015306084],"genre_scores_gemma":[0.0000026604448,0.996641,0.0013117655,0.0007156101,0.00015600552,0.0007806835,0.000023332916,0.000023379625,0.0003455583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977847,0.0002296445,0.001266396,0.0003997229,0.00016234358,0.00015722198],"domain_scores_gemma":[0.99676,0.0023202484,0.00044932938,0.00036545322,0.000055459506,0.000049481096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015888215,0.00022165601,0.002064641,0.000030165622,0.00011570639,0.000005653483,0.00017920649,0.00008393719,0.00010016185],"category_scores_gemma":[0.00012889977,0.00010948116,0.0013678249,0.00016702128,0.00040873367,0.000010367987,0.00034044473,0.00045111947,0.0000028491386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022806445,0.00023241821,0.000004355366,0.25805956,0.0024833314,0.000004869203,0.0000067152337,2.0074754e-8,2.5696671e-8,0.000030297264,0.00007038464,0.7390852],"study_design_scores_gemma":[0.00034867795,0.0007824063,0.000029101047,0.2794412,0.016653582,0.000017350907,0.000045541732,0.0000012462914,1.0049818e-7,0.000033309287,0.7025481,0.00009940845],"about_ca_topic_score_codex":3.1384735e-7,"about_ca_topic_score_gemma":1.88813e-7,"teacher_disagreement_score":0.7389858,"about_ca_system_score_codex":0.000024020552,"about_ca_system_score_gemma":0.000061962404,"threshold_uncertainty_score":0.44645122},"labels":[],"label_agreement":null},{"id":"W4287094865","doi":"10.1016/j.clinthera.2022.07.007","title":"Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry Survey","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacovigilance; Revenue; Workload; Business; Pandemic; Quarter (Canadian coin); Data collection; Coronavirus disease 2019 (COVID-19); Product (mathematics); Marketing; Accounting; Medicine; Economics; Management","score_opus":0.45276977082375525,"score_gpt":0.547388937798317,"score_spread":0.09461916697456174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287094865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940014,0.002875802,0.000020821435,0.0003032439,0.001117287,0.00068787317,0.0008219193,0.000051542265,0.0001201497],"genre_scores_gemma":[0.98638135,0.004505993,0.0000055907053,0.008728865,0.00013600122,0.00006466287,0.000029514753,0.000024025367,0.00012397685],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539477,0.0029561936,0.00070456957,0.0003852472,0.00023404774,0.00032515376],"domain_scores_gemma":[0.992168,0.0066101025,0.00053832534,0.00024436513,0.00011992919,0.00031923954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029095036,0.00023649364,0.00053476886,0.000064135886,0.00044502114,0.000013721246,0.00045502203,0.00033416605,0.000061585255],"category_scores_gemma":[0.0003966682,0.00018572704,0.00007570756,0.00037328602,0.0006501024,0.00007742928,0.00021382613,0.0022255708,0.0000010298448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001434309,0.0021759896,0.9758871,0.001156934,0.0006231382,0.0000146496095,0.00079107383,0.0079668425,0.007509456,0.00040248886,0.0005614238,0.0014765625],"study_design_scores_gemma":[0.024199296,0.0030383065,0.38653207,0.00017673295,0.0022827755,0.00021717937,0.0037798963,0.017219407,0.013495858,0.0007510517,0.54693323,0.0013742046],"about_ca_topic_score_codex":0.000040558334,"about_ca_topic_score_gemma":0.000043261316,"teacher_disagreement_score":0.58935505,"about_ca_system_score_codex":0.00004978227,"about_ca_system_score_gemma":0.00055742654,"threshold_uncertainty_score":0.9669122},"labels":[],"label_agreement":null},{"id":"W4288459167","doi":"10.1016/j.clinthera.2022.06.003","title":"Maternal Predictors of Breast Milk Plasmalogens and Associations with Infant Body Composition and Neurodevelopment","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Center for Advancing Translational Sciences; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Breast milk; Composition (language); Breast feeding; Pediatrics; Physiology; Biochemistry","score_opus":0.05349197174470594,"score_gpt":0.35340519290995137,"score_spread":0.29991322116524544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288459167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964243,0.00009340887,0.00005998201,0.002704998,0.0002341248,0.00020578518,0.00020309526,0.000020963282,0.000053306794],"genre_scores_gemma":[0.9979565,0.0001681781,0.00080726884,0.00095558644,0.00004974375,0.000009264882,0.00002959667,0.000012933146,0.000010896948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987198,0.00027640938,0.00034753507,0.00017207918,0.00028952054,0.0001946264],"domain_scores_gemma":[0.99926686,0.0003286798,0.00013360995,0.0001008104,0.00005589855,0.0001141432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053185044,0.00007757874,0.00019236989,0.000047872494,0.00027355342,0.00001983573,0.00007471215,0.000044853903,0.00001690255],"category_scores_gemma":[0.000012994724,0.00006511728,0.000026318166,0.0000919686,0.00017393727,0.00003460667,0.00008654269,0.00034534256,6.784015e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079366827,0.0002456144,0.99150556,0.00002984427,0.00010326345,0.000004273173,0.00036214088,0.000024843113,0.0032935026,0.00007423366,0.00009361414,0.003469441],"study_design_scores_gemma":[0.001086374,0.0010784894,0.99467945,0.000015419399,0.000044250268,0.00004916586,0.00007934457,0.0009509007,0.00089848414,0.0000849151,0.0009589545,0.00007427471],"about_ca_topic_score_codex":0.000032741435,"about_ca_topic_score_gemma":0.000015922113,"teacher_disagreement_score":0.0033951665,"about_ca_system_score_codex":0.00004459636,"about_ca_system_score_gemma":0.00006130545,"threshold_uncertainty_score":0.26554057},"labels":[],"label_agreement":null},{"id":"W4289337629","doi":"10.1016/j.clinthera.2022.07.005","title":"Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Dronedarone; Medicine; Atrial fibrillation; Post-hoc analysis; Hazard ratio; Placebo; Internal medicine; Population; Proportional hazards model; Atrial flutter; Cardiology; Adverse effect; Confidence interval; Amiodarone","score_opus":0.12176342128678642,"score_gpt":0.4461778000437556,"score_spread":0.3244143787569692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289337629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937167,0.00041419908,0.0000068244203,0.0036964838,0.0003345829,0.0016651109,0.000017640694,0.00000427974,0.00014415749],"genre_scores_gemma":[0.99902564,0.0002287501,0.000018637875,0.00013449395,0.00047289423,0.0000043778014,0.00005916577,0.000007531363,0.000048490932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960855,0.0020467865,0.0010812673,0.00015255089,0.00052784214,0.00010604205],"domain_scores_gemma":[0.995774,0.0031269623,0.00053038716,0.00052383606,0.000032167045,0.000012683725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029141011,0.00011756141,0.00071674323,0.00016600607,0.00006456832,0.0000057851166,0.00020069267,0.00006969926,0.00005731694],"category_scores_gemma":[0.00018890653,0.000052851934,0.0011080182,0.0013148064,0.000099533834,0.000022083466,0.00003628021,0.00012822758,3.929932e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038204264,0.00012441493,0.8925111,0.000020878208,0.0011165595,0.0000012138336,0.002205092,0.0035659329,0.000022087566,0.0006469912,0.000004940473,0.06157649],"study_design_scores_gemma":[0.033587597,0.012739187,0.9391432,0.000012783341,0.004803569,7.6607927e-7,0.00078182813,0.0031235619,0.00002426794,0.00019690508,0.005509688,0.00007669106],"about_ca_topic_score_codex":0.00007239877,"about_ca_topic_score_gemma":0.0000627014,"teacher_disagreement_score":0.0614998,"about_ca_system_score_codex":0.00005929984,"about_ca_system_score_gemma":0.000038417824,"threshold_uncertainty_score":0.21552393},"labels":[],"label_agreement":null},{"id":"W4296623163","doi":"10.1016/j.clinthera.2022.08.010","title":"Population Pharmacokinetics and Exposure–Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Janssen Research and Development","keywords":"Ustekinumab; Medicine; Vedolizumab; Population; Pharmacokinetics; Crohn's disease; Internal medicine; Immunology; Gastroenterology; Pharmacology; Tumor necrosis factor alpha; Disease; Adalimumab","score_opus":0.050024190595045266,"score_gpt":0.3703212175923325,"score_spread":0.32029702699728724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296623163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99912316,0.00007224779,0.00011095756,0.00006026008,0.00007123936,0.00038370676,0.00015940629,0.0000061573623,0.00001285144],"genre_scores_gemma":[0.998689,0.0000197673,0.00020138675,0.00086245564,0.00003150204,0.00003087943,0.00010447438,0.000024440664,0.00003607677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984089,0.00053032086,0.00037836595,0.00031194938,0.0002135621,0.00015691055],"domain_scores_gemma":[0.9992618,0.00006820465,0.00013968429,0.0002762691,0.000104881525,0.00014915025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029798652,0.00013802691,0.00018259797,0.000063955755,0.00006558582,0.000010877273,0.00013188245,0.00005309798,0.000018483695],"category_scores_gemma":[0.00009025489,0.00012891568,0.00006574122,0.00012043921,0.000069692425,0.000005768224,0.00015672176,0.00013357111,5.819953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19335271,0.000966481,0.7823523,0.0000231032,0.00022259912,0.00006047686,0.000121682206,0.014757685,0.0012395912,0.000011624988,0.000027566828,0.006864155],"study_design_scores_gemma":[0.0024053806,0.0006683461,0.9951412,0.0000061618794,0.000090994865,2.9650846e-7,0.0000389566,0.00063444005,0.00044629182,0.00004022824,0.00035942052,0.00016830156],"about_ca_topic_score_codex":0.0000042953243,"about_ca_topic_score_gemma":0.000004867865,"teacher_disagreement_score":0.21278886,"about_ca_system_score_codex":0.0000256599,"about_ca_system_score_gemma":0.000096943506,"threshold_uncertainty_score":0.52570283},"labels":[],"label_agreement":null},{"id":"W4301370539","doi":"10.1016/j.clinthera.2022.09.005","title":"Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States","year":2022,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Treatment-resistant depression; Major depressive disorder; Depression (economics); Electroconvulsive therapy; Antidepressant; Cohort; Internal medicine","score_opus":0.13181719513554183,"score_gpt":0.3929121260090837,"score_spread":0.26109493087354185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301370539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971155,0.00007236553,0.000008638586,0.0010021613,0.00018104281,0.001008143,0.00034603957,0.00004801491,0.00021807927],"genre_scores_gemma":[0.99413174,0.0005911223,0.00021140257,0.0021937233,0.00005968878,0.000097559416,0.0024000902,0.00004895535,0.0002657293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966815,0.0010448253,0.0009267653,0.0003379364,0.0007515576,0.0002574299],"domain_scores_gemma":[0.99663776,0.0020588355,0.00050376705,0.0005430764,0.00017577992,0.000080775695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057733606,0.00028918695,0.00063770125,0.00024779123,0.00018180023,0.000018339826,0.00023145998,0.00009143629,0.00022217842],"category_scores_gemma":[0.00007318397,0.00014918971,0.0001482966,0.0006090012,0.00024135683,0.00004008103,0.0000662663,0.0004510291,0.0000031354366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030555328,0.011366995,0.9458864,0.00002619626,0.00055050466,0.00009357322,0.00061555486,0.000025670759,0.00009955606,0.000092161456,0.000093567956,0.010594494],"study_design_scores_gemma":[0.01598028,0.01052228,0.95998883,0.00016520116,0.00035609715,0.0000028128354,0.0002715892,0.00013932736,0.00014951003,0.000046663565,0.012215985,0.00016141761],"about_ca_topic_score_codex":0.00009837224,"about_ca_topic_score_gemma":0.00012385375,"teacher_disagreement_score":0.014575049,"about_ca_system_score_codex":0.00015035456,"about_ca_system_score_gemma":0.0001778987,"threshold_uncertainty_score":0.608378},"labels":[],"label_agreement":null},{"id":"W4315785450","doi":"10.1016/j.clinthera.2022.12.005","title":"Drug–Drug Interactions: A Pharmacovigilance Road Less Traveled","year":2023,"lang":"en","type":"editorial","venue":"Clinical Therapeutics","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Medicine; Pharmacovigilance; Drug; Pharmacology; Drug-drug interaction","score_opus":0.3180098632796656,"score_gpt":0.5693123128962005,"score_spread":0.2513024496165349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315785450","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006319375,0.001799824,0.000046060606,0.0024763865,0.9804314,0.00096204237,0.0019380718,0.00114461,0.0048822584],"genre_scores_gemma":[0.0072945543,0.0556592,0.00008435684,0.007372037,0.86193424,0.0004484539,0.0014916046,0.0004318517,0.06528369],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912308,0.002166639,0.0024873603,0.0016264707,0.0009627885,0.0015259798],"domain_scores_gemma":[0.97964656,0.016606446,0.0012969694,0.0009694698,0.00066147285,0.0008190478],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.003724554,0.0012002627,0.001836996,0.00037505213,0.0007348626,0.00014187548,0.0017619721,0.0016033672,0.0009669486],"category_scores_gemma":[0.0010522064,0.0011895868,0.0013815585,0.00086998934,0.0008208074,0.00038218178,0.00035603298,0.012966438,0.004334183],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009056747,0.0011311858,0.00044352334,0.00017370992,0.0023679459,0.00019549501,0.0003107163,0.0001906794,0.0005600463,0.000027745675,0.9172518,0.07644147],"study_design_scores_gemma":[0.0041962,0.000058210706,0.00010242108,0.00017538847,0.0020311757,0.0000073770602,0.00031744983,0.0026334098,0.00081125105,0.00021670308,0.9882332,0.0012172275],"about_ca_topic_score_codex":0.00008110693,"about_ca_topic_score_gemma":0.0001871535,"teacher_disagreement_score":0.118497126,"about_ca_system_score_codex":0.0003600203,"about_ca_system_score_gemma":0.0011483032,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W4317538211","doi":"10.1016/j.clinthera.2022.12.012","title":"Multidrug Interactions: Why Do They Occur and How to Handle?","year":2023,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Polypharmacy; Intensive care medicine; Pharmacogenomics; Regimen; Drug; Population; Adverse effect; Psychological intervention; Pharmacotherapy; Pharmacology; Internal medicine; Psychiatry","score_opus":0.6950129762825652,"score_gpt":0.6109867662293008,"score_spread":0.08402621005326438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317538211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000061155755,0.98922694,0.000082746665,0.0054095727,0.0022636545,0.0018635797,0.00009710682,0.00016688714,0.0008283542],"genre_scores_gemma":[0.00005994017,0.98640937,0.0005927062,0.0085153375,0.00089927414,0.000075713986,0.000060261984,0.00011213238,0.003275257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709785,0.0005562191,0.0009873313,0.0006513014,0.00032561723,0.00038166554],"domain_scores_gemma":[0.9906916,0.007581744,0.00043924348,0.0006431443,0.00010930222,0.00053498906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011083611,0.00046864778,0.002141573,0.0001729311,0.0001011627,0.00014113881,0.00024154087,0.00042309664,0.00006812567],"category_scores_gemma":[0.0014461941,0.0003119298,0.00080094516,0.00029922993,0.00012377418,0.00011202708,0.00024516895,0.0017470239,0.00059678836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010778402,0.0002540429,0.00047679304,0.0043873624,0.0011985394,0.000034246328,0.000076584365,9.343867e-8,2.3765809e-7,0.00008807147,0.0031447457,0.9902315],"study_design_scores_gemma":[0.00071216054,0.00035237757,0.00004437396,0.0066628777,0.003766024,0.00004724367,0.000050317638,0.00008702447,2.296523e-7,0.00012904008,0.98782164,0.00032667047],"about_ca_topic_score_codex":0.0000046873524,"about_ca_topic_score_gemma":0.000009331123,"teacher_disagreement_score":0.9899048,"about_ca_system_score_codex":0.00005902391,"about_ca_system_score_gemma":0.00014424766,"threshold_uncertainty_score":0.9999333},"labels":[],"label_agreement":null},{"id":"W4366277612","doi":"10.1016/j.clinthera.2023.03.016","title":"A Scoping Review of Vitamin D for Nonskeletal Health: A Framework for Evidence-based Clinical Practice","year":2023,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brandon University","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Vitamin D and neurology; Rickets; Osteomalacia; vitamin D deficiency; Osteoporosis; Disease; Diabetes mellitus; Clinical trial; Randomized controlled trial; Observational study; Intensive care medicine; Internal medicine; Physiology; Pediatrics; Endocrinology","score_opus":0.7547652192973424,"score_gpt":0.6948700386683466,"score_spread":0.05989518062899579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366277612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.149849e-7,0.9456061,0.020319,0.010272257,0.001347956,0.022077799,0.00023685518,0.00012104167,0.00001878138],"genre_scores_gemma":[1.2827017e-7,0.8719832,0.10676407,0.01578026,0.0019609933,0.0029778653,0.00013356845,0.00022304186,0.00017691846],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9865166,0.0027157937,0.0075436584,0.0012566191,0.000997999,0.0009693628],"domain_scores_gemma":[0.758955,0.23253985,0.004195307,0.0018540227,0.0018968135,0.00055902224],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.027411476,0.00071341166,0.009644219,0.00021570016,0.00019362886,0.000031096646,0.00071141875,0.0012474833,0.000018918077],"category_scores_gemma":[0.2042104,0.0005149304,0.0054748426,0.00097005756,0.00090351346,0.00009488405,0.00027368686,0.00235204,0.000056291756],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014137659,0.00047505184,0.0000077966515,0.4811536,0.001365656,0.0000067998367,0.0000052604764,2.5328866e-8,8.0564275e-9,0.00013623113,0.0020822962,0.5146259],"study_design_scores_gemma":[0.00078275433,0.0035699552,0.0000055783853,0.5344112,0.0044338796,0.000007912894,0.000012584817,0.000024219435,8.536394e-8,0.00009171049,0.45644033,0.00021983427],"about_ca_topic_score_codex":0.0000016181469,"about_ca_topic_score_gemma":0.0000015763588,"teacher_disagreement_score":0.5144061,"about_ca_system_score_codex":0.00020576993,"about_ca_system_score_gemma":0.008508857,"threshold_uncertainty_score":0.9999496},"labels":[],"label_agreement":null},{"id":"W4383198110","doi":"10.1016/j.clinthera.2023.06.005","title":"The Use and Availability of Musculoskeletal Ultrasonography for Psoriatic Disease Among Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Members and the Unmet Needs","year":2023,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Enthesitis; Psoriasis; Ultrasonography; Dermatology; Rheumatology; Physical therapy; Internal medicine; Gynecology; Surgery","score_opus":0.1860133822031371,"score_gpt":0.4641174795594809,"score_spread":0.2781040973563438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383198110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895321,0.0054439893,0.00018800779,0.0020782568,0.00011341948,0.0025387118,0.00006457963,0.000017437553,0.00002348307],"genre_scores_gemma":[0.9389636,0.05980331,0.0006068738,0.000074094525,0.00007257944,0.00036193148,0.000018506407,0.000027393848,0.00007172576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974018,0.0005942618,0.0009007076,0.00031757884,0.000417072,0.00036858866],"domain_scores_gemma":[0.981913,0.016862432,0.00019997492,0.0004866172,0.000351421,0.00018659045],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0076912697,0.00015915328,0.0006272286,0.00014603275,0.00037813652,0.00008144522,0.00012944889,0.000135713,0.0000048902893],"category_scores_gemma":[0.0027388053,0.00009403844,0.00020998677,0.00045504697,0.0042123003,0.000117097494,0.00013561794,0.0003842578,1.2861926e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004957564,0.00052766467,0.617512,0.0022510097,0.0015087757,0.0000016600694,0.0014181115,0.000002775179,0.00009418696,0.019984864,0.00054148375,0.35119992],"study_design_scores_gemma":[0.014371692,0.0024393427,0.92897666,0.00021023414,0.00054954906,0.0000014388851,0.0033906046,0.020660618,0.00001776492,0.01705267,0.012158394,0.00017102667],"about_ca_topic_score_codex":0.000031822965,"about_ca_topic_score_gemma":0.000021067752,"teacher_disagreement_score":0.3510289,"about_ca_system_score_codex":0.000010460166,"about_ca_system_score_gemma":0.0001224524,"threshold_uncertainty_score":0.99849766},"labels":[],"label_agreement":null},{"id":"W4384301415","doi":"10.1016/j.clinthera.2023.06.004","title":"Protocol for a Prospective, Observational Cost-effectiveness Analysis of Returning Secondary Findings of Genome Sequencing for Unexplained Suspected Genetic Conditions","year":2023,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; University of Ottawa; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Government of Canada; Ontario Genomics; Ontario Genomics Institute; Genome Canada","keywords":"Medicine; Observational study; Economic evaluation; Exome sequencing; Public health; Protocol (science); Index case; Intervention (counseling); Genetic testing; Exome; Cost effectiveness; Family medicine; Pediatrics; Genetics; Internal medicine; Nursing; Alternative medicine; Disease; Pathology; Risk analysis (engineering); Gene","score_opus":0.1873006830068213,"score_gpt":0.4485893318328177,"score_spread":0.2612886488259964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384301415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95102113,0.00002296761,0.008342166,0.00003148992,0.00005617618,0.039208647,0.0012751109,0.000016101661,0.000026226347],"genre_scores_gemma":[0.94744444,0.000014902156,0.0022250304,0.00011529217,0.00010349532,0.04827397,0.0017185261,0.000032230466,0.00007208949],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99866647,0.00009397954,0.0006118197,0.00033896658,0.00009358609,0.00019519594],"domain_scores_gemma":[0.9983128,0.00057278015,0.0002755442,0.00024898179,0.00053432584,0.00005560817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005447697,0.00013437768,0.00039310273,0.00012467643,0.00009093287,0.000010807082,0.00016226634,0.00016237011,0.000015334677],"category_scores_gemma":[0.0003079952,0.00012648372,0.00048510113,0.00047193374,0.00014731848,0.0000037101056,0.000051684812,0.00006996149,4.0676275e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021133635,0.00036710605,0.20674492,0.00056860305,0.0052755005,0.0000020558102,0.00011219972,0.009139491,0.7737036,0.0012231825,0.000092548864,0.00065745314],"study_design_scores_gemma":[0.0038226543,0.0011852747,0.93925935,0.00003932915,0.00095065933,0.0000011461507,0.00010976267,0.011805538,0.035973724,0.0022498658,0.004340714,0.0002619564],"about_ca_topic_score_codex":0.0000018786102,"about_ca_topic_score_gemma":0.000006889016,"teacher_disagreement_score":0.73772985,"about_ca_system_score_codex":0.000029109711,"about_ca_system_score_gemma":0.00032995368,"threshold_uncertainty_score":0.51578563},"labels":[],"label_agreement":null},{"id":"W4385297837","doi":"10.1016/j.clinthera.2023.07.006","title":"Assessing the Performance of the Clinician-reported Genetic Testing Utility InDEx (C-GUIDE): Further Evidence of Inter-rater Reliability","year":2023,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Institute for Clinical Evaluative Sciences; SickKids Foundation","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Vignette; Inter-rater reliability; Genetic testing; Concordance; Reliability (semiconductor); Intraclass correlation; Test (biology); Repeated measures design; Genetic counseling; Clinical psychology; Psychometrics; Statistics; Internal medicine; Rating scale; Genetics","score_opus":0.21687860928341768,"score_gpt":0.46489248246884946,"score_spread":0.24801387318543178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385297837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967636,0.00048957235,0.0008078389,0.0007292244,0.0007145752,0.00029589765,0.000005531134,0.000017702585,0.00017609884],"genre_scores_gemma":[0.9976265,0.000385039,0.00091930054,0.00065657677,0.00020300064,0.000017437558,0.0000028832221,0.000024571222,0.00016468386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725425,0.00055098155,0.0013302865,0.000404295,0.00023692117,0.00022326047],"domain_scores_gemma":[0.9963467,0.0010170148,0.0006603741,0.0014429409,0.00049954304,0.0000334249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032211726,0.00015193321,0.0002555778,0.000020787227,0.00010711173,0.000023325916,0.0006564777,0.00023059698,0.000015700582],"category_scores_gemma":[0.002231299,0.00009232167,0.00023256052,0.0004895157,0.00092345884,0.000010279576,0.00037435614,0.00031978043,0.000004272893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005372082,0.000071049304,0.92570966,0.00005246505,0.00010738782,3.34116e-7,0.00009841109,0.000891334,0.016430944,7.769461e-7,0.00013424217,0.056449663],"study_design_scores_gemma":[0.00026266224,0.00026583,0.9499089,0.00015644022,0.00010135587,0.0000041367744,0.00019415609,0.019714806,0.025895914,0.00016173405,0.0032019052,0.00013214155],"about_ca_topic_score_codex":0.000015186513,"about_ca_topic_score_gemma":0.000012343752,"teacher_disagreement_score":0.056317523,"about_ca_system_score_codex":0.000023021643,"about_ca_system_score_gemma":0.0004952499,"threshold_uncertainty_score":0.37647685},"labels":[],"label_agreement":null},{"id":"W4385323521","doi":"10.1016/j.clinthera.2023.07.005","title":"Defining Need Amid Exponential Change: Conceptual Challenges in Workforce Planning for Clinical Genetic Services","year":2023,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"Provincial Health Services Authority; Genome British Columbia; Genome Canada","keywords":"Workforce; Workforce planning; Context (archaeology); Medicine; Relevance (law); Service (business); Health care; Risk analysis (engineering); Process management; Business; Marketing; Economic growth; Economics; Political science","score_opus":0.8839214828419063,"score_gpt":0.5912766697263316,"score_spread":0.29264481311557466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385323521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91611856,0.04367675,0.0017054483,0.03070141,0.0046407245,0.0017837783,0.000219844,0.00028184796,0.0008716131],"genre_scores_gemma":[0.9123814,0.034006584,0.00635925,0.0415632,0.004361966,0.00069011585,0.00018221502,0.00017334046,0.00028192147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906333,0.00075855904,0.006813574,0.000930784,0.00011689295,0.0007468616],"domain_scores_gemma":[0.98845285,0.008703325,0.0019335815,0.0006136105,0.00006667238,0.00022995532],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024067353,0.00027754356,0.0015281864,0.00029458365,0.00016619329,0.000074403775,0.0005318893,0.0005740815,0.00005025528],"category_scores_gemma":[0.0015862162,0.00034545295,0.0003708268,0.0003073337,0.00024498987,0.0002557039,0.00012840894,0.00048578565,0.0011082501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019856168,0.00034061878,0.90233094,0.00043150556,0.0002756387,0.00000614703,0.01076604,0.00046362018,5.2330046e-7,0.055598292,0.0018400515,0.027748082],"study_design_scores_gemma":[0.0047222236,0.00064857095,0.6375172,0.0004110459,0.00003727253,0.0000023374032,0.012616985,0.06531579,9.2262593e-7,0.015842859,0.26209444,0.0007903684],"about_ca_topic_score_codex":0.000038396225,"about_ca_topic_score_gemma":0.00005257118,"teacher_disagreement_score":0.26481372,"about_ca_system_score_codex":0.00010734304,"about_ca_system_score_gemma":0.00009168151,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W4386788696","doi":"10.1016/j.clinthera.2023.08.002","title":"Enthesitis in Spondyloarthritis Including Psoriatic Arthritis—To Inject or Not To Inject?: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Psoriatic arthritis; Enthesitis; Dermatology; Narrative review; Psoriasis; Intensive care medicine","score_opus":0.3910920873184047,"score_gpt":0.544218505201958,"score_spread":0.1531264178835533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386788696","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000490809,0.9877732,0.000009595811,0.001547926,0.0016242572,0.0076357163,0.00035771093,0.00023008116,0.00033070863],"genre_scores_gemma":[0.00007310876,0.9826614,0.0008416432,0.01201153,0.000987866,0.0015499288,0.00016792525,0.000309349,0.0013972364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99116236,0.0011391009,0.0040165917,0.0016503052,0.0008479657,0.0011836931],"domain_scores_gemma":[0.99356127,0.003476401,0.00068904064,0.0012917643,0.00025161623,0.00072991406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002225442,0.0012216938,0.008128775,0.0006733712,0.00025382265,0.00007436343,0.0005264588,0.00078695704,0.0003151601],"category_scores_gemma":[0.0033579904,0.000947803,0.0015946147,0.0031119792,0.0001866263,0.00008091369,0.0006367847,0.0015543402,0.0019759699],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038464784,0.0004925329,0.000050833918,0.01166558,0.0012919287,0.0022293425,0.0009377791,1.5772257e-7,1.2579308e-7,0.000035491263,0.0021061972,0.9808054],"study_design_scores_gemma":[0.0024254338,0.0029711185,0.00014587659,0.25984958,0.0016349969,0.00028339966,0.00024840806,0.0000011642343,5.4966756e-7,0.0000306377,0.73170036,0.0007084659],"about_ca_topic_score_codex":0.00004712423,"about_ca_topic_score_gemma":0.0006820641,"teacher_disagreement_score":0.98009694,"about_ca_system_score_codex":0.00056986365,"about_ca_system_score_gemma":0.0009171747,"threshold_uncertainty_score":0.99929726},"labels":[],"label_agreement":null},{"id":"W4387107296","doi":"10.1016/j.clinthera.2023.09.009","title":"Adverse Events During Dosing of Delayed-release/Extended-release Methylphenidate: Learnings From the Open-label Phase of a Registration Trial and a Real-world Postmarketing Surveillance Program","year":2023,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Lakehead University; Adler; START Clinic","funders":"","keywords":"Medicine; Tolerability; Postmarketing surveillance; Adverse effect; Discontinuation; Dosing; Clinical trial; Methylphenidate; Pediatrics; Internal medicine; Psychiatry; Attention deficit hyperactivity disorder","score_opus":0.19548968499852237,"score_gpt":0.489872202593365,"score_spread":0.29438251759484263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387107296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965957,0.0001969123,0.00010974749,0.0009212753,0.00018275924,0.0016784475,0.000043036544,0.00010189361,0.00017027694],"genre_scores_gemma":[0.99668044,0.0011052848,0.0013130904,0.00018021456,0.00014447924,0.000043389642,0.00012425377,0.00004673636,0.00036209548],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969539,0.0006582834,0.0012230756,0.00045762502,0.00043241255,0.00027470852],"domain_scores_gemma":[0.9956865,0.0024562848,0.00094265136,0.00054937956,0.00024620205,0.00011898231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002483608,0.0002075795,0.0006866346,0.00007985071,0.00013348987,0.000021287176,0.00024496412,0.0001568905,0.0000645962],"category_scores_gemma":[0.0016281921,0.00016347534,0.00017198482,0.0006469463,0.00027712458,0.00015380306,0.00020143793,0.00051478954,0.0000061007536],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18536834,0.013333221,0.36308262,0.00032614454,0.002362991,0.0000620708,0.0008597938,0.00006708569,0.04073692,0.00019078456,0.00014221933,0.3934678],"study_design_scores_gemma":[0.25184545,0.006312736,0.7047924,0.00087548734,0.0015180735,0.000015926853,0.0032125541,0.027551362,0.00086899544,0.00052088563,0.0018421933,0.0006439547],"about_ca_topic_score_codex":0.0004229294,"about_ca_topic_score_gemma":0.00017578839,"teacher_disagreement_score":0.39282387,"about_ca_system_score_codex":0.00002914941,"about_ca_system_score_gemma":0.00017126054,"threshold_uncertainty_score":0.66663307},"labels":[],"label_agreement":null},{"id":"W4387873321","doi":"10.1016/j.clinthera.2023.09.027","title":"Safety and Efficacy of Direct Oral Anticoagulant in Addition to Antiplatelet Therapy After Acute Coronary Syndrome: A Systemic Review and Meta-analysis of 53,869 Patients","year":2023,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta","funders":"","keywords":"Medicine; Acute coronary syndrome; Internal medicine; Relative risk; Myocardial infarction; Clinical endpoint; Randomized controlled trial; Stroke (engine); Major bleeding; Confidence interval","score_opus":0.35972118774939194,"score_gpt":0.4901924621937713,"score_spread":0.13047127444437934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387873321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01118646,0.98470783,0.000008639533,0.00015480357,0.000091327274,0.003230625,0.00058518304,0.000024909908,0.000010243772],"genre_scores_gemma":[0.007337215,0.99133533,0.00010024878,0.0004557682,0.00002450695,0.000021200256,0.00048319495,0.000048117876,0.00019441477],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99556196,0.0006906791,0.0027043435,0.0005112137,0.00033722006,0.00019458325],"domain_scores_gemma":[0.9964974,0.0018209395,0.00092815916,0.0005241974,0.0001221169,0.000107219355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014524963,0.00039460848,0.00935814,0.00048076603,0.000019647448,0.000010048594,0.00012344618,0.0002493611,0.00011096168],"category_scores_gemma":[0.00017269334,0.00025135657,0.0019747461,0.0013412918,0.00011612613,0.000041162577,0.00013127309,0.00022859352,0.000008168864],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011284472,0.00021326121,0.04156102,0.03709563,0.45089716,0.00009646137,0.00005787606,0.0000027249077,2.5937595e-7,0.000019402416,0.00006500176,0.46886274],"study_design_scores_gemma":[0.0017610567,0.000786721,0.11727611,0.0056582517,0.7823206,0.000014857048,0.0000036644042,0.000015300791,1.03683675e-7,0.000003888214,0.091857456,0.00030196455],"about_ca_topic_score_codex":0.000003958464,"about_ca_topic_score_gemma":0.0000022362608,"teacher_disagreement_score":0.46856079,"about_ca_system_score_codex":0.000027759053,"about_ca_system_score_gemma":0.000049340626,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W4389210383","doi":"10.1016/j.clinthera.2023.10.015","title":"Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records","year":2023,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AbbVie","keywords":"Medicine; Discontinuation; Internal medicine; Retrospective cohort study; Weight change; Weight loss; Weight gain; Body weight; Obesity","score_opus":0.06478629451811883,"score_gpt":0.4057682864289358,"score_spread":0.34098199191081696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389210383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995095,0.0017892829,0.0000058572036,0.0019895432,0.000035811565,0.0010409974,0.000008029881,0.000029269488,0.000006216122],"genre_scores_gemma":[0.99311775,0.0043941815,0.002036539,0.00015723606,0.00005628656,0.00016826214,0.000005934383,0.000021526152,0.000042282216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986203,0.00016982807,0.0003205007,0.00033756637,0.00019984752,0.00035197427],"domain_scores_gemma":[0.9992776,0.00019535652,0.00009748787,0.00023351483,0.000042755873,0.00015329456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048560978,0.0001586212,0.00062154455,0.00013704579,0.000038740414,0.000010785155,0.000029334928,0.0000567009,0.0000037161167],"category_scores_gemma":[0.00003523885,0.00009705672,0.000038369133,0.00036644223,0.00012595132,0.00002243794,0.000031739728,0.00022771553,0.0000011871866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030996816,0.00063124305,0.8097668,0.000020018662,0.00056363497,0.00004863187,0.0011049783,0.0000010605279,0.0000014395384,0.000034334153,9.557066e-7,0.18472718],"study_design_scores_gemma":[0.008737317,0.033513937,0.9547672,0.00006969968,0.00022263882,0.000013628518,0.00044424614,0.0015736863,0.00001829486,0.0005180425,0.00005290631,0.00006839263],"about_ca_topic_score_codex":0.00022160949,"about_ca_topic_score_gemma":0.012428366,"teacher_disagreement_score":0.18465878,"about_ca_system_score_codex":0.00011344298,"about_ca_system_score_gemma":0.00020005794,"threshold_uncertainty_score":0.693532},"labels":[],"label_agreement":null},{"id":"W4390903051","doi":"10.1016/j.clinthera.2023.12.008","title":"The International Working Group on New Developments in Pharmacovigilance: Advancing Methods and Communication in Pharmacovigilance","year":2024,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Novo Nordisk; CSL Behring; Alexion Pharmaceuticals; Celgene; Gilead Sciences; University of Portsmouth; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pharmacovigilance; Medicine; Timeline; Best practice; Knowledge management; Risk analysis (engineering); Pharmacology; Computer science; Adverse effect; Political science","score_opus":0.3403489431486682,"score_gpt":0.6136861542037463,"score_spread":0.2733372110550781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390903051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7931327,0.066183075,0.0036817947,0.046369396,0.03308886,0.0028620258,0.00007241785,0.000906245,0.05370345],"genre_scores_gemma":[0.8908994,0.08869054,0.003536878,0.0151104,0.0006341736,0.00008997208,0.000026184833,0.00004921999,0.0009632409],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966795,0.0010569864,0.00095664954,0.0005351069,0.00021229545,0.00055947877],"domain_scores_gemma":[0.9933077,0.0060347435,0.00015759023,0.0002612282,0.000033907203,0.00020481407],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0046793623,0.00028859716,0.0003347417,0.00019358864,0.00027502235,0.00013433081,0.00069006055,0.00025755647,0.000083604864],"category_scores_gemma":[0.00016070197,0.00023829311,0.000116156094,0.00053159986,0.00025218644,0.00027667027,0.00019353865,0.0026325504,0.00006179538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007601735,0.00034513962,0.07727019,0.000029514547,0.00034838894,0.00006538202,0.00075177685,0.0009149909,0.011641367,0.0042279772,0.0027636772,0.9008814],"study_design_scores_gemma":[0.0022606938,0.000036187077,0.0058180727,0.00021377997,0.00006651641,0.00001259153,0.0001649269,0.03192973,0.0027504726,0.0022100902,0.9542539,0.00028305422],"about_ca_topic_score_codex":0.000012248427,"about_ca_topic_score_gemma":0.00005800124,"teacher_disagreement_score":0.9514902,"about_ca_system_score_codex":0.0002528751,"about_ca_system_score_gemma":0.00021568032,"threshold_uncertainty_score":0.9996684},"labels":[],"label_agreement":null},{"id":"W4400791461","doi":"10.1016/j.clinthera.2024.06.006","title":"Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults","year":2024,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Glycogen Storage Diseases and Myoclonus","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aurinia (Canada)","funders":"UCB Pharma; Zogenix","keywords":"Medicine; Pharmacokinetics; Open label; Pharmacology; Adverse effect","score_opus":0.1932673866686603,"score_gpt":0.5034243509285348,"score_spread":0.3101569642598745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400791461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9110431,0.08704471,0.000023692546,0.0007290183,0.0002459857,0.0007465927,0.00010359306,0.00001677319,0.000046505433],"genre_scores_gemma":[0.96933657,0.029053565,0.000724281,0.0007018098,0.00011703825,0.0000107311835,0.000014006384,0.000025820875,0.000016177553],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984053,0.00015002192,0.00073991594,0.0003625056,0.00014375999,0.00019849991],"domain_scores_gemma":[0.9980354,0.0013853301,0.00013060065,0.0001738666,0.00009612877,0.00017867427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007138264,0.00019446813,0.00079446647,0.00008774842,0.00003310034,0.000018887118,0.00007075187,0.000121520825,0.0000071641907],"category_scores_gemma":[0.00023397806,0.00014470617,0.000057880385,0.0002103677,0.00040583243,0.000053998556,0.00016785982,0.0002809451,2.3324226e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057689045,0.00537192,0.015896304,0.011593403,0.0024881773,0.00082736945,0.0028646989,0.000001261774,0.013825084,0.00041008048,0.0002983853,0.8887343],"study_design_scores_gemma":[0.51717794,0.3092933,0.030650489,0.028962519,0.014160458,0.0021337857,0.0052172407,0.026832879,0.013372731,0.0020994483,0.04764365,0.002455575],"about_ca_topic_score_codex":0.0000047320477,"about_ca_topic_score_gemma":0.0000046733153,"teacher_disagreement_score":0.8862787,"about_ca_system_score_codex":0.000016843167,"about_ca_system_score_gemma":0.00005342295,"threshold_uncertainty_score":0.5900946},"labels":[],"label_agreement":null},{"id":"W4402563246","doi":"10.1016/j.clinthera.2024.08.007","title":"The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab","year":2024,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Hexal AG","keywords":"Medicine; Biosimilar; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.8425130437616768,"score_gpt":0.6390781168110089,"score_spread":0.2034349269506679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402563246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022428374,0.9933433,0.0006303116,0.0017172039,0.0023497646,0.0013942958,0.00034605002,0.000067162866,0.00014967403],"genre_scores_gemma":[0.000024934829,0.99418133,0.0014836155,0.0011782264,0.00017602787,0.00012822624,0.000019563555,0.000052042866,0.0027560482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951189,0.0013668272,0.0021236883,0.00077325705,0.00008604438,0.0005312391],"domain_scores_gemma":[0.9839657,0.014109998,0.00047758812,0.0011400513,0.00023528041,0.00007140195],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043515135,0.0004883952,0.002218144,0.000071765986,0.00018641287,0.000056865894,0.0012687737,0.0015519967,0.000048064307],"category_scores_gemma":[0.0020191697,0.00022198149,0.0015636558,0.00041862804,0.0009083496,0.000024771109,0.00038638094,0.0012653078,0.00021057394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001390599,0.000098490826,0.0000030602976,0.0030348774,0.0015287789,0.0000010956245,0.000012970892,1.4919548e-8,0.000017627875,0.0022321213,0.008325589,0.9846063],"study_design_scores_gemma":[0.00015976214,0.0007578047,0.000005818426,0.0060748695,0.0048889695,0.000010360964,0.000011805691,0.0000024275162,0.000051648323,0.0011259486,0.98660487,0.00030571324],"about_ca_topic_score_codex":0.000003191931,"about_ca_topic_score_gemma":0.000007732947,"teacher_disagreement_score":0.9843006,"about_ca_system_score_codex":0.0000556373,"about_ca_system_score_gemma":0.00041755446,"threshold_uncertainty_score":0.9997442},"labels":[],"label_agreement":null},{"id":"W4405933673","doi":"10.1016/j.clinthera.2024.12.002","title":"Treatment Persistence Among Anti-Tumor Necrosis Factor–experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti–Tumor Necrosis Factor Agent","year":2024,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Tumor necrosis factor alpha; Ulcerative colitis; Tumor necrosis factor α; Tumor necrosis factors; Persistence (discontinuity); Necrosis; Mode of action; Internal medicine; Immunology; Gastroenterology; Cancer research; Disease; Toxicology","score_opus":0.06944688030640472,"score_gpt":0.3510866952191969,"score_spread":0.28163981491279216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405933673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944132,0.000021468733,0.003733877,0.00006590303,0.00024742904,0.0011705335,0.000281696,0.000048985916,0.000016897313],"genre_scores_gemma":[0.99825066,0.000068955764,0.00053061364,0.000685578,0.00009553433,0.0001606462,0.000037885973,0.00006417406,0.00010596805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769706,0.00019715069,0.00058336277,0.00083145325,0.0002607319,0.0004302164],"domain_scores_gemma":[0.9987639,0.00010532736,0.00020079793,0.00047848868,0.00017941245,0.00027205187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007241896,0.00043197974,0.0005035524,0.00007601521,0.00014452529,0.00010972193,0.0002373789,0.00014961297,0.00003718633],"category_scores_gemma":[0.000062712694,0.00025836064,0.00023746555,0.0001870268,0.00018275439,0.000020937485,0.000093948256,0.00015782427,0.0000059601757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007917321,0.0013900787,0.80325556,0.00012354676,0.0011655482,0.00009964186,0.004453122,0.0004390433,0.17097437,0.000014766266,0.0000125148445,0.010154484],"study_design_scores_gemma":[0.0016647446,0.0056439517,0.9235655,0.00024721594,0.00018573196,0.0000031841155,0.0006576506,0.0011204315,0.065950185,0.000006186203,0.0003864102,0.0005688035],"about_ca_topic_score_codex":0.000031624255,"about_ca_topic_score_gemma":0.0001898716,"teacher_disagreement_score":0.12030995,"about_ca_system_score_codex":0.00012859063,"about_ca_system_score_gemma":0.00017675894,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4406061650","doi":"10.1016/j.clinthera.2024.12.006","title":"Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Montana Water Center, Montana State University; Janssen Scientific Affairs","keywords":"Medicine; Suicidal ideation; Nasal spray; Psychiatry; Major depressive disorder; Health care; Emergency medicine; Suicide prevention; Poison control; Nasal administration; Pharmacology","score_opus":0.09103261607493786,"score_gpt":0.40177048799917475,"score_spread":0.3107378719242369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406061650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949427,0.00024023505,0.000030008927,0.0029415754,0.00005781339,0.0015112049,0.00021590239,0.000042681524,0.000017872495],"genre_scores_gemma":[0.9902674,0.00064855366,0.00020389902,0.005952192,0.00003293989,0.00012441596,0.002597131,0.000030663414,0.00014283077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976029,0.0005418735,0.0005839834,0.00042875312,0.0005803181,0.00026220948],"domain_scores_gemma":[0.99665886,0.0025497533,0.00018316056,0.00029163674,0.00012289654,0.00019368637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024951226,0.0002715406,0.00046554254,0.00015011714,0.0001706401,0.000053200543,0.000103215956,0.00023467359,0.000023383907],"category_scores_gemma":[0.00025145372,0.0001338235,0.000046197314,0.00034588613,0.0003301171,0.000103449434,0.000043003307,0.00046217383,7.7866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074188476,0.0025681094,0.9624714,0.000030207011,0.00041582578,0.0001703802,0.0004124088,0.0000028936215,0.0000010889829,0.000016868713,0.0001179952,0.026373928],"study_design_scores_gemma":[0.022303892,0.0050416603,0.9702238,0.0005050656,0.0007801489,0.00001451895,0.00038671837,0.00019100934,0.000015120567,0.000007970622,0.00040251017,0.00012760508],"about_ca_topic_score_codex":0.00019497848,"about_ca_topic_score_gemma":0.0007130977,"teacher_disagreement_score":0.026246324,"about_ca_system_score_codex":0.00015558253,"about_ca_system_score_gemma":0.0002038431,"threshold_uncertainty_score":0.5457164},"labels":[],"label_agreement":null},{"id":"W4409567485","doi":"10.1016/j.clinthera.2025.03.005","title":"A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; McMaster University; Bausch Health (Canada); Probity Medical Research; Dermatrials Research","funders":"Bausch Health","keywords":"Tazarotene; Medicine; Lotion; Dermatology; Psoriasis; Plaque psoriasis; Pharmacology","score_opus":0.07841509737631215,"score_gpt":0.3605263565612945,"score_spread":0.28211125918498237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409567485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938634,0.00090247084,0.0002470347,0.00084789377,0.0010108354,0.0026139428,0.00026484163,0.000018252944,0.00023132307],"genre_scores_gemma":[0.9960683,0.0012703241,0.00012879603,0.000101826954,0.000026289823,0.00022908395,0.00010532903,0.000016204292,0.002053862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981253,0.0004148081,0.0008720478,0.0002944814,0.000054066226,0.0002392561],"domain_scores_gemma":[0.997612,0.0012769538,0.0003116593,0.00048124162,0.000282516,0.0000356412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004236345,0.00020705377,0.0006372368,0.00020452886,0.00015673702,0.0000061078285,0.00023305653,0.00023902136,0.00003073454],"category_scores_gemma":[0.000049386334,0.00014022345,0.00024861956,0.00033439754,0.00012438698,0.000028759223,0.000022587876,0.00008855771,0.0000051259185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012142482,0.018318594,0.14464343,0.00014507057,0.01155463,0.00000355081,0.004174928,0.00090437196,0.007960862,0.007250845,0.00045259862,0.79244864],"study_design_scores_gemma":[0.06569952,0.03269693,0.7149728,0.00035257378,0.008652156,0.000004021694,0.0028776175,0.0016012106,0.13282311,0.0050363685,0.034395546,0.0008881589],"about_ca_topic_score_codex":0.00964389,"about_ca_topic_score_gemma":0.043800656,"teacher_disagreement_score":0.7915605,"about_ca_system_score_codex":0.00013616703,"about_ca_system_score_gemma":0.00031153567,"threshold_uncertainty_score":0.996951},"labels":[],"label_agreement":null},{"id":"W4413257463","doi":"10.1016/j.clinthera.2025.06.020","title":"Prevalence of Three Prominent Corticosteroid Side Effects in a Large Asthma Population by Age, Sex and ICD-10 Asthma Severity with Recommendations for Screening","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Asthma; Corticosteroid; Population; Pediatrics; Immunology; Internal medicine; Environmental health","score_opus":0.048640265147797894,"score_gpt":0.34437235694332896,"score_spread":0.29573209179553106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413257463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868649,0.0020857428,0.009369789,0.00038920454,0.00019317384,0.0008821146,0.00014273245,0.000025107782,0.000047212616],"genre_scores_gemma":[0.9953793,0.00027706134,0.0026751712,0.0002751518,0.000012465377,0.00009077969,0.00023085855,0.000011333394,0.0010478477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987574,0.00026777256,0.00046629287,0.0002802535,0.000025802348,0.00020243597],"domain_scores_gemma":[0.99849445,0.001074737,0.00017304768,0.00019953524,0.00004133564,0.000016906964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048515486,0.000141394,0.00033494178,0.00005369577,0.00008879135,0.0000090586655,0.00009245098,0.00021312425,0.000014252179],"category_scores_gemma":[0.00008299193,0.000115344505,0.000070163405,0.00009242734,0.00009093983,0.000051738713,0.000047162768,0.00014009063,0.0000015925691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011672854,0.0005676878,0.6131481,0.00019669654,0.00044673253,0.0000016014931,0.00012498297,0.0000016524871,0.0030514752,0.00015789714,0.0001261882,0.3810097],"study_design_scores_gemma":[0.005915609,0.001072737,0.9817172,0.00026787084,0.00023732877,0.00000323584,0.00003483228,0.00022869495,0.003483774,0.00052444165,0.0063565616,0.00015770675],"about_ca_topic_score_codex":0.00001472464,"about_ca_topic_score_gemma":0.00014501771,"teacher_disagreement_score":0.38085198,"about_ca_system_score_codex":0.000017399825,"about_ca_system_score_gemma":0.000024716484,"threshold_uncertainty_score":0.47036123},"labels":[],"label_agreement":null},{"id":"W4414499458","doi":"10.1016/j.clinthera.2025.08.013","title":"Building Equitable Partnerships Between Industry Sponsors and Indigenous Communities to Enhance Engagement in Clinical Trials","year":2025,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Indigenous Health, Education, and Rights","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada); Western University","funders":"Sanofi","keywords":"Indigenous; Clinical trial; Diversity (politics); Public health; MEDLINE","score_opus":0.6421461556299339,"score_gpt":0.6264969607855257,"score_spread":0.015649194844408187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414499458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014134314,0.9727228,0.00010341515,0.00035828477,0.0027239507,0.004558015,0.00007630979,0.00008916122,0.0052337484],"genre_scores_gemma":[0.00063984323,0.9908036,0.000858736,0.00049642235,0.0026845029,0.00005320694,0.000038502378,0.000045170196,0.0043800264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9533239,0.03929965,0.005030695,0.0006458489,0.0004829053,0.0012170235],"domain_scores_gemma":[0.93979734,0.057324335,0.0013458389,0.00080985663,0.00017685103,0.00054577197],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.10728965,0.00048875844,0.0041455063,0.00041178087,0.0038416588,0.00022106055,0.0012316551,0.003006805,0.000062534345],"category_scores_gemma":[0.0011927687,0.00039328868,0.00066408416,0.0009200732,0.00082073465,0.00011548178,0.00005368932,0.0047894437,0.00003600905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002673862,0.00039997624,0.0020004667,0.0027737613,0.00035502217,0.0000036828778,0.06643284,2.835922e-7,1.510357e-9,0.011645804,0.000052375337,0.91630906],"study_design_scores_gemma":[0.00018842083,0.00019288895,0.00012358789,0.0061606425,0.00071761536,3.6713996e-7,0.0045051174,2.1966261e-7,1.7968719e-7,0.0009834217,0.98670393,0.00042358635],"about_ca_topic_score_codex":0.005171414,"about_ca_topic_score_gemma":0.057622056,"teacher_disagreement_score":0.9866516,"about_ca_system_score_codex":0.0004124163,"about_ca_system_score_gemma":0.02800074,"threshold_uncertainty_score":0.9998519},"labels":[],"label_agreement":null},{"id":"W4414919246","doi":"10.1016/j.clinthera.2025.09.014","title":"Differential Effects of Anti-Seizure Medications on Sarcopenia in Patients With Epilepsy","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cheng Kung University Hospital; National Cheng Kung University; National Science and Technology Council","keywords":"Sarcopenia; Epilepsy; Differential effects; Selection (genetic algorithm); Differential diagnosis; Clinical neurology; Clinical trial","score_opus":0.03289043900185498,"score_gpt":0.39321305451386845,"score_spread":0.3603226155120135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414919246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612385,0.00012549742,0.00021979315,0.0016175505,0.0003274338,0.0007242021,0.0000052590153,0.000024028293,0.000832403],"genre_scores_gemma":[0.99519134,0.00027054973,0.000107691616,0.004226241,0.00005327375,0.000019471881,0.0000090708,0.000008484205,0.00011385353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988247,0.0001481044,0.00042286792,0.00022703542,0.00020661832,0.00017065028],"domain_scores_gemma":[0.99795127,0.0015742315,0.000098878045,0.00022240281,0.000084655956,0.00006859229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013488643,0.00013228896,0.000556387,0.00007696019,0.00004130261,0.0000040540945,0.00010907201,0.00013695614,0.00003452628],"category_scores_gemma":[0.00023075445,0.00007866874,0.0000986665,0.00025704305,0.00027893632,0.000014960894,0.00005311765,0.00040098367,0.0000061753817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011115788,0.004163367,0.96735406,0.00016497093,0.00057849876,0.000008657851,0.000036057903,0.0000025682916,0.00040723558,0.00048539002,0.00027454935,0.025413094],"study_design_scores_gemma":[0.00762424,0.0022056696,0.98644626,0.00038113116,0.00036201955,9.542865e-8,0.000004929666,0.00010481539,0.0016039836,0.00016975014,0.0010223017,0.000074781055],"about_ca_topic_score_codex":0.0000018995225,"about_ca_topic_score_gemma":0.0000017382258,"teacher_disagreement_score":0.025338313,"about_ca_system_score_codex":0.000022992539,"about_ca_system_score_gemma":0.000055177803,"threshold_uncertainty_score":0.3208018},"labels":[],"label_agreement":null},{"id":"W4416554771","doi":"10.1016/j.clinthera.2025.10.006","title":"Evaluation of Colorectal Cancer Incidence in the United States From 2021 to 2024 Using a National Multi-Payer Claims Database","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Incidence (geometry); Colorectal cancer; National database; MEDLINE; Cancer incidence","score_opus":0.31087756224509205,"score_gpt":0.5214539127059087,"score_spread":0.21057635046081663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416554771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914864,0.00063165306,0.0051952074,0.0014782138,0.00052487093,0.0005071114,0.00007619559,0.0000096103295,0.00009074803],"genre_scores_gemma":[0.9943709,0.00024339596,0.0019141749,0.0031803881,0.0001302186,0.00005372651,0.0000645941,0.000007603666,0.000035022447],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997984,0.0004914864,0.0004862835,0.00024522742,0.00067244365,0.000120570585],"domain_scores_gemma":[0.99799126,0.0008803633,0.00010278262,0.00018185317,0.0008032588,0.000040488758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029130531,0.00009645235,0.00022187179,0.00016715222,0.000046511366,0.000015432379,0.0001162124,0.00010494193,0.000117538795],"category_scores_gemma":[0.0007603984,0.0000715163,0.00007346795,0.0010163127,0.000091825925,0.000041793777,0.000051355008,0.0003359234,0.000003410143],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021314254,0.0029874444,0.40395525,0.000121798104,0.0018400949,0.00001954374,0.0066103367,0.0881117,0.03193515,0.0001815913,0.0016993715,0.44122347],"study_design_scores_gemma":[0.002239174,0.0004257417,0.15182433,0.00032047878,0.00049083447,0.0000013949219,0.00060174335,0.84040403,0.0014461258,0.0006397445,0.001516145,0.00009028256],"about_ca_topic_score_codex":0.0019910468,"about_ca_topic_score_gemma":0.0017577255,"teacher_disagreement_score":0.75229234,"about_ca_system_score_codex":0.00023747089,"about_ca_system_score_gemma":0.00070340955,"threshold_uncertainty_score":0.30098805},"labels":[],"label_agreement":null},{"id":"W4416554774","doi":"10.1016/j.clinthera.2025.10.009","title":"Increased Bone Mineral Content in Response to Electrical Stimulation","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grain Research Centre; Bell (Canada); Université du Québec à Montréal","funders":"","keywords":"Bone mineral content; Stimulation; Attrition; Bone mineral; Randomization; Differential effects; Inclusion (mineral)","score_opus":0.19357578210981952,"score_gpt":0.4879624959760992,"score_spread":0.2943867138662797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416554774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812985,0.0004624471,0.00021801055,0.016458698,0.0001474947,0.0008023556,0.000002674449,0.000038271133,0.0005715444],"genre_scores_gemma":[0.9630735,0.00013780048,0.0010736699,0.03279506,0.0000917744,0.000031984702,0.0000096971735,0.000012520365,0.0027739904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976857,0.0005643814,0.0008122851,0.00028853066,0.0002687863,0.00038034157],"domain_scores_gemma":[0.9970944,0.0020293233,0.00004489183,0.00032817887,0.00018157106,0.00032164555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024384994,0.000109108245,0.0004321994,0.0002543106,0.00004167944,0.000014313988,0.00008080229,0.0002273141,0.000041331],"category_scores_gemma":[0.0023153764,0.0000909189,0.000112628375,0.0006426825,0.00007146329,0.000016989217,0.000043924196,0.0005764846,0.000053256477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05894738,0.0017148567,0.7672379,0.000056863602,0.00006659285,0.00008969423,0.000075991644,0.000011533015,0.022259079,0.00036245026,0.002625359,0.14655226],"study_design_scores_gemma":[0.0055089705,0.0015511472,0.9481775,0.00008393825,0.000034009347,0.0000042915585,0.000018737323,0.004086745,0.0002271686,0.00013458701,0.040091183,0.00008169994],"about_ca_topic_score_codex":0.00006527414,"about_ca_topic_score_gemma":0.000029345221,"teacher_disagreement_score":0.1809396,"about_ca_system_score_codex":0.00015394519,"about_ca_system_score_gemma":0.0005665255,"threshold_uncertainty_score":0.3707565},"labels":[],"label_agreement":null},{"id":"W4416975952","doi":"10.1016/j.clinthera.2025.10.011","title":"Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Energetic Materials and Combustion","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Propellant; Formoterol; Inhaler; Formoterol Fumarate; Metered-dose inhaler","score_opus":0.050153067769571145,"score_gpt":0.27281567367288206,"score_spread":0.2226626059033109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416975952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97829723,0.00046289535,0.018143395,0.00068212417,0.00034443542,0.0014613569,0.000017335009,0.00017058123,0.00042063498],"genre_scores_gemma":[0.9822088,0.00030839693,0.014741485,0.0008129558,0.0001615682,0.00018977985,0.000021089134,0.00009091742,0.0014650283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977623,0.00019688753,0.0007043875,0.000584211,0.00031754316,0.00043463625],"domain_scores_gemma":[0.9988047,0.000100709716,0.00014396236,0.00059351244,0.00016060467,0.00019650144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043553984,0.0004805395,0.0006844881,0.00008941867,0.0001141315,0.0002954996,0.0001962014,0.00025661988,0.000056691086],"category_scores_gemma":[0.000014238156,0.0002639113,0.000059987466,0.00016319238,0.00013026659,0.00016164631,0.000062572864,0.00028694596,0.0000068084805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028411457,0.0014471122,0.019537628,0.0022052235,0.0045521767,0.0002516841,0.0040934067,0.0117904395,0.7812116,0.0007029544,0.0006316865,0.14516462],"study_design_scores_gemma":[0.041040402,0.034640737,0.017182717,0.0035672546,0.0040820846,0.00035935882,0.0008031828,0.09486282,0.7263763,0.00078155135,0.07085728,0.005446304],"about_ca_topic_score_codex":0.000016106322,"about_ca_topic_score_gemma":0.00022094611,"teacher_disagreement_score":0.13971831,"about_ca_system_score_codex":0.000037866404,"about_ca_system_score_gemma":0.000086934284,"threshold_uncertainty_score":0.9999813},"labels":[],"label_agreement":null},{"id":"W74059060","doi":"10.1016/j.clinthera.2010.01.020","title":"Foreword","year":2010,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine","score_opus":0.1474031009666449,"score_gpt":0.47084995599229174,"score_spread":0.32344685502564685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W74059060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102414,0.00012248542,0.0001370616,0.005177211,0.0004968013,0.00021078678,0.000004597708,0.00006797254,0.0027589554],"genre_scores_gemma":[0.98302686,0.0001714951,0.012224959,0.0024391562,0.0005853189,0.0000098856235,0.0000068770696,0.000016179925,0.0015192883],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99919116,0.000028779788,0.00023638183,0.00016631909,0.00017616827,0.00020117156],"domain_scores_gemma":[0.99895805,0.0003064754,0.000029206609,0.0003923225,0.000068816735,0.00024510516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003134009,0.00007845259,0.00018733769,0.000025606823,0.000038824317,0.00000907982,0.000079135,0.00013759061,0.00038281863],"category_scores_gemma":[0.00013435626,0.000052422398,0.00016864312,0.000079534955,0.00016514811,0.000017696337,0.000027058692,0.00060454576,0.00033380283],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032435101,0.000947714,0.2786432,0.000008950976,0.00032008137,0.00008655095,0.000016312757,4.358183e-8,0.0010245228,0.011592585,0.00073359837,0.7033829],"study_design_scores_gemma":[0.007357439,0.0015871282,0.82013816,0.000016161444,0.00020221142,0.000079038786,0.000015974449,0.0008424934,0.0016497467,0.01229338,0.15566954,0.00014871264],"about_ca_topic_score_codex":0.0000021683652,"about_ca_topic_score_gemma":0.000029465942,"teacher_disagreement_score":0.7032342,"about_ca_system_score_codex":0.0000075560547,"about_ca_system_score_gemma":0.00014013852,"threshold_uncertainty_score":0.42904714},"labels":[],"label_agreement":null}]}